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Figure 1. General structure of nuclear receptors. The nuclear receptors consist of six 
regions, A/B, C, D, E and F A / B is located at the tertiary N-terminus and contains the 
activation function (AF-1). C is composed of the DNA binding domain (DBD), while D is the 
minimally conserved hinge region. Regions C & D have nuclear localization signal (NLS). E 
is the ligand binding domain (LBD) and carries the function of AF-2 ligand-dependent 
transactivation Some nuclear receptors exhibit an extremely variable F domain whose 
function is not known. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Classification of nuclear receptors. The nuclear receptors are classified in 
function to their capacity to fix to ligands (Chawla et al., 2001)  
 
Receptors: to estrogen (ER); to progesterone (PR); to androgens (AR); to glucocorticoids (GR); to 
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Factor 1(SF-1); Liver Receptor Homolog-1(LRH-1); Dosage sensitive sex reversal-Adrenal hypoplasia 
congenita critical region on the X chromosome, gene 1 (DAX-1); Small heterodimer Partner (SHP); 
tailless homolog (TLX): Photoreceptor-specific Nuclear Receptor (PNR); Nerve Growth Factor IB-like 
receptor (NGFI-B); related receptor to retinoid receptor (ROR); Estrogen-related receptor (ERR); Germ 
Cell Promoter Transcription Factor (COUP-TF); Neuron-derived orphan receptor (NOR); Neuron-
derived clone (NUR);V-erbA-related (EAR-2).  
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Chapter 1 : Nuclear receptors CAR and PXR 
1.1. Generalities on nuclear receptors 
Nuclear receptors (NRs) are ligand-dependent transcription factors that belong to a 
superfamily of intracellular receptors comprising 49 members in humans and 48 in mice 
(McKenna et al., 2009). They regulate a variety of physiological processes by inducing the 
transcription of target genes. These nuclear receptors generally possess a structure 
composed of 6 functional domains, namely, A/B, C, D, E and F. Domain A/B is situated at 
the extremity of the N-terminal region and contains the activating function (AF1). Domain C 
is composed of the DNA binding domain (DBD), consisting of two zinc finger patterns that 
recognizes specific response elements. Domain D can contain nuclear localization signals 
and provides flexibility to the protein. Domain E, situated at the extremity of the region of 
the C-terminal contains the ligand binding domain (LBD) and contains the ligand-
dependent activating function (AF2). Finally, the domain F is a very variable region, absent 
in certain NRs and exercises a regulatory function (Figure 1). 
1.2. Classification/Nomenclature 
In function to their phylogenetic similarity, NRs can be subdivided into 6 subfamilies 
(NR1-NR6) and further subdivided into 28 groups (A to K). Each group can then be 
regrouped into numerous gene paralogs (https://nursa.org/nursa/molecules/index.jsf). 
According to their capacity to function in monomer or in homo/heterodimer and according 
to the type of element of response to which they fix themselves, these NRs can also be 
distributed into 4 different classes I, II,, II, IV) (Evans & Mangelsdorf, 2014; Germain, et al., 
2006; Mangelsdorf et al., 1995). 
13
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In addition, NRs can equally be classified in function of their capacity for ligand binding. 
Thus, endocrine receptors bind to steroid hormones while adopted orphan receptors link 
to dietary lipid ligands and orphan receptors do not have identified ligands. Adopted 
orphan NRs have been discovered before the identification of their respective ligands 
(Alaynick, 2008) (Figure 2).  
The family of endocrine NRs includes the glucocorticoid (GR), estrogen (ER), 
progesterone (PG) androgen (AR) and mineralocorticoid (MR) receptors. Their ligands are 
exclusively from endogenous source and under the control of the hypothalamic-pituitary 
axe (Wilson, 1992). Steroid hormones bind to their receptors with high affinity. Adopted 
orphan receptors forms a heterodimer with RXR (Retinoid X Receptor) to induce the 
transcription of their target genes. The members of this group include the receptors for fatty 
acids - the peroxisome proliferator-activated receptors (PPARs), oxysterols - the liver x 
receptor (LXR), bile acids – the farensoid x receptor (FXR), as well as xenobiotics – the 
constitutive androstane receptor (CAR) and pregnane x receptor (PXR) (Chawla, et al., 
2001). 
 
1.3.  Mode of action of NRs 
NR ligands may have an exogenous or endogenous origin and are generally of 
lipophilic nature. They exert several actions on the receptor: agonist (increase in basal 
transcriptional activity), pure antagonist (non-modification of transcriptional activity), inverse 
agonist (decrease in basal transcriptional activity) and partial agonist/antagonist (partial 
transcriptional modification compared to pure agonist/antagonist transcriptional activity). 
NRs regulate the expression of their target genes by binding to their DNA on specific 
response elements. Generally, these response elements are located upstream of the 
14
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promoting region of the target gene. These response elements are composed of two 
hexameric nucleotide sequences forming direct, indirect or inverse repetitions separated 
by a number of determined nucleotides. NRs bind to these response elements in the form 
of a monomer, homodimer or heterodimer. RXR is the principal partner for 
heterodimerization (Kliewer et al., 1992). 
Gene activation by the nuclear receptors takes place in 3 stages. First is the binding of 
the ligand, followed by the recruitment of co-regulators and lastly, the recruitment of the 
transcriptional complex. The ligand binds the hydrophobic pocket (LBD) and induces a 
change of conformation that stabilizes the transactivation domain (AF2) (Thompson et al., 
1998). This stage permits the transition from the inactive form to the active form of the 
receptor. This ligand binding also allows the modulation of the interaction with cytoplasmic 
proteins such as Hsp (Heat shock protein) and further proceeding towards nuclear 
translocation (Hager et al.,  2000). 
Co-regulators are members of protein complexes, which are associated to NRs and 
modulate their activity (Rosenfeld & Glass, 2001). Co-activators are grouped in more than 
100 members. For example, they can activate histone acetlytransferase, thereby favoring 
the decondensation of DNA to access the transcriptional machinery. In this group, there is 
a family of p160 proteins including steroid receptor co-activator (SRC) 1, 2 and 3 and the 
p300 family, where PPARg co activator 1a (PGC1a) allows the binding of SRC1. This co-
activator is specific of the nutritional status and the cellular environment, and is induced 
upon fasting (Mastropasqua et al., 2018). 
The co-repressors interact with NRs that are constitutively bound to DNA or with those 
that are linked to antagonists or partial agonists and adopt conformations allowing the 
15
Chapter 1 : Nuclear receptors CAR and PXR 
fixation of co-repressors. The fixation of co-repressors allows the recruitment of enzymatic 
complexes containing histone deacetylases that prevents transcriptional activity (Bourguet 
et al., 1995). The most known co-repressors are NCoR (nuclear receptor co-repressor) and 
SMRT (silencing mediator for retinoid and thyroid receptor) (Heinzel et al., 1997). 
1.4.  Major hepatic roles 
Among the 48 NRs expressed in the liver, 20 are subject to a circadian rhythm where 
their expression and their activity are highly modulated according to the day/night cycle 
and the food supply (Yang et al., 2006). NRs participate in the regulation of carbohydrate 
and lipid homeostasis. PPARa, PPARb, PPARg, FXR, LXRa, vitamin D receptor (VDR) and GR 
are the most active hepatic NR regulating energy homeostasis, while CAR and PXR are 
specifically involved in xenobiotic metabolism. 
1.4.1. Energy metabolism 
PPARs: Fatty acid sensors (NR1C1, NR1C2, NR1C3) 
PPAR receptors are important regulators of energy metabolism and they are, 
therefore, pharmacological targets of numerous pharmaceuticals for the treatment of 
diabetes and obesity (López-Velázquez et al., 2012). PPARs are activated by saturated fatty 
acids, eicosanoids, and several other synthetic ligands. Each isotype of PPAR (a, b, g) 
exercise a specific function to maintain lipid homeostasis. PPARa (NR1C1) is the most 
abundant isotype in a healthy liver. During fasting, PPARα senses increased levels of free 
fatty acids released from adipocytes, and in response, controls the expression of hundreds 
of genes involved in fatty acid uptake, transport, and catabolism in hepatocytes (Montagner, 
Polizzi, et al., 2016). Fibroblast growth factor 21 (FGF21) is a hepatokine, a liver-derived 
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hormone produced by hepatocytes. FGF21 controls a broad range of endocrine responses 
involved in the regulation of energy metabolism, growth, fertility and longevity (Kliewer & 
Mangelsdorf, 2019). The laboratory has provided recent evidence that hepatocyte FGF21 
expression is strongly induced in response to fasting (Montagner, Polizzi, et al., 2016; 
Régnier et al., 2018) and in response to glucose overload (Iroz et al., 2017), two contrasted 
metabolic signals. In both cases, FGF21 expression is under the specific control of the 
PPARa. Thus, mice with a hepatocyte-specific deletion of Ppara show impaired fatty acid 
catabolism leading to hepatic steatosis and defective ketonemia in response to 
fasting (Montagner et al., 2016; Régnier et al., 2018). Ketogenesis is a metabolic pathway 
occurring in the liver that produces ketone bodies from adipose fatty acids. Ketone bodies 
are used as an alternative energy source by peripheral tissues to survive episodes of 
starvation. Thus, ketogenesis is a crucial metabolic adaptation to prolonged periods of 
nutrient insufficiency (Puchalska & Crawford, 2017). Altogether, data from the laboratory 
show that PPARa is a pioneering transcription factor required for the control of FGF21 and 
is critical for ketogenesis. 
LXR (NR1H3) : Sterol sensor 
LXRa is abundantly expressed in tissues associated to lipid metabolism such as the 
liver, adipose tissues, kidneys, and the intestine while LXRb is expressed ubiquitously. LXR 
is activated by oxysterols (Quinet et al., 2004). It is a key factor in cholesterol metabolism: in 
response to elevated levels of cholesterol, LXR  promotes its transport, its catabolism and 
its elimination (Chawla et al., 2001). The activation of LXR at the hepatic level induces the 
expression of transporters of cholesterol ATP binding cassette subfamily G member 5 
(ABCG5) and ABCG8 to augment the secretion of cholesterol in the form of bile (Peet et al., 
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1998). The expression of CYP7A1, the limiting enzyme of biliary synthesis and the 
elimination of cholesterol, is also regulated by LXR. Lastly, LXRa also regulates the 
expression of genes implicates in lipogenesis such as sterol regulatory element binding 
protein 1-c (SREBP-1c), stearoyl-CoA desaturase-1 (SCD1) and fatty acid synthase (FASN) 
(Repa et al., 2000). 
FXR (NR1H4) : Bile acid sensor 
FXR is highly expressed at the entero-hepatic system including the liver and intestine 
where it acts as a sensor of bile acids, thereby protecting the organism against elevated 
level of bile acids. The endogenous ligands of this receptor are for example, cholic and 
chenodeoxycholic acids. Activation of hepatic FXR induces the expression of the bile salt 
export pump (BSEP) allowing the efflux of bile acids through bile and leads to the repression 
of the cholesterol 7α-hydroxylase (CYP7A1) gene which regulates the pathway through 
which cholesterol is converted into bile acids (Sinal et al., 2000). 
1.4.2. Detoxification 
CAR-PXR (NR1l3-NR1l2) 
The constitutive androstane receptor (CAR), and the pregnane X receptor (PXR) are 
members of the adopted orphan nuclear receptor subfamily. Based on their structural 
features, CAR and PXR have been placed in nuclear receptor group 1, subgroup I; which 
also contains VDR. CAR and PXR are relatively promiscuous nuclear receptors that 
are activated by numerous xenobiotics, drugs, bile acids, and hormones.    
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 Therefore, they may be considered adopted orphans that recognize a number of 
endobiotic and xenobiotic chemicals. In turn, they act as master regulators of the 
phase I, phase II, and phase III enzymes and transporters critical for detoxification and 
elimination of steroids, bile acids, and xenobiotics following heterodimerization with 
RXRa. These two NRs will be further described in sections 1.5 and 1.6. 
AhR(ARNT) 
The aryl hydrocarbon receptor (AhR) is not per se a nuclear receptor, but a 
transcription factor structurally distinct from the nuclear receptor superfamily. It belongs 
to the Per-Arnt-Sim family of transcription factors and possesses helix-loop-helix 
interaction domains. AhR is present in the mammary glands, the liver, the central 
nervous system, the cardiovascular system and the uterus of all vertebrates (Guéguen 
et al., 2006). In the absence of the ligand, AhR is sequestered into the cytoplasm in a 
complex of chaperone molecules. Upon ligand binding, it translocates into the nucleus 
and associates with its partner AhR-nuclear translocator (Arnt). The target genes of AhR 
are principally phase l and ll xenobiotic metabolizing enzymes such as CYP1A1, CYP1A2, 
CYP1B1, UGT1A1 and MDR1 (Nebert et al., 2000). It was demonstrated that the 
pharmacologic activation of AhR is able to induce the expression of CAR and its target 
genes in the liver in rodent and human hepatocytes (Patel et al., 2007). 
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Figure 3. Expression of Pregnane X Receptor in specific tissue systems of C57Bl/6 
mice. PXR is highly expressed in the gastroenteric system, liver and kidneys of C57Bl/6 mice 
which implies the existence of common transcriptional mechanisms to regulate their 
expression (Bookout et al., 2006). 
Figure 4. 3D image of the human Pregnane X Receptor. LBD in complex with colupulone 
bound to the ligand binding pocket (LBP), highlighting different regions of interest. The α-
helices are shown in magenta and β-strands are in cyan. PXR heterodimerizes with RXR 
through the interface formed at α5, α9 and α10 helices. The AF2-surface, formed with αAF 
(known as activation function-2 helix), that facilitates the interaction with transcriptional 
coactivators and corepressors, is also labeled. The flexible loop region between α1 and α3 
helices is highlighted in green color (Chandran & Vishveshwara, 2016). 
20
Chapter 1 : Nuclear receptors CAR and PXR 
1.5. Pregnane X receptor (PXR) 
1.5.1. General Characteristics 
The pregnane X receptor (PXR; NR1I2), identified in 1998, has been established as 
a xenosensor and master regulator of xenobiotic responses (Gao & Xie, 2010; Ma et al., 
2008). It is also known as steroid and xenobiotic receptor (SXR), as it was identified by 
different research teams independently in mouse  and in human (Willson & Kliewer, 2002). 
PXR is expressed predominantly in the liver, specifically in the hepatocytes and Kupffer 
cells (Haughton et al., 2006; Wright, 2006) and in the intestine (Figure 3), which are 
important organs involved in the absorption, distribution, metabolism and elimination 
of potentially harmful xenobiotics and endobiotics (Gao & Xie, 2010; Ihunnah et al., 2011; 
Ma et al., 2008). It is also expressed in the lungs, bone marrow and the brain (Lamba 
et al., 2004). PXR has the capacity to recognize a large spectrum of ligands due to its 
wide and flexible binding pocket (Timsit & Negishi, 2007). It is activated by exogenous 
chemicals and endogenous metabolites and controls the transcription of xenobiotic 
metabolizing enzymes (XMEs) when activated by its ligand (Bookout et al., 2006; 
Honkakoski, Sueyoshi, & Negishi, 2003; Ma et al., 2008a). Moreover, its role in 
energy metabolism is now increasingly recognized.  
1.5.1.1. Structure 
Similar to other NRs, PXR is composed of an N-terminal nuclear receptors (AF1), a 
DNA binding domain (DBD), a ligand binding domain (LBD) binding domain, and a C-
terminal activation domain (AF2) (Figures 1 and 4). PXR is activated by a wide variety of 
ligands of various structures due to several hallmark  features: (1) a small number of polar 
residues spaced through a smooth, hydrophobic large ligand-binding domain (LBD), (2) a  
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Compounds Category Species References 
Ketoconazole 
Dexamethasone Anti-inflammatory agent Human, 
Rabbit, Rat 
Ihunnah et al., 2011; Ma et al.,  
2008; Jones et al., 2000 
Acetaminophen 
Rifampicin Antibiotic Human, 
Rabbit 
Ihunnah et al., 2011; Ma et al.,  
2008; Jones et al., 2000, 
Hernandez et al, 2009 
Rifaximin Human Ihunnah et al., 2011 
Clotrimazole Antibiotic Human, 
Rabbit, Rat 
Ihunnah et al., 2011; Jones et al., 
2000 
Metyrapone Anti-hypercortisolism drug Human Ihunnah et al., 2011 
Ritonavir Antibiotic Human Ma et al.,  2008 
Paclitaxel Chemotherapeutic 
Taxol Chemotherapeutic 
Pregnolone-16a-carbonitrile (PCN) Anti-glucocorticoid drug Mice, Rat Ihunnah et al., 2011; Ma et al.,  
2008; Hernandez et al, 2009 
Progesterone Steroid 
Ethinylestradiol Steroid 
Cyclophosphamide Antineoplastic drug Human Ma et al.,  2008 
Cyproterone acetate Antineoplastic drug Human Ma et al.,  2008 
Taxol Antineoplastic drug Human Ma et al.,  2008 
Tamoxifen Antineoplastic drug Human Ma et al.,  2008 
RU486 Antineoplastic drug Human, 
Rabbit, Rat 
Ma et al.,  2008; Jones et al., 
2000 
Troglitazone Anti-diabetic drug Human Ma et al.,  2008 
Lovastatin Anti-hypertensive drug Human Lehmann et al., 1998 ; Ihunnah 
et al., 2011 
Nifedipine Anti-hypertensive drug Human Ma et al.,  2008 
Spironolactone Anti-hypertensive drug Human, 
Rabbit, Rat 
Ma et al., 2008; Jones et al., 
2000 
Glutethimide  Sedative Human Ma et al.,2008 
Phenobarbital. Sedative Human, 
Rabbit, Rat 
Ma et al., 2008; Jones et al., 
2000 
Piper methysticum (chloraseptic) Chloraseptic (Herbal medicine) Human Ihunnah et al., 2011 
Schisandra chinensis  Anti-perspiration (Herbal medicine) Human Ihunnah et al., 2011 
Agauria salicifolia  Arrhythmia (Herbal medicine) Human Ihunnah et al., 2011 
St. John’s Wort Herbal medicine Human Ma et al.,2008 
Gugulipid®  Herbal medicine Human Ma et al.,2008 
Kava kava Human Ma et al.,2008 
nutritional compounds flavonoids Herbal medicine 
Vitamin E Dietary Supplement Human Ma et al., 2008 
Vitamin K2 Dietary Supplement Human Ma et al., 2008 
Organochlorine pesticides Pesticides  
(Environmental pollutant) 
Human Ma et al., 2008 
1,1,1-trichloro-2,2-bis(p-
chlorophenyl)ethane (DDT) 
Pesticide Human Ihunnah et al., 2011 
di-n-butyl phthalate (DBP) Plasticizer Ihunnah et al., 2011 
Chlordane Pesticide Human Ihunnah et al., 2011 
Dieldrin Pesticide Human Ihunnah et al., 2011 
Endosulfan Pesticide Human Ihunnah et al., 2011 
Bisphenol analogs (BPA) Plasticizer 
Polychlorinated biphenyls (PCBs) Environmental pollutant 
Dethylhexyl phthalates (DHEP) Plasticizer 
Organochlorides Environmental pollutant
Trans-nonachlor Pesticide Rabbit, Rat Jones et al., 2000 
Chlordane Pesticide 
Polybrominated diphenyl ether  Flame retardant Human Ma et al., 2008 
Bile acid precursors Endobiotic Human Ma et al., 2008 
Estrogens Endobiotic Human Ma et al., 2008 
Progestogen Endobiotic Human  Ma et al., 2008 
Table 1. List of PXR ligands 
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flexible loop which may be responsible for PXR’s ability to bind ligands of different sizes, 
and (3) its ability to use only a portion of its pocket to bind and in turn, be activated by 
ligands, allowing for PXR to serve as a more promiscuous receptor unlike other nuclear 
receptors (Hernandez, Mota, & Baldwin, 2009). 
 
1.5.1.2.  Ligands  
PXR ligands are structurally diverse and include prescription drugs, herbal 
medicines, dietary supplements, environmental pollutants, and endobiotics (Table 1). 
Therefore, it may be considered as an adopted orphan that recognizes a number of 
endobiotic and xenobiotic chemicals (Garcia et al., 2018; Hernandez et al., 2009). Among 
these ligands, the catatoxic steroid pregnenolone 16α-carbonitrile (PCN), was first known 
to induce the transcription of CYP3A, which metabolizes most prescription drugs (Kliewer, 
2015). PCN robustly induces CYP3A in rodent but not human hepatocytes. Conversely, 
rifampicin induces CYP3A in human but not rodent hepatocytes. These species-specific 
differences are due to 76% similarity on the ligand-binding domains of mPXR vs hPXR, which 
is much lower than the identity between orthologs of other nuclear receptors. This 
divergence provided the first hint that mouse and human PXR may have distinct 
pharmacologic activation profiles. Thus, PCN is considered a rodent-specific PXR ligand (Ma 
et al., 2008a) while Rifampicin is the prototypical pharmaceutical ligand used in human 
studies. PXR activation regulates a large network of genes involved in the metabolism and 
transport of xenobiotics.  
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Figure 5. Activation of PXR. Ligand (●) activation of PXR triggers the release of co-
repressors and histone deacetylases, and the subsequent interaction of PXR with co-
activators and histone acetylases, leading to transcription of target genes( Hernandez et al.,  
2009). 
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1.5.2. Activation 
As illustrated in Figure 5, the classical mechanism of activation of PXR involves the 
binding of a ligand specific to its LBD, modification of the conformation of the receptor and  
the transition from an inactive state to an active state. When bound to and activated by a 
ligand, PXR translocates from the cytoplasm to the nucleus of the cells and forms a 
heterodimer with the RXR that binds to PXR response elements, located in the 5′-flanking 
regions of PXR target genes, thereby activating the transcription of target genes. PXR is also 
capable of recruiting a host of coactivators which includes members of the p160 family of 
coactivators such as SRC-1, transcriptional intermediary factor (TIF)/glucocorticoid receptor 
interacting protein (GRIP) (SRC-2), and PGC-1a (Ihunnah et al., 2011). 
 
1.5.3. Target genes 
PXR primarily induces the transcription of the cytochromes P450 CYP3A family such 
as CYP3A4 and 3A7, but the prototypical target gene of PXR in humans is CYP3A4 (Goodwin 
et al., 1999). CYP3A4 is the most abundant of the P450s expressed in the liver, and 
participates in the metabolism of more than 50% of marketed drugs, and some endogenous 
substrates such as steroids and bile acid (Ma et al., 2008; Tolson & Wang, 2010).  PXR shares 
a vast amount of target genes with the nuclear receptor CAR among them CYP2B6, CYP2C8 
and 2C9 (Hernandez et al., 2009), glutathione S transferase (GSTA1), sulfotransferase 
(SULT2A1), UDP glucuronosyltransferase (UGT1A1). PXR activation also upregulates 
transporter genes such as the MDR1 gene that encodes the P-glycoprotein, organic anion 
transporting polypeptide-2 (OATP2) and multidrug resistance-related protein-3 (MRP3). 
Due to the role of PXR in regulation of metabolic enzymes and transporters, PXR activation 
therefore extensively affects the fate of xenobiotics (Ma et al., 2008). A summary of the  
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Figure 6. PXR target genes. A summary of both human and mouse PXR encoded target 
genes for detoxification enzymes (Hernandez et al., 2009). 
PXR CAR
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regulated genes in human and mouse is listed in Figure 6. 
 
1.5.4. Experimental models 
High-throughput in vitro PXR activation and binding assays have been used to 
identify PXR ligands. Primary cultures of human hepatocytes have also been frequently 
utilized to study PXR activation and PXR target gene regulation, and for prediction of drug-
drug interactions. However, there are limitations of extrapolating from in vitro findings to 
the clinical situation in vivo and several animal models complement to evaluate the functions 
of PXR in a whole animal system (Ma et al., 2008b).  
The Pxr-null mouse model was generated by disrupting the mouse Pxr gene by 
homologous recombination and did not display any overt phenotypic abnormalities, 
suggesting that PXR is not essential for mouse development or physiological homeostasis. 
The first described Pxr-null mice were confirmed to be fertile and viable with PXR expression 
absent in both the liver and intestine (Xie et al., 2000). Thus, the Pxr-null mouse was 
validated as a reliable model to identify PXR-dependent signaling pathways.  Recently, liver- 
and intestine-specific Pxr-deletion models have been published that allowed to unravel 
organ-autonomous functions of Pxr (Gwag et al., 2019; Meng et al., 2019). 
PXR-humanized mouse models provided a solution to the problem of species 
differences in ligand specificity. So far, three different humanized mouse models have been 
created that aimed to delete the mPxr and replace it with the hPXR either at the whole 
organism level or in a liver-specific way: the Alb-hPXR mice (produced by use of a cDNA), 
BAC-hPXR (generated with a bacterial artificial chromosome (BAC)), and the P-hPXR (the 
human PXR protein was fused to a viral VP16 coactivator). The Alb-hPXR mice was bred into 
a PXR-null background, and the resulting PXR-null/SXR-transgenic mice lacked mouse PXR 
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gene but had human SXR transgene (Xie et al., 2000). In the hPXR mouse model, PXR was 
selectively expressed in the liver and intestine, the same tissue expression pattern as CYP3A. 
Both models were developed in the Pxr-null mouse background and responded to the 
human-specific PXR ligand rifampicin but not the rodent-specific Pxr ligand PCN. The 
notable differences between first 2 models is driven by heterologous promoter that yields 
liver-specific expression, while the BAC transgene, containing the complete PXR gene, is 
under control of the native human PXR promoter. This distinction is quite important since 
PXR is also expressed in the gut where it can influence the metabolism and transport of 
drugs. (Ma et al., 2008). VP-hPXR (the human PXR protein was fused to a viral VP16 
coactivator). VP-hPXR was expressed in the liver and throughout the intestinal tract, 
including the duodenum, jejunum, ileum, cecum, and colon. In contrast, the expression of 
hPXR was undetectable in the stomach and kidney. The tissue distribution of transgene 
expression was similar to that of endogenous mouse PXR (mPXR), although the relative 
expression of the transgene was higher in the cecum and colon (Gong et al., 2006).  
 
1.5.5.  Physiological functions 
1.5.5.1.  Drug-drug interaction 
The identification of PXR revealed a molecular mechanism for many drug-drug 
interactions. When two or more drugs are combined, and one is a PXR ligand, and others 
are the substrates of PXR target gene encoded enzymes or transporters, drug-drug 
interactions can occur consequently leading to decreased therapeutic efficacy. This is for 
example illustrated by decreased Rifampicin efficacy to cyclosporin in patients 
simultaneously taking either oral contraceptives, midazolam for dental extractions, anti-HIV 
protease inhibitors, and St. John’s Wort (a herbal medicine used for mental disorders and  
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simultaneously taking either oral contraceptives, midazolam for dental extractions, anti-HIV 
protease inhibitors, and St. John’s Wort (a herbal medicine used for mental disorders and 
nerve pain) to cyclosporine (Zhang, Xie, & Krasowski, 2008). 
 
1.5.5.2. Lipid Metabolism 
Lipogenesis. Transgenic mice expressing a constitutively activated PXR showed 
hepatomegaly and marked hepatic steatosis, and treatment of mice with a PXR agonist 
elicited a similar effect. PXR-induced lipogenesis was independent of the activation of 
SREBP-1c and was associated with the induction of fatty acid translocase (FAT/CD36), 
peroxisome proliferator-activated receptor g2 (PPARg2), and Scd1 (Gao & Xie, 2010; Zhou 
et al., 2008) and long-chain free fatty acid elongase (Ma et al., 2008). 
Lipid oxidation. In mice, activation of PXR by its agonist PCN can inhibit lipid 
oxidation by down-regulating the mRNA expression of carnitine palmitoyltransferase1a 
(CPT1a) and mitochondrial 3-hydroxy-3-methylglutarate-CoA synthase 2 (HMGCS2), two 
key enzymes involved in b-oxidation and ketogenesis, in a PXR-dependent manner (Gao & 
Xie, 2010). 
 
1.5.5.3. Glucose Metabolism 
Hepatic gluconeogenesis. The regulation of the gluconeogenic pathway by PXR was 
initially suggested by the suppression of phosphoenolpyruvate carboxykinase (PEPCK) and 
glucose-6-phosphatase (G6Pase) in VP-hPXR transgenic mice (Zhou et al., 2006). Treatment 
of wild-type mice with the PXR agonist PCN also suppressed cyclic adenosine 
monophosphate (cAMP)-dependent induction of G6Pase in a PXR-dependent manner 
(Kodama et al., 2004) where PXR can form a complex with phosphorylated cAMP response 
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element-binding protein (CREB) in a ligand-dependent manner to prevent CREB binding to 
the cAMP (Gao & Xie, 2010). 
PXR can also physically bind to Forkhead box O1 (FoxO1) and suppress its 
transcriptional activity by preventing its binding to the insulin response sequence in the 
gluconeogenic enzyme gene promoters (Kodama et al., 2004). PXR and CAR may also 
inhibit hepatocyte nuclear factor-4a (HNF4a) activity by competing for the DR1 (direct 
repeat spaced by one nucleotide) binding motif in the gluconeogenic enzyme gene 
promoters (Miao et al., 2006). 
 
1.5.5.4. Bilirubin Detoxification 
Bilirubin, the breakdown product of heme proteins, conjugates with UGT converting 
the neurotoxic unconjugated bilirubin to nontoxic bilirubin glucuronide. Xie et al. (2003) 
reported that activation of PXR prevented experimental hyperbilirubinemia in mice. PXR 
activates the transcription of UGT1A1 and several other genes critically involved in bilirubin 
detoxification, such as OATP2 and MRP2. OATP2 mediates bilirubin uptake from blood into 
liver, whereas multidrug resistant protein (MRP2) facilitates the excretion of conjugated 
bilirubin to bile canaliculus. Ihunnah et al. (2011) therefore reports that PXR ligands may 
represent potential therapeutic agents in treating hyperbilirubinemia. 
 
1.5.5.5. Bile Acid Regulation and Detoxification 
Bile acids, synthesized in the liver via the primary pathway for cholesterol elimination, 
are end products of cholesterol catabolism. They are produced in the liver from 
cholesterol via multiple enzyme-dependent steps with the rate-limiting step being 7-
hydroxylation of cholesterol by CYP7A1. Upon cholesterol entry in the intestine, bile acids 
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promote its absorption of and that of fat-soluble vitamins. However, when cholesterol 
synthesis becomes dysregulated, excess bile acids become cytotoxic and can lead to 
pathological cholestasis. Therefore, bile acid levels need to be tightly regulated to protect 
the human body from their toxic effects (Ihunnah et al., 2011). Studies have established that 
PXR regulates several detoxification enzymes and transporters important to bile acid 
metabolism including Cyp2b10 and Cyp3a11, Sult2a1, dehydroepiandrosterone 
sulfotransferase (STD), Mrp 2,3,4, and Oatp2  (Hernandez et al., 2009). In humans, 
positive regulation of SULT2A1 gene expression by FXR and PXR may play a central role in 
regulating bile acid sulfation in conjunction with the constitutive androstane receptor (CAR) 
(Garcia et al., 2018). Staudinger et al. (2001) have also reported that ligand activated PXR 
reduced the expression of Cyp7a1 without affecting Shp expression in mice. However, hPXR 
can regulate SHP expression directly in HepG2 cancer cells . (Frank et al., 2005). PXR has 
also been reported as an FXR target gene (Garcia et al., 2018; Jung et al., 2006). Finally, 
treatment of mice with PCN is known to alleviate the lithocholic acid-induced hepatotoxicity 
(Staudinger et al., 2001; Xie et al., 2003). Altogether, these results suggested the link 
between PXR and FXR in protecting the human body from bile acid toxicity. 
1.5.5.6. Inflammation 
Numerous studies have suggested a negative correlation between 
infectious disease/inflammation and drug metabolism capacity that would involve 
PXR. Teng & Piquette-Miller (2005) showed that IL6-treated wild type mice decreased 
PXR protein levels, and its target genes’ expression of Mrp2, Bsep, and Cyp3a11. A 
study by Beigneux et al. (2002) revealed that lipopolysaccharide (LPS) challenge induced the acute phase response 
in mouse liver and caused a significant decrease in the mRNA expression of Pxr and its 
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target genes. In rifampicin-treated patients, immunosuppression is expected. Zhou et al. 
(2006) further elucidated in vitro and in vivo that the attenuation of nuclear factor k B (NF-kb) 
proteins may be due to PXR activation by rifampicin. NF-kb proteins are important in 
facilitating immune response and inflammation suggesting that basal PXR activity is integral 
to proper mucosal health (Terc et al., 2014). 
1.5.5.7. Regulation of intestinal mucosal homeostasis and intestinal 
permeability 
A rapidly increasing amount of studies have also demonstrated that PXR may play a 
role in regulating intestinal mucosal homeostasis.  PXR has been implicated to regulate 
similar cellular processes in intestinal epithelial cells (IECs) and hepatocytes, initiating the 
transcription of genes related to metabolism and detoxification, as well as the regulation of 
additional processes in non-IEC systems; the regulation of cell migration, cell survival, 
apoptosis, and autophagy. PXR’s interaction with signaling cascades like p38 mitogen-
activated protein kinases (MAPKs), c-Jun N-terminal kinases (JNKs1/2) and 5' adenosine 
monophosphate-activated protein kinases (AMPKs), has basically linked it to key functions 
of IECs that contribute to intestinal mucosal barrier function (Ranhotra et al., 2016). Other 
studies using animal models of intestinal bowel disease have reported that the selective 
activation of PXR attenuates colonic inflammation and tissue damage (Dou et al., 2013; Ma 
et al., 2007; Shah et al., 2007; Terc et al., 2014), while others have shown that PXR activity 
attenuates inflammation-induced barrier dysfunction and accelerates mucosal healing after 
a bout of colitis (Terc et al., 2014; Venkatesh et al., 2014). 
Intestinal microbial metabolites are conjectured to affect mucosal integrity through 
mechanisms that have yet to be fully understood. Venkatesh et al. (2014) showed that 
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microbial-specific indoles regulated intestinal barrier function through PXR. Indole 3-
propionic acid (IPA), a PXR ligand in vivo, downregulated enterocyte tumor necrosis-α (TNF-
α) while it upregulated junctional protein-coding mRNAs. Furthermore, PXR-deficient mice 
showed a distinctly "leaky" gut physiology coupled with upregulation of the toll-like 
receptor (TLR) signaling pathway demonstrating the direct chemical communication 
between the intestinal symbionts and PXR, thereby regulating mucosal integrity through a 
pathway that involves luminal sensing and signaling by TLR4. 
 
1.6. Constitutive androstane receptor (CAR) 
1.6.1. General Characteristics 
The Constitutive Androstane Receptor (CAR) or (NR1i3) has been cloned for the first 
time in 1994 and named MB67 by the Baes team (Baes et al., 1994). They demonstrated that 
it is essentially expressed in the liver and its LBD has been fused with the DNA binding 
domain by the thyroid hormone receptor (TRb) and with a plasmid containing the response 
elements to TRb. The authors have also shown that, even in the absence of an exogenous 
ligand, this construction was still able to activate a reporter gene under the control of the 
response elements of TRb. Therefore, CAR was shown to be active in a constitutive manner 
and is capable of heterodimerization with RXR. 
Between 1997 and 1998, the characterization in the murine form of the receptor 
showed the capacity to form a heterodimer with RXR and binds to the response elements 
of the retinoic acid (RARE) even in the absence of an exogenous ligand  (Choi et al., 1997). 
The authors named this receptor “Constitutive Androgen Receptor”. It is identified in two 
isoforms: CAR1 and CAR3 which differ by their LBD. CAR3 is truncated to one part of the  
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Compound Species Reference 
Perfluorocarboxylic acid, PFCA (detergent) Mouse Abe et al., 2017; Cheng & Klaassen, 2008 
Perfluorooctanoic acid, PFOA (detergent) Mouse Kawamoto et al., 2000; Oshida et al., 2015 
Perfluorooctanesulfonic acid, PFOS (detergent) Rat Elcombe et al., 2012 
Alachlor (pesticide) Mouse Baldwin & Roling, 2009 
Arsenite (chemical) Mouse Baldwin and Roling, 2009 
Azoic colorants (paint) Mouse 
Rat 
Pakharukova et al., 2007 
Bisphenol A (chemical) Mouse Baldwin and Roling, 2009 
Butylate (pesticide) Mouse Baldwin and Roling, 2009 
Chlorpropham (pesticide) Mouse Baldwin and Roling, 2009 
Chlorpyriphos (pesticide) Mouse Baldwin and Roling, 2009 
Cypermythrin (pesticide) Mouse Baldwin and Roling, 2009 
Cyproconazole (pesticide) Mouse Peffer et al., 2007 
Di-n-butylphthalate, DBP (plastifiant) Rat Wyde et al., 2005 
Dichlorodiphenyldicholorethylene, DDE 
(pesticide) 
Mouse Wyde et al., 2003 
Di-isonyl phthalate, DiBP (plastifiant) Human Laurenzana et al., 2016 
O, p-DDT,1, 1, 1-Trichloro-2-(2-chlorophenyl)-2-(4-
chlorophenyl)ethane (pesticide) 
Mouse 
Rat 
Sueyoshi et al., 1999; Wyde et al., 2003 
DEHP (plastifiant) Human 
Mouse 
Baldwin and Roling, 2009; DeKeyser et al., 2009 
Dieldrine (pesticide) Mouse Wei et al., 2002 
Endosulfan (pesticide) Human 
Mouse 
Baldwin and Roling, 2009;                      Savary et al., 
2014 
Fernitrothion (pesticide) Mouse Baldwin and Roling, 2009 
Polycyclic aromatic hydrocarbons Mouse Zhang et al., 2015 
Imazalil (pesticide) Mouse Baldwin and Roling, 2009 
Kepone (pesticide) Mouse Baldwin and Roling, 2009 
MEHP (plastifiant) Mouse Baldwin and Roling, 2009 
Metolachlor (pesticide) Mouse Baldwin and Roling, 2009 
Methoxychlor (pesticide) and metabolites Human 
Mouse 
Rat 
Baldwin and Roling, 2009;                       (Blizard et al., 
2001); Savary et al., 2014 
Monosodium methane arsenate Mouse Baldwin and Roling, 2009 
Nonylphenol (plastifiant) Human Hernandez et al., 2007) 
Parathion (pesticide) Mouse Hernandez et al., 2007 
Polchlorobiphenyls, PCB (derived chemicals) Mouse Sueyoshi et al., 1999 
Propachlor (pesticide) Mouse Baldwin and Roling, 2009 
2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin (TCDD) Mouse Prokopec et al., 2015 
SSS-Tributylphoshorotithioate (pesticide) Mouse Baldwin and Roling, 2009 
Valproic acid Human Cerveny et al., 2007 
Acetaminophene Mouse Zhang et al., 2002; Zhang et al., 2004 
Antifungal triazoles Mouse Goetz et al., 2006; Peffer et al., 2007 
Artemisinine Human 
Mouse 
Burk et al., 2005; Swales & Negishi, 2004 
Benzodiazepines Human Li et al., 2008 
Clotrimoxazole Human Moore et al., 2000 
Cocaine Human Malaplate-Armand et al., 2005 
Dexamethasone Human Pascussi et al., 2000; Qatanani, Wei, & Moore, 2004 
Ketoconazole Human Duret et al., 2006 
Meclizine Human 
Mouse 
Huang et al., 2004 
Metamizole Human Saussele et al., 2007 
Methotrexate Mouse Chen et al., 2006; Shibayama et al., 2006 
Orphenadrine Rat Murray et al., 2003 
Phenobarbital Mouse 
Rat 
Currie et al., 2014; Li et al., 2017 
Phenytoin Human  Jackson et al., 2004; Wang et al. et al., 2004 
Statines Human Howe et al., 2011 
Table 2. Activators of CAR 
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region C-terminal and cannot bind to the DNA nor can it form a heterodimer with RXR. The 
murine form of CAR1 possesses an independent ligand-binding trans-activator. 
The tissue distribution of CAR is the same in both human and mice. It is strongly 
expressed in the liver and intestine (Wei et al., 2002; Xu et al., 2005).  Lower mRNA levels 
are found in the heart, muscles, kidneys, lungs and the brain. At the hepatic level CAR is 
highly expressed around the centrilobular vein. 
 
1.6.1.1.  Structure  
In the human liver, 2 isoforms have been identified: CAR1 and CAR3 (Auerbach et 
al., 2005) that possess respectively 4 or 5 more amines in their LBD. This insertion could 
modify the structure of the ligand binding pocket and, thus, accommodates different 
ligands for CAR. CAR possesses a typical structure of nuclear receptors, although the 
studies show a particularity to this receptor: its ligand pocket is smaller than others, 500 Ä, 
compared to 1200 Ä for PXR and 990 Ä for VDR, which limits the number of potential ligands 
(Suino et al., 2004). 
 
1.6.1.2. Ligands 
In 1998, Forman’s research paved way to the identification of two endogenous ligands, 
androstanol and androstenol acting like inverse agonists. The LBD possesses a 
conformation even in the absence of a ligand, however in the presence of an inverse 
agonist, this conformation is lost. This receptor is the first example of a transcription factor 
regulated negatively by an endogenous ligand (Forman et al., 1998). Listed in Table 2 are 
ligands of CAR. CITCO is the prototypical pharmaceutical ligand of CAR for CYP2B6 
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Figure 7. Direct activation (TCPOBOP) and indirect activation (Phenobarbital) of the 
constitutive androstane receptor (CAR). The fixation of TCPOBOP in the ligand binding 
pocket of CAR allows the recruitment of phosphatase protein 2A (PP2A) and the 
dephosphorylation of CAR ant the liberation of its cytosolic retention complex (PPP1R16A, 
CCRP, HSP90). CAR translocates in the nucleus, forms a heterodimer with RXR and recruits 
different co-activators (SRC-1, GRIP-1,PGC-1a). Phenobarbital prevents the fixation of EGF 
(Epidermal Growth Factor) on its receptor EGFR, SRC kinase cannot anymore phosphorylate 
protein kinase RACK1, RACK1 activates PP2A, which results in the dephosphorylation of 
CAR. 
 
CCRP: cytoplasmic CAR retention protein, EGF: Epidermal Growth Factor, EGFR: Epidermal 
Growth Factor Receptor, GRIP-1, Glutamate Receptor Interacting Protein 1, HSP90: heat 
shock protein 90, PBREM: phenobarbital (PB)-responsive enhancer module, PGC-1: PPARg 
coactivator-1, PP2A: protein phosphatase2 (isoforma), PPP1R16A: protein phosphatase 1 
regulatory subunit 16A , RACK1: Receptor for Activated C Kinase 1, RXR: retinoid X receptor, 
SRC: steroid receptor coactivator: ,SRC-1: steroid receptor coactivator-1, TCPOBOP: 1,4-
Bis[2-(3,5-dichloropyridyloxy)]benzene. 
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expression in humans, while TCPOBOP is the prototypical pharmaceutical ligand for 
Cyp2b10 expression in murine models.  
 
1.6.2. Mechanisms of activation 
CAR possesses certain particularities which differentiates it from the other NRs. One 
of this particularity is the localization in the cytoplasm in an active conformation forming a 
complex of different chaperone proteins: cytoplasmic CAR retaining protein (CCRP), 
HSP90, and the membrane subunit of protein phosphatase 1b (Kobayashi et al., 2003; 
Sueyoshi et al., 2008; Yoshinari et al., 2003). In addition, it has the capacity to be active in 
an indirect or direct manner (Figure 7). Once active, it migrates to the nucleus. After its 
heterodimerization with its partner, RXR, CAR can link to its response elements of type DR4 
or DR5 (Direct repetitive separate sequence 4 to 5 nucleotides) named PBREM 
(phenobarbital response element module). These PBREMs are situated on the promoters of 
the target genes of CAR, like CYP2B6, the human prototypical target gene or Cyp2b10, the 
murine prototypical target gene in murine form (Mäkinen et al., 2002). 
 
1.6.2.1.  Direct Activation 
The fixation of a synthetic agonist ligand such as TCPOBOP (murine form) or CITCO 
(human form) in the ligand binding pocket induces CAR nuclear translocation (Tzameli et 
al., 2000). This transformation solicits the recruitment of the protein phosphatase A2 (PP2A) 
in charge of the dephosphorylation at the threonine level 38 (human form) or 48 (murine 
form) of CAR  (Mutoh et al., 2009) and of its liberation of the cytosolic complex (Tatsuya 
Sueyoshi et al., 2008; Yoshinari et al., 2003). Freed from its complex, CAR migrates to the 
nucleus after heterodimerization with RXR and recruits different co-activators allowing its 
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interaction with the transcriptional machinery. GRIP-1) PGC-1a and SRC-1 are the co-
activators allowing initiation of the transcription of the target genes of CAR (Min et al.,  2002; 
Wright et al.,  2007).  The co-repressors prevent the fixation of these co-activators. Thus, the 
small heterodimer partner interacting leucine zipper protein (SMILE) can enter in 
competition with other co-activators for the recruitment of histones, deacetylases  (Xie, et 
al., 2009). CAR can also interact with other co-repressors such as NCoR, SMRT, small 
heterodimer protein (SHP) and dosage-sensitive sex reversal, adrenal hypoplasia critical 
region, on chromosome X, gene 1 (DAX1) modulating its transcriptional activity (Bae et al., 
2004; Laurenzana et al., 2012.; Lempiäinen et al., 2005). 
 
1.6.2.2. Indirect Activation 
CAR can also be activated by endogenous or exogenous molecules via the stimulation of 
the translocation without direct binding to the ligand binding pocket. Such is the case of 
phenobarbital which induces the transcriptional activity of CAR through the induction of its 
nuclear translocation. The cytoplasmic retention of CAR is due to the phosphorylation 
initiated by the kinase C protein (Mutoh et al., 2009). The phenobarbital enters in 
competition with the epidermal growth factor (EGF) compared to the fixation by its receptor 
EGFR. Thus, it prevents the activity of kinase Src, inducing the dephosphorylation of the 
receptor of protein C kinase 1 (RACK1). RACK1 activates PP2A which results into the 
dephosphorylation of CAR by PP2A and its nuclear translocation (Mutoh et al., 2009). A new 
signaling path controlling the activity of CAR has been identified by the team of Negishi. It 
interacts to the signalization cascade of mitogen activated protein kinase kinase/extra-
cellular signal regulated kinase (MEK/ERK). Immunoprecipitation experiments showed an 
interaction between CAR and ERK1/2 in Hugh-7 cells. This interaction prevents the   
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Type Mice Human 
Phase I Cyp1a1,  Cyp1a2,Cyp2a4, Cyp2b10, 
Cyp2c29, Cyp2c37, Cyp2c55, 
Cyp3a11, Nqo1, Aldh1a1, Aldh1a7, 
Akr1b7, Ces6 
CYP1A1,CYP1A2, CYP2B6, 
CYP2C8, CYP2C9, 
CYP2C19, CYP3A4, 
CYP3A5 
Phase II Ugt1a1, Ugt1a9, Ugt2b34, Ugt2b35, 
Ugt2b36, Sult1e1, Sult2a1, Sult2a2, 
Sult3a1, Sult5a1, Gsta1, Gsta4, Gstm1, 
Gstm1, Gstm2, Gstm3, Gstm4, Gstp, 
Gst1 
UGT1A1, SULT2A1 
Transporters Mrp2, Mrp3, Mrp4, Oatp1a4 MDR1 
 
Table 3. Target genes of CAR in the different phases of detoxification. 
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dephosphorylation of CAR and thus explains the nuclear translocation. The activation of p38 
mitogen-activated protein kinase by anisomycin increases the expression of CAR target 
genes, CYP2B6 certifying its activities in HepG2 cells (Saito et al., 2013) Thus, the growth 
hormones and cytokines have an equal impact on the expression of CAR target genes. 
In cases of energetic depletion, the protein kinase activated by adenosine 
monophosphate (AMP), AMPK is activated, thus the AMP/ATP ratio increases. This enzyme 
then proceeds to initiate catabolic pathways after the generation of ATP (Hardie & Ashford, 
2014). In vivo, the activator of AMPK induces the nuclear translocation of CAR but fails to 
induce the expression of its target genes (Shindo et al., 2007). Other studies also show that 
metformin, an activator drug of AMPK can remove the induction of CAR target genes by 
modulating the phosphorylation of CAR. Yang et al. (2014) have shown that metformin 
phosphorylates CAR through AMPK and ERK1/2 and prevents its translocation. Although 
the precise role of AMPK in the activation of CAR remains controversial, research shows the 
importance of the physiological status for the control of CAR activation.  
1.6.3. Target genes 
Table 3 presents target genes of CAR involved in the different phases of 
detoxification. CYP2B6 is the prototypical target gene in humans, while Cyp2b10 in mice. 
1.6.4. Sexual dimorphism 
The link of CAR to sex hormones is strong and numerous elements in the literature report 
an important sexual dimorphism that relates to CAR activity. A number of studies have 
already shown that CAR is more expressed and more active in females than in males. Thus, 
female mice treated with TCPOBOP present a higher induction of CAR target genes 
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compared to males (Ledda-Columbano et al., 2003; Lu et al., 2013). The same observation 
has been made in humans after treatment with phenobarbital (Weghorst & Klaunig, 1989). 
Basal CAR expression is also higher in females compared to males (Petrick & Klaassen, 
2007). Basal CAR activity is also higher in females: the constitutive expression of Cyp2b 
mRNA in the liver of mice in the prepubertal stage was demonstrated to be sex-
independent and the expression of Cyp2b9 was diminished markedly only in males during 
the maturation stage, resulting in a sexually dimorphic expression in adult mice 
(Jarukamjorn, Sakuma, & Nemoto, 2002). Functional studies confirmed these results using 
Zoxazolamine, a myorelaxant, a known substrate for CAR-target CYPs. Upon treatment, an 
increase in the time of paralysis signifies an inhibition of CYPs, while a decrease signifies an 
increase of CYP activity. Female mice deficient in CAR (Car-/-) are more resistant than males 
presenting a shorter paralysis time. In addition, none of the female Car-/- mice died 
after treatment while in male Car-/- mice, 5 out of 6 did not recover from the 
paralysis  (Hernandez et al., 2009). These phenotypes could be explained by the 
inhibition of CAR activity in males by metabolites from testosterone like androstanol, 
which is identified as inverse agonists of CAR. It could also be explained by the effect 
of CAR activation by estrogens reported in certain studies (Kawamoto et al., 2000). 
This difference could be explained by a more significant CAR activity by the nuclear 
receptor HNF4a in females (Kamiyama et al., 2007). This nuclear receptor is involved in 
the dimorphic regulation of the basal expression of CYPs (Holloway et al., 2008). 
Numerous data on human and mice suggest that HNF4a regulates the expression of 
CAR (Wiwi et al., 2004; Wortham et al., 2007).  
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Reciprocally, CAR seems to play an important role in the status of androgens in the 
liver (Hernandez et al., 2009). Testosterone is metabolized through several steps of 
hydroxylation. The activity of hydroxylase 6a is more significant in females than hydroxylase 
15a in males. The ratio of 6a/15a hydroxylase reveals the state of androgen levels and is 
considered a biomarker of androgen perturbations (Wilson et al., 1999). A study further 
showed that the metabolism of testosterone and in particular the ratio of 6a/15a 
hydroxylase is decreased in CAR deficient females. This ratio, decreased in Car-/- females, 
demonstrates the masculinization of these mice (Hernandez et al., 2009). 
1.6.5.  Physiological functions 
The generation of CAR-deficient mice by the team of D.D. Moore (Wei et al., 2000) 
demonstrated the major role of CAR in the detoxification of xenobiotics. CAR deletion 
altered the sensitivity of mice to toxins, rendering Car-/- mice incapable of inducing key 
enzymes for detoxification. CAR also plays a major role in the metabolism of different 
endogenous substances wherein its accumulation to the cells may lead to toxicity. 
1.6.5.1.  Xenobiotic detoxification 
CAR coordinates the expression of numerous hepatic genes involved in xenobiotic 
catabolism. It induces the biotransformation of phase I and II genes, as well as transporters 
(Table 3). The hepatoprotective action of CAR against xenobiotics does not only consists of 
the induction of the expression of detoxifying genes, but also the conduction of the 
repression of expression of certain genes. Thus, CAR prevents, for example the induction of 
CYP4A, a major enzyme for lipid peroxidation by inducing of the superoxide dismutase-3 
(SOD)  thereby limiting oxidative stress (Swales & Negishi, 2004). 
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1.6.5.2.  Detoxification of endogenous compounds 
Through the regulation of these xenobiotic metabolic enzymes, CAR is equally 
involved in the metabolism of a certain number of endogenous substances such as steroids, 
thyroid hormones, bile acids and bilirubin.  
Steroid hormones were the first identified ligands of CAR causing the dissociation 
of CAR from the co-activator SRC1 (Forman et al., 1998). Similarly, the progesterone and 
testosterone also inhibits the activity of CAR (Swales & Negishi, 2004). Levels of steroid 
hormone are regulated due to a dynamic balance between their synthesis and their 
activation. The storage capacity of steroid hormones is limited; therefore, a coordination of 
their synthesis and their biotransformation is essential for the regulation of normal 
physiological functions. A number of CYPs (CYP11, CYP17, CYP19, CYP21) are specifically 
responsible for hormone synthesis, their catabolism, as well as their inactivation (Ruckpaul 
et al.,1985). The liver is the major site of the catabolism of steroid hormones and CAR plays 
a fundamental role in this catabolism through the regulation of the expression of CYPs and 
sulfotransferases. The activation of CAR and its target genes by TCPOBOP induces the 
catabolism of estrogens and favors their excretion (Yamamoto et al., 2006). 
Thyroid hormones. The level of thyroid hormone is also controlled by the balance 
between synthesis, metabolism, and secretion. CAR is equally implicated in the catabolism 
of thyroid hormones. This catabolism implies the conjugation of sulfate or glucuronide 
groups (Visser et al., 1998). These reactions are catabolized by two enzymes of phase II, 
UGT1A1 and SULT1A1 which are both CAR-regulated (Hernandez et al., 2009). 
Bilirubin and heme. Bilirubin is a product of degradation from heme, one of the most 
toxic compounds of an organism. Its accumulation is associated with jaundice and in cases 
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of prolonged accumulation this leads to neurotoxicity. The glucuronidation by the enzyme 
UGT1A1 is the major pathway of detoxification of this compound, which then is secreted in 
bile by the active transporter MRP2. CAR is involved in the clearance of bilirubin by the 
induction of enzymes UGT1A1, GSTa1 (Sugatani et al., 2001) and transporters OATP and 
MRP2 (Guo et al., 2002). On mouse primary hepatocytes, bilirubin like phenobarbital is 
capable of inducing nuclear translocation of CAR. 
1.6.5.3. Regulation of hepatic energy metabolism 
The role of CAR in the regulation of energy metabolism has been recently attributed 
to this receptor on the basis of clinical studies which have been then confirmed by animal 
studies. 
Glucose Metabolism. The role of CAR on carbohydrate homeostasis had been first 
suggested after different clinical studies in diabetic patients treated with phenobarbital 
presented an improvement in their sensitivity to insulin as well as the decrease of their 
glycemia (Lahtela et al., 1985; Sotaniemi et al., 1983). Diabetic mice also presented an 
improvement in their glucose tolerance after treatment with TCPOBOP (Dong et al., 2009). 
The improvement of glucose tolerance is principally allowed by the suppression of the 
production of hepatic glucose by neoglucogenesis. The activation of CAR leads to the 
repression of limiting enzymes of neoglucogenesis: PEPCK and G6Pase. Various models 
propose the repression of these genes by CAR. In the first model, CAR competes with the 
FoxO1 and HNF4a for the fixation of their response elements IRE (iron-responsive element) 
and HNF4RE (HNF4-responsive element), respectively, on the promoter of PEPCK and 
G6Pase (Kodama et al., 2004). In the second model, CAR binds to 
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SRC2/GRIP1 and PGC1a which are the two co-activators of HNF4a, thus, decreasing the 
gene expression of neoglucogenesis (Miao et al., 2006). The third model proposes the 
nuclear translocation of CAR leading to the physical interaction of CAR with PGC1a. This 
interaction will allow the recruitment of ligase E3 culline allowing in turn to address nuclear 
bodies PML (promyelocytic leukemia) macromolecular nuclei sequestering and liberating 
the transcription factors and co-activators in the nucleus. In this structure, PGC1a is 
ubiquitinated after being degraded by the proteasome. With the decreased availability of 
PGC1a, the gene expression of neoglucogenesis is repressed (Gao et al., 2015) (Figure 8). 
Finally, the last model proposes that CAR through its regulation of SULT2b1 on the 
deacetylation of HNF4a prevents its nuclear translocation and its action on the genes for  
neoglucogenesis  (Shi et al., 2014). The CAR-dependent repression of neoglucogenesis is 
confirmed in primary cultures of human hepatocytes (Lynch et al., 2014). 
The fact that xenobiotic receptors induce the repression of neoglucogenesis can 
explain the involvement of this pathway in the synthesis of the co factor NADPH (Nicotamide 
adenine dinucleotide phosphate), which is essential for the activities of cytochromes P450. 
In consequence, the hepatic pathway of phosphate pentoses allows the conversion of 
glucose-6-phosphate in ribose-5-phosphate after NADPH generation. The increase in the 
production of glucose-6-phosphate by the repression of G6Pase is a way to generate 
NADPH. Therefore, the repression of neoglucogenesis by CAR allows the sufficient storage 
of NADPH for detoxification. 
Lipid metabolism. CAR acts on the b-oxidation pathway of fatty acids in interfering 
with the major regulator of this pathway, which is PPARa. CAR competes with PPARa in the 
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Figure 8. Repression of neoglucogenesis genes expressed by CAR. The different 
proposed models: (i) CAR enters in competition for the same elements as HNF4a (HNF RE) 
and FoxO1 (1RE) situated on the promoter of the genes of neoglucogenesis, (ii) CAR enters 
in competition with HNF4a for the recruitment of the same co-activators (SRC1 and GRIP1), 
thus decreasing its transactivating activity on neoglucogenic genes, (iii) CAR binds to 
PGC1a to be ubiquitylated and degraded by the proteasome (Gao et al., 2015; Yan et al., 
2015). 
 
FoxO1: Foxhead box protein O1, GRIP1: Glutamat Receptor Interacting Protein 1, HNF4a: 
Hepatocyte nuclear factor 4 alphaf,  IRE: insulin responsive elements,  PGC1a: PPARg 
coactivator-1-alpha, PML: promyelocytic leukemia, SRC1: steroid receptor coactivator-1 
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binding of response elements on the promoter of the 3-hyoxyacyl-CoA dehydrogenase 
(HADH) gene, a key enzyme of the peroxisomal b-oxidation (Kassam et al., 2000). In 
addition, the activation of CAR by phenobarbital in wild-type mice leads to the repression 
of PPARa and its target genes such as Cyp4a14, Cpt1a and cytosolic acyl-CoA thioesterase 
(CTE). This effect is not observed in CAR-deficient (Car-/-) mice (Maglich et al., 2004; Ueda 
et al., 2002) (Figure 9B). 
Numerous studies have also shown the involvement of CAR in de novo lipogenesis, 
however the results obtained are contradictory. In obese mice (type ob/ob) subjected to a 
high fat diet, the activation of CAR by prolonged exposition to TCPOBOP allows the 
decrease of hepatic steatosis by the inhibition of de novo lipogenesis via the repression of 
the following genes: Scd1, Fas, Acc (Acetyl-CoA carboxylase) and SREBP-1c (Dong et al., 
2009b; Gao et al., 2009). An alternative hypothesis is that CAR interacts on de novo 
lipogenesis genes by the intermediary nuclear receptor LXR which is one of the regulator 
genes of hepatic lipogenesis. It accomplishes this by contributing to the inactivation of 
oxysterols, the endogenous ligands of LXR, through the regulation of the expression of 
sulfotransferase Sult2B1b. The inactivation of oxysterols allows the decreased activation of 
LXR and reduction of the LXR-SREBP pathway (Chen et al., 2007). In agreement with this, 
Sult2B1b-deficient mice treated with TCPOBOP do not present anymore this repression of 
de novo lipogenesis genes (Figure 9A). 
However, the effect of CAR on the regulation of de novo lipogenesis gene 
expression stays controversial as one study shows the inverse activation of CAR in human 
primary hepatocyte cultures inducing the expression of de novo lipogenesis genes, such as 
Fatty acid synthase (Fasn) and Scd1 (Breuker et al., 2010). 
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Figure 9. Involvement of CAR in the regulation of lipid metabolism: (A) de novo 
lipogenesis. Sult2B1b is a CAR target gene that allows the inactivation of oxysterols, 
endogenous ligands of LXR. The transactivating activity of LXR on these target genes are 
thus decreased. Car induces the expression of Insig-1 which links to SCAP and prevents its 
proteolytic action and the maturation of Srebp1c. (B) b-oxidation. CAR enters in 
competition with PPARa in binding to response elements, by the promoter 3-hydroxyacyl-
CoA dehydrogenase, the key gene for b-oxidation, the activation of CAR leads to 
the repression of gene expression of CPT1a, CTE (Yan et al., 2015; Gao et al., 2015). 
CPT1a: Carnitine Palmitol transferase 1a, CTE: constitutive transport element, Fas: Fatty acid synthase, 
GRIP-1: Glutamate Receptor Interacting Protein 1, Insig-1: Insulin induced gene 1, LXR: Liver X 
receptor, LXREs: LXR response elements, PGC-1a: PPARg coactivator-1, SREBP1c: Sterol regulatory 
element-binding transcription factor 1, Sult2B1b: Hydroxysteroid sulfotransferase 2B1b. 
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1.6.5.4. Cholesterol Metabolism and Bile Acids 
The same research team also showed that Spot14, a CAR target gene is an important 
modulator for hepatic lipogenesis. However, these results were not demonstrated in 
another team using CITCO (Lynch et al., 2014). On the contrary, this effect is found in vivo 
in mice fed with a standard diet and treated with TCPOBOP inducing the increase of de 
novo lipogenesis, as well as ketogenesis with a repression of the mitochondrial b-oxidation 
(Rezen et al., 2009). These contradictory results could be explained by a different role of the 
nuclear receptor CAR in function of the physiopathology found within organisms. The 
lipoprotein profile is modified after CAR activation in mice, as shown in an experimental 
study where the activation of CAR via TCPOBOP leads to decreased plasma concentrations 
of total cholesterol, high-density lipid (HDL) and low-density lipid (LDL)-cholesterol. It 
seemed that these effects were partly due to the repression of the gene transcription of 
lipoprotein A-I at the hepatic level by CAR (Masson et al., 2008). The same team also showed 
that when mice are fed with a high-fat diet, CAR activation reduces hepatic cholesterol load 
by stimulating the expression of synthesis enzymes of bile acids and thus their fecal 
excretion in the bile form (Sberna et al., 2011). In a similar manner, Car-/- mice showed an 
increase of HDL-cholesterol in the condition of cholestasis.  
Hepatic transcriptomic analysis show that the activation of CAR induces expression 
of genes in cholesterogenesis such that 3-Hydroxy-3-Methylglutaryl-CoA Reductase 
(HMGCR), squalene epoxidase (SQLE), and lanosterol synthase (LSS). However, this effect is 
not associated to the ratio increase of lathosterol/cholesterol indicating that the change in 
gene expression is not associated with the increase of the biosynthesis of cholesterol (Rezen 
et al., 2009). 
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The activation of CAR also prevents the formation of gallstones by decreasing the 
gene expression of Abcg5 and Abcg8 and increasing the expression of Cyp7a1, favoring 
the conversion of cholesterol in bile acids. In the intestine, CAR favors bile reabsorption in 
inducing the expression of transporters Asbt (apical sodium-dependent bile acid 
transporter) and Ostb (organic solute transporter  b). This allows the decrease of cholesterol 
load of bile acids and to limit the formation of gallstones (Cheng et al., 2017). 
The hepatoprotective role of CAR against bile acids have been largely described in 
the induction of their metabolization by the stimulation of SULT(2A1 and 2A9) and their 
excretion by the increase of bile acid transporters (MRP2/ABCC2; MRP3/ABCC3) in 
hepatocytes (Cherrington et al., 2002; Kast et al., 2002; Staudinger et al., 2003). In 
agreement with these observations, CAR agonist drugs are used for the treatment of 
cholestasis (Stedman et al., 2005). 
` 
1.6.5.5. Bone Mass Regulation 
Given the extensive crosstalk with many nuclear receptors including VDR (Moreau et 
al., 2007), ER (Min et al., 2002), GR (Pascussi et al., 2000) and PPARs, (Guo et al., 2007) it was 
hypothesized that CAR may play a role in regulation of bone metabolism. Cho et al., 2014 
demonstrated that in vivo deletion of CAR resulted in higher bone mass in male mice, 
resulting from the reduced metabolism of testosterone, the major gonadal androgen in 
males. Furthermore, this was directly corelated to the suppression of Cyp2b9 and Cyp2b10 
in CAR-/- mice, key enzymes for testosterone metabolism. There was no difference in bone 
mass in female CAR-/- mice compared to WT females. However, the exact mechanism for 
these sex-specific bone phenotypes is still unknown and remains to be further studied.  
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1.6.5.5. Inflammation 
Given the similarities between PXR and CAR and the emerging evidence of the 
strong intestinal role of PXR, it can be hypothesized that CAR also plays a role in IECs, as 
well as a sensor for microbial metabolites (Cheng et al., 2010; Garg et al., 2016; Shah et al., 
2007; Venkatesh et al., 2014). Though, CAR’s role on the intestinal mucosa has yet to be 
explored, its expression on the intestinal epithelium has already been confirmed (Burk et 
al., 2005; Martin et al., 2008; Rezen et al., 2009).  Having similar function as PXR, sharing a 
number of ligands and target genes in xenobiotic metabolism, Hudson et al. (2017) tested 
the hypothesis that CAR would also function as a protective entity in the intestinal mucosa. 
Quite recently, their study has identified a novel role for CAR in regulation of intestinal 
mucosal healing demonstrating that CAR transcript expression was significantly reduced in 
mild to moderately inflamed colonic mucosa from patients with either ulcerative colitis (UC) 
or Crohn’s disease (CrD) and was reproduced in vivo in colitic mice. Furthermore, their in 
vitro and in vivo approaches provided functional evidence that CAR can regulate intestinal 
epithelial wound healing and mucosal repair following inflammation-associated tissue 
damage. This is accomplished by CAR’s activation enhancing IEC migration through p38 
MAPK activation. On the other hand, CAR expression was also demonstrated in tumor-
associated macrophages in the airways implicating that its activation may regulate 
inflammation (Fukumasu et al., 2015).
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2.1. Introduction 
The microbiome consists of the ecological community of commensal, symbiotic, and 
pathogenic microorganisms that share our body (Lederberg & McCray, 2001).  The human 
body is estimated to be composed of 3 × 1013 eukaryotic cells and is colonized by 3.9 × 1013 
microorganisms, with a ratio of prokaryotic to eukaryotic cells of at least 1:1 up to 10:1 
(Sender et al., 2016). In addition, the gene content of the microbiome is estimated to have 
2–20 million microbial genes, exceeding the ∼20,000 human genes by at least a factor of 
100 (Knight et al., 2017; Rastelli, Knauf & Cani, 2018). The host’s microbiota is well tolerated 
by our immune system due to the coevolution of these microorganisms over time (Thomas 
et al., 2017). The human microbiota comprises all the microorganisms that reside on the 
skin and in all other tissues and organs including the gastrointestinal tracts. The largest 
concentrations of microbes occupy the gut, skin, and oral cavity. Among the host’s various 
sites of microbial communities, the gut microbiota is the most stable, dense, diversified, and 
individually specific (Turroni et al., 2018), with the vast majority of commensal bacteria 
residing in the colon (Sender et al., 2016).   
2.2. General characteristics of human gut microbiota 
The human symbiont gut microbiota is a diverse and complex community composed 
of more than 100 trillion cells and 5 million non-redundant genes (Li et al., 2014), thus, 
making the human gut microbiota probably the most densely populated bacterial 
ecosystem described (Turroni et al., 2018). The microbiome includes bacteria, fungi, and 
archaea. As established by the Human Project Consortium in 2012, the community in stool 
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was one of the most diverse microbial communities in terms of number of different 
organisms present, exhibiting tremendous variability. To date, thousands of different 
bacterial species have been detected. The physicochemical conditions in the gut influence 
the composition of the intestinal microbiota and the microbial density increases along the 
gastro-intestinal (GI) tract with101–104 microbial cells in the stomach and duodenum, 104 
to 108 cells in the jejunum and ileum, to 1010 to 1012 cells per gram in the colon and feces. 
The great majority belongs to only 6 of the hundreds of bacterial phyla populating our 
planet: Firmicutes and Bacteroidetes, which together represent approximately 90% of the 
community, and Actinobacteria, Proteobacteria, Fusobacteria and Verrucomicrobia, as 
subdominant phyla (Turroni et al., 2018). The methanogens, Methanobrevibacter and 
Methanosphaera are the most dominant archaeal groups. The two common fungal phyla in 
the gut include Ascomycota (which includes the genera Candida and Saccharomyces) and 
Basidiomycota (Thomas et al., 2017). 
 
2.3. Factors affecting the gut microbiome  
2.3.1. Age 
Humans initially develop their microbiota at birth, with bacterial exposure through 
the vaginal birth canal or via maternal skin contact by transferring at least some portion of 
the maternal microbiome to the baby (Costello et al., 2009). Infants delivered vaginally tend 
to harbor microbiota that are typically encountered in the female reproductive tract, such 
as Lactobacillus. In contrast, cesarean delivery is typically associated with Staphylococcus 
spp. and other bacteria that are associated with the mother's skin and hospital environment. 
In general, the infant microbiome is often dominated by the genera Bifidobacterium, 
Bacteroidetes, and members of clostridial taxa (Thomas et al., 2017). Infancy is a period of  
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Rapid colonization by microbial consortia that shifts in response to events such as illness or 
changes in diet (i.e. introduction to solid food, Figure 10A and B). Opportunistic microbes 
then modify this initial microbiota during infancy in an ecological succession to ultimately 
form a predominantly anaerobic microbial community (clostridia, bifidobacteria, 
bacteroides) in the gut luminal habitat within the first few days after birth. After which, this 
microbiota is subsequently modulated by environmental, genetic, and epigenetic factors 
that ultimately form the unique microbial landscape within an individual (Costello et al., 
2009). These microbial populations converge toward an adult community by three years of 
age (Thomas et al., 2017). Gut communities start with low phylogenetic and species 
richness, which increases with the rate of encounters with new bacteria, the increasing size 
of the gut or the proliferation of ecological niches that consequently promote diversity.  
The composition of the microbiome changes as humans age. Aging is accompanied 
by the onset of various clinical changes, including a basal proinflammatory state (“inflamm-
aging”) that directly interfaces with the microbiota of older adults and enhances their 
susceptibility to age-related diseases. Studies in older adults demonstrate that the gut 
microbiota correlates with diet, basal level of inflammation and location of residence (e.g., 
community dwelling, long-term care settings). The most drastic change associated with the 
aging gut is the change in the relative proportion of organisms, such as the domination of 
Firmicutes in the young vs. Bacteroidetes in the elderly. 
2.3.2. Diet 
Diet is also a critical factor in shaping the composition of the gut microbiota. Vegans, 
vegetarians, and omnivores have distinct microbiomes. Total counts of Bacteroides spp., 
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Figure 10. Assembly and stability of the gut microbiota and environmental factors 
affecting the gut microbiota during life. A) The succession of bacterial consortia (in terms 
of the four dominant phyla) over time (days after birth) in a developing infant gut 
microbiome from birth to around 2.5 years of age, according to 16S ribosomal RNA 
sequencing). B) Various factors that influence the microbiome throughout the lifetime of a 
typical Westernized human (Spor, Koren, & Ley, 2011). 
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Bifidobacterium spp., Escherichia coli, and Enterobacteriaceae spp. were significantly lower 
in vegan samples than in controls. In contrast, total counts of Klebsiella spp., Enterobacter 
spp., Enterobacteriaceae, Enterococcus spp., Lactobacillus spp., Citrobacter spp., 
and Clostridium spp. were similar in people with different diets. Subjects on a vegetarian 
diet ranked between vegans and omnivores. However, the total microbial count did not 
differ between the dietary groups (Zimmer et al., 2012). Moreover, the microbiome of a 
person can be rapidly modified simply by changing dietary patterns. David et al., (2014) 
have demonstrated that short-term consumption (5 days) of diets of purely animal or plant 
products can alter the microbial community composition. An animal-based diet increased 
the abundance of bile-tolerant microorganisms, including Alistipes, Bilophila, 
and Bacteroides and decreased the levels of Firmicutes that metabolize dietary plant 
polysaccharides (Roseburia spp, Eubacterium rectale, and Ruminococcus bromii) (Thomas 
et al., 2017).  Spor, Koren, & Ley (2011) further highlight that Erysipelotrichaceae, from 
bacterial phylum Firmicutes, is dependent on changes in the amount of dietary fat; 
Butyrate-producing Roseburia spp. depends on the amount of certain carbohydrates; 
and Bacteroides spp. differ in their ability to use specific substrates such as inulin. He 
further reiterates that these differences can predict the outcomes of competitive 
interactions between the species and actually drive the niche space according to their 
substrate preference, thus, altering the relative abundances of the taxa that are present.  
Microbiota can also metabolize estrogen-like compounds from the diet to 
biologically active forms, and these estrogen-like compounds may promote the 
proliferation and growth of certain types of bacteria (Frankenfeld et al., 2014).  Soy 
isoflavones, such as genistein and glycitin, can alter the structure and the composition of 
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the fecal bacterial community in post-menopausal women by increasing the concentration 
of the beneficial gram-positive Bifidobacterium, while suppressing Clostridiaceae 
(Frankenfeld et al., 2014; Nakatsu et al., 2014); equol, produced by bacteria upon activation 
of soy phytoestrogens may LDL lipoprotein levels, (Usui et al., 2013) ; and supplementation 
of chalconoid isoliquiritigenin, a low-affinity ER ligand found in licorice root, alter gut 
microbiotaactivity although the exact mechanism remains unclear (Madak-Erdogan et al., 
2016). 
 
2.3.3. Host genetics 
Host genetics is also hypothesized to influence gut microbiota composition. 
Various studies have been done to measure this heritability. In human studies between 
identical and fraternal twins, using metagenomics and 16S ribosomal RNA gene sequence 
data from clone libraries and from deep pyrosequencing, significant differences were not 
detected in fecal microbiomes and did not detect any heritable components (Turnbaugh et 
al., 2009). Thus, if host genotype does exert an effect on the composition of the microbiota, 
they are likely to be small and detecting them in a healthy population will require a large 
number of subjects (Spor et al., 2011). 
In addition, using an approach called ‘quantitative trait loci’ (QTL), a large scale 
mouse study of 645 mice has revealed that host genetic control was found to affect the 
tips of the bacterial tree (genus and species levels rather than higher-order taxa), 
particularly for the Bacteroidetes and Firmicutes (Benson et al., 2010). A QTL associated 
with specific bacterial abundances was found to contain genes with important roles in 
mucosal immunity (Presley et al., 2010). 
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2.3.4. Sexual dimorphism 
It is also hypothesized that the gut microbiota could be sexually dimorphic. Several 
human cohorts have indeed demonstrated gender differences in the composition of the gut 
microbiota (Haro et al., 2016; Santos-Marcos et al., 2019).  Recent research suggests that 
women harbor a higher ratio of Firmicutes/Bacteriodetes (F/B) in comparison to men 
(Dominianni et al., 2015; Li et al., 2008; Mueller et al., 2006) and a higher relative abundance 
of Lachnospira and Roseburia was found in pre-menopausal vs. post-menopausal women 
who had similar levels to men (Santos-Marcos et al., 2018), suggesting that  in humans, 
estrogenic status influences gut microbiota composition. Estrogens have been shown to 
directly influence the composition of the gut microbiota with both 17β-estrogen 
supplementation and ovariectomy significantly affecting the microbiota taxa (Kaliannan et 
al., 2018). 
The F/B ratio is heavily influenced by the body mass index (BMI) (Kasai et al., 2015) 
and overall adiposity represents an additional mechanism by which sex might influence 
the gut microbiota (Haro et al., 2016). Min et al. (2019) present a high-resolution 
association between microbiome, android and gynoid fat ratio using the precise 
measurement of fat distribution. The sex-induced difference in regional adiposity could 
potentially lead to the difference in the species of functioning microbiome that are in turn 
modulating fat distribution.  With a BMI greater than 33, a significantly lower F/B ratio 
has been seen in men compared to women, while the opposite holds true in those with a 
BMI less than 33 as well as in postmenopausal women (Haro et al., 2016). Adjusting for 
BMI, higher proportions of Firmicutes have been found in women compared to men. 
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Figure 11. A comparison of the bacterial diversity from 16S rRNA analysis of mouse 
caeca and human colons. The bar represents 15% sequence divergence. Bacterial genera 
in human microbiomes (11,831 colon-associated 16S rRNA sequences) and mice 
microbiomes (5,088 caecum-associated 16S rRNA sequences) where only 15% of the 
mouse microbiome genera have been found to be represented in humans. (modified from 
Ley et al., 2005). 
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Furthermore, higher numbers  of Proteobacteria, Veillonella, and Blautia have been 
reported in women (Haro et al., 2016; Li et al., 2008; Schnorr et al., 2014). 
2.4. Animal & human models in gut microbiota research 
2.4.1. Mice 
The laboratory mouse has been instrumental for establishing roles for the gut 
microbiota in many aspects of mammalian physiology: obesity and malnutrition (Smith et 
al., 2013; Turnbaugh et al., 2006), hepatic function (Dapito et al., 2012; Henao-Mejia et al., 
2012), intestinal response to injury and repair (Rakoff-Nahoum et al., 2004; Swanson et al., 
2011), and innate and adaptive immune function (Hooper, Littman, & Macpherson, 2012; 
Littman & Pamer, 2011). Ninety-nine percent of mouse genes are shared with humans at the 
host genetic level and differ by 14% in genome size (2.5 gigabases and 2.9 gigabases 
respectively) (Waterston et al., 2002). In addition, mouse microbial genes share key 
similarities with the human gut microbiome at the phylum through family levels (Figure 11), 
making them a powerful model system for evaluating host–microbiota interactions 
applicable to human biology (Spor et al., 2011).  In most studies with disease models, germ-
free systems or dietary interventions, inbred strains that originate from either the Mus 
musculus domesticus  or M. musculus musculus  and show considerable genetic and 
phenotypic similarity (Beck et al., 2000; Hugenholtz & de Vos, 2018) are utilized. An 
important confounder has shown to be the housing of mice. In some cases, complete 
phenotypes disappeared after a mouse house was renovated or renewed (Dingemanse et 
al., 2015). The housing effect seems even to be larger than the effect of the genetic 
background (Friswell et al., 2010; Verbeke et al., 2015; Xiao et al., 2015). In addition, what 
the effect the birth mother has on microbiota composition is at the moment under debate 
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Figure 12. Comparison of the intestinal tract features of human and mouse. The main 
similarities and differences are listed in a venn diagram (Hugenholtz and de Vos, 2018).  
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since in some studies, the genotype (mouse strain) of the mouse had a more pronounced 
effect on the microbiota development than the genotype of the birth (Friswell et al., 2010; 
Kovacs et al., 2011). 
 
2.4.1.1. Comparison of mouse and human intestinal physiology 
Mice and humans vastly differ in overall body size, intestinal physiology and diet. The 
main difference is the size of the intestinal tract in relation to the total size of the species 
(Figure 12). relative to body weight, the large intestine is a much larger organ in mice than 
in man. Both humans and mice have a ceca appendix, although it is not a pronounced 
separate section in humans as it is in mice (Scholtens et al., 2012). The human colon is 
segmented, with pouches called haustra, while the mouse colon has a smooth serosal 
appearance. In addition, the outer mucosa layer of the small intestine differs the most 
between human and mouse. The overall appearance of the mouse mucosal surface is 
smooth, while the human mucosal contains circular folds, known as plicae circularis, to 
increase the surface area (Treuting et al., 2011). This specificity in the human small intestine 
provides a niche for mucus-associated bacteria, which is not present in mice and could, 
therefore contribute an important difference, influencing microbial composition. Similarly, 
the architecture of the villi varies through the small intestine with distinct differences in 
mouse and human. Other factors such as the overall intestinal transit time, mucus growth 
rate, final mucus layer, mucus penetrability, structural Muc proteins, intestinal pH values, 
oxygen tension levels, a different glycan profile in the mucus, and the presence of a non-
glandular forestomach in mice affect the differences in intestinal microbiota. Furthermore, 
differences in body size, eating behavior, feeding patterns and biorhythms between mouse 
and human yield different metabolic turnover rates. And lastly, coprophagy, the murine 
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behavior by which feces is re-ingested, is known to affect the intestinal microbiota 
(Hugenholtz & de Vos, 2018).  
 
2.4.1.2. Comparison of mouse and human microbiota 
Similar phyla dominate the distal guts of mice and humans: Firmicutes (usually 60–80% of 
16S ribosomal RNA gene sequences) (Ley et al., 2005), Bacteroidetes (usually 20–40% of 
16S rRNA gene sequences) (Ley et al., 2005) and Actinobacteria. In addition, these same 
bacterial phyla are found to inhabit the gastrointestinal tracts of many other mammals as 
well (Ley et al., 2008). However, when comparing the bacterial genera in human 
microbiomes (11,831 colon-associated 16S rRNA sequences) and mice microbiomes (5,088 
caecum-associated 16S rRNA sequences), only 15% of the mouse microbiome genera have 
been found to be represented in humans (Figure 11) (Ley et al., 2005).  
However, recently when the mouse microbial genes were compared with that found 
in human, only 4% were found to share 95% identity and a coverage of 90%. Remarkably, 
almost 80% of the annotated functions were common between the two datasets, indicating 
significant functional overlap (Hugenholtz & de Vos, 2018). Around 80 microbial gut genera 
were reportedly shared between mouse and man, and this number was recently confirmed 
in a comparison of murine and human 16S rDNA datasets (Nguyen et al., 2015).However, 
there are considerable variations in the genera that were observed in the mouse data sets 
and, for instance, Faecalibacterium, Succinivibrio and Dialister were not found in some 
laboratory mice, due to the use of different mouse strains and providers and differences in 
analysis (Hildebrand et al., 2013; Krych et al., 2013). Another extensive mouse microbiome 
catalog confirmed that the human and mouse intestinal microbiota show considerable 
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similarity at the genus level but reveal large quantitative differences (Figure 13) (Xiao et al., 
2015).  
2.4.1.3. Germ-free models 
Gnotobiotics is the science of well-controlled microbial environments within and for 
biological specimens encompassing the generation and maintenance of both germ-free 
(GF) and defined microbial community animals (Ward & Trexler, 1958). GF life is a biological 
condition characterized by the complete absence of living microorganisms (Geurts et al., 
2011; Ley et al., 2005). Gnotobiotic techniques have been essentially used to interrogate 
host–microbiota dialogue mechanisms in mice (Yi & Li, 2012). Rederivation of any 
combination of genetic mutant mice is possible via embryo transfer into GF pseudo 
pregnant mice or aseptic harvesting of a gestational uterine package and transfer of the 
fetuses to a GF foster female. Colonization of GF mice with one or two bacteria has been 
useful both to understand the features of microbes needed to colonize the intestinal 
ecosystem and to dissect how specific microbes contribute to immune system development 
and disease (Kostic et al., 2013). However, generating and maintaining these mice requires 
specialized facilities, and the cost, labor, and skills required to maintain them can make 
these models inaccessible to many researchers. GF mice must be monitored regularly for 
contamination using a combination of culturing microscopy, serology, gross morphology, 
and sequencing-based detection techniques (Fontaine et al., 2015; Nicklas, Keubler, & 
Bleich, 2015). 
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Figure 13. Major different human and murine intestinal genera. Only genera are 
shown that showed consistent differences in relative abundance between humans 
and mice (Hugenholtz and de Vos, 2018). 
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2.4.1.4. Depletion of microbiota by antibiotics  
Treatment with broad-spectrum antibiotics is an alternate method commonly used 
to deplete the gut microbiota of mice, and can be readily applied to any genotype or 
condition of mouse. Compared to the GF model, antibiotics can deplete bacterial 
populations in mice which were normally colonized since birth. Unlike GF mice where many 
aspects of development and early immune education are broadly impaired, the antibiotic 
model in adult mice specifically allows for study of the role of bacteria in maintaining cell 
functionality and signaling pathways after development (Deshmukh et al., 2014; Gonzalez-
Perez et al., 2016; Lamousé-Smith, Tzeng, & Starnbach, 2011; Li et al., 2017). 
Antibiotics can selectively deplete different populations of the microbiota through 
varying mechanisms of action. For example, metronidazole and clindamycin both target 
anaerobes, while vancomycin is only effective against gram-positive bacteria, and 
polymyxin B specifically targets gram-negative bacteria (Atarashi et al., 2008; Schubert, 
Sinani, & Schloss, 2015). Individual antibiotics can be used to make composition changes in 
the gut microbiota in order to identify classes of bacteria relevant to different phenotypes 
(Schubert, Sinani, & Schloss, 2015; Zackular et al., 2016). In contrast, a cocktail of different 
classes of antibiotics can be used to broadly deplete the gut microbiota. Researchers have 
used various regimens, which differ in antibiotic combination, dose, and length of treatment 
(Table 4). All of these combinations broadly target gram-positive, gram-negative, and 
anaerobic bacteria. Often, antibiotics are diluted in drinking water and mice are allowed to 
drink ad libitum throughout the course of treatment.  
Antibiotic-treated mice are not completely cleared of bacteria, but significant 
reductions in bacterial load are associated with shifts in cell populations, signaling  
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Method Antibiotics Concentration Duration References 
Drinking water 
(ad libitum) Vancomycin + metronidazole 0.5–1.0 g/L each 10 weeks Atarashi et al., 2008 
  Ciprofloxacin + metronidazole 1 g/L each 2 weeks Josefsdottir et al., 2017 
  
Vancomycin + ampicillin + 
polymixin 
0.1–1.0 g/L each 4 weeks Kim et al., 2017 
  
Vancomycin + neomycin + 
metronidazole 
0.5–1.0 g/L each 7 days 
Brandl et al., 2008;         
Kinnebrew et al., 2010 
      2 weeks Josefsdottir et al., 2017 
  
Streptomycin + colistin + 
ampicillin 
1–5 g/L each 6 weeks Sawa et al., 2011 
  
Ampicillin + neomycin + 
streptomycin + vancomycin 
0.5–1.0 g/L each 4–5 weeks Khosravi et al., 2014 
  
Cefoxitin + gentamicin + 
metronidazole + vancomycin 
1 g/L 10 days Ganal et al., 2012 
  
Gentamicin + ciprofloxacin + 
streptomycin + bacitracin 
0.15–2 g/L each 4 weeks Yan et al., 2016 
  
Vancomycin + neomycin + 
kanamycin + metronidazole 
0.5–1.0 g/L each 3 weeks Gury-BenAri et al., 2016 
  
Vancomycin + ampicillin + 
kanamycin + metronidazole 
0.5–1.0 g/L each   Levy et al., 2015 
  
Vancomycin + neomycin + 
ampicillin + metronidazole 
0.35–1.0 g/L each 7 days Ochoa-Repáraz et al., 2009 
      2 weeks 
Hägerbrand et al., 2015; 
Hashiguchi et al., 2015;       
Knoop et al., 2015;                
Brown et al., 2017;                  
Emal et al., 2017;          
Josefsdottir et al., 2017;             
Steed et al., 2017;                    
Burrello et al., 2018;            
Thackray et al., 2018 
      
3 or more 
weeks 
Rakoff-Nahoum et al., 2004; 
Ivanov et al., 2008;           
Vaishnava et al., 2008;       
Ichinohe et al., 2011;              
Ismail et al., 2011;               
Yoshiya et al., 2011;                   
Naik et al., 2012;                     
Corbitt et al., 2013;                    
Diehl et al., 2013;                      
Balmer et al., 2014;                
Mortha et al., 2014;                    
Oh et al., 2014;                
Johansson et al., 2015;             
Wu et al., 2015;                         
Zhang et al., 2015;                      
Park et al., 2016;                         
Yan et al., 2016;                
Cervantes-Barragan et al., 2017; 
Ge et al., 2017; Li et al., 2017; 
Durand et al., 2018 
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3 4-day 
treatments 
with 3 day 
rests 
Adami et al., 2018 
 
Ampicillin + Neomycin + 
Métronidazole + Vancomycin 
7mg/L each except  
Vancomycin 3.5mg/L 
49 days 
Lasserre, 2013 (In-house 
experiments, ToxAlim) 
 
Ampicillin + Neomycin + 
Métronidazole + Vancomycin 
1.0g/L each except  
Vancomycin 0.5g/L 
28 days 
Lasserre, 2013 (In-house 
experiments, ToxAlim) 
Gavage 
Vancomycin + neomycin + 
ampicillin + metronidazole + 
gentamicin 
200 μl of 0.5–1.0 g/L 
each by daily gavage 
3 day Kelly et al., 2015 
      10 days Hill et al., 2010 
  
Bacitracin + neomycin + 
streptomycin 
200 mg/kg body 
weight 
3 days 
Sayin et al., 2013;                
Wichmann et al., 2013; 
Fernández-Santoscoy et 
al., 2015 
  Neomycin + bacitracin 
20 mg each in 200 μl 
by daily gavage 
7 days Grasa et al., 2015 
Combination 
Ampicillin by drinking water; 
vancomycin + neomycin + 
metronidazole by gavage 
1.0g/L in water 10 
ml/kg of 5–10 g/L by 
gavage every 12 h 
10–21 days 
Reikvam et al., 2011;           
Hintze et al., 2014 
  
Vancomycin + neomycin + 
ampicillin + metronidazole 
10 mg each by daily 
gavage 0.5–1.0 g/L 
each in water 
5 days gavage 
followed by 7–
10 days 
drinking water 
Kuss et al., 2011 
  
Kanamycin + gentamicin + 
colistin + metronidazole + 
vancomycin 
200 μl of 0.35–4 
mg/ml by daily 
gavage, and mixed 
2:100 into drinking 
water 
7 days gavage 
followed by 
administration 
in water 
Bashir et al., 2004;                   
Stefka et al., 2014 
  
Metronidazole + colistin + 
streptomycin by gavage, 
vancomycin by drinking water 
0.3–2 mg each by 
daily gavage, and 
0.25 mg/ml in water 
2 weeks Zákostelská et al., 2016 
  
Oral streptomycin + ampicillin in 
drinking water 
20 mg/mouse orally 
and 1 g/L in drinking 
water 
1–2 weeks Kim et al., 2018 
  
Streptomycin by gavage, 
followed by vancomycin + 
neomycin + ampicillin + 
metronidazole by drinking water 
100 mg/mouse for 
single gavage and 
0.5–1.0 g/L in drinking 
water 
single gavage 
followed by >7 
days drinking 
water 
Kernbauer et al., 2014 
         Table 4. Broad spectrum antibiotics treatment regimen (modified from Kennedy, King, & 
Baldridge, 2018) 
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pathways, and organ morphology, offering a model system similar to that of germ-free mice 
(Kennedy, King, & Baldridge, 2018). 
2.4.2. Other animal models 
The tiny Hawaiian bobtail squid (Euprymna scolopes) selectively acquires the bacteria V. 
fischeri from its environment to create one of the best-understood models of bacterial–
animal symbiosis. E. scolopes does not harbor V. fischeri within its gut, and this symbiosis 
does not contain a consortium of microbes. Instead, the squid forms a naturally occurring 
one-on-one relationship with V. fischeri within a ventrally located cavity called the light 
organ. The development of this light organ only occurs with a specific association with V. 
fischeri, as squid raised without V. fischeri remain uncolonized by other bacteria, and the 
light organ fails to mature (McFall-Ngai & Ruby, 1991). This model offers several 
experimental advantages, as it is a naturally occurring one-on-one relationship where each 
participant can be grown independently. The use of microbial genetics with V. fischeri has 
provided surprising and powerful insights into the molecular and even photoluminescent 
dialogue that mediates a productive relationship between microbes and their hosts (Kostic 
et al., 2013). 
The fruit fly (Drosophila melanogaster) has contributed greatly to the understanding 
of basic cellular and developmental biology over the past decades. The Drosophila model 
is a powerful model to explore innate immunity and microbial pathogenesis, more 
particularly, toll-like receptor (TLR) functioning (Dionne & Schneider, 2008; O’Callaghan & 
Vergunst, 2010). The Drosophila model provides substantial genetic tools with a relatively 
simple microbiota to create an experimentally tractable system to discover the molecular 
mechanisms of host–commensal interactions (Kostic et al., 2013). 
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The zebrafish (Danio rerio), having a diverse microbiota but still among the simplest 
vertebrate models, is considered a powerful model system for studying the complexities of 
host–microbiota interactions. Due to the high degree of homology between zebrafish and 
mammals not only in the adaptive immune system, but also in the digestive system. To date, 
most GF zebrafish studies have centered on the early post-embryonic period and therefore 
focused on the impact of the microbiota on the innate immune system, as the adaptive 
immune system has yet to fully develop at that time. Inflammatory bowel disease, which 
involves the dysfunctional mucosal immune responses to commensal bacteria, can also be 
modeled in zebrafish using a chemical called oxazolone, which induces intestinal 
inflammation (Brugman et al., 2009).   
 
2.4.3. SHIME® 
SHIME is an acronym for the Simulator of the Human Intestinal Microbial Ecosystem 
and it is a multi-compartment dynamic simulator of the human gut developed in 1993 
(Molly et al., 1993). Since 2010, the name has been jointly registered by ProDigest and 
Ghent University. Built as a modular setup, the SHIME is highly flexible and it can be 
technically modified to target digestive conditions of interest. The development of multi-
compartment simulators of (parts of) the human gut originated from the awareness that 
fecal microbiota significantly differs from the in vivo colon microbiota in terms of 
community composition and metabolic activity (Figure 14) (Van de Wiele et al., 2015).  
 
2.5. Roles of the gut microbiota  
The estimated 1013 microbes with its immense catalog of genes allow these 
microbes to easily adapt to their environment and energy sources available. Gut microbes 
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Figure 14. Schematic representation of the SHIME®(Van de Wiele et al., 2015). 
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metabolize an extensive list of dietary compounds to extract nutrients and energy, varying 
substantially among individuals. This may be due to variability of presence and abundance 
of gut microbial enzymes, and their corresponding bioactivities and metabolites. This 
qualifies the gut microbiota to be a massive “organ” able to perform complex biological 
processes (metabolic, nutritional, physiological) and immune system modulation (Rastelli et 
al., 2018). 
2.5.1. Roles of the gut microbiota in metabolic and nutritional processes 
The gut lumen is rich in both host and microbial proteases, and research are 
increasingly associating human disease to differential microbial proteolytic activity. For 
example, celiac disease (CD), a common autoimmune disorder characterized by an 
inflammatory response to dietary gluten found in wheat-based foods, gut microbiota is 
implicated via alterations in gluten proteolysis. This proline-rich protein evades complete 
digestion by host proteases, resulting in the generation of high-molecular weight, 
immunogenic peptides (Caminero et al., 2015). Gut microbes can also metabolize amino 
acids obtained from dietary protein, including L-phenylalanine, L-tyrosine, and L-tryptophan 
into a range of bioactive products. Gut microbiota can specifically metabolize L-tryptophan 
into the antioxidant IPA, the neurotransmitter tryptamine, and indole, the latter of which can 
undergo hydroxylation and sulfation by hepatic enzymes to generate the uremic toxin 
indoxyl sulfate (Devlin et al., 2016; Wikoff et al., 2009; Williams et al., 2014) 
Gut microbiota is also associated in the metabolism of lipids and lipid-derived 
compounds (Cho & Caudill, 2017; Fennema, Phillips, & Shephard, 2016). For example, gut 
microbial reduction (bacteria Eubacterium coprostanoligenes) of cholesterol generates 
coprostanol, which cannot be reabsorbed and is excreted. This transformation 
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aWhen available, for each gut microbiome-derived bioactive compound, the substrate, the metabolic activity involved, and
the specific role in human biology are reported. In red are the metabolites with a link to disease.  
Table 5. Principal Gut Microbiome Bioactive Compounds with a Major Role in Human 
Physiology and Pathophysiologya ( modified  from Turroni et al., 2018) .
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consequently removes cholesterol from circulation, making up to 50% of the steroids in 
human feces (Macdonald et al., 1983) and GF mice colonized with microbes from high and 
low cholesterol-reducing patients produce distinct amounts of coprostanol (Gérard et al., 
2004). 
Gut microbiota is involved in the digestion of indigestible dietary polysaccharides 
including resistant starch and dietary fibers thereby leading to the production of important 
nutrients, such as short chain fatty acids (SCFAs) (Macfarlane & Macfarlane, 2012), vitamins 
(vitamin K, vitamin B2 & B12, folic acid)((O’Hara & Shanahan, 2006) and certain amino acids 
(O’Mahony et al, 2015; Rothhammer et al., 2016) that humans are unable to 
synthesize themselves (Table 5). The plant polysaccharides in our diet are rich in xylan-, 
pectin-, and arabinose-containing carbohydrate structures. The human genome lacks 
most of the enzymes required for degrading these glycans. Nevertheless, the distal 
gut microbiome provides us with this capacity to process these polysaccharides. The 
human gut microbiome is enriched for genes involved in glucose, galactose, fructose, 
arabinose, mannose, and xylose, starch and sucrose metabolism. Our microbiome also 
has significantly enriched metabolism of glycans, amino acids, and xenobiotics; 
methanogenesis; and 2-methyl-d-erythritol 4-phosphate pathway-mediated 
Gut mbiosynthesisicrobio tofa  alsovitamins met aba dol izes pisoprenoidsoorly a bs(Gillor bete d, al.,p oly2006)phe. nolic compounds from plant-
derived foods such as soy isoflavones (Atkinson, Frankenfeld, & Lampe, 2005), lignans from 
flaxseed and sesame seeds, flavonoids like the catechins and gallate esters found in tea, 
and ellagic acid (García-Villalba et al., 2013) from nuts and berries (Clavel et al., 2006). 
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2.5.2. Metabolism of xenobiotics 
Gut microbes also modify the chemical structures of numerous ingested foreign 
compounds (xenobiotics), including, environmental pollutants, and 
pharmaceuticals thereby producing an exhaustive list of different metabolites (Turroni et 
al., 2018). Gut microbial xenobiotic metabolism alters bioactivity, bioavailability, and 
toxicity, and interfere with the fates of ingested molecules. Clinical studies have 
revealed tremendous interindividual variability in these microbial transformations 
resulting in equivocal consequences to the host. Gut microbiota metabolites and gut microbiota-
derived bioactive molecules represent the functional connection between the 
gut microbiota and the physiology of the human holobiont. 
2.5.2.1 Common metabolizing enzymes 
Both the host and gut microbiota use hydrolytic chemistry to break down large 
ingested compounds into smaller products that may be further metabolized. Hydrolase 
enzymes catalyze the addition of a water molecule to a substrate, followed by bond 
cleavage. The most abundant and relevant hydrolases in the gastrointestinal tract are 
proteases, glycosidases, and sulfatases, with the microbiota contributing a broader range 
of activities than host enzymes. Host and gut microbes possess Lyase activities modify 
polysaccharides that contain a glycosidic bond β- to a carboxylic acid (e.g. alginate, pectin, 
chondroitin and heparan). As in the host, gut microbes can also reduce a wide range of 
functional groups, including alkenes and α, β-unsaturated carboxylic acid derivatives, nitro-
, N-oxide, azo-, and sulfoxide group. Reduction typically decreases the polarity of 
compounds and can alter charge, hybridization, and electrophilicity, which can affect the 
lifetimes and activities of metabolites in the body. The gut microbiota has transferase 
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activities and transfers methyl and acyl groups to or from xenobiotic scaffolds. Key classes 
of gut microbial radical enzymes include radical S-adenosyl-L-methionine (SAM) enzymes, 
cobalamin (B12)-dependent enzymes, and glycyl radical enzymes (GREs) (Koppel et al., 
2017).  
 
2.5.2.2.  Metabolism of pharmaceuticals 
The human gut microbiota can directly or indirectly transform a wide spectrum of 
drugs and host targets into metabolites with altered pharmacological properties. Anti-
inflammatory drugs and gastrointestinal agents rely on microbial metabolism for converting 
inactive precursors (prodrugs) to pharmaceutically active compounds  (Deloménie et al., 
2001; Lavrijsen et al., 1995; Peppercorn & Goldman, 1972). In cancer chemotherapy, patient 
response can dramatically differ between individuals, in terms of efficacy and severity of 
side effects due to gut microbiota composition. It was shown that E. coli or Listeria 
welshimeri either increased or decreased the efficacy of half of a panel of 30 anticancer 
drugs towards cancer cell lines. In addition to modulating the host immune system, gut 
microbes can directly alter the structures of cancer therapies molecules and their 
metabolites, affecting their interactions with host cells (Lehouritis et al., 2015). In addition to 
affecting drugs that act locally, gut microbial metabolism can also influence the efficacy of 
therapeutics that target distant organ systems such as the central nervous system (CNS) 
(Lehouritis et al., 2015). Extensive metabolism (Goldin et al., 1973) within the gut by both 
host and microbial enzymes affect the concentration of drug reaching the brain. (Bergmark 
et al., 1972). Differences in these activities may contribute to the substantial variation 
observed in patient response to L-dopa for Parkinson’s disease. (Nutt & Holford, 1996). 
 
77
Chapter 2 : Gut microbiota and its impact to the host 
  
2.5.2.3. Metabolism of contaminants 
A recent review from literature indicates that gut microbes have an extensive 
capacity to metabolize environmental chemicals and are involved in the metabolism of >30 
environmental contaminants generally classified in five core enzymatic families 
(azoreductases, nitroreductases, β-glucuronidases, sulfatases and β-lyases). Moreover, 
there is clear evidence that bacteria-dependent metabolism of pollutants modulates the 
toxicity for the host (Claus, Guillou, & Ellero-Simatos, 2016). Specific examples include 
metabolization of azo compounds (textile dyes, food colorings, and pharmaceuticals), some 
of the first industrially important synthetic chemicals (Rafii, Franklin, & Cerniglia, 1990). Gut 
microbes also metabolize melamine, an industrial chemical used in the production of 
various plastics. Melamine added to infant formula in China caused kidney stones in 
300,000 children and led to at least six deaths (Ingelfinger, 2008). Subsequent studies in 
mice revealed that gut microbes from the Klebsiella species are associated with the 
production of cyanuric acid in (Wang et al., 2014; Zheng et al., 2013). In addition to organic 
pollutants, human gut microbes modify the structures and alter the toxicities of various 
heavy metals, including bismuth, arsenic, and mercury. Mercury bioaccumulates in living 
organisms, posing a threat to human health, and gut microbial metabolism may affect 
mercury toxicity and lifetime in the body. Pesticide molecules like glyphosate, the active 
component of the herbicide Roundup (Montsanto, St Louis, MO, USA), has been shown to 
perturb the growth of beneficial bacteria Enterococcus faecalis in cattle and horse (Krüger 
et al., 2013), Enterococcus faecium, Bacillus badius, Bifidobacterium adolescentis and 
Lactobacillus sp. in poultry  (Shehata et al., 2013). 
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The microbiome may also interact with components of our diets that are added in 
the process of food manufacturing (e.g. artificial sweeteners, emulsifiers, and preservatives). 
For example, gut microbes convert the artificial sweetener cyclamate into cyclohexylamine 
via hydrolytic cleavage of its sulfamate linkage. The mutagenic potential of heterocyclic 
amines, poorly absorbed molecules produced during charring of meat and fish, can be 
altered by gut microbial metabolism. These results appear to implicate the gut microbiota 
in the known link between charred meat and cancer (Cross et al., 2010). A variety of other 
environmental chemicals presented in Table 6 shows the metabolism by the gut microbiota 
and conversely the effect on the composition of the gastrointestinal tract. The exposure to 
these environmental chemicals has been linked to various health disorders, including 
obesity, type 2 diabetes, cancer and dysregulation of the immune and reproductive systems 
highlighting that gastrointestinal microbiota critically contributes to a variety of host 
metabolic and immune functions (Claus et al., 2016). 
 
2.5.3. Role of gut microbiota in host Immunity 
The immune system plays a central role in shaping the composition of the microbiota 
as well as its proximity to host tissues. It maintains a well-orchestrated “inside-out” control 
over microbiota localization and community composition by minimizing direct contact 
between intestinal bacteria and the epithelial cell surface, and, by confining  and limiting 
the exposure from pathogenic bacteria to intestinal sites and the systemic immune 
compartment (Hooper, Littman & Macpherson, 2012).  
The commensal gut microbiota, thus, has important effects on the normal 
development of immunity. Germ-free mice models have been paramount in revealing the 
profound effect of microbial colonization on the formation of lymphoid tissues and  
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Table 6. Human exposure to pollutants and their interaction with the 
gastrointestinal microbiota (Claus, Guillou and Ellero-Simatos, 2016). 
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subsequent immune system development. This furthered current knowledge that the 
microbiota influences the immune system from “outside-in”. Recent studies have greatly 
expanded this understanding and have revealed some of the cellular and molecular 
mediators of these interactions. In addition, gut microbiota has been shown to enhance the 
anti-inflammatory branches of the adaptive immune system. However, recent studies in 
animal models have shown that commensal microbiota may contribute to systemic 
autoimmune and allergic diseases at sites distal to the intestinal mucosa , although 
mechanisms are still unclear (Wu et al., 2010).Gut bacteria can also trigger inflammatory 
responses in immunodeficient hosts. Surprisingly, gut microbiota can protect against 
autoimmune disease like Type1 diabetes (Schmidt et al., 1999; Verdaguer et al., 1997). 
Altogether, interactions with a faulty innate immune system can result in dysbiosis of the gut 
microbiota with downstream metabolic consequences for the host. 
 
2.5.4.  Role of gut microbiota in other host processes 
The microbiota of the intestine is also involved in promoting bone formation as well 
as resorption leading to skeletal growth. Microbiota induces the hormone insulin-like 
growth factor 1 (IGF-1), promoting bone growth and remodeling (Yan et al., 2016). When 
the microbiota ferment fiber, SCFAs are produced leading to induction of IGF-1 that 
promotes bone growth. 
Lastly, the gut microbiota has been increasingly recognized as an integral 
component of our CNS, with a significant capacity to modulate our behavior via neural, 
endocrine and immune pathways (Duszka & Wahli, 2018; Rastelli et al., 2018). Multiple 
potential mechanisms have been proposed. Exogenously administered potential probiotic 
bacteria or infectious agents can alter the composition of the gut microbiota  and can 
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compete for dietary ingredients as growth substrates, bioconvert sugars into fermentation 
products with inhibitory properties, produce growth substrates for other bacteria, produce 
bacteriocins, compete for binding sites on the enteric wall, improve gut barrier function, 
reduce inflammation (thereby altering intestinal properties for colonization and 
persistence), and stimulate innate  and adaptive immune responses (O’Toole & Claesson, 
2010). Gut bacteria also modulate various host metabolic reactions, resulting in the 
production of metabolites such as, bile acids, choline and short-chain fatty acids (Dalile et 
al., 2019; Nicholson et al., 2012) such as n-butyrate, acetate and propionate, which are 
known to have neuroactive properties (Barrett et al., 2012; Lyte, 2011) and tryptophan to 
serotonin (Ruddick et al.,, 2006). In addition, bacteria have the capacity to generate many 
neurotransmitters and neuromodulators by the following: Lactobacillus spp. and 
Bifidobacterium spp. produce gamma-Aminobutyric acid (GABA); Escherichia spp., Bacillus 
spp. and Saccharomyces spp. produce noradrenalin; Candida spp., Streptococcus spp., 
Escherichia spp. and Enterococcus spp. produce serotonin; Bacillus spp. produce 
dopamine; and Lactobacillus spp. produce acetylcholine (Barrett et al., 2012; Lyte, 2011; 
Matur & Eraslan, 2012). To date, research predominate on behavioral disorders (anxiety, 
depression, and cognitive dysfunction) but evidence on the involvement of gut microbiota 
with CNS conditions like pain, autism, multiple sclerosis and obesity is growing (Cryan & 
Dinan, 2012). 
2.5.5. Gut microbiota dysbiosis’ association with chronic diseases  
In the recent years, an immensely growing number of publications have associated 
the gut microbiota to other diseases (e.g. liver diseases, digestive diseases, cancer, 
neurodegenerative disorders), yet its exact role on the onset of these diseases remain to be 
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explored. Current knowledge establishes the disease state as a result from the progression 
of a pre-existing dysbiosis, or an unbalanced compositional and functional layout of the gut 
microbiota (Turroni et al., 2018). Although a direct causality is not completely proven, 
numerous studies have consistently associated the link between gut microbiota 
composition, its metabolic activity (e.g., metabolite production), and its host metabolism. In 
other words, the activity of the gut bacteria may influence not only our health but also the 
risk of developing diseases (Rastelli, Kanuf, & Cani, 2018).  
Overweight, obesity, type 2 diabetes and related metabolic disorders have reached 
epidemic proportions and are considered one of the most serious global health issues in 
our society. Obesity results from an imbalance of food intake, basal metabolism, digestive 
tract microbial composition and energy expenditure (Turnbaugh et al., 2006). According to 
Turnbaugh et al. (2006) the gut microbiome should be considered as a set of genetic factors 
that together with host genotype and lifestyle contribute to the pathophysiology of obesity. 
It is observed that the intestinal bacteria in obese humans and mice differ from those in lean 
individuals. Obese mice microbiota was found to be rich in Firmicutes compared to the lean 
mice microbiota, which was abundant in Bacteroidetes (Turnbaugh et al., 2006). Strikingly, 
colonization of germ-free mice with microbiota from obese mice was sufficient to cause a 
significant increase in total body fat, as compared to colonization with microbiota from lean 
mice (Turnbaugh et al., 2006). The obese microbiome has an increased capacity to harvest  
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energy from the diet, thereby increasing weight gain in the host (Turnbaugh et al., 2006; 
Kallus et al., 2012). Colonization of adult germ-free mice with a gut microbial community 
harvested from conventionally raised mice increased body fat within 10–14 days, despite an 
associated decrease in food consumption. This change involves several linked mechanisms: 
microbial fermentation of dietary polysaccharides that cannot be digested by the host; 
subsequent intestinal absorption of monosaccharides and short-chain fatty acids; their 
conversion to more complex lipids in the liver; and microbial regulation of host genes that 
promote deposition of the lipids in adipocytes (Bäckhed et al., 2004). 
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver damage ranging from 
simple steatosis (or non-alcoholic fatty liver, NAFL) to non-alcoholic steatohepatitis (NASH) 
with the development of fibrosis, cirrhosis and hepatocellular carcinoma (HCC) (Burt, 
Lackner, & Tiniakos, 2015; Gerbes et al., 2018; Stickel & Hellerbrand, 2010). The 
pathogenesis of NAFLD involves environmental, genetic and metabolic factors, such as 
limited physical activity and a dysbalanced diet (Day, 2010) leading to changes in the 
intestinal microbiota (Le Roy et al., 2013). Multiple studies found that germ-free C57BL/6 
mice gained less weight than conventional mice when given a sugar-rich and lipid-rich diet 
despite similar amounts of food consumption indicating the critical role of microbes in the 
pathology of obesity and NAFLD. Interestingly, total body fat and liver triglyceride content 
increased following microbial colonization of germ-free (Bäckhed et al., 2004; Bäckhed et 
al., 2007). Mice lacking the nod-like receptorpyrin domain-containing protein 3 (NLRP3) and 
NLRP6 inflammasomes have increased susceptibility to NASH, due to changes in the gut 
microbiota. Co-housing inflammasome-deficient mice with wild-type mice increased the 
susceptibility of wild-type mice to NASH, so fatty liver risk might be affected by the 
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surrounding faecal microbiota (Henao-Mejia et al., 2012). Moreover, epididymal fat weight, 
hepatic steatosis, multifocal necrosis and infiltration of liver by inflammatory cells were 
significantly increased in germ-free mice colonized with faeces from patients with NASH and 
then fed a high-fat diet (HFD) (Burt et al., 2015). 
Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, 
is characterized by chronic immune-mediated intestinal inflammation that is driven by both 
genetic predisposition and environmental factors such as diet, antibiotic use and 
socioeconomic development (Manichanh et al., 2012). IBDs are characterized by aberrant 
innate and adaptive immune responses to commensal luminal bacteria (Ciorba et al., 2010) 
and associated with compositional and metabolic changes in the intestinal microbiota 
(dysbiosis) (Ni et al., 2017). In IBD, the key role of the gut microbiota and its interplay with a 
compromised gastrointestinal barrier has been extensively reviewed. However, definitive 
cause-effect mechanisms have been challenging to prove outside of specific animal models. 
Evidence from these experimental models suggest that although gut bacteria often drive 
immune activation, chronic inflammation in turn shapes the gut microbiota and contributes 
to dysbiosis (Ni et al., 2017).  
Ulcerative colitis (UC) is thought to be caused by some strains of E. coli (Campieri & 
Gionchetti, 2001), associated with Enterobacteriaceae, particularly certain strains of 
adherent-invasive E. coli (AIEC) (Darfeuille-Michaud et al.,1998) and Fusobacterium 
nucleatum with a link to the development of colon cancer (Zeller et al., 2014). Pathogenic E. 
coli have been implicated in Crohn's disease, (Darfeuille-Michaud, 2002). 
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2.6. Gut microbiota and host dialogue  
2.6.1. The gut-liver axis 
Gut microbiota interacts with the host in multiple different ways, with numerous links 
between the gut and other organs, such as brain (Sampson & Mazmanian, 2015), kidney 
(Whiteside et al., 2015),and liver (Schnabl & Brenner, 2014). The term ‘gut-liver axis’ was first 
described in 1978, when Volta et al., (1987) showed the production of immunoglobulin A 
antibodies to dietary antigens in patients with liver cirrhosis, indicating interactions between 
gut and liver. The liver is a unique organ that has two sources of blood supply flowing into 
the liver, from the hepatic artery and portal vein. About 70%–75% of the liver blood supply 
comes from the portal vein, which drains blood from mesenteric veins of the intestinal tract 
(Abdel-Misih & Bloomston, 2010). Small molecules such as monosaccharides and amino 
acids are then absorbed by specialized transporters on enterocytes and reach the liver 
through the portal vein, where many are taken up by hepatocytes and metabolized. If the 
gut barrier is disrupted, the liver is the first organ in the body that encounters the microbial 
metabolites, toxins and microorganisms from the intestine. Thus, the liver serves as a large 
collection base for compounds and substances originating from the intestine (Chu et al., 
2019).  
 
2.6.2. Bile acids 
Bile acid synthesis begins in the liver and can be accomplished via two different 
pathways (Figure 15). The classical (or neutral) pathway produces at least 75% of bile acid 
production under normal conditions and is initiated by 7a-hydroxylation of cholesterol 
catalyzed by CYP7A1 (Thomas et al., 2008)the rate-limiting enzyme that determines the 
amount of bile acids produced. The alternative (or acidic) pathway is initiated by sterol-27-
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hydroxylase (CYP27A1) (Russell, 2003). The 27-hydroxycholesterol formed is further 
hydroxylated by oxysterol 7a-hydroxylase (CYP7B1). The primary bile acids produced are 
different between human and rodent (Falany et al., 1997; Falany et al., 1994; Sayin et al., 
2013). Conjugated bile acids are then actively transported into bile via the BSEP. 
Approximately 95% of biliary secreted bile acids are then reabsorbed from the intestine, 
predominantly as conjugated bile acids in the distal ileum by the ASBT (also known as IBAT), 
and recirculated via the portal vein to the liver, from which they are secreted again. This 
process is called enterohepatic circulation and occurs in humans about six times per day.  
Certain studies have shown that in the absence of bacteria (as in GF or ATB-treated 
mice or rats), the bile acid pool consists of mainly primary conjugated bile acids (Kellogg, 
Knight, & Wostmann, 1970; Kellogg & Wostmann, 1969; Sayin et al., 2013; Selwyn et al., 
2016). However, the primary bile acid synthesis has been shown to be regulated by 
microbiota, through several enzymes or reaction steps in the liver (Wahlström et al., 2016). 
The complex process of 7-dehydroxylation comprises a number of reactions carried out by 
bacteria with bile acid-inducible (bai) genes (Doerner et al. 1997; Ridlon, Kang, & Hylemon, 
2006). Bacteria with capability to produce secondary bile acids have been identified in 
Clostridium (clusters XIVa and XI) and in Eubacterium, both genera belonging to the 
Firmicutes phylum (Kitahara et al., 2000, 2001; Ridlon et al., 2014; Ridlon, Kang, & Hylemon, 
2006). Synthesis of taurine as well as bile acid acyl-CoA-synthetase, which is the first of two 
enzymes required for bile acid conjugation, is also under microbial regulation (Sayin et al., 
2013). ASBT is under microbial regulation, providing additional functional evidence that the 
gut microbiota may not only regulate bile acid synthesis but also bile acid uptake, both   
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Figure 15. Bile Acid Synthesis and Metabolism. Schematic representation 
of synthetic pathways of primary bile acids in hepatocytes (pink) and secondary 
bile acids in the intestine (orange). Inset top right: table summarizing sites of 
hydroxylation on steroid nucleus of most common bile acid species. Inset 
bottom right: murine bile acid species that differ from humans. Asterisks 
indicate enzymes or reaction steps regulated by microbiota. G, glycine-
conjugated species; T, taurine-conjugated species. (Wahlström et al., 2016). 
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contributing to the larger bile acid pool in GF mice (Sayin et al., 2013). Moreover, Gut 
Microbiota is in charge of bile acid deconjugation (i.e., removal of the glycine or taurine 
conjugate) that prevents active reuptake from the small intestine via the ASBT. Bile acid 
deconjugation is carried out by bacteria with bile salt hydrolase (BSH) activity. Metagenomic 
analyses demonstrated that functional BSH is present in all major bacterial divisions and 
archaeal species in the human gut including members of Lactobacilli, Bifidobacteria, 
Clostridium and Bacteroides (Archer, Chong, & Maddox, 1982; Jones et al., 2000; Ridlon et 
al., 2006). Deconjugated primary bile acids that escape uptake through ASBT enter the 
colon, where they are further metabolized through 7-dehydroxylationinto secondary bile 
acids (Figure 15); lithocholic acid (LCA) from chenodeoxycholic acid (CDCA) and 
deoxycholic acid (DCA) from cholic acid (CA) (Macdonald et al., 1983; Ridlon & Bajaj, 2015). 
Another major microbial biotransformation of bile acids is the generation of oxo- (or keto-) 
bile acids by oxidation of hydroxyl groups at ring position 3, 7, or 12 that are catalyzed by 
bacteria with hydroxysteroid dehydrogenases (HSDHs), which are present in Actinobacteria, 
Proteobacteria, Firmicutes, and Bacteroidetes (Fukiya et al., 2009; Kisiela, Skarka, Ebert, & 
Maser, 2012; Macdonald et al., 1983; Sutherland & Macdonald, 1982).  
Microbial metabolism of bile acids leads to increased diversity and in general a more 
hydrophobic bile acid pool, which facilitates fecal elimination of bile acids, in total about 
5%. A minor part of deconjugated secondary bile acids is also absorbed from the gut 
through passive diffusion and gets enriched in the enterohepatic circulation and may then 
act as signaling molecules in the host.  
These bioconversions of bile acid by microbiota activity modulate the signaling 
properties of bile acids via FXR and the G protein-coupled bile acid receptor-1 (Takeda G 
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protein-coupled receptor 5 [TGR5]), which regulates bile acid metabolism and glucose and 
insulin sensitivity. Thus, the gut microbiota plays a critical role in bile acid metabolism and 
signaling to regulate metabolic homeostasis in health and disease. For example Pathak et 
al., (2018) shown that FXR activation of intestinal FXR shaped the gut microbiota to induce 
Acetatifactor and Bacteroides to convert CDCA to LCA, which activates TGR5 to stimulate 
glucagon-like peptide-1 (GLP-1) secretion, ultimately improving liver function and insulin 
and glucose tolerance. 
 
2.6.3. Short-chain fatty acids 
SCFAs are organic fatty acids that are end-products of gut microbiota fermentation 
of non-digestible dietary fibers, proteins and glycoproteins (Rastelli et al., 2018) (Table 5) 
Acetate, propionate, and butyrate compose 95% of SCFAs.  SCFA concentration varies 
along the gut, showing a higher value in the proximal colon (70− 140 mM), which 
progressively declines toward the distal colon (20− 40 mM) (den Besten et al., 2013). SCFAs 
are involved in all the main physiological functionalities of the human host, such as 
metabolic regulation, immune function, and the activity of the CNS. At the molecular level, 
they act primarily through the activation of the “metabolite sensing” G-protein-coupled 
receptors (namely  GPR41 and GPR43) (Sun et al., 2019), which are expressed by several 
cell types throughout the body (including colonocytes but also immune cells, endocrine 
cells, and adipocytes).  
Another mechanism of action for SCFAs involves the inhibition of histone 
deacetylases (HDACs) which are important in several aspects of our metabolic homeostasis. 
SCFAs also play an important role as signaling molecules, controlling the expression and 
secretion of the major appetite and glucose regulatory peptides, peptide YY (PYY), and the 
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incretin hormone GLP-1 (Martin et al., 2019). Absorbed SCFAs are then released into the 
bloodstream and reach the liver through the portal vein. From there, they can diffuse 
systemically to the peripheral venous system. As a preferred energy source for colonocytes, 
butyrate is mostly consumed locally, while propionate is metabolized in the liver.  
Propionate and butyrate occur at low concentration in the periphery. Conversely, 
acetate abounds in the peripheral circulation. Able to cross the blood− brain barrier (BBB), 
it can be considered the most “systemic” of the SCFAs. However, despite their low 
peripheral concentration, propionate and butyrate still retain the potential to control distant 
organs by activating hormonal and nervous systems. Acetate and propionate are the most 
potent activators of GPCRs. Moreover, butyrate and propionate have been reported, in rats, 
to activate intestinal gluconeogenesis (IGN) by (i) butyrate triggering IGN gene expression 
by increasing the cAMP concentration in colonocytes, and (ii) propionate activating IGN by 
regulating gene expression through a gut− brain neural circuit involving GPCR41 and itself 
can be converted into glucose by IGN.  This IGN mechanism ultimately regulates body 
weight, modulating the host glucose control by increased insulin sensitivity and glucose 
tolerance. Finally, butyrate also represents an important energy source for the host, 
providing its total daily energy requirement while maintaining anaerobiosis in the gut lumen 
(De Vadder et al., 2014).  
SCFAs are also potent immune regulators. The mammalian immune system, 
especially the adaptive immunity, has evolved in parallel to gut microbiota acquisition, 
probably in response to the need to maintain control over the millions of microbial cells 
inhabiting our gut (Belkaid & Harrison, 2017). On the other hand, the microbiota has 
become an active and essential component of the host immune system, being strategic for 
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training the immune system during infancy as well as for its functional tuning for the rest of 
our lives (Martin et al.,, 2010; Torow & Hornef, 2017). First, the SCFA action is of primary 
importance in fortifying the innate immunity of the intestinal mucosa by reinforcing the IEC 
barrier, increasing mucus production by goblet cells, and strengthening the tight junctions 
(TJs). Moreover, by supporting the production of the inflammasome-related cytokine 
interleukin (IL)-18 by IECs (Spiljar, Merkler, & Trajkovski, 2017), as demonstrated in mouse 
models, SCFAs may contribute to the maintenance of epithelial integrity. Finally, by 
signaling to GPCRs, SCFAs have been reported in mice to control the activation process of 
the inflammasome (Kabat, Pott, & Maloy, 2016; Spiljar et al., 2017). 
 
2.6.4. Other GM-derived small molecules 
Endogenous vitamins. Bacterial metabolites or structural components, can diffuse 
throughout the body, affecting organs either directly or by hormonal and neuronal 
signaling. To fulfill their metabolic needs, some gut microorganisms can produce 
menaquinone, folate (Pompei et al., 2007), cobalamin and riboflavin, which, from the host 
perspective, act as vitamins K2, B9, B12, and B2 (Bacher,et al., 2000; Rowland et al., 2018). 
These vitamins are known to be involved in several biological functions, from blood 
coagulation to bone metabolism and insulin sensitivity (Vernocchi, Del Chierico, & 
Putignani, 2016).  
Neurotransmitters. Several neurotransmitters, including serotonin, catecholamines 
(adrenaline, noradrenalin, and dopamine), GABA), amino acids, and indolic compounds, 
are controlled by the gut microbiota. In addition, some intestinal bacteria have been 
reported to be sources of 5-hydroxytryptamine (5HT) and nitric oxide (Rastelli, Knauf, & 
Cani, 2018; Turroni et al., 2018).  
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Tryptophan metabolites. The gut microbiota can produce a range of tryptophan 
metabolites with an important role in modulating the host immune and metabolic 
homeostasis (Agus et al., 2018). In particular, tryptophan is metabolized by intestinal 
microbes to several AhR agonists, such as indole, indolic acid, IPA, indole-3-acetaldehyde, 
tryptamine, nicotinic acid, skatole, and tryptamine (Gao et al., 2018; Roager & Licht, 2018).  
Lactate. Another noteworthy GM-produced metabolite is lactate. Principally 
produced by the milk-fermenting GM ecosystem of breast-fed infants, bacterial lactate can 
exert important metabolic and regulatory effects being an energy source and acting as an 
immune modulator, HDAC inhibitor, and signaling molecule (Engevik & Versalovic, 2017).  
Very long chained fatty acids. Intestinal microbes are potentially capable of 
producing a range of fatty acids with longer chain lengths than SCFAs, with different impacts 
on the host health. For instance, gut microbiota-produced long-chain fatty acid that can 
modulate lymphocyte T-helper 17 (Th17) gene expression, forcing the balance between 
homeostatic and potentially pathogenic Th17 cells toward the latter, as shown in murine T 
cell cultures.  In contrast, some gut microbes can conjugate ω -6 fatty acids to produce 
conjugated linoleic acid, which has been reported to have anti-inflammatory properties and 
increase insulin sensitivity, reducing adiposity, atherosclerosis, and carcinogenesis. These 
effects are likely related to its action on PPARa and g, cyclooxygenases, and lipoxygenases 
(Abdul Rahim et al.,, 2019; Engevik & Versalovic, 2017). 
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General Objectives 
The liver is a unique organ in the human body that has two sources of blood 
supply, from the hepatic artery and from the portal vein. The hepatic portal vein transports 
nutrients and xenobiotics present in food from the gastrointestinal tract to the liver and 
ensures that these are processed in the liver before they reach the rest of the organism. 
This enables the liver with a broad range of functions that can be divided into 
detoxification of xenobiotics, intermediary metabolism (including a central role in 
carbohydrate, lipid and nitrogen metabolism), secretion of bile, synthesis of various serum 
proteins, degradation of hormones, and immunological activity. If the gut barrier is 
disrupted, the liver is the first organ in the body that encounters the microbial metabolites, 
toxins and microorganisms from the intestine. The liver therefore stands at the crossroad 
between the portal blood flow coming from the intestine and the rest of the organism. In 
the liver, transcription factors from the nuclear receptor superfamily can sense fluctuating 
levels of nutrients and xenobiotics and promptly adapt hepatic metabolism by modulating 
the transcription of genes. Among these, 2 nuclear receptors, the pregnane X receptor 
(PXR) and the constitutive androstane receptor (CAR) are commonly described as 
xenobiotic sensors in the liver. They are known to regulate the expression of phase 1 
xenobiotic metabolizing enzymes (XMEs) from the cytochrome p450 family (CYPs), 
thereby facilitating the elimination of xenobiotics. A growing number of studies have also 
demonstrated that CAR and PXR play a role in energy homeostasis through the regulation 
of glucose and lipid metabolism. Recently, several new natural ligands, kynurenine and 
planar indoles resulting from the microbial metabolism of dietary tryptophan for AhR, a 
ligand-activated transcription factor from the helix-loop-helix Per-Arnt-Sim family and also 
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 a xenobiotic sensor, have been discovered. Microbial ligand-driven activation of AhR is 
thought to limit intestinal inflammation and intestinal permeability and may be 
dysfunctional in inflammatory bowel disease (IBD) and in metabolic diseases (Lamas et al., 
2016). Indole derivatives, such as indole-3-propionic acid (IPA) from gut microbial 
conversion of tryptophan has also been implicated to activate PXR and to decrease 
intestinal permeability in the small intestine in a PXR-dependent way (Venkatesh et al., 
2014). Furthermore, a study by Montagner et al. (2016) has demonstrated that gut 
microbiota influences the circadian activity of CAR & PXR in the liver. Lastly, Cyp3a11 
mRNA expression in the liver of germ-free mice is significantly reduced compared to 
control mice (Claus et al., 2011). These studies have raised the awareness that factors 
involved in xenobiotic metabolism could be intimate partners with the gut microbiota.  
 
In this PhD work, we aimed to further study the interactions between the xenobiotic 
sensors CAR and PXR and addressed the following objectives: 
1. To investigate the hepatic responses dependent on PXR in vivo in mouse using a 
pharmaceutical approach and transcriptomic analysis; 
2. To investigate the role of PXR in the ileum and compare it to previously obtained 
liver data using microarray analysis; 
3. To understand the impact of the gut microbiota on the PXR-dependent hepatic 
functions and whether PXR may in turn influence the gut microbiota. Thus, we 
aimed at establishing the importance of the bi-directional interaction of PXR and 
the gut microbiota using animal models, molecular biology, transcriptomic and 
metabolomic approaches, and microbiota sequencing; 
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 4. To investigate the bi-directional interaction between CAR and the gut microbiota 
through similar approaches. 
 
Furthermore, the question of a potential sexual dimorphism in the interactions 
between CAR/PXR and the gut microbiota was present throughout this work and 
particularly in our 3rd and 4th objectives.  
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Chapter 3.1 
Context: In this first experimental chapter, we used a pharmacological approach to 
investigate the hepatic responses dependent on PXR in vivo in mouse. Through unbiased 
transcriptome analysis we provided a novel set of experimental data highlighting PXR’s 
roles in both xenobiotic and metabolic homeostasis. We also first report the role of PXR in 
the control of the liver-derived hormone FGF21. This body of work was published in the 
“International Journal of Molecular Sciences”. 
Gene Expression Profiling Reveals that PXR Activation Inhibits Hepatic PPARα 
Activity and Decreases FGF21 Secretion in Male C57Bl6/J Mice 
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Abstract: The pregnane X receptor (PXR) is the main nuclear receptor regulating the expression
of xenobiotic-metabolizing enzymes and is highly expressed in the liver and intestine. Recent
studies have highlighted its additional role in lipid homeostasis, however, the mechanisms of these
regulations are not fully elucidated. We investigated the transcriptomic signature of PXR activation
in the liver of adult wild-type vs. Pxr-/- C57Bl6/J male mice treated with the rodent specific ligand
pregnenolone 16α-carbonitrile (PCN). PXR activation increased liver triglyceride accumulation
and significantly regulated the expression of 1215 genes, mostly xenobiotic-metabolizing enzymes.
Among the down-regulated genes, we identified a strong peroxisome proliferator-activated receptor
α (PPARα) signature. Comparison of this signature with a list of fasting-induced PPARα target genes
confirmed that PXR activation decreased the expression of more than 25 PPARα target genes, among
which was the hepatokine fibroblast growth factor 21 (Fgf21). PXR activation abolished plasmatic
levels of FGF21. We provide a comprehensive signature of PXR activation in the liver and identify
new PXR target genes that might be involved in the steatogenic effect of PXR. Moreover, we show
that PXR activation down-regulates hepatic PPARα activity and FGF21 circulation, which could
participate in the pleiotropic role of PXR in energy homeostasis.
Keywords: nuclear receptors; hepatokines; transcriptomics
1. Introduction
Pregnane X receptor (PXR, systematic name NR1I2) is a member of the nuclear receptor superfamily
and is highly expressed in the liver and intestine of mammals [1]. PXR was characterized as a
xenosensor that regulates the expression of xenobiotic-metabolizing enzymes and transporters, thereby
facilitating the elimination of xenobiotics and endogenous toxic chemicals such as bile acids [2]. Upon
ligand-binding, PXR translocates to the nucleus, heterodimerizes with retinoid X receptor (RXR, NR2B1)
and binds to PXR direct repeat 4 (DR-4) response elements (PXRE) that are usually located upstream of
target genes. Because of an unusually large and flexible binding pocket, PXR can be activated by a
variety of structurally diverse chemicals, including pharmaceutical drugs, dietary supplements, herbal
medicines, environmental pollutants, and endogenous molecules [3]. In line with the role of PXR
as a master regulator of xenobiotic metabolism, its first described target gene was cytochrome P450
(CYP) 3A4 in humans [4], which represents 10% of all clinically relevant drug-metabolizing CYPs in
the human liver and up to 75%–85% in the intestine [5] and is responsible for the metabolization of
60% of marketed drugs [6].
Int. J. Mol. Sci. 2019, 20, 3767; doi:10.3390/ijms20153767 www.mdpi.com/journal/ijms
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Besides its original function as part of the detoxification machinery, recent studies have also
unveiled functions for PXR in intermediary metabolism. There is an increasing amount of clinical
evidence showing that PXR agonists cause hyperglycemia in humans [7] and pre-clinical work
suggesting that PXR regulates hepatic glucose metabolism, however, there is still no solid understanding
of the consequences, or of the mechanisms involved. Activated PXR has been shown to repress
expression of the gluconeogenic genes glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate
carboxykinase (PCK1) [8], and of genes involved in glucose uptake such as GLUT2 and of glucokinase
(GCK) [9]. Although there is limited data on the relationship between PXR and fatty liver in humans
in vivo, many studies have demonstrated that PXR activation also causes hepatic lipid accumulation
in human cell models, and in vitro and in vivo mouse models [7,10]. This pro-steatotic effect is
thought to result from both the activation of lipogenesis and inhibition of ß-oxidation [7]. However,
the mechanisms by which PXR activation induces perturbations of lipid metabolism are not fully
elucidated. Recently, it was shown that the activation of intestinal PXR signaling induced dyslipidemia
and intestinal cholesterol accumulation [11], while activation of hepatic PXR signaling was sufficient to
promote hypercholesterolemia and hepatic lipid accumulation [12].
Here, we aimed to gain insights into the potential metabolic dysregulations induced upon PXR
activation and performed a transcriptomic comparison of the hepatic gene profiles of wild type
(WT) vs. Pxr-/- male mice treated with the rodent specific PXR ligand pregnenolone 16α-carbonitrile
(PCN). As expected, we observed that PCN treatment-induced hepatic steatosis. We unraveled several
previously unknown PXR target genes involved in liver lipid accumulation and discovered a very robust
peroxisome proliferator-activated receptor α (PPARα) signature amongst the PXR down-regulated
target genes. The PXR-induced decrease in PPARα activity included the regulation of the hepatokine
FGF21, a liver-derived hormone with major endocrine roles [13]. This cross-talk between PXR and
PPARα in the regulation of FGF21 may contribute to endocrine disruption by xenobiotics acting as
ligands for PXR.
2. Results
2.1. Effect of PXR Activation on Physiological Parameters and Liver Lipids
We investigated the effect of PXR activation by its pharmacological ligand PCN in WT and
Pxr-/- male mice. PCN treatment did not affect body weight but increased relative liver mass in a
PXR-dependent way (Figure 1a). In the liver, PXR activation significantly increased cholesterol esters
and triglyceride levels but did not significantly impact free cholesterol (Figure 1a). In the plasma, PXR
activation increased alanine transaminase (ALT) and decreased total cholesterol levels but did not
impact free fatty acids, triglycerides (Figure 1a), HDL, LDL, or glucose levels (Figure S1).
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Figure 1. Effect of pregnenolone 16α-carbonitrile (PCN) treatment on liver parameters (a) and plasma
biochemistry (b). Data are shown as mean ± SEM of n = 5–6 per group. * p ≤ 0.05, ** p ≤ 0.01,
*** p ≤ 0.005 for PCN effect using 2-way ANOVA and Tukey’s post-tests. $ p ≤ 0.05 for genotype effect.
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2.2. Effects of PXR Activation on the Hepatic Transcriptome
Using microarrays, we obtained global transcriptional profiles. Principal component analysis
(PCA) first illustrated that PCN treatment significantly impacted the hepatic transcriptome (Figure 2a).
The discrimination of WT PCN vs. WT Cont seems stronger than that of the Pxr-/- PCN vs. Pxr-/- Cont,
confirming, as expected, a significant PXR-dependent transcriptional effect of PCN. We next used
linear models and considered genes to be significantly regulated with a fold-change >1.5 and a false
discovery rate (FDR) <0.05. Heatmap clustering confirmed the PCA results (Figure S2). It indeed
revealed five gene clusters with the largest cluster (1602 probes) comprised of genes up-regulated
by PCN in WT mice only (cluster 5). Another cluster (cluster 2) showed 407 probes down-regulated
upon PCN treatment in WT mice only. Cluster 4 contained 498 probes that showed genes differentially
regulated in WT vs. Pxr-/- mice, independently of PCN. Finally, cluster 3 (605 probes) illustrated a PCN
effect in both WT and Pxr-/- mice.
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We next sought to decipher the biological functions affecte by activation. PCN treatment
significantly up-regulated t e i n of 1258 genes in WT anim ls, and of 333 genes in Pxr-/-
mice (Figure 2c). Using the 1029 “prototypical” PXR tar t genes (those that were up-regulated o ly
in T i als), e c nducted a ath ay enrichment analysis, which revealed seven functional
clusters significantly enriched (Figure 2d and Table S1) with genes involved in cell cycle, cell division
and mitosis, glutathione metabolism, cytochromes P450, lipid metabolism, chemotaxis, and positive
regulation of inflammatory response. Figure 2e confirms these results by illustrating the fold-changes
of the top 30 most up-regulated genes. These results first confirmed the well-described influence
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of PXR activation on hepatic xenobiotic-metabolizing enzymes, mainly those from the Cyp3 family.
Table S2 provides a full description of the impact of PCN treatment on all xenobiotic-metabolizing
enzymes. Induction of two of the most well-described PXR targets, Cyp2c55 and Cyp3a11 were further
confirmed using RT-qPCR (Figure 2b). Interestingly, the “lipid metabolism” pathway was also highly
significantly enriched upon PXR activation and, among the 30 genes with the highest fold-change,
the patatin-like phospholipase domain containing 3 (Pnpla3), the thyroid hormone-responsive spot 14
(Thrsp or Spot14), and the growth/differentiation factor 15 (Gdf15) belonged to this pathway. Induction
of Gdf15 was also confirmed by RT-qPCR (Figure 2b). Finally, the regulation of genes involved in
de novo lipogenesis was also confirmed by qPCR and showed a significant increase of the SREBP-1
lipogenic pathway in Pxr-/- mice compared to WT mice (Figure S3).
We next investigated the effect of PCN on gene down-regulation. PCN treatment significantly
decreased the expression of 186 genes in a PXR-dependent manner (Figure 2f). GO analyses revealed that
these genes were involved in lipid metabolic process, biological rhythms, transforming growth factor-β
(TGFβ) signaling pathway, glucose metabolism, and cytochromes P450 (Figure 2g). The 30 genes with
the highest fold-changes are illustrated in Figure 2h. Interestingly, among these 30 genes, five
(namely Fgf21, Cyp4a10, Cyp4a31, Acot1, and Plin4) are well-described target genes of PPARα, a key
hepatic transcriptional regulator involved in lipid homeostasis.
2.3. Comparison of PXR and PPARα-Dependent Transcriptome
This prompted us to investigate the intersection between PXR and PPARα activation to test the
hypothesis that PXR activation influenced PPARα activity. We took advantage of our previously
published microarray dataset [14], in which C57Bl6/J male mice carrying an hepatocyte-specific deletion
of Pparα (Pparαhep-/-) were fasted for 24 h to induce PPARα activity and compared to their wild-type
littermates (Pparαhep+/+). We have indeed previously shown that, during fasting, PPARα senses
increased levels of free fatty acids released from adipocytes, and in response, controls the expression
of hundreds of genes involved in fatty acid uptake, transport, and catabolism in hepatocytes [14,15].
Figure 3a indeed illustrates that a large number of the fasting-induced hepatic genes are PPARα
sensitive, with 538 genes significantly up-regulated in a PPARα-dependent manner. Also, 461 genes
were significantly down-regulated in a PPARα-dependent manner upon fasting (Figure 3d). We
compared these genes with those regulated upon PXR activation. We found 27 genes that were both
up-regulated upon PPARα activation and down-regulated upon PXR activation (Figure 3b). These
genes are illustrated in Figure 3c and include, among others, Pparα itself, Cyp4a14, Cyp4a10, Cyp4a31,
and Fgf21. There were also 46 genes that were regulated in the opposite direction, i.e., that were
down-regulated upon PPARα activation and up-regulated upon PXR activation (Figure 3e,f).
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2.4. Regulation of FGF21
Using RT-qPCR analyses, we confirmed that PXR activation down-regulated Pparα and its target
genes expression (Figure 4a), among which was Fgf21. FGF21 is a recently described hepatokine with
systemic metabolic effects [16]. We measured plasmatic FGF21 and confirmed that circulating FGF21
was decreased upon PCN treatment, since its levels were not detectable anymore in WT-treated mice
(Figure 4b). Surprisingly, PXR deletion also influenced FGF21 level since Pxr-/- mice also showed no
detectable levels of circulating FGF21. These differences were not due to different fasting states since
glycemia was not significantly different between the four groups (Figure S1).
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3. Discussion
The liver is one of the major organs involved in energy production. Hepatic lipid metabolism
play a crucial role during fasting and/or prolonged exercise. Upon lowering of blood glucose, the
liver increases glucose production by augmenting gluconeogenesis and glycogenolysis to maintain
blood glucose levels, increases fatty acid oxidation and ketogenesis to provide extra-hepatic tissues
with ketone bodies, and decreases lipogenesis to attenuate triglyceride storage. These processes are
under tight transcriptional control and, in response to hormones such as glucagon and glucocorticoids,
many transcription factors cooperate to regulate various genes involved in metabolic pathways aimed
at restoring homeostasis [17]. Among those, hep tic PPARα has been well described as crucial for
this adaptatio . However, recent dat have highlighted that ot e nucl ar receptor , such s the
aryl H receptor (AhR), the constitutive ndrostane receptor (CAR), and PXR, which w re historically
described as xenobiotic sensors, can also interact with the hormone-responsive transcription factors to
regulate the liver metabolic processes [18].
Here, we investigated the transcriptomic effects of a pharmacological activation of PXR. The
expression of PXR was not described as highly circadian, however, its activity, as measured by the
expression of its prototypical target gene Cyp3a11, has been shown to be influenced by the time of the
day, and is highest as zeitgeber time (ZT)6 [19]. Therefore, we decided to investigate the effects of PXR
activation at ZT6, a time at which mice were in a physiological semi-fasted state.
Several studies have already investigated the hepatic signature of PXR activation in vivo [20–22]
or in vitro [23]. However, most of these studies focused on the effect of PXR activation on xenobiotic-
metabolizing enzymes. H re, we confirm that the regulation f xenobioti m tab lism i one of PXR’s
most potent functions in the hepatocytes (Figure 2; Table S3). However, our gene enrichment analyses
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also revealed that lipid metabolism was among the top-dysregulated pathways upon PXR activation,
considering both the up-regulated, as well as the down-regulated genes.
First, PXR activation induced a very significant decrease in plasma cholesterol levels and a
significant increase in liver triglycerides and cholesterol esters (Figure 1). The pro-steatotic effects
of acute PXR activation have been shown in many studies. However, its role in the regulation of
cholesterol homeostasis is more controversial. The anti-HIV drug Efavirenz has been recently shown
to induce steatosis and hypercholesterolemia, an effect that was absent in a model of hepatic deletion
of PXR [12]. These perturbations were mediated through increased fatty acid transport and cholesterol
synthesis, via the PXR-dependent regulation of Cd36 and Sqle. In our data, we confirmed that PXR
activation significantly affected Cd36 and other transporters involved in cholesterol transport, but did
not observe any regulation of genes involved in cholesterol biosynthesis, such as Cyp7a1, Sqle, and
Hmgcr (Figure S4). This resulted in decreased circulating cholesterol.
Among the up-regulated genes in the liver, we observed that PXR activation increased the
expression of several genes that correlate with lipogenesis, such as the patatin-like phospholipase
domain containing 3 (Pnpla3) and the thyroid hormone-responsive spot 14 (Thrsp or Spot14). Spot14 was
first identified as a thyroid-responsive gene and is known to transduce hormone- and nutrient-related
signals to genes involved in lipogenesis [24]. Regulation of SPOT14 by PXR was previously described
in human hepatocytes [25] and led to increased fatty acid synthase (FASN) expression and triglyceride
accumulation. The PNPLA3 protein has lipase activity towards triglycerides in hepatocytes and a
loss-of-function polymorphism of this gene has been shown to be strongly associated with nonalcoholic
fatty liver disease [26]. However, to our knowledge, the regulation of Pnpla3 expression by PXR has
not been previously described. Among the lipid-metabolic-related genes, we also observed that the
expression of the growth/differentiation factor 15 (Gdf15), also known as MIC-1, was increased by
a factor of four upon PCN treatment, in a PXR-dependent way. GDF15 is a distant member of the
transforming growth factor-ß (TGF-ß) superfamily that is considered a crucial hormone in regulating
lipid and carbohydrate metabolism. In animal models, overexpression of GDF15 leads to a lean
phenotype and improvements of metabolic parameters by increasing the expression of key thermogenic
and lipolytic genes in brown and white adipose tissue [27]. Hepatic and circulating GDF15 levels
were also increased in animals with blunted ß-oxidation (Cpt2hep-/- mice) to maintain systemic energy
homeostasis upon fasting [28]. Whether the observed increase in Gdf15 mRNA upon PCN treatment
results from direct regulation of Gdf15 by PXR or represents a secondary adaptation to decreased
ß-oxidation remains to be determined. In both cases, regulation of GDF15 levels upon PXR activation
might be of physiological relevance since GDF15 has been implicated in a wide variety of biological
functions including control of food intake and body weight [29].
Among the genes that were down-regulated upon PXR activation, we observed a very consistent
PPARα-like signature, with the decreased expression of many Cyp4 genes, which are highly sensitive
PPARα target genes [14,15]. These results coincide with previous findings in which PCN decreased the
hepatic expression of Pparα, Cyp4a10, and Cyp4a14 [21]. Neonatal exposure to a single dose of PCN also
persistently down-regulated Cyp4a expression and decreased PPARα binding to the Cyp4a gene loci in
adult mice [20]. By comparing the list of genes down-regulated upon PXR activation to a list of genes
up-regulated upon PPARα activation, we here extend these previous findings and demonstrate that the
inhibition of PPARα activity by PXR affects more than the expression of Cyp4 genes. For example, the
PXR–PPARα interaction probably inhibited the expression of the acetyl-Coenzyme A acyltransferase 1B
(Acaa1b), of the acyl-coA thioesterase 3 (Acot3), of Krt23 and Rab30, of the rate-limiting enzyme in
ketogenesis 3-hydroxy-3-methylglutaryl-CoenzymeA synthase 2 (Hmgcs2) and of the hepatokine Fgf21,
all of which are well-described PPARα targets [14]. Using a similar approach in human primary
hepatocytes treated with the hPXR ligand rifampicine and the hPPARα ligand WY14643, Kandel et al.
had previously shown that more than 14 genes were responsive to both WY14643 (up-regulated)
and to rifampicine (down-regulated), among which ACAA2, CYP4A11, and HMGCS2 [23], therefore
suggesting the human relevance of our results.
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FGF21 is predominantly produced in the liver [30] and exerts pleiotropic effects on the body to
maintain overall metabolic homeostasis. FGF21 metabolic benefits range from reducing body weight
to alleviating hyperglycemia, insulin resistance, and improvement of lipid profiles [16]. In animal
models of obesity, as well as in obese patients, FGF21 has been shown to induce body weight loss and
to increase insulin sensitivity and lipid homeostasis [30]. The effects of FGF21 on fertility, growth, and
longevity are also well documented [31,32]. Finally, FGF21 seems to be involved in food preferences.
For example, FGF21 production in response to carbohydrate intake significantly decreases sugar
preferences [33].
Although PXR is mainly expressed in the liver and in the intestine, and not in adipose tissue [34],
deletion of Pxr appears to influence insulin sensitivity in white adipose tissue and in the muscle [35],
serum leptin, and adiponectin levels [36] and PXR activation regulates gene expression in both white
and brown adipose tissues [37]. This suggests systemic effects of Pxr deletion and activation for which
mechanisms have not been described yet. White and brown adipose tissues are among the most
described target tissues of FGF21 [16]. Whether FGF21 could be an effector of the systemic effects of
PXR remains an open question. Here, we demonstrate that both PXR-activation and PXR deletion
decrease the hepatic Fgf21 mRNA levels and completely abolished the circulating FGF21 levels. This
apparent contradictory effect was not limited to the regulation of FGF21 but was also observed in
other PPARα target genes (Figure 4). Therefore, it seems that both PXR activation and silencing
result in the inhibition of PPARα activity, probably through distinct mechanisms that would need
additional investigations. However, it is worth noticing that the same apparent contradictory effect
was observed for the regulation of de novo lipogenesis. In human HepG2 cells, PXR activation by
rifampicin promoted steatosis via induction of SREBP-1 pathway (mainly SREBP-1a), whereas PXR
silencing enhanced AKR1B10 expression, which subsequently stabilized the acetyl-CoA carboxylase,
thereby promoting de novo lipogenesis [10]. However, these mechanisms are probably species-specific
as, in our data, we did not observe this increase in AKR1B10 expression, whereas the SREBP-1 pathway
was increased by PXR ablation and not by PCN treatment (Figure S3). Overall, this demonstrated that
complex species-specific mechanisms occur in the regulation of lipogenic pathways by PXR activation
and ablation, and our results suggest that this might also be true for the regulation of ß-oxidation and
PPARα activity.
Perspectives and limitations of our study include the use of male mice only, while PXR activation
has been shown to impact both xenobiotic-metabolizing enzymes and glucose and lipid metabolism in
a sexually-dimorphic way [38,39]. Therefore, it would be interesting to decipher whether the signature
of PXR activation described in our study is also valid in female mice. Second, our study focused on
short-term changes. An important remaining question is to determine the effect of multiple weak PXR
agonists such as those present in our environment on the observed regulations, especially on FGF21
secretion. Indeed, PXR’s main target gene CYP3A4 is known to be involved in the metabolism of more
than 60% of the currently marketed drugs [6] and several hundreds of environmental, occupational, and
natural products are demonstrated PXR agonists in both mice and humans [3]. Therefore, regulation
of hepatic lipid accumulation by acute or chronic PXR activation might be an important mechanism of
xenobiotic-induced steatosis. Finally, the fact that we did not generate the PXR and PPARα dependent
transcriptomes in a parallel fashion might have underestimated the number of genes affected by the
cross-talk between the two receptors. Therefore, it would be interesting to investigate the effect of PXR
activation upon prolonged fasting such as the one used to trigger PPARα. It could also be interesting
to decipher whether the pro-steatotic effect of PCN depends on PPARα by treating PPARα knock-out
mice with PCN.
Altogether, our results present an additional resource of transcriptome analyses that confirm
and extend previous findings on the genes involved in the pro-steatotic effects of PXR. As previously
observed in various models [7], we confirm that the observed pro-steatotic effect of PXR activation
probably results from both induction of lipogenesis and repression of β-oxidation, and further highlight
that this repression is certainly mediated, at least in part, through inhibition of PPARα. We also provide
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new hypotheses regarding the yet poorly explored pleiotropic effects of PXR that could result from
the regulation of recently discovered hepatokines, such as GDF15 and/or FGF21. More studies are
needed to confirm the physiological relevance of these regulations. Our findings might have clinical
and public health relevance given the wide range of drugs and environmental xenobiotics that have
been described as PXR ligands and potential endocrine disruptors.
4. Materials and Methods
4.1. Animals
In vivo studies were performed in a conventional laboratory animal room following the
European Union guidelines for laboratory animal use and care. The current project was approved
by an independent ethics committee (CEEA-86 Toxcométhique) under the authorization number
2018062810452910. The animals were treated humanely with due consideration to the alleviation of
distress and discomfort. All mice were housed at 21–23 ◦C on a 12 h light (ZT0–ZT12) 12 h dark
(ZT12–ZT24) cycle and allowed free access to the diet (Teklad Global 18% Protein Rodent Diet) and tap
water. ZT stands for Zeitgeber time; ZT0 is defined as the time when the lights are turned on. Twelve
six-week-old wild-type (WT) C57BL/6J male mice were purchased from Charles River and 12 Pxr-/-
animals (backcrossed on the C57Bl/6J background) were engineered in Pr. Meyer’s laboratory [40] and
were bred for 10 y in our animal facility. Mice were acclimatized for two weeks, then randomly allocated
to the different experimental groups: Wild-type control (WT CONT, n = 6), wild-type PCN-treated
(WT PCN, n = 6), Pxr-/- control (Pxr-/- CONT, n = 6), Pxr-/- PCN-treated (Pxr-/- PCN, n = 6). PCN-treated
mice received a daily intraperitoneal injection of PCN (100 mg/kg) in corn oil for 4 days while control
mice received corn oil only. Mice were killed at ZT6, 6 h after the last PCN injection.
4.2. Blood and Tissue Samples
Bodyweight was monitored at the beginning and at the end of the experimental period. Prior to
sacrifice, the submandibular vein was lanced, and blood was collected into lithium heparin-coated
tubes (BD Microtainer, Franklin Lake, NJ, USA). Plasma was prepared by centrifugation (1500 g, 10 min,
4 ◦C) and stored at −80 ◦C. At sacrifice, the liver was removed and snap-frozen in liquid nitrogen and
stored at −80 ◦C until used for RNA extraction.
4.3. Gene Expression
Total RNA was extracted with TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Gene expression
profiles were obtained at the GeT-TRiX facility (GénoToul, Génopole Toulouse Midi-Pyrénées, France)
using Sureprint G3 Mouse GE v2 microarrays (8 × 60 K; design 074,809; Agilent Technologies, Santa
Clara, CA, USA) following the manufacturer’s instructions Microarray data and experimental details
are available in NCBI’s Gene Expression Omnibus [41] and are accessible through GEO Series accession
numbers GSE123804. For real-time quantitative polymerase chain reaction (qPCR), 2 µg RNA samples
were reverse-transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems,
Foster City, CA, USA). Table S3 presents the SYBR Green assay primers. Amplifications were performed
using an ABI Prism 7300 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). qPCR data
were normalized to TATA-box-binding protein mRNA levels and analyzed with LinRegPCR.v2015.3.
4.4. Plasma Analysis
Alanine transaminase (ALT), total cholesterol, triglycerides and free fatty acids (FFA) were
determined using a Pentra 400 biochemical analyzer (Anexplo facility, Toulouse, France). Plasma
FGF21 was assayed using the rat/mouse FGF21 ELISA kit (EMD Millipore, Billerica, MA, USA)
following the manufacturer’s instructions.
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4.5. Liver Neutral Lipid Analysis
Tissue samples were homogenized in methanol/5 mM EGTA (2:1, v/v); then, lipids (corresponding
to an equivalent of 2 mg tissue) were extracted according to the Bligh and Dyer method [42] with
chloroform/methanol/water (2.5:2.5:2.1, v/v/v), in the presence of the following internal standards:
glyceryl trinonadecanoate, stigmasterol, and cholesteryl heptadecanoate (Sigma, Saint-Louis, MO, USA).
Triglycerides, free cholesterol, and cholesterol esters were analyzed with gas–liquid chromatography
on a Focus Thermo Electron system equipped with a Zebron-1 Phenomenex fused- silica capillary
column (5 m, 0.25 mm i.d., 0.25 mm film thickness). The oven temperature was programmed to increase
from 200 to 350 ◦C at 5 ◦C/min, and the carrier gas was hydrogen (0.5 bar). Injector and detector
temperatures were 315 ◦C and 345 ◦C respectively.
4.6. Statistical Analysis
Microarray data were processed using R (http://www.r-project.org, accessed at 22 September
2017) and Bioconductor packages (www.bioconductor.org, accessed at 22 September 2017, v 3.0). Raw
data (median signal intensity) were filtered, log2 transformed, corrected for batch effects (microarray
washing bath), and normalized using CrossNorm method [43]. Normalized data were first analyzed
using Matlab (v2014.8). The principal component analysis was performed using an in-house function.
The linear model was fitted using the limma lmFit function [44]. Pair-wise comparisons between
biological conditions were applied using specific contrasts. A correction for multiple testing was
applied using the Benjamini–Hochberg procedure for false discovery rate (FDR). Probes with FDR
≤ 0.05 and |fold-change| > 1.5 were considered to be differentially expressed between conditions.
Gene-annotation enrichment analysis and functional annotation clustering were evaluated using
DAVID [45]. For non-microarray data, differential effects were analyzed by analysis of variance
followed by Tukey’s post-hoc tests. A p-value < 0.05 was considered significant.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/15/
3767/s1.
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Abbreviations
ACAA acetyl-Coenzyme A acyltransferase
Acot acyl-coA thioeserase
AhR aryl H receptor
CAR constitutive androstane receptor
Cpt carnitine palmitoyltransferase
CYP cytochrome P450
DR4 direct repeat 4
FASN fatty acid synthase
FDR false discovery rate
FGF21 fibroblast growth factor 21
G6Pase glucose-6-phosphatase
GDF15 growth/differentiation factor 15
GCK glucokinase
GO gene ontology
GLUT2 glucose transporter 2
HMGCS 3-hydroxy-3-methylglutaryl-CoenzymeA synthase
hPPARα Human PPARα
hPXR human PXR
Krt23 keratin 23
PXR pregnane X receptor
PXRE pregnane X receptor response elements
PCA principal component analysis
PCN pregnenolone 16α-carbonitrile
PEPCK phosphoenopyruvate carboxykinase
PNPLA3 patatin-like phospholipase domain containing 3
PPARα peroxisome proliferator-activated receptor α
Rab30 ras-related protein rab-30
RT-qPCR quantitative reverse transcription PCR
RXR retinoid X receptor
SPOT14 thyroid hormone-responsive spot 14
TGFβ transforming growth factor-ß
Thrsp thyroid hormone-responsive spot 14
WT wild-type
ZT Zeitgeber time
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Chapter 3.2 
Gene expression profiling reveals intestine and liver specific PXR target genes in 
C57Bl6/J male mice 
Context: The role of PXR in the liver has been studied by many different groups. By 
contrast, little is known about the significance of PXR activity in the intestine. In 
this second experimental chapter, we analyzed the role of PXR in the ileum through 
microarray analysis. Our data was compared to those obtained in the liver in order to 
highlight intestine specific functions that may depend on PXR. This body of work is 
subject to a publication in preparation. 
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ABSTRACT 
The pregnane X receptor (PXR) is the main nuclear receptor regulating the 
expression of xenobiotic metabolizing enzymes and is highly expressed in the liver and 
intestine. Recent studies have highlighted its additional role in energy homeostasis, 
intestinal barrier function and innate immunity. However, its intestinal role remains poorly 
described.    
We performed a transcriptomic comparison of the PXR-regulated genes in the liver and 
intestine (ileum and colon) using microarrays in adult wild-type (WT) vs Pxr-/- C57Bl6/J male 
mice treated with the rodent specific PXR ligand pregnenolone 16α-carbonitrile (PCN) (100 
mg/kg i.p. once daily for 4 days). 
In the liver, PXR activation significantly regulated the expression of 1215 genes, while in the 
ileum and colon the number of significant PXR-targets were much lower (119 and 0). Thirty-
four prototypical PXR target genes were shared among the liver and ileum, mostly xenobiotic 
metabolizing enzymes. In the liver and the ileum, up-regulated genes were also involved in 
immune processes, such as the bacteria-recognizing toll-like receptors 1, 2, 4, 5 and 6. We 
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provide a comprehensive description of the transcriptomic signature of PXR activation in the 
intestine.  
INTRODUCTION 
Pregnane X receptor (PXR, systematic name NR1I2) is a member of the nuclear 
receptor superfamily and is highly expressed in the liver and intestine of mammals (Bookout 
et al. 2006). These 2 organs are the two major determinants of oral drug bioavailability and 
of food contaminant toxicity. In both organs, activity of xenobiotic-metabolizing enzymes 
(XMEs) and transporters are the major players. PXR was characterized as a xenosensor that 
regulates the expression of XMEs and transporters, thereby facilitating elimination of 
xenobiotics and endogenous toxic chemicals such as bile acids (Kliewer et al., 1998). Upon 
ligand-binding, PXR translocates to the nucleus, heterodimerizes with retinoid X receptor 
(RXR, NR2B1) and binds to PXR direct repeat 4 (DR-4) response elements (PXRE) that are 
usually located upstream of target genes. Because of an unusually large and flexible binding 
pocket, PXR can be activated by a variety of structurally diverse chemicals including 
pharmaceutical drugs, dietary supplements, herbal medicines, environmental pollutants and 
endogenous molecules (Hernandez et al., 2009). In line with the role of PXR as a master 
regulator of xenobiotic metabolism, its first described target gene was cytochrome P450 
(CYP) 3A4 in humans (Guengerich 1999), which represents 10% of all clinically relevant drug-
metabolizing CYPs in the human liver and up to 75-85% in the intestine (Drozdzik et al., 2018) 
and is responsible for the metabolization of 60% of marketed drugs (Yu et al. 2018).       
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Besides its original function as part of the detoxification machinery, recent studies 
have also unveiled functions for PXR in intermediary metabolism. There are increasing 
clinical evidence that PXR agonists cause hyperglycaemia in humans (Hakkola et al., 2016) 
and experimental evidence indicating that PXR regulates hepatic glucose metabolism but 
there is still no solid understanding of the consequences or of the mechanisms involved. 
Activated PXR has been shown to repress expression of the gluconeogenic genes glucose-
6-phosphatase (G6Pase) and phosphoenopyruvate carboxykinase (PEPCK) (Kodama et al.
2004), and of genes involved in glucose uptake such as GLUT2 and of glucokinase (GCK) 
(Rysä et al., 2013). Although there are limited data on the relationship between PXR and fatty 
liver in humans in vivo, many studies have demonstrated that PXR activation also causes 
hepatic lipid accumulation in human cell models and in vitro and in vivo mouse models (Bitter 
et al., 2015; Hakkola et al., 2016): the main mechanisms involved are the induction of 
lipogenesis and inhibition of β-oxidation. Moreover, previous work suggests an intestine-
specific impact of PXR-ligands that could impact cholesterol homeostasis (Sui et al., 2015). 
Finally PXR has also been shown to play a role in inflammatory processes across many 
tissues, with PXR activation being mostly anti-inflammatory through inhibition of NFkB (Garg 
et al., 2016). In the intestine, PXR activation by gut microbiota-produced indoles protects 
against inflammation-induced gut barrier defects and histologic damages by inhibiting 
downstream toll-like receptor 4 (TLR-4)-activated kinase activation (Venkatesh et al., 2014). 
Indeed, PXR agonists such as rifampicin have been proposed as therapies for inflammatory 
bowel disease (Cheng et al., 2012).  
Despite an established role at the cross-road of xenobiotic detoxification, energy 
metabolism and control of inflammatory processes, and a growing awareness of the 
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importance of the intestinal role of PXR, the transcriptomic signature of PXR activation in the 
intestine remains poorly investigated. One study used PXR agonists in rats (Hartley et 
al.,2004) but this study did not control for off-target effects of the ligands since no Pxr-null 
rodent models were used. Here, we performed a comparison of the hepatic and intestinal 
gene profiles after pharmacological activation of PXR in WT vs. Pxr-/- mice.   
MATERIALS AND METHODS 
Animals 
     In vivo studies were performed in accordance with European guidelines for the use and 
care of laboratory animals, and were approved by an independent Ethics Committee. All 
mice were housed at 21-23°C on a 12-hour light (ZT0-ZT12) 12-hour dark (ZT12-ZT24) cycle 
and allowed free access to the diet (Teklad Global 18% Protein Rodent Diet) and tap water. 
ZT stands for Zeitgeber time; ZT0 is defined as the time when the lights are turned on. Study 
1: Sixteen male and 8 female six-week old C57BL/6J mice were purchased from Charles 
River, kept for two weeks of acclimatization and killed at ZT6 (males, n=8) or ZT18 (males, 
n=8 and females, n=8). Study 2: Twelve six-week old wild-type (WT) C57BL/6J male mice 
were purchased from Charles River and 12 Pxr-/- animals (backcrossed on the C57Bl/6J 
background) were engineered in Pr. Meyer’s laboratory (Staudinger et al. 2001) and are 
bred for 10y in our animal facility. Mice were acclimatized for two weeks, then randomly 
allocated to the different experimental groups: wild-type control (WT CONT, n=6), wild-type 
PCN-treated (WT PCN, n=6), Pxr-/- control (Pxr-/- CONT, n=6), Pxr-/- PCN-treated (Pxr-/- PCN, 
n=6). PCN-treated mice received a daily intraperitoneal injection of PCN (100 mg/kg, Bertin 
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Technologies, Saint-Quentin-en-Yvelines, France) in corn oil for 4 days while control mice 
received corn oil only. Mice were killed at ZT6, 6 hours after the last PCN injection, in the 
fed state.  
For the oral gavage experiment, the same protocol was used using both male and 
female C57Bl6/J mice. Mice were acclimatized for two weeks, then randomly allocated to 
the different experimental groups: wild-type control (WT CONT, n=6), wild-type PCN-
treated (WT PCN, n=6), Pxr-/- control (Pxr-/- CONT, n=6), Pxr-/- PCN-treated (Pxr-/- PCN, n=6). 
PCN-treated mice received a daily oral gavage of PCN (100 mg/kg) in corn oil for 4 days 
while control mice received corn oil only. Mice were killed at ZT6, 6 hours after the last PCN 
injection, in the fed state.  
Tissue samples 
Body weight was monitored at the beginning and at the end of experimental period. 
At sacrifice, the liver, the three parts of the small intestine (duodenum, jejunum, ileum), and 
the colon were removed and snap-frozen in liquid nitrogen and stored at -80°C until used 
for RNA extraction.  
Gene expression 
Total RNA was extracted with TRIzol reagent (Invitrogen). Gene expression profiles 
were obtained at the GeT-TRiX facility (GénoToul, Génopole Toulouse Midi-Pyrénées, 
France) using Sureprint G3 Mouse GE v2 microarrays (8x60K; design 074,809; Agilent 
technologies) following the manufacturer's instructions Microarray data and experimental 
details are available in NCBI's Gene Expression Omnibus (Edgar et al. 2002) and are 
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accessible through GEO Series accession numbers GSE123804. For real-time quantitative 
polymerase chain reaction (qPCR), 2 μg RNA samples were reverse-transcribed using the 
High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Amplifications were 
performed using an ABI Prism 7300 Real-Time PCR System (Applied Biosystems). qPCR 
data were normalised to TATA-box-binding protein mRNA levels, and analyzed with 
LinRegPCR.v2015.3.  
 
Statistical analysis 
Microarray data were processed independently for each organ using R 
(http://www.r-project.org) and Bioconductor packages (www.bioconductor.org, v 3.0, 
Gentleman, Carey et al. 2004). Raw data (median signal intensity) were filtered, log2 
transformed, corrected for batch effects (microarray washing bath) and normalized using 
CrossNorm method (Cheng et al. 2016) for liver dataset and using quantile method (Bolstad 
et al. 2003) for ileum and colon datasets. Normalized data were first analysed using Matlab 
(v2014.8). Principal component analysis was performed using an in-house function. Two-way 
ANOVA was used to investigate the effect of PCN treatment, the effect of Pxr deletion and 
the interaction between the 2 factors. Then a model was fitted using the limma lmFit function 
(Smyth 2004). Pair-wise comparisons between biological conditions were applied using 
specific contrasts. A correction for multiple testing was applied using Benjamini-Hochberg 
procedure for False Discovery Rate (FDR). Probes with FDR ≤ 0.05 and |fold-change| > 1.2 
were considered to be differentially expressed between conditions. Gene-annotation 
enrichment analysis and functional annotation clustering were evaluated using DAVID 
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(Huang et al. 2009). For non- microarray data, differential effects were analyzed by analysis 
of variance followed by Tukey’s post-hoc tests. A p-value <0.05 was considered significant.  
RESULTS 
Circadian rhythm and sex have minor impact on Pxr and its target gene expression in 
the liver and in the intestine.  
Because Pxr activity has been shown to be influenced by both circadian rhythm and 
sex (Montagner et al., 2016), we first investigated the expression of Pxr ant its 2 most-
described target genes, Cyp3a11 and Cyp2c55, in the liver and the different portions of the 
intestine (duodenum, jejunum, ileum and colon) at different time points in male and female 
WT mice (Figure 1). Bmal1 and Rev-erbα, 2 genes of the circadian clock served as positive 
controls. Pxr was expressed to the same levels in the liver and ileum, and to a lower extend 
in the colon, Cyp3a11 expression was mostly hepatic, while Cyp2c55 was highly expressed 
in the colon. We observed no significant circadian difference in Pxr, Cyp3a11 or Cyp2c55 
expression. We next assessed the effect of sex and found no significant difference in the 
expression of these 3 genes between males and females. In light of these results, we decided 
to continue our study in male mice at ZT6. 
Effects of Pxr activation on the hepatic and intestinal transcriptomes 
Using microarrays, we obtained global transcriptional profiles in the liver, and in one 
representative section of the small (ileum) and of the large intestine (colon). Principal 
component analysis (PCA) first illustrated that PCN-treatment significantly impacted the 
hepatic transcriptome (Figure 2A). The discrimination of WT PCN vs WT Cont seems stronger 
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than that of the Pxr-/- PCN vs. Pxr-/- Cont, suggesting a significant PXR-dependent 
transcriptional effect of PCN in this organ. In the ileum, the PCN-treated groups also 
clustered separately from their respective controls, but to a similar extent in the WT and the 
Pxr-/- animals (Figure 2B). In the colon, the clustering of PCN-treated vs. control groups was 
not seen (Figure 2C). Two-way ANOVA models were then fitted to further investigate the 
effect of PCN treatment, the effect of Pxr deletion and the interaction between these factors. 
We observed a large transcriptional response to PCN in the liver (3351 genes, blue circle in 
Figure 2D), a less pronounced one in the ileum (1710 genes, Figure 2E) and a very weak one 
in the colon (107 genes, Figure 2F). The effect of Pxr deletion on the transcriptome followed 
the same pattern with 3363 genes affected by the genotype independently of PCN in the 
liver (green circle, Figure 2D), 489 genes in the ileum (Figure 2E) and only 117 in the colon 
(Figure 2F).  
 
Deciphering prototypical Pxr-target genes  
 We next sought to decipher the biological functions affected by PXR activation. We 
used linear models and considered genes to be significantly regulated with a fold-change > 
1.2 and a FDR < 0.05. In the liver, PCN treatment significantly up-regulated the expression of 
1258 genes in WT animals, and of 333 genes in Pxr-/- mice (Figure 3A). Using the 1029 
“prototypical” PXR target genes (those that were up-regulated only in WT animals), we 
conducted a pathway enrichment analysis, which revealed 7 functional clusters significantly 
enriched (Figure 3B and Supplementary Table 1) with genes involved in cell cycle, cell 
division and mitosis, glutathione metabolism, cytochromes P450, lipid metabolism, 
chemotaxis and positive regulation of inflammatory response. Figures 3C & D confirm these 
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results by illustrating the overall enrichment of XMEs in the PCN-affected genes in WT (Figure 
3C) but not in Pxr-/- animals (Figure 3D). 
In the ileum, PCN treatment significantly up-regulated the expression of 359 genes 
in WT animals, and of 816 genes in Pxr-/- mice (Figure 3E). Pathway enrichment analysis of 
the 179 ileal prototypical PXR targets highlighted 5 significantly enriched clusters (Figure 3F 
and Supplementary Table 2) with genes involved in xenobiotic metabolism, inflammation 
and innate immunity and glycosyl transfer. Figure 3G illustrates the enrichment of the PCN-
affected genes in XMEs in WT animals, however, with lower fold-changes and higher p-values 
compared to what was observed in the liver. 
In the colon, no gene was significantly regulated considering a FDR < 0.05. 
We next investigated the shared target genes of PXR in the 2 organs and we found 
46 common PXR targets (Figure 3I). As expected, these common target genes were mainly 
involved in xenobiotic metabolism, among which 12 genes encoding for phase I XME; 7 
genes encoding for phase II XMEs and 2 encoding for phase III XMEs (Figure 3J). Overall, 
these shared target-genes were regulated to a higher extend in the liver than in the ileum 
(Figure 3K). The comprehensive effect of PCN treatment on hepatic and ileal XMEs is 
provided in Supplementary Table 3.   
Among the shared PXR-targets, we also observed Toll-Like Receptor 1 (Tlr1), which 
was induced to a similar extent in the liver and the ileum (Figure 3J). Because TLRs are 
important receptors in the regulation of innate immunity, this prompted us to further 
investigate the impact of Pxr activation on Tlrs expression (Supplementary Figure 1). PCN-
induced the expression of Tlr1 and Tlr5 in the liver and the ileum in a PXR-dependent way, 
and of Tlr2, 4 and 6 in the liver only.    
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Liver- and ileal-specific PXR prototypical target genes are illustrated in 
Supplementary Figure 2.  
PXR-dependent transrepression in the liver and the intestine 
We investigated the effect of PCN on gene down-regulation (Figure 4, 
Supplementary Table 4). In the ileum, PCN treatment down-regulated the expression of 27 
genes in WT mice among which 19 were PXR dependent (Figure 4D-E). Enrichment analyses 
did not highlight any specific pathway related to this set of genes.  
Comparison of ip vs. oral activation of PXR 
Given the much lower number of genes affected by PCN treatment in the ileum and 
colon vs. the liver, we wondered if this was due to the mode of administration of the ligand 
(intraperitoneal) that could have favored liver over intestinal exposure. We repeated the 
protocol of PXR activation in both male and female C57Bl6/J WT vs. Pxr-/- mice using oral 
gavage. Surprisingly, we observed that both in the ileum and the liver, the fold-changes of 
induction of PXR target genes were lower using oral gavage compared to intraperitoneal 
route (Figure 5).  
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DISCUSSION 
We aimed to compare the effect of PXR activation in the liver and in intestine. We first 
observed that the number of genes affected by PCN treatment independently of the 
genotype was much higher in the liver (3351 genes) > ileum (1710) > colon (107). We 
hypothesized that this might be explained by the intraperitoneal administration that favored 
liver over intestinal exposure. To increase intestinal PXR activation, we tested another 
protocol of PCN administration via oral gavage. Using qPCR, we observed that the induction 
of PXR target genes was not higher, and even much lower, when mice received PCN orally 
than with ip PCN treatment. Moreover, in the ip protocol, Cyp3a11 mRNA levels were 
increased by a factor of 24 in the ileum vs. a factor of 10 in the liver. Therefore, the ip 
administration protocol induced Cyp3a11 mRNA transcription in the ileum to a similar extent 
than in the liver, therefore supporting a satisfactory activation of PXR in the intestine with this 
protocol.   
Another hypothesis explaining the much lower number of genes activated upon PXR 
activation in the intestine vs. the liver could also be that PXR is less activated by PCN in the 
intestine. Supporting this idea, we found 479 genes with a significant PCN*genotype 
interaction in the liver upon 3351 genes significantly impacted by PCN, which represents 
14.3%, while in the ileum, the proportion of PXR-dependent genes (83) compared to the 
total number of PCN responsive genes (1710) represents only 4.8%. Similarly, the number of 
genes impacted by Pxr deletion reaches 3363 in the liver, for only 489 in the ileum and 117 
in the colon, despite a relatively similar expression of Pxr itself in the 3 organs. These results 
suggest a lower basal, as well as ligand-activated, transcriptional activity of PXR in the 
intestine compared to the liver. They are in agreement with a previous rat study with two PXR 
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agonists given orally in which the number and factors of induction of XME genes were much 
higher in the liver than in the intestine (Hartley et al., 2004).  
 We confirm the strong Pxr-dependent induction of Cyp3a11 mRNA with similar fold-
changes in the liver and ileum. This might be of toxicological relevance since a broad 
assessment of >300 drugs in humans indicated that for 30% of the compounds, the fraction 
escaping intestinal metabolism was less than 0.8 (Varma et al.,2010). Moreover, CYP3A4, the 
human homolog of Cyp3a11, was recently demonstrated as the major XME in the human 
intestine, representing up to 85% of all CYPs (Drozdzik et al., 2018). The same authors 
showed that the quantity of CYPs in the human colon was very low, an organ in which we also 
observe a low transcriptional activity of PXR. Therefore, our data confirm that PXR plays a key 
role in regulating the expression of the most toxicologically relevant XMEs in the small 
intestine.  
 PXR-activation also enhanced the transcription of many genes involved in the 
regulation of innate immunity, among which some members of the TLR family. TLRs are 
pattern recognition receptors that recognize molecules shared by pathogens, by the 
resident microbiota or endogenous molecules derived by tissue damage. We observed a 
PXR-dependent up-regulation of Tlr2 and its heterodimer partners, Tlr1 and Tlr6, as well as 
Tlr4 and 5 in the liver and ileum. These are all the main bacteria-recognizing TLRs, notably 
interacting with the gut microbiota. PXR activation by PCN has recently been shown to 
modulate the gut microbiota composition (Dempsey et al.,  2018). Gut microbiota might 
have also been perturbated in our study, which could explain the observed changes in TLR 
expression. However, Tlr5 expression is not modulated by presence of the gut microbiota 
(Brandão et al.,  2015), therefore, there might also be a direct transcriptional effect of PXR on 
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Tlr genes. Activation of TLRs regulates the release of pro- and anti-inflammatory cytokines, 
and, in mice, deletion of Tlr2, 4 and 5 or of the TLR signaling adapter MyD88 contributes to 
exacerbated disease in models of inflammatory bowel disease (Rakoff-Nahoum et al. 2004; 
Chassaing et al. 2014), while hepatocyte deletion of Tlrs or MyD88 regulates glucose and 
lipid metabolism (Duparc et al., 2016; Etienne-Mesmin et al., 2016).       
Perspectives and limitations of our study include first the use of only one ligand (PCN) 
for PXR activation. Although we have several arguments in favor of a significant activation of 
PXR in the intestine using this protocol, the number of PXR responsive genes in the intestine 
was much lower than in the liver. Furthermore, we observe more genes induced in Pxr-/- mice 
compared to WT mice in the intestine (Figures 3E and 4D). This could be due to the hepatic 
first pass effect that is stronger in WT than in Pxr-/- mice. But this could also suggest that PXR 
might not be the main factor mediating PCN response in the intestine. It was previously 
shown that different PXR ligands could induce weakly over-lapping gene signatures (Hartley 
et al.,  2004). Therefore, it might be interesting to test several other PXR agonists such as 
dexamethasone. The antipsychotic drug quetiapine was also recently described as a gut 
activator of PXR (Meng et al., 2019) and might be an interesting ligand to provide a more 
comprehensive view of the intestinal PXR signature. Second, littermates were not used, which 
did not allow extensive analysis of the impact of Pxr deletion, especially in the ileum and 
colon for which differences in gut microbiota composition impact gene expression. However, 
our results mainly focus on the effect of PCN treatment within genotypes. Third, we used only 
male mice, but PXR activation has a sexually dimorphic impact on both XMEs and glucose 
and lipid metabolism (Lu et al., 2013; Spruiell et al., 2015). Therefore, it would be interesting 
to decipher whether the signature of PXR activation described in our study is also valid in 
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female mice. Finally, our study focused on short-term changes. An important remaining 
question is to determine the effect of multiple weak PXR agonists such as those present in 
our environment on the observed regulations.  
In conclusion, we present a comprehensive gene signature of PXR activation in the 
liver and in ileum. In both tissues, PXR activation mainly impacted the expression of XMEs 
and of genes involved in innate immunity such as the TLRs. More studies are necessary to 
study the physiological relevance of these regulations. 
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FIGURE LEGENDS 
 
Figure 1: Effect of circadian rhythm on clock genes and sex on the expression of Pxr and 
its target genes. RT-qPCR in male mice at ZT6 and ZT18 (A) or in males vs females at ZT18 
(B). C57Bl6/J wild-type male mice were killed at ZT6 or ZT18. RT-qPCR was conducted in the 
liver and the different parts of the intestine. Results are presented as mean+/- SEM for n=6 
per group. P-values were derived from 2-way ANOVA analyses. Letters refer to significant 
differences in gene expression compared to the liver (L), duodenum (D), jejunum (J), ileum 
(I) and colon (C) at p>0.05 using Tukey’s post-tests.    
 
Figure 2: Impact of PCN treatment and Pxr deletion on the liver and intestinal 
transcriptomes. (A-C) PCA score plots of the whole transcriptomic datasets in the liver (A), 
the ileum (B) and the colon (C). (D-F) Venn diagram representing the number of genes 
affected by PCN treatment independently of the genotype (blue circles), by the genotype 
independently of PCN (green circles) and affected under the interaction between PCN and 
genotype (red circles) in the liver (D), ileum (E) and colon (F). Genes were considered 
significant at p<0.001 using 2-way ANOVA. N=4-6 per group.   
 
Figure 3: PXR-dependent up-regulated genes. (A) Venn diagram of genes significantly up-
regulated by PCN in the liver (FC>1.2 & FDR<0.05). (B) Gene enrichment analysis of the 
1029 hepatic prototypical target genes of PXR. (C) Volcano plot of differences in gene 
expression between WT PCN and WT Cont. Colors indicate phase I XMEs (red), phase II 
XMEs (green) and phase III XMEs (blue). (D) Volcano plot of differences in gene expression 
between Pxr-/- PCN and Pxr-/- Cont in the liver. Color code is identical to (C). (E) Venn diagram 
of genes significantly up-regulated by PCN in the ileum (FC>1.2 & FDR<0.05). (F) Gene 
enrichment analysis of the 179 ileal prototypical target genes of PXR. (G) Volcano plot of 
differences in gene expression between WT PCN and WT Cont in the ileum. Color code is 
identical to (C). (H) Volcano plot of differences in gene expression between Pxr-/- PCN and 
Pxr-/- Cont in the ileum. Color code is identical to (C). (I) Venn diagram of genes significantly 
up-regulated by PCN in WT mice only in the liver vs. the ileum. (J) The 35 genes with the 
highest fold-change in WT PCN vs. WT mice that are prototypical targets of PXR in the liver 
and ileum. (K) Log2 fold-changes in WT PCN vs. WT Cont for the 46 PXR-targets shared 
between the liver and ileum.   
 
Figure 4: Shared and tissue-specific PXR-dependent down-regulated genes in the liver and 
ileum. (A) Venn diagram of genes significantly down-regulated by PCN in the liver (FC<-1.2 
& FDR<0.05) (B) Gene enrichment analysis of the 186 hepatic genes down-regulated by 
PCN in a PXR-dependent way (C) The 40 genes with the highest fold change in WT PCN vs 
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WT mice. (D) Venn diagram of genes significantly ileal down-regulated by PCN (FC<-1.2 & 
FDR<0.05). (E) The 19 ileal genes with the highest fold change in WT PCN vs. WT mice.  
 
Figure 5: Impact of PXR activation on hepatic and intestinal PXR activity by intraperitoneal 
injection and oral gavage. Gene expression of Cyp3a11 and Cyp2c55 from qPCR 
experiments in the (A) liver of male mice by intraperitoneal injection; (B) male and (C) female 
mice by oral gavage.  Gene expression of Cyp3a11 and Cyp2c55 from qPCR experiments 
in the (D) ileum of male mice by intraperitoneal injection; (E)   male and (F) female mice by 
oral gavage.  Data are mean±SEM of n=6-7 per group. *p≤0.05, **p≤0.01, ***p≤0.005 for 
PCN effect, #p≤0.05 ##p≤0.01, ###p≤0.005for genotype effect using 2-way ANOVA and 
Tukey’s post-tests.  
 
 
SUPPLEMENTARY FIGURE LEGENDS 
 
Supplementary Figure 1:  Effect PXR activation on the expression of Tlrs in the (A) liver and 
(B) ileum.  
 
Supplementary Figure 2:  Effect PXR activation on the expression of prototypical genes in 
the liver and ileum. Forty genes with the highest fold change in the (A) liver and the (B) 
ileum. 
 
 
SUPPLEMENTARY TABLE LEGENDS 
 
Supplementary Table 1:  Effect PXR activation on the expression of Tlrs in the (A) liver 
and (B) ileum. 
 
Supplementary Table 2:  Gene enrichment analyses of upregulated genes in the liver.  
 
Supplementary Table 3: The comprehensive effect of PCN treatment on hepatic and ileal 
XMEs. 
 
Supplementary Table 4:  Gene enrichment analyses of downregulated genes upon Pxr 
activation in the liver.  
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Figure 1: Effect of circadian rhythm on clock genes and sex on the expression of Pxr 
and its target genes. 
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Figure 2: Impact of PCN treatment and Pxr deletion on the liver and intestinal 
transcriptomes. 
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Figure 3: PXR-dependent up-regulated genes.	
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Figure 4: Shared and tissue-specific PXR-dependent down-regulated genes in the liver 
and ileum. 
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Figure 5: Impact of PXR activation on hepatic and intestinal PXR activity by 
intraperitoneal injection and oral gavage. 
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SUPPLEMENTARY FIGURES 
Supplementary Figure 1:  Effect PXR activation on the expression of Tlrs in the (A) liver and 
(B) ileum.
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Supplementary Figure 2:  Effect PXR activation on the expression of prototypical genes in 
the liver and ileum.  
140
Chapter 3.2 : Experimental Results 
SUPPLEMENTARY TABLES 
Supplementary Table 1:  Effect PXR activation on the expression of Tlrs in the (A) liver and (B) ileum. 
Cluster 
number 
Enrichment 
score 
Adjusted 
P-value Ontology 
Gene 
count Genes 
1 6.94 
1.50E-09 mitosis Up_keywords 41 BUB1B, mitotic checkpoint serine/threonine kinase(Bub1b);CTF18, chromosome transmission fidelity 
factor 18(Chtf18);E2F transcription factor 7(E2f7);Fanconi anemia, complementation group I(Fanci);H2A 
histone family, member X(H2afx);H2A histone family, member Y3(H2afy3);H2B histone family, member 
M(H2bfm);MAD1 mitotic arrest deficient 1-like 1(Mad1l1);MAD2 mitotic arrest deficient-like 
1(Mad2l1);MAD2 mitotic arrest deficient-like 2(Mad2l2);MIS18 binding protein 1(Mis18bp1);N-terminal 
Xaa-Pro-Lys N-methyltransferase 1(Ntmt1);NSL1, MIS12 kinetochore complex component(Nsl1);NUF2, 
NDC80 kinetochore complex component(Nuf2);Opa interacting protein 5(Oip5);RAN, member RAS 
oncogene family(Ran);Rac GTPase-activating protein 1(Racgap1);Ras association (RalGDS/AF-6) domain 
family member 4(Rassf4);SET domain containing (lysine methyltransferase) 7(Setd7);SPC24, NDC80 
kinetochore complex component, homolog (S. cerevisiae)(Spc24);TOPBP1-interacting checkpoint and 
replication regulator(Ticrr);TPX2, microtubule-associated(Tpx2);asp (abnormal spindle)-like, 
microcephaly associated (Drosophila)(Aspm);aurora kinase A(Aurka)aurora kinase B(Aurkb);baculoviral 
IAP repeat-containing 5(Birc5);cAMP-regulated phosphoprotein 19(Arpp19);cell division cycle 
20(Cdc20);cell division cycle associated 3(Cdca3);cell division cycle associated 5(Cdca5);cell division 
cycle associated 8(Cdca8);centriole, cilia and spindle associated protein(Ccsap);centromere protein 
E(Cenpe);centromere protein F(Cenpf);centromere protein I(Cenpi);centromere protein 
M(Cenpm);checkpoint kinase 1(Chek1);chromatin assembly factor 1, subunit B 
(p60)(Chaf1b);chromosome alignment maintaining phosphoprotein 1(Champ1);cyclin A2(Ccna2);cyclin 
B1(Ccnb1);cyclin B2(Ccnb2);cyclin-dependent kinase 1(Cdk1);cyclin-dependent kinase 4(Cdk4);cyclin-
dependent kinase 7(Cdk7);cyclin-dependent kinase inhibitor 1A (P21)(Cdkn1a);cyclin-dependent kinase 
inhibitor 3(Cdkn3);cytoskeleton associated protein 2(Ckap2);denticleless E3 ubiquitin protein 
ligase(Dtl);ect2 oncogene(Ect2);extra spindle pole bodies 1, separase(Espl1);forkhead box 
M1(Foxm1);high mobility group box 2(Hmgb2);histone cluster 1, H2bq(Hist1h2bq);inner centromere 
protein(Incenp);interleukin 33(Il33);kinesin family member 20B(Kif20b);kinesin family member 
23(Kif23);kinetochore associated 1(Kntc1);kinetochore-localized astrin/SPAG5 binding(Knstrn);lysyl 
oxidase-like 2(Loxl2);maternal embryonic leucine zipper kinase(Melk);non-SMC condensin I complex, 
subunit D2(Ncapd2);non-SMC condensin II complex, subunit G2(Ncapg2);nucleolar and spindle 
associated protein 1(Nusap1);nucleolar protein interacting with the FHA domain of 
MKI67(Nifk);pescadillo ribosomal biogenesis factor 1(Pes1);polo-like kinase 3(Plk3);proline rich 5 
(renal)(Prr5);proline/serine-rich coiled-coil 1(Psrc1);protein phosphatase 1, catalytic subunit, gamma 
isoform(Ppp1cc);regulator of cell cycle(Rgcc);retinoblastoma binding protein 8(Rbbp8);serine/threonine 
kinase 10(Stk10);shugoshin-like 1 (S. pombe)(Sgol1);sperm associated antigen 5(Spag5);sphingomyelin 
phosphodiesterase 3, neutral(Smpd3);spindle and kinetochore associated complex subunit 
3(Ska3);thioredoxin interacting protein(Txnip);topoisomerase (DNA) II alpha(Top2a);transforming, acidic 
coiled-coil containing protein 3(Tacc3);ubiquitin-conjugating enzyme E2C(Ube2c);ubiquitin-like, 
containing PHD and RING finger domains, 1(Uhrf1);vasohibin 1(Vash1) 
2.40E-08 cell cycle Up_keywords 67 
2.20E-07 cell division Goterm_BP_direct 46 
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Cluster 
number 
Enrichment 
score 
Adjusted 
P-value Ontology 
Gene 
count Genes 
2 4.75 
2.10E-06 
Glutathione 
metabolism 
Kegg_pathway 18 
SH3 domain binding glutamic acid-rich protein-like 3(Sh3bgrl3);UDP 
glucuronosyltransferase 1 family, polypeptide A6B(Ugt1a6b);UDP glucuronosyltransferase 
2 family, polypeptide A1(Ugt2a1);UDP glucuronosyltransferase 2 family, polypeptide 
B34(Ugt2b34);UDP glucuronosyltransferase 2 family, polypeptide B35(Ugt2b35);UDP 
glycosyltransferase 1 family, polypeptide A10(Ugt1a10);alanyl (membrane) 
aminopeptidase(Anpep);alcohol dehydrogenase 1 (class I)(Adh1);aldehyde 
dehydrogenase family 1, subfamily A3(Aldh1a3);carbonyl reductase 2(Cbr2);carbonyl 
reductase 3(Cbr3);cystathionase (cystathionine gamma-lyase)(Cth);cytochrome P450, 
family 1, subfamily b, polypeptide 1(Cyp1b1);epoxide hydrolase 1, 
microsomal(Ephx1);ethylmalonic encephalopathy 1(Ethe1);eukaryotic translation 
elongation factor 1 epsilon 1(Eef1e1);gamma-glutamyl cyclotransferase(Ggct);glucose-6-
phosphate dehydrogenase X-linked(G6pdx);glutaredoxin(Glrx);glutathione S-transferase, 
alpha 2 (Yc2)(Gsta2);glutathione S-transferase, alpha 4(Gsta4);glutathione S-transferase, 
mu 1(Gstm1);glutathione S-transferase, mu 3(Gstm3);glutathione S-transferase, mu 
4(Gstm4)glutathione S-transferase, mu 5(Gstm5);glutathione S-transferase, mu 
6(Gstm6);glutathione S-transferase, theta 3(Gstt3);glutathione peroxidase 
3(Gpx3);glutathione peroxidase 7(Gpx7);glutathione peroxidase 8 
(putative)(Gpx8);glutathione reductase(Gsr);phosphogluconate 
dehydrogenase(Pgd);predicted gene 10639(Gm10639);ribonucleotide reductase 
M2(Rrm2);spermidine synthase(Srm) 
2.70E-06 
Metabolism of 
xenobiotics by 
cytochrome P450 
Kegg_pathway 19 
1.40E-03 
Drug metabolism - 
CYP450 
Kegg_pathway 15 
3 4.45 
8.80E-05 Glycoprotein Up-keywords 233 
  4.00E-04 Disulfide bound Up_keywords 192 
7.60E-03 Signal Up_keywords 253 
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Cluster 
number 
Enrichment 
score 
Adjusted 
P-value Ontology 
Gene 
count Genes 
4 4.41 
4.20E-06 Retinol metabolism Kegg_pathway 22 
UDP glucuronosyltransferase 1 family, polypeptide A6B(Ugt1a6b);UDP 
glucuronosyltransferase 2 family, polypeptide A1(Ugt2a1);UDP glucuronosyltransferase 2 
family, polypeptide B34(Ugt2b34);UDP glucuronosyltransferase 2 family, polypeptide 
B35(Ugt2b35);UDP glycosyltransferase 1 family, polypeptide A10(Ugt1a10);alcohol 
dehydrogenase 1 (class I)(Adh1);aldehyde dehydrogenase family 1, subfamily 
A1(Aldh1a1);aldehyde dehydrogenase family 1, subfamily A7(Aldh1a7);alkB homolog 1, 
histone H2A dioxygenase(Alkbh1);carboxylesterase 2C(Ces2c);cholesterol 25-
hydroxylase(Ch25h);cytochrome P450, family 1, subfamily b, polypeptide 
1(Cyp1b1);cytochrome P450, family 2, subfamily a, polypeptide 22(Cyp2a22);cytochrome 
P450, family 2, subfamily a, polypeptide 4(Cyp2a4);cytochrome P450, family 2, subfamily a, 
polypeptide 5(Cyp2a5);cytochrome P450, family 2, subfamily b, polypeptide 
10(Cyp2b10);cytochrome P450, family 2, subfamily b, polypeptide 9(Cyp2b9);cytochrome 
P450, family 2, subfamily c, polypeptide 29(Cyp2c29);cytochrome P450, family 2, subfamily 
c, polypeptide 55(Cyp2c55);cytochrome P450, family 2, subfamily g, polypeptide 
1(Cyp2g1);cytochrome P450, family 26, subfamily a, polypeptide 1(Cyp26a1);cytochrome 
P450, family 3, subfamily a, polypeptide 11(Cyp3a11);cytochrome P450, family 3, subfamily 
a, polypeptide 16(Cyp3a16);cytochrome P450, family 3, subfamily a, polypeptide 
25(Cyp3a25)cytochrome P450, family 3, subfamily a, polypeptide 
41A(Cyp3a41a);cytochrome P450, family 3, subfamily a, polypeptide 
44(Cyp3a44);cytochrome P450, family 3, subfamily a, polypeptide 
57(Cyp3a57);cytochrome P450, family 3, subfamily a, polypeptide 
59(Cyp3a59);cytochrome P450, family 4, subfamily f, polypeptide 18(Cyp4f18);cytochrome 
b-245, alpha polypeptide(Cyba);cytochrome b5 type B(Cyb5b);epoxide hydrolase 1, 
microsomal(Ephx1);heme oxygenase 1(Hmox1);hemochromatosis(Hfe);hydroxysteroid (17-
beta) dehydrogenase 6(Hsd17b6);microtubule associated monooxygenase, calponin and 
LIM domain containing 1(Mical1);myeloperoxidase(Mpo);myo-inositol 
oxygenase(Miox);nitric oxide synthase 3, endothelial cell(Nos3);phospholipase A2, group 
VI(Pla2g6);phospholipase A2, group XIIA(Pla2g12a);polymerase I and transcript release 
factor(Ptrf);procollagen lysine, 2-oxoglutarate 5-dioxygenase 2(Plod2);progesterone 
receptor membrane component 1(Pgrmc1);prolyl 3-hydroxylase 3(P3h3);protein 
phosphatase 3, catalytic subunit, gamma isoform(Ppp3cc);retinol dehydrogenase 
11(Rdh11);ribonucleotide reductase M2(Rrm2);sideroflexin 3(Sfxn3);solute carrier family 
25, member 37(Slc25a37);sulfotransferase family 1E, member 1(Sult1e1);tet methylcytosine 
dioxygenase 3(Tet3);transmembrane 7 superfamily member 2(Tm7sf2) 
2.40E-04 Microsome Up_keywords 20 
2.50E-04 Monooxygenase Up_keywords 20 
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Cluster 
number 
Enrichment 
score 
Adjusted 
P-value Ontology 
Gene 
count Genes 
5 3.55 
9.10E-04 Lipid metabolism Up_keywords 39 
1-acylglycerol-3-phosphate O-acyltransferase 4 (lysophosphatidic acid acyltransferase, 
delta)(Agpat4);2-hydroxyacyl-CoA lyase 1(Hacl1);3-hydroxyacyl-CoA dehydratase 
4(Hacd4);7-dehydrocholesterol reductase(Dhcr7);ELOVL family member 6, elongation of 
long chain fatty acids (yeast)(Elovl6);ER lipid raft associated 1(Erlin1);JAZF zinc finger 
1(Jazf1);abhydrolase domain containing 5(Abhd5);acetyl-Coenzyme A carboxylase 
beta(Acacb);acyl-CoA synthetase long-chain family member 5(Acsl5);acyl-CoA 
synthetase medium-chain family member 1(Acsm1);acyl-CoA synthetase medium-chain 
family member 2(Acsm2);carboxylesterase 1D(Ces1d);ceramide synthase 
2(Cers2);ceramide synthase 6(Cers6);cholesterol 25-hydroxylase(Ch25h);cytochrome b5 
reductase 3(Cyb5r3);elongation of very long chain fatty acids (FEN1/Elo2, 
SUR4/Elo3,yeast)-like 1(Elovl1);hydroxysteroid (17-beta) dehydrogenase 
6(Hsd17b6);insulin induced gene 2(Insig2);lanosterol synthase(Lss);membrane bound O-
acyltransferase domain containing 1(Mboat1);neuraminidase 3(Neu3);patatin-like 
phospholipase domain containing 3(Pnpla3)patatin-like phospholipase domain 
containing 5(Pnpla5);phospholipase A2, group VI(Pla2g6);phospholipase A2, group VII 
(platelet-activating factor acetylhydrolase, plasma)(Pla2g7);phospholipase A2, group 
XIIA(Pla2g12a);phospholipase A2, group XV(Pla2g15);phospholipase B domain 
containing 2(Plbd2);phospholipase C, eta 2(Plch2);prosaposin(Psap);prostaglandin E 
synthase(Ptges);protein kinase, AMP-activated, beta 1 non-catalytic 
subunit(Prkab1);protein tyrosine phosphatase, mitochondrial 1(Ptpmt1);solute carrier 
family 16 (monocarboxylic acid transporters), member 1(Slc16a1);sortilin-related 
receptor, LDLR class A repeats-containing(Sorl1);sphingomyelin phosphodiesterase 3, 
neutral(Smpd3);sterol O-acyltransferase 2(Soat2);sulfotransferase family 1D, member 
1(Sult1d1);thyroid hormone responsive(Thrsp);transmembrane 7 superfamily member 
2(Tm7sf2) 
1.30E-02 
Lipid 
biosynthesis 
Up_keywords 18 
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Cluster 
number 
Enrichment 
score 
Adjusted 
P-value Ontology 
Gene 
count Genes 
6 
3.05 5.50E-06 Chemotaxis Goterm_BP_direct 25 
BMP-binding endothelial regulator(Bmper);CCAAT/enhancer binding protein (C/EBP), 
beta(Cebpb);FGR proto-oncogene, Src family tyrosine kinase(Fgr);FMS-like tyrosine kinase 1(Flt1);Fc 
receptor, IgE, high affinity I, gamma polypeptide(Fcer1g);GLI pathogenesis-related 
2(Glipr2);NAD(P)H dehydrogenase, quinone 2(Nqo2);RAS-related C3 botulinum substrate 
2(Rac2);Rap guanine nucleotide exchange factor (GEF) 4(Rapgef4);SH3 domain binding glutamic 
acid-rich protein-like 3(Sh3bgrl3);SRY (sex determining region Y)-box 9(Sox9);a disintegrin-like and 
metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 12(Adamts12);amyotrophic 
lateral sclerosis 2 (juvenile)(Als2);atypical chemokine receptor 2(Ackr2);bridging integrator 
2(Bin2);cardiotrophin-like cytokine factor 1(Clcf1);cathelicidin antimicrobial peptide(Camp);cathepsin 
S(Ctss);chemokine (C-C motif) ligand 12(Ccl12);chemokine (C-C motif) ligand 2(Ccl2);chemokine (C-
C motif) ligand 24(Ccl24);chemokine (C-C motif) ligand 3(Ccl3);chemokine (C-C motif) ligand 
4(Ccl4);chemokine (C-C motif) ligand 6(Ccl6)chemokine (C-C motif) ligand 9(Ccl9);chemokine (C-C 
motif) receptor 2(Ccr2);chemokine (C-C motif) receptor 8(Ccr8);chemokine (C-X-C motif) ligand 
5(Cxcl5);chemokine (C-X3-C motif) receptor 1(Cx3cr1);complement component 5a receptor 
1(C5ar1);cytochrome b-245, alpha polypeptide(Cyba);drebrin 1(Dbn1);ect2 
oncogene(Ect2);endothelial cell surface expressed chemotaxis and apoptosis 
regulator(Ecscr);eukaryotic translation initiation factor 2B, subunit 3(Eif2b3);fatty acid binding protein 
4, adipocyte(Fabp4);glucose phosphate isomerase 1(Gpi1);glycoprotein (transmembrane) 
nmb(Gpnmb);growth differentiation factor 15(Gdf15);heat shock protein 1 (chaperonin)(Hspd1);high 
mobility group box 2(Hmgb2);integrin beta 2(Itgb2);interleukin 1 alpha(Il1a);interleukin 17 receptor 
B(Il17rb);interleukin 33(Il33);jun proto-oncogene(Jun);leukocyte cell-derived chemotaxin 
2(Lect2);lymphocyte specific 1(Lsp1);myelocytomatosis oncogene(Myc);neuroepithelial cell 
transforming gene 1(Net1);neutrophil cytosolic factor 1(Ncf1);nuclear factor of kappa light 
polypeptide gene enhancer in B cells inhibitor, beta(Nfkbib);oncostatin M(Osm);peptidoglycan 
recognition protein 1(Pglyrp1);phosphatidylinositol 3-kinase catalytic delta 
polypeptide(Pik3cd);phosphatidylinositol 3-kinase, C2 domain containing, gamma 
polypeptide(Pik3c2g);phospholipase A2, group VI(Pla2g6);platelet derived growth factor receptor, 
alpha polypeptide(Pdgfra);platelet factor 4(Pf4);prostaglandin E receptor 4 (subtype 
EP4)(Ptger4);regulator of G-protein signalling 10(Rgs10);regulatory factor X, 1 (influences HLA class II 
expression)(Rfx1);roundabout guidance receptor 1(Robo1);secreted and transmembrane 
1A(Sectm1a);secreted phosphoprotein 1(Spp1);serine (or cysteine) peptidase inhibitor, clade B, 
member 9(Serpinb9);serine (or cysteine) peptidase inhibitor, clade E, member 
1(Serpine1);suppression of tumorigenicity 5(St5);toll-like receptor 1(Tlr1);transforming growth factor, 
beta 1(Tgfb1);transglutaminase 2, C polypeptide(Tgm2);tumor necrosis factor (ligand) superfamily, 
member 14(Tnfsf14);tumor necrosis factor receptor superfamily, member 10b(Tnfrsf10b);tumor 
necrosis factor receptor superfamily, member 21(Tnfrsf21);vav 1 oncogene(Vav1);wingless-type 
MMTV integration site family, member 5A(Wnt5a) 
  4.70E-05 
Positive 
regulation of 
inflammatory 
response 
Goterm_BP_direct 17 
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Cluster 
number 
Enrichment 
score 
Adjusted 
P-value Ontology 
Gene 
count Genes 
7 2.56 2.00E-03 Collagen Up_keywords 14 
ATPase, Na+/K+ transporting, alpha 3 polypeptide(Atp1a3);C1q and tumor necrosis 
factor related protein 6(C1qtnf6);C1q and tumor necrosis factor related protein 
7(C1qtnf7);ankyrin repeat and SOCS box-containing 4(Asb4);collagen triple helix repeat 
containing 1(Cthrc1);collagen, type II, alpha 1(Col2a1);collagen, type IV, alpha 
1(Col4a1);collagen, type IV, alpha 2(Col4a2);collagen, type V, alpha 1(Col5a1);collagen, 
type V, alpha 2(Col5a2);collagen, type VI, alpha 3(Col6a3);collagen, type VIII, alpha 
1(Col8a1);collagen, type XII, alpha 1(Col12a1);collagen, type XVI, alpha 
1(Col16a1);collagen, type XX, alpha 1(Col20a1);mannan-binding lectin serine peptidase 
1(Masp1);potassium intermediate/small conductance calcium-activated channel, 
subfamily N, member 4(Kcnn4);procollagen C-endopeptidase enhancer 
protein(Pcolce);protein S (alpha)(Pros1);pyruvate kinase, muscle(Pkm) 
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Supplementary Table 2:  Gene enrichment analyses of upregulated genes in the liver.  
Cluster 
number 
Enrichment 
score 
Adjusted 
P-value Ontology 
Gene 
count Genes 
1 10.1 
9.70E-18 chemical carcinogenesis Kegg_pathway 20 UDP glucuronosyltransferase 1 family, polypeptide A 
6B(Ugt1a6b);UDP glucuronosyltransferase 2 family, 
polypeptide A 3(Ugt2a3);cytochrome P450, family 2, 
subfamily b, polypeptide 10(Cyp2b10);cytochrome P450, 
family 2, subfamily b, polypeptide 9(Cyp2b9);cytochrome 
P450, family 2, subfamily c, polypeptide 
55(Cyp2c55);cytochrome P450, family 2, subfamily c, 
polypeptide 65(Cyp2c65);cytochrome P450, family 2, 
subfamily c, polypeptide 66(Cyp2c66);cytochrome P450, 
family 3, subfamily a, polypeptide 
11(Cyp3a11);cytochrome P450, family 3, subfamily a, 
polypeptide 16(Cyp3a16);cytochrome P450, family 3, 
subfamily a, polypeptide 25(Cyp3a25);cytochrome P450, 
family 3, subfamily a, polypeptide 
41A(Cyp3a41a);cytochrome P450, family 3, subfamily a, 
polypeptide 44(Cyp3a44);glutathione S-transferase, alpha 
2 (Yc2)(Gsta2);glutathione S-transferase, alpha 
4(Gsta4);glutathione S-transferase, mu 
1(Gstm1);glutathione S-transferase, mu 
2(Gstm2);glutathione S-transferase, mu 
3(Gstm3);glutathione S-transferase, mu 
4(Gstm4);glutathione S-transferase, mu 
6(Gstm6);microsomal glutathione S-transferase 2(Mgst2) 
9.20E-07 Metabolism of xenobiotics by cytochrome P450 Kegg_pathway 10 
4.20E-05 Glutathione metabolism Kegg_pathway 8 
2 8.1 
9.70E-18 Chemical carcinogenesis Kegg_pathway 20 
UDP glucuronosyltransferase 1 family, polypeptide A 
6B(Ugt1a6b);UDP glucuronosyltransferase 2 family, 
polypeptide A 3(Ugt2a3);cytochrome P450, family 2, 
subfamily b, polypeptide 10(Cyp2b10);cytochrome P450, 
family 2, subfamily b, polypeptide 9(Cyp2b9);cytochrome 
P450, family 2, subfamily c, polypeptide 
55(Cyp2c55);cytochrome P450, family 2, subfamily c, 
polypeptide 65(Cyp2c65);cytochrome P450, family 2, 
subfamily c, polypeptide 66(Cyp2c66);cytochrome P450, 
family 3, subfamily a, polypeptide 
11(Cyp3a11);cytochrome P450, family 3, subfamily a, 
polypeptide 16(Cyp3a16);cytochrome P450, family 3, 
subfamily a, polypeptide 25(Cyp3a25);cytochrome P450, 
family 3, subfamily a, polypeptide 
41A(Cyp3a41a);cytochrome P450, family 3, subfamily a, 
polypeptide 44(Cyp3a44);glutathione S-transferase, alpha 
2 (Yc2)(Gsta2);glutathione S-transferase, alpha 
4(Gsta4);glutathione S-transferase, mu 
1(Gstm1);glutathione S-transferase, mu 
2(Gstm2);glutathione S-transferase, mu 
3(Gstm3);glutathione S-transferase, mu 
4(Gstm4);glutathione S-transferase, mu 
8.40E-09 Steroid hormone biosynthesis Kegg_pathway 13 
2.40E-08 Monooxygenase Up_keywords 13 
147
Chapter 3.2 : Experimental Results 
 
  
6(Gstm6);microsomal glutathione S-transferase 2(Mgst2) 
 
 
Cluster 
number 
Enrichment 
score 
Adjusted 
P-value Ontology 
Gene 
count Genes 
3 2 4.50E-02 Membrane Up_keywords 78   
4 2 
1.80E-02 Inflammatory response Up-keywords 7 chemokine (C-C motif) ligand 
19(Ccl19);complement component 4B (Chido 
blood group)(C4b)   ;interleukin 1 receptor 
accessory protein(Il1rap);nuclear factor of kappa 
light polypeptide gene enhancer in B cells 
inhibitor, delta(Nfkbid);phosphatidylinositol 3-
kinase catalytic delta polypeptide(Pik3cd);toll-like 
receptor 1(Tlr1) ;toll-like receptor 5(Tlr5)     
3.00E-01 Innate immunity Up-keywords 6 
5 1.66 
5.00E-02 Glycosyltransferase Up-keywords 7 
MFNG O-fucosylpeptide 3-beta-N-
acetylglucosaminyltransferase(Mfng;UDP 
glucuronosyltransferase 1 family, polypeptide 
A6B(Ugt1a6b);UDP glucuronosyltransferase 2 
family, polypeptide A3(Ugt2a3) ;UDP-
Gal:betaGlcNAc beta 1,3-galactosyltransferase, 
polypeptide 5(B3galt5);UDP-GlcNAc:betaGal 
beta-1,3-N-acetylglucosaminyltransferase 6 (core 
3 synthase)(B3gnt6);glycoprotein 
galactosyltransferase alpha 1, 
3(Ggta1);mannoside 
acetylglucosaminyltransferase 4, isoenzyme 
A(Mgat4a) 
3.00E-01 Signal-anchor Up_keywords 8 
 
148
Chapter 3.2 : Experimental Results 
 
  
      LIVER 
 
    
    GeneName 
log2FC   
WTPCN-
WTCtl 
log2FC       
PXRKOPCN-
PXRKOCtl 
adj.P.Val                
WTPCN-WTCtl 
adj.P.Val                     
PXRKOPCN-PXRKOCtl 
Phase I Cyptochomes P450 Cyp17a1 -0.207 -0.186 0.354594684 0.552695003 
    Cyp1a1 0.015 -0.297 0.954617498 0.256128505 
    Cyp1a2 0.285 0.892 0.381205224 0.017437424 
    Cyp1b1 0.960 0.403 0.000545541 0.214793339 
    Cyp20a1 0.405 -0.021 0.071042008 0.965460249 
    Cyp21a1 0.517 1.004 0.168059036 0.025826814 
    Cyp26a1 1.600 -1.442 0.001357012 0.011928216 
    Cyp26b1 -2.634 0.610 0.000398851 0.534259276 
    Cyp27a1 0.576 0.704 0.043420983 0.040420788 
    Cyp2a12 -0.044 -0.080 0.864932529 0.829474334 
    Cyp2a22 0.799 0.368 0.028228105 0.472005496 
    Cyp2a4 1.043 0.148 0.003186099 0.800529575 
    Cyp2a5 0.633 0.060 0.00478295 0.885230963 
    Cyp2b10 6.943 1.618 1.31E-07 0.167757172 
    Cyp2b9 6.591 1.464 8.19E-08 0.176379042 
    Cyp2c29 1.127 0.401 5.22E-06 0.094661353 
    Cyp2c37 0.185 0.508 0.596006078 0.201336035 
    Cyp2c38 2.070 0.605 5.34E-09 0.0311444 
    Cyp2c40 -0.090 -0.031 0.772898105 0.955515244 
    Cyp2c44 -0.259 0.105 0.171981523 0.736868714 
    Cyp2c50 0.505 0.045 0.13333446 0.948934169 
    
Cyp2c53-
ps 1.258 0.190 0.003304934 0.787236834 
    Cyp2c54 0.333 0.555 0.284557367 0.141533412 
    Cyp2c55 6.418 0.587 2.03E-14 0.185230396 
    Cyp2c65         
Supplementary Table 3: The comprehensive effect of PCN treatment on hepatic and ileal XMEs. 
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    Cyp2c66 0.261 0.104 0.110716192 0.6923277 
    Cyp2c67 -0.368 -0.259 0.114215689 0.41645564 
    Cyp2c68 -0.276 -0.180 0.228870045 0.595629585 
    Cyp2c69 -0.352 -0.189 0.130732056 0.585741341 
    Cyp2c70 0.233 0.035 0.352547408 0.943314469 
    Cyp2d10 0.098 0.007 0.553842022 0.982179407 
    Cyp2d11 0.075 0.091 0.78069673 0.820511303 
    Cyp2d12 0.184 0.266 0.468660244 0.413051654 
    Cyp2d13 -0.393 0.084 0.092562608 0.84207906 
    Cyp2d22 0.395 0.241 0.064805156 0.409705177 
    Cyp2d26 0.214 0.247 0.394146507 0.459331721 
    Cyp2d34 0.394 0.383 0.437010067 0.591307547 
    
Cyp2d37-
ps 
-0.203 0.121 0.346150698 0.719044505 
    Cyp2d40 -0.565 0.157 0.110263791 0.795360257 
    Cyp2d9 0.339 0.358 0.478004592 0.591307547 
    Cyp2e1 0.071 0.286 0.741251364 0.223265676 
    Cyp2f2 0.027 -0.380 0.882047443 0.02887591 
    Cyp2g1 1.238 -0.347 0.003209173 0.559516077 
    Cyp2j13 0.348 0.290 0.051871259 0.20010032 
    Cyp2j5 0.251 0.266 0.053201236 0.095291456 
    Cyp2j6 0.306 0.327 0.127051182 0.196735385 
    Cyp2j8 0.295 0.247 0.040827806 0.171780994 
    Cyp2j9 -0.577 -0.278 0.02195992 0.420136956 
    Cyp2r1 -0.041 -0.109 0.81768424 0.623314556 
    Cyp2s1 -0.073 0.668 0.911222003 0.317036881 
    Cyp2t4 0.085 0.015 0.551666973 0.955967419 
    Cyp2u1 -1.077 -0.445 6.32E-07 0.02236629 
    Cyp2w1 0.363 0.163 0.022244414 0.459331721 
    Cyp39a1 -0.474 -0.007 0.291258635 0.994971281 
    Cyp3a11 3.642 0.358 2.08E-10 0.451653488 
    Cyp3a13 0.222 0.214 0.220599946 0.373614877 
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    Cyp3a16 3.329 0.285 1.54E-10 0.520463869 
    Cyp3a25 1.585 0.023 8.26E-09 0.953468102 
    Cyp3a41a 1.706 0.216 7.00E-07 0.569460901 
    Cyp3a44 1.241 0.036 1.56E-06 0.927438575 
    Cyp3a57 1.757 0.021 1.76E-09 0.957596744 
    Cyp3a59 2.778 0.276 2.06E-11 0.368290271 
    Cyp46a1 -0.033 -0.277 0.928740916 0.49276261 
    Cyp4a10 -1.539 -0.860 0.001789337 0.139267429 
    Cyp4a12a -0.118 -0.524 0.844262835 0.440375754 
    Cyp4a12b -0.031 -0.473 0.961398971 0.503889528 
    Cyp4a14 -0.919 -0.148 0.051227515 0.864625771 
    Cyp4a31 -1.741 -1.063 0.002076411 0.109923899 
    Cyp4b1 -0.623 -0.028 0.004126175 0.950324529 
    Cyp4f13 -0.277 -0.141 0.071566449 0.525702155 
    Cyp4f14 0.335 -0.125 0.065799883 0.66172333 
    Cyp4f15 0.371 0.244 0.023104582 0.239940605 
    Cyp4f16 0.558 0.075 0.001393616 0.787718568 
    Cyp4f17 0.235 0.175 0.066549401 0.294719193 
    Cyp4f18 0.881 0.379 2.14E-05 0.066217803 
    Cyp4f40         
    Cyp4f41-ps 0.224 0.042 0.096401344 0.86567057 
    Cyp4v3 -0.469 0.130 0.008742124 0.629074268 
    Cyp4x1         
    Cyp51 0.130 0.317 0.628337335 0.317592494 
    Cyp7a1 -0.295 0.284 0.28253931 0.447240471 
    Cyp7b1 -0.374 0.166 0.475688316 0.85234487 
    Cyp8b1 1.210 -0.291 0.052535773 0.783625551 
  
Alcohol 
dehydrogenases 
Adh1 0.600 0.369 0.00375224 0.13703633 
    Adh4 -0.525 -0.295 0.008465973 0.239073432 
    Adh5 0.196 0.195 0.152699396 0.266331759 
    Adh6-ps1 -0.843 -0.535 0.011262535 0.197442451 
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    Adh6a 0.516 0.003 0.150450063 0.997547388 
    Adh7 0.389 0.156 0.034983167 0.567469789 
  Aldo-keto reductases Akr1a1 0.152 0.068 0.237741562 0.747980181 
    Akr1b10 0.380 0.141 0.135676362 0.737182478 
    Akr1b3 0.753 0.263 0.000783503 0.342913331 
    Akr1b7 4.871 0.522 6.63E-10 0.436451105 
    Akr1b8 0.214 0.315 0.307544517 0.224195859 
    Akr1c12 0.116 0.126 0.450119448 0.552246932 
    Akr1c13 0.109 0.115 0.472701746 0.589416119 
    Akr1c14 0.292 -0.067 0.260257246 0.889885008 
    Akr1c18 0.310 -0.238 0.145502005 0.413051654 
    Akr1c19 0.364 0.296 0.140156064 0.371792182 
    Akr1c20 0.277 0.432 0.073671843 0.020825565 
    Akr1c6 0.250 0.363 0.092819684 0.04329317 
    Akr1cl 1.413 -0.059 0.260782747 0.982179407 
    Akr1d1 1.739 0.747 2.77E-06 0.031881594 
    Akr1e1 0.275 0.032 0.08595976 0.920261591 
    Akr7a5 0.304 -0.044 0.071945043 0.889551356 
  
Aldehyde 
dehydrogenases 
Aldh16a1 0.141 0.092 0.410117226 0.731866998 
    Aldh18a1 0.613 0.294 0.001247957 0.194223241 
    Aldh1a1 0.875 0.246 0.000102213 0.343164819 
    Aldh1a2 0.539 0.651 0.072759726 0.076549889 
    Aldh1a3 1.603 0.565 1.32E-06 0.0646244 
    Aldh1a7 1.111 0.472 1.13E-05 0.056227638 
    Aldh1b1 1.381 0.149 0.000682648 0.822784187 
    Aldh1l1 0.365 0.087 0.090536001 0.818182689 
    Aldh1l2         
    Aldh2 0.354 0.224 0.144393915 0.519621351 
    Aldh3a1 0.078 0.004 0.542350937 0.988703678 
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    Aldh3a2 -0.453 -0.116 0.072028222 0.786601603 
    Aldh3b1 0.264 -0.094 0.23542302 0.803556501 
    Aldh3b2         
    Aldh3b3 0.113 0.137 0.383294037 0.417259047 
    Aldh4a1 0.711 0.422 5.80E-05 0.020042103 
    Aldh5a1 0.022 -0.217 0.907839768 0.248470208 
    Aldh6a1 -0.022 -0.055 0.904953726 0.824088909 
    Aldh7a1 0.391 0.131 0.022853311 0.61462553 
    Aldh8a1 0.367 0.092 0.115089966 0.822250907 
    Aldh9a1 0.234 0.160 0.321566748 0.65156902 
  Carboxylesterases Ces1b 0.048 0.456 0.870278156 0.111248622 
    Ces1c 0.590 0.272 0.00034409 0.142562802 
    Ces1d 1.283 0.466 0.000234403 0.242321641 
    Ces1e 0.235 -0.463 0.415525361 0.177802511 
    Ces1f 0.117 -0.048 0.460154294 0.860345771 
    Ces1g 1.263 0.981 0.000235613 0.008808571 
    Ces2a 3.559 0.752 3.17E-13 0.007778188 
    Ces2b 1.222 1.009 0.015457505 0.101222258 
    Ces2c 1.118 1.013 0.0209954 0.086611671 
    Ces2e 0.094 -0.214 0.751025662 0.563394735 
    Ces2f 3.044 0.527 6.12E-13 0.032993137 
    Ces2g 1.126 0.187 6.28E-07 0.419283812 
    Ces3a 0.105 0.072 0.35158257 0.673164911 
    Ces3b 0.298 0.254 0.342654775 0.568072742 
    Ces4a -0.809 -0.385 0.055209561 0.527170292 
Phase II 
Glutathione S-
transferases 
Gsta2 2.788 0.588 0.00046201 0.587534164 
    Gsta3 0.537 -0.005 0.002240258 0.989163394 
    Gsta4 1.343 -0.330 0.000110056 0.42796389 
    Gstcd 0.376 -0.013 0.020522338 0.968306079 
    Gstk1 -0.095 -0.272 0.497922493 0.08823388 
    Gstm1 2.142 0.299 5.88E-08 0.430782343 
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    Gstm2 2.597 0.831 7.33E-09 0.020318855 
    Gstm3 1.756 0.308 4.91E-08 0.288645858 
    Gstm4 2.638 0.383 7.43E-10 0.260598097 
    Gstm5 0.590 0.157 0.000286784 0.43937882 
    Gstm6 2.354 0.496 1.58E-09 0.100502896 
    Gstm7 0.551 -0.015 0.008119886 0.973481687 
    Gsto1 0.296 0.010 0.054417479 0.976290177 
    Gsto2 0.167 0.157 0.348072149 0.525144671 
    Gstp1 0.143 0.058 0.447499159 0.859162837 
    Gstp2 0.049 -0.057 0.653250604 0.710843534 
    Gstt1 0.297 0.007 0.065709576 0.98522723 
    Gstt2 -1.150 -0.819 0.004674929 0.090947951 
    Gstt3 1.758 0.118 1.44E-06 0.806376748 
    Gstz1 0.064 0.058 0.662205463 0.795264416 
  Sulfotransferases Sult1a1 0.579 0.391 0.020048815 0.214513288 
    Sult1b1 0.532 0.309 0.020794314 0.303500836 
    Sult1c1 -0.224 0.166 0.212304986 0.514913513 
    Sult1c2 0.294 -0.566 0.223138971 0.048616017 
    Sult1d1 0.893 0.410 0.000869292 0.195046478 
    Sult1e1 1.302 0.691 0.001116758 0.137484215 
    Sult2a7 2.385 -0.028 6.42E-05 0.979818386 
    Sult2a8 -0.428 0.127 0.11043721 0.780374755 
    Sult2b1         
    Sult4a1 0.328 0.004 0.008567473 0.989091557 
    Sult5a1 0.551 -0.165 0.107093977 0.775618739 
  
UDP 
glycosyltransferases 
Ugt1a10 1.663 0.070 0.032440178 0.966053868 
    Ugt1a6a 0.077 -0.204 0.826663738 0.649879758 
    Ugt1a6b 0.927 0.343 8.45E-05 0.178423037 
    Ugt2a1 0.763 0.041 0.000139508 0.903145107 
    Ugt2a3 -0.013 -0.098 0.945800485 0.682471496 
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    Ugt2b1 0.443 -0.632 0.13019971 0.077548112 
    Ugt2b34 0.843 0.047 0.000112842 0.898381451 
    Ugt2b35 0.933 0.006 5.93E-05 0.98975358 
    Ugt2b36 0.186 -0.128 0.249642745 0.587303954 
    Ugt2b37 0.016 -0.221 0.955988947 0.478430785 
    Ugt2b38 -0.050 -0.224 0.810548106 0.331294432 
    Ugt2b5 0.023 -0.180 0.932388795 0.547467398 
    Ugt3a1 -0.002 0.170 0.991727773 0.499360517 
    Ugt3a2 0.132 0.199 0.473132178 0.390165436 
Phase III 
ATP-binding 
cassettes 
Abca1 0.441 0.309 0.014420766 0.16670699 
    Abca12         
    Abca14         
    Abca17 0.055 0.178 0.85460872 0.63585783 
    Abca2 0.287 -0.350 0.165204162 0.175615159 
    Abca3 0.114 -0.006 0.439806524 0.983433163 
    Abca4 0.160 0.095 0.356233155 0.728618069 
    Abca5 -0.075 -0.287 0.790830001 0.366340841 
    Abca6 0.200 0.215 0.226545878 0.316096111 
    Abca7 -0.235 -0.101 0.086994599 0.630066325 
    Abca8a -0.133 0.366 0.546097581 0.14604884 
    Abca8b 0.274 0.313 0.282626697 0.345116039 
    Abca9 0.302 0.173 0.101987854 0.514407311 
    Abcb10 -0.203 -0.494 0.225739383 0.014140284 
    Abcb11 0.545 0.090 0.006981563 0.788490603 
    Abcb1a 1.442 -0.129 0.000277031 0.840097555 
    Abcb1b 0.618 0.487 0.011612536 0.101237526 
    Abcb4 -0.569 -0.654 0.000180635 0.000458236 
    Abcb6 -0.087 0.051 0.552760396 0.831791839 
    Abcb7 0.055 0.017 0.7166416 0.95053373 
    Abcb8 0.384 -0.016 0.042919393 0.967784066 
    Abcb9 -0.214 -0.253 0.355091294 0.402014972 
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    Abcc1 -0.370 -0.291 0.003252886 0.046685918 
    Abcc10 -0.089 -0.228 0.59356963 0.234738913 
    Abcc12 -0.200 0.069 0.533917326 0.904928088 
    Abcc2 0.475 0.075 0.004657993 0.786601603 
    Abcc3 1.597 0.428 2.78E-09 0.040420788 
    Abcc4 0.296 0.337 0.055654358 0.074362511 
    Abcc5 0.194 0.114 0.298651162 0.69535162 
    Abcc6 -0.149 -0.009 0.289362498 0.97643671 
    Abcc8         
    Abcc9 0.067 0.147 0.77392958 0.626040888 
    Abcd1 0.524 0.376 0.02928331 0.218320755 
    Abcd2 1.151 -0.581 0.055342641 0.49793098 
    Abcd3 -0.168 -0.023 0.359705926 0.951057252 
    Abcd4 0.208 0.224 0.328295197 0.428448926 
    Abce1 0.314 0.142 0.063060541 0.570330469 
    Abcf1 0.506 0.379 0.078593279 0.31694254 
    Abcf2 0.175 0.109 0.525794173 0.803587644 
    Abcf3 0.387 0.247 0.014995834 0.218746914 
    Abcg1 0.410 0.391 0.065678849 0.159118045 
    Abcg2 0.184 0.135 0.352568376 0.646381839 
    Abcg3 0.346 0.046 0.224526693 0.93643713 
    Abcg4 0.880 -0.115 0.000975509 0.785899795 
    Abcg5 0.301 -0.112 0.04811495 0.629271906 
    Abcg8 -0.019 -0.219 0.928458194 0.301611537 
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      ILEUM       
    
GeneNam
e 
log2FC   
WTPCN-WTCtl 
log2FC       PXRKOPCN-
PXRKOCtl 
adj.P.Val                
WTPCN-WTCtl 
adj.P.Val                     
PXRKOPCN-PXRKOCtl 
Phase I Cyptochomes P450 Cyp17a1 0.154 -0.144 7.80E-01 6.56E-01 
    Cyp1a1         
    Cyp1a2         
    Cyp1b1 0.396 0.521 1.25E-01 1.39E-02 
    Cyp20a1 0.088 0.045 7.25E-01 7.87E-01 
    Cyp21a1 -0.534 -0.097 5.07E-01 8.89E-01 
    Cyp26a1         
    Cyp26b1 -0.323 0.502 7.30E-01 3.34E-01 
    Cyp27a1 0.290 0.340 4.39E-01 1.73E-01 
    Cyp2a12         
    Cyp2a22         
    Cyp2a4         
    Cyp2a5 0.207 0.337 8.20E-01 4.70E-01 
    Cyp2b10 4.566 0.706 1.00E-07 2.49E-01 
    Cyp2b9 4.052 0.280 4.74E-08 6.22E-01 
    Cyp2c29 0.479 0.408 3.47E-01 2.61E-01 
    Cyp2c37         
    Cyp2c38 -0.048 -0.084 9.01E-01 6.32E-01 
    Cyp2c40 0.522 0.455 2.90E-01 2.08E-01 
    Cyp2c44 0.242 0.513 6.24E-01 7.83E-02 
    Cyp2c50         
    
Cyp2c53-
ps         
    Cyp2c54         
    Cyp2c55 3.478 1.312 1.40E-04 9.10E-02 
    Cyp2c65 1.295 0.681 7.69E-03 1.11E-01 
    Cyp2c66 1.311 0.611 9.35E-03 1.69E-01 
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    Cyp2c67 0.198 0.245 6.86E-01 3.95E-01 
    Cyp2c68 0.167 0.258 7.79E-01 4.25E-01 
    Cyp2c69 0.209 0.196 6.98E-01 5.57E-01 
    Cyp2c70 -0.137 -0.075 6.13E-01 6.86E-01 
    Cyp2d10 -0.250 0.982 8.20E-01 6.16E-02 
    Cyp2d11 -0.202 0.685 8.23E-01 1.13E-01 
    Cyp2d12 -0.259 0.775 7.57E-01 7.86E-02 
    Cyp2d13 -0.087 0.080 6.97E-01 5.61E-01 
    Cyp2d22 -0.114 -0.020 7.40E-01 9.39E-01 
    Cyp2d26 -0.279 0.937 7.76E-01 6.32E-02 
    Cyp2d34 -0.067 0.148 9.11E-01 5.66E-01 
    
Cyp2d37-
ps -0.606 0.171 2.90E-01 7.27E-01 
    Cyp2d40 0.081 1.461 9.61E-01 1.33E-02 
    Cyp2d9 -0.208 0.102 6.35E-01 7.38E-01 
    Cyp2e1 0.058 0.609 9.86E-01 5.68E-01 
    Cyp2f2 -0.303 0.037 4.98E-01 9.27E-01 
    Cyp2g1         
    Cyp2j13 0.133 0.303 8.26E-01 3.02E-01 
    Cyp2j5         
    Cyp2j6 0.258 0.261 4.24E-01 2.31E-01 
    Cyp2j8 0.211 0.495 5.56E-01 2.74E-02 
    Cyp2j9 -0.027 0.261 9.64E-01 2.20E-01 
    Cyp2r1 0.183 0.091 5.53E-01 6.78E-01 
    Cyp2s1 0.196 0.426 6.52E-01 8.92E-02 
    Cyp2t4 -0.155 -0.176 6.81E-01 4.36E-01 
    Cyp2u1 -0.181 0.469 7.41E-01 1.10E-01 
    Cyp2w1 0.048 -0.278 9.34E-01 1.95E-01 
    Cyp39a1 0.115 0.047 8.27E-01 8.87E-01 
    Cyp3a11 3.495 -0.048 1.62E-06 9.51E-01 
    Cyp3a13 0.462 0.082 5.54E-02 7.27E-01 
    Cyp3a16 3.727 -0.031 2.10E-06 9.73E-01 
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    Cyp3a25 2.217 0.776 2.51E-03 2.39E-01 
    Cyp3a41a 3.918 -0.101 8.31E-06 9.15E-01 
    Cyp3a44 3.211 0.119 7.25E-05 8.97E-01 
    Cyp3a57 2.308 0.671 1.36E-03 3.01E-01 
    Cyp3a59 2.432 0.614 3.95E-04 3.16E-01 
    Cyp46a1 -0.198 0.260 7.16E-01 4.08E-01 
    Cyp4a10 -0.103 -0.655 9.24E-01 1.10E-01 
    Cyp4a12a         
    Cyp4a12b         
    Cyp4a14         
    Cyp4a31 -0.076 -0.135 8.73E-01 5.52E-01 
    Cyp4b1 0.394 0.068 3.82E-01 8.68E-01 
    Cyp4f13 -0.029 0.119 9.59E-01 5.85E-01 
    Cyp4f14 0.028 0.183 9.56E-01 3.06E-01 
    Cyp4f15         
    Cyp4f16 -0.336 0.246 4.40E-01 4.16E-01 
    Cyp4f17 -0.140 0.162 7.11E-01 4.68E-01 
    Cyp4f18 0.456 0.254 2.04E-02 1.36E-01 
    Cyp4f40 -0.136 -0.133 7.74E-01 6.31E-01 
    
Cyp4f41-
ps -0.003 -0.136 9.95E-01 4.23E-01 
    Cyp4v3 -0.339 0.269 4.12E-01 3.45E-01 
    Cyp4x1 0.098 0.193 8.05E-01 3.39E-01 
    Cyp51 0.225 -0.328 3.99E-01 6.87E-02 
    Cyp7a1         
    Cyp7b1 0.413 0.669 8.79E-02 2.14E-03 
    Cyp8b1         
  
Alcohol 
dehydrogenases Adh1 0.409 0.277 2.44E-01 2.96E-01 
    Adh4 -0.225 -0.337 6.33E-01 2.28E-01 
    Adh5 -0.002 0.049 9.96E-01 7.26E-01 
    Adh6-ps1         
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    Adh6a 0.231 -0.648 8.63E-01 2.86E-01 
    Adh7         
  Aldo-keto reductases Akr1a1 0.014 -0.051 9.65E-01 6.92E-01 
    Akr1b10 0.110 0.059 6.20E-01 6.97E-01 
    Akr1b3 -0.094 -0.050 8.71E-01 8.82E-01 
    Akr1b7 0.856 -0.528 3.56E-03 4.32E-02 
    Akr1b8 0.381 0.108 5.75E-01 8.40E-01 
    Akr1c12 0.308 0.249 1.79E-01 1.60E-01 
    Akr1c13 0.348 0.356 2.43E-01 1.06E-01 
    Akr1c14 0.561 0.821 1.73E-01 1.31E-02 
    Akr1c18 0.162 0.058 6.99E-01 8.49E-01 
    Akr1c19 0.876 0.853 7.54E-02 3.65E-02 
    Akr1c20         
    Akr1c6         
    Akr1cl 0.118 -0.165 7.33E-01 4.00E-01 
    Akr1d1         
    Akr1e1 -0.144 0.004 6.95E-01 9.88E-01 
    Akr7a5 -0.073 -0.025 8.51E-01 9.17E-01 
  
Aldehyde 
dehydrogenases Aldh16a1 0.236 -0.084 5.91E-01 7.96E-01 
    Aldh18a1 -0.346 -0.053 2.78E-02 7.43E-01 
    Aldh1a1 0.426 0.533 1.36E-01 2.00E-02 
    Aldh1a2 0.150 0.424 6.00E-01 1.57E-02 
    Aldh1a3 0.388 0.422 1.97E-01 6.40E-02 
    Aldh1a7 0.383 0.182 2.11E-01 4.58E-01 
    Aldh1b1 -0.112 0.030 7.79E-01 9.14E-01 
    Aldh1l1 -0.459 -0.469 9.65E-02 3.72E-02 
    Aldh1l2 0.261 0.214 1.25E-01 1.13E-01 
    Aldh2 -0.126 -0.074 6.72E-01 7.09E-01 
    Aldh3a1 -0.014 -0.040 9.75E-01 8.26E-01 
    Aldh3a2 0.170 0.078 5.76E-01 7.17E-01 
    Aldh3b1 0.201 0.087 3.49E-01 6.04E-01 
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    Aldh3b2 0.105 -0.033 8.11E-01 9.08E-01 
    Aldh3b3 0.072 -0.177 8.84E-01 4.18E-01 
    Aldh4a1 0.032 -0.438 9.85E-01 4.15E-01 
    Aldh5a1 -0.332 -0.181 2.60E-01 4.30E-01 
    Aldh6a1 -0.099 0.018 6.43E-01 9.14E-01 
    Aldh7a1 0.129 0.226 6.40E-01 1.62E-01 
    Aldh8a1         
    Aldh9a1 -0.100 0.080 7.16E-01 6.45E-01 
  Carboxylesterases Ces1b         
    Ces1c 0.024 0.214 9.85E-01 6.23E-01 
    Ces1d 0.417 0.185 4.11E-01 6.33E-01 
    Ces1e 0.109 -0.005 8.95E-01 9.93E-01 
    Ces1f -0.517 -0.617 1.11E-01 1.93E-02 
    Ces1g 0.003 0.032 9.99E-01 9.61E-01 
    Ces2a 2.486 0.568 1.00E-07 8.57E-02 
    Ces2b 0.556 0.450 9.94E-03 1.93E-02 
    Ces2c 0.505 0.414 4.32E-02 4.92E-02 
    Ces2e 0.188 0.209 5.00E-01 2.53E-01 
    Ces2f 1.215 0.163 1.15E-05 4.97E-01 
    Ces2g 0.076 -0.244 8.86E-01 2.84E-01 
    Ces3a 0.627 0.778 3.32E-01 8.71E-02 
    Ces3b         
    Ces4a         
Phase II 
Glutathione S-
transferases Gsta2 1.847 0.204 7.54E-04 7.17E-01 
    Gsta3 0.487 -0.003 3.43E-01 9.96E-01 
    Gsta4 0.980 0.032 2.04E-02 9.52E-01 
    Gstcd -0.172 -0.132 6.91E-01 6.31E-01 
    Gstk1 0.533 0.159 9.74E-02 5.83E-01 
    Gstm1 0.801 -0.145 2.83E-03 5.86E-01 
    Gstm2 0.562 0.058 2.47E-02 8.33E-01 
    Gstm3 2.040 -0.116 1.44E-05 8.07E-01 
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    Gstm4 0.720 -0.165 7.44E-03 5.19E-01 
    Gstm5 -0.086 -0.171 8.33E-01 3.94E-01 
    Gstm6 0.983 -0.099 7.60E-05 6.82E-01 
    Gstm7 -0.198 -0.286 5.19E-01 1.45E-01 
    Gsto1 0.085 0.185 7.34E-01 1.72E-01 
    Gsto2 0.208 0.229 3.13E-01 1.20E-01 
    Gstp1 -0.081 0.011 7.38E-01 9.55E-01 
    Gstp2 -0.042 -0.016 8.77E-01 9.23E-01 
    Gstt1 0.028 0.225 9.51E-01 1.52E-01 
    Gstt2 -0.139 -0.042 5.38E-01 8.13E-01 
    Gstt3 0.127 -0.001 5.37E-01 9.97E-01 
    Gstz1 -0.165 -0.081 4.06E-01 5.90E-01 
  Sulfotransferases Sult1a1 0.120 0.430 8.62E-01 1.62E-01 
    Sult1b1 0.100 0.122 7.25E-01 4.59E-01 
    Sult1c1 -0.028 -0.037 9.62E-01 8.93E-01 
    Sult1c2 0.244 0.157 6.18E-01 6.34E-01 
    Sult1d1 0.830 0.207 4.31E-04 3.28E-01 
    Sult1e1         
    Sult2a7         
    Sult2a8 -0.178 -0.074 5.18E-01 7.22E-01 
    Sult2b1 -0.067 -0.012 8.50E-01 9.59E-01 
    Sult4a1 -0.026 -0.023 9.69E-01 9.45E-01 
    Sult5a1 0.142 0.472 6.68E-01 1.54E-02 
  
UDP 
glycosyltransferases Ugt1a10 0.053 0.030 9.25E-01 9.17E-01 
    Ugt1a6a 0.291 0.161 3.04E-01 4.57E-01 
    Ugt1a6b 0.569 0.195 7.34E-03 3.07E-01 
    Ugt2a1 0.529 0.191 6.53E-02 4.46E-01 
    Ugt2a3 1.571 0.073 1.70E-03 9.02E-01 
    Ugt2b1         
    Ugt2b34 0.487 0.368 2.55E-03 1.34E-02 
    Ugt2b35 0.142 -0.125 4.55E-01 3.36E-01 
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    Ugt2b36 0.259 0.366 5.89E-01 2.10E-01 
    Ugt2b37 0.331 0.353 2.37E-01 8.86E-02 
    Ugt2b38 0.251 0.349 5.82E-01 2.12E-01 
    Ugt2b5 0.335 0.419 2.69E-01 5.86E-02 
    Ugt3a1         
    Ugt3a2         
Phase III ATP-binding cassettes Abca1 0.846 0.489 4.67E-04 2.24E-02 
    Abca12 -0.144 0.285 9.10E-01 6.12E-01 
    Abca14 0.041 -0.140 9.10E-01 3.30E-01 
    Abca17 0.011 0.020 9.85E-01 9.36E-01 
    Abca2 -0.046 -0.041 8.92E-01 8.14E-01 
    Abca3 0.153 0.191 4.62E-01 1.66E-01 
    Abca4 0.278 0.147 4.80E-01 6.10E-01 
    Abca5 -0.088 0.103 7.13E-01 4.69E-01 
    Abca6         
    Abca7 0.051 -0.359 8.98E-01 2.96E-02 
    Abca8a -0.092 0.142 8.59E-01 5.84E-01 
    Abca8b -0.535 0.503 3.86E-02 2.38E-02 
    Abca9 -0.039 0.230 9.41E-01 2.30E-01 
    Abcb10 -0.064 -0.158 7.85E-01 1.89E-01 
    Abcb11 -0.022 0.041 9.72E-01 8.80E-01 
    Abcb1a 1.468 1.057 2.14E-05 9.36E-04 
    Abcb1b 1.581 0.953 1.14E-05 2.44E-03 
    Abcb4 1.497 1.107 4.13E-05 1.24E-03 
    Abcb6 0.001 0.001 9.99E-01 9.96E-01 
    Abcb7 -0.123 -0.076 6.93E-01 7.10E-01 
    Abcb8 -0.188 -0.186 4.52E-01 2.69E-01 
    Abcb9 0.103 0.118 7.09E-01 4.68E-01 
    Abcc1 0.084 -0.015 8.71E-01 9.63E-01 
    Abcc10 0.069 -0.102 8.68E-01 6.16E-01 
    Abcc12         
    Abcc2 1.351 0.701 1.70E-03 6.40E-02 
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    Abcc3 0.373 -0.421 4.43E-01 1.94E-01 
    Abcc4 -0.060 0.198 8.84E-01 2.68E-01 
    Abcc5 0.274 0.358 3.83E-01 9.57E-02 
    Abcc6 0.305 0.453 4.62E-01 9.77E-02 
    Abcc8 -0.030 0.074 9.50E-01 6.99E-01 
    Abcc9 0.422 0.438 3.15E-01 1.45E-01 
    Abcd1 -0.178 -0.293 6.85E-01 2.43E-01 
    Abcd2         
    Abcd3 0.125 0.272 6.49E-01 8.72E-02 
    Abcd4 -0.053 0.061 8.98E-01 7.62E-01 
    Abce1 -0.278 -0.310 4.13E-01 1.77E-01 
    Abcf1 0.089 -0.033 7.49E-01 8.65E-01 
    Abcf2 -0.146 -0.298 7.08E-01 1.69E-01 
    Abcf3 -0.120 -0.094 4.05E-01 3.50E-01 
    Abcg1 0.094 0.126 7.36E-01 4.25E-01 
    Abcg2 -0.170 -0.399 5.18E-01 1.94E-02 
    Abcg3 -0.122 0.210 6.59E-01 1.88E-01 
    Abcg4 0.530 0.042 2.14E-05 7.25E-01 
    Abcg5 0.520 -0.067 1.60E-02 7.68E-01 
    Abcg8 0.723 0.364 6.56E-02 2.69E-01 
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Cluster 
number 
Enrichment 
score 
Adjusted 
P-value Ontology 
Gene 
count Genes 
1 1.77 
1.80E-03 Lipid metabolic process Goterm_BP_direct 12 
acetyl-Coenzyme A acyltransferase 1B (Acaa1b); acyl-CoA 
thioesterase 1 (Acot1); acyl-Co A thioesterase 3 (Acot3); carnitine O-
octanoyl transferase (); peroxisome proliferator activated receptor 
alpha (Ppara); similar to DNA-directed RNA polymerase II 7.6k Da 
polypeptide (RPB10)(RPB7.6)(RPABC5); hypothetical protein 
LOC100044218; predicted gene 13015; polymerase (RNA) II (DNA); 
directed polypeptide L (); cytochrome P450 family 4 subfamily a 
polypeptide 31 (Cyp4a31); cytochrome P450 family 4 subfamily a 
polypeptide 32 (Cyp4a32); predicted gene 1077;cytochrome P450 
family 4 subfamily a polypeptide 10 (Cyp4a10)            
5.20E-02 Lipid metabolism Up_keywords 8 
2 1.5 
1.90E-02 Biological rhythms Up_keywords 5 D site albumin promoter binding protein (Dbp); hepatic leukemia 
factor (Hlf); CCR4 carbon catabolite repression 4-like (CCrn4l); 
thyrotroph embryonic factor (Tef)  2.30E-02 Rhythmic process Goterm_BP_direct 5 
3 1.44 8.30E-03 TGF-beta signaling pathway Kegg_pathway 5 
MAD homolog 7 (); MAD homolog 9 (); follistatin (Fst); inhibin beta E 
(Inhbe); inhibin beta-C (Inhbc) 
4 1.35 2.60E-03 Glucose metabolic process Goterm_BP_direct 5 
peroxisome proliferator activated receptor alpha (Ppara); cytosolic 
phosphoenolpyruvate carboxykinase 1 (Pck1); phosphoglucomutase 
2-like 1; phosphorylase kinase alpha 2 (Phka2); lactate 
dehydrogenase A (Ldha)    
5 1.29 
1.10E-02 Cytochrome P450 Interpro 5 
cytochrome P450 family 4 subfamily a polypeptide 31 (Cyp4a31); 
cytochrome P450 family 4 subfamily a polypeptide 32 (Cyp4a32); 
;cytochrome P450 family 4 subfamily a polypeptide 10 (Cyp4a10); 
cytochrome P450 family 2 subfamily u polypeptide 1 (Cyp2u1); 
cytochrome P450 family 26 subfamily b polypeptide 1 (Cyp26b1); 
cytochrome P450 family 4 subfamily b polypeptide 1 (Cyp4b1) 
2.20E-02 Monooxygenase Up_keywords 5 
Supplementary Table 4:  Gene enrichment analyses of downregulated genes upon Pxr activation in the liver. 
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Pregnane X receptor is a major sexually dimorphic hepatic sensor of the gut 
microbiota that controls the host xenobiotic metabolism in male mice 
Context: Xenobiotics act as ligands for PXR which plays a central role in the 
transcriptional control of genes encoding rate-limiting enzymes in detoxication. Several 
groups have also recently reported that microbial metabolites can act as ligands for this 
nuclear receptor. These recent findings led us to investigate whether the gut microbiota 
may influence the hepatic functions that we previously identified as PXR-dependent 
and whether PXR may influence the composition of gut microbiota. This body of work 
which aims at establishing the importance of the bi-directional interaction of PXR and 
gut microbiota is subject to a publication in preparation. 
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Pregnane X receptor is a sexually dimorphic hepatic sensor of gut 
microbiota that controls the host xenobiotic metabolism 
Barretto S, Lasserre F et al. 
INTRODUCTION 
The liver is the heaviest organ in the human body with a wide array of functions that 
can be divided into immunological activity, intermediary metabolism (including a central 
role in carbohydrate, lipid and nitrogen metabolism), secretion of bile, synthesis of various 
serum proteins, degradation of hormones, and detoxification of xenobiotics. The hepatic 
portal vein transports nutrients and xenobiotics present in food from the gastrointestinal 
tract to the liver and ensures that these are processed in the liver before they reach the 
rest of the organism. The liver therefore stands at the crossroad between the portal blood 
flow coming from the intestine and the rest of the organism. In the liver, transcription 
factors from the nuclear receptor superfamily can sense fluctuating levels of nutrients and 
xenobiotics and promptly adapt hepatic metabolism by modulating the transcription of 
genes. Among these, 2 nuclear receptors, the pregnane X receptor (PXR) and the 
constitutive androstane receptor (CAR), and one ligand-activated transcription factor from 
the helix-loop-helix Per-Arnt-Sim family, the aryl hydrocarbon receptor (AhR), are 
commonly described as xenobiotic sensors. They are known to regulate the expression of 
phase 1 xenobiotic metabolizing enzymes (XMEs) from the cytochrome p450 family 
(CYPs), thereby facilitating the elimination of xenobiotics. Although the list of their target 
genes overlaps, it is usually described that AhR regulates the expression of CYP1, while 
CAR and PXR regulate the expression of CYP2 and CYP3. Recently, several new natural 
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AhR ligands have been discovered, including kynurenine and planar indoles resulting 
from the microbial metabolism of dietary tryptophan (reviewed in [1]). Microbial ligand-
driven activation of AhR is thought to limit intestinal inflammation and intestinal 
permeability and may be dysfunctional in inflammatory bowel disease (IBD) [2] and in 
metabolic diseases [3]. These studies have raised the awareness that factors involved in 
xenobiotic metabolism could be intimate partners with the gut microbiota. 
The nuclear receptor PXR (systematic name NR1I2) is highly expressed in the liver 
and intestine of mammals [4] and was characterized as a xenosensor [5]. Regulation of 
XMEs by PXR is of high clinical and toxicological relevance since its first described target 
gene was CYP3A4 in humans [6], which represents 10% of all clinically relevant drug-
metabolizing CYPs in the human liver and up to 75-85% in the intestine [7] and is 
responsible for the metabolization of 60% of marketed drugs [8]. Beside its role as a 
master regulator of xenobiotic metabolism, recent studies have also unveiled roles of PXR 
in intermediary metabolism such as control of hepatic glucose [9-11] and lipid metabolism 
[9,12,13]. Moreover, we have recently reported that PXR might also be involved in the 
control of hepatokine secretion [14]. 
Because of an unusually large and flexible binding pocket, PXR can be activated by 
a variety of structurally diverse chemicals including pharmaceutical drugs, dietary 
supplements, herbal medicines, and environmental pollutants [15]. In the intestine, indole-
3-propionic acid (IPA), a bacterial metabolite produced from tryptophan, was recently 
shown to activate PXR, thereby impacting the intestinal permeability of the host [16]. In the 
liver, others, and we, have observed that PXR activity was strongly decreased in germ-free 
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(GF) male mice compared to specific-pathogen-free (SPF) animals [17-19]. Therefore, PXR 
has emerged as a potential sensor of gut microbiota signals.  
Here, we aimed to gain insights into the bidirectional relationships between PXR 
and the gut microbiota. Our results show that PXR is a broad sensor of gut microbial 
signals in the liver and the small intestine, but not in the colon. Focusing on the liver, we 
demonstrate that, in male mice, the lack of PXR reduces transcriptional regulations upon 
microbiota depletion. PXR-dependent regulations of microbial signals were mostly 
involved in controlling xenobiotic metabolism, and to a lower extent fatty acid metabolism 
in male mice. Conversely, PXR was involved in shaping the gut microbiota. Interestingly, 
this PXR-mediated gut-liver dialogue was strongly sexually dimorphic. Altogether our 
results identify PXR as a central hepatic sensor of gut microbial signals that controls the 
host’s hepatic xenobiotic capacities in a sexually dimorphic way.     
 
MATERIALS AND METHODS 
In vivo studies 
In vivo studies were performed in accordance with European guidelines for the use 
and care of laboratory animals, and were approved by an independent Ethics Committee. 
All mice were housed at the Toxalim-INRA rodent facility (Toulouse, France). The room 
where the mice were housed was kept at a temperature of 21-23°C on a 12-hour light (ZT0-
ZT12) 12-hour dark (ZT12-ZT24) cycle and mice were allowed free access to the diet 
(Teklad Global 18% Protein Rodent Diet) and tap water. ZT stands for Zeitgeber time; ZT0 is 
defined as the time when the lights are turned on and ZT12 as the time when lights are 
turned off.  
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In the first set of experiments, forty-six-week old C57BL/6J male mice were 
purchased from Charles River, kept for two weeks of acclimatization and then randomly 
allocated to the different experimental groups: control (CONT, n=8), ampicillin-treated (A, 
n=8), neomycin-treated (N, n=8), vancomycin-treated (V, n=8), wild-type ANV cocktail-
treated (ANV, n=8). The individual antibiotics [1g/L ampicillin (Euromedex, 
Souffelweyersheim, France), 1 g/L neomycin (Sigma Aldrich, Steinheim, Germany), 0.5 g/L 
vancomycin (MP Biomedicals, Illkirch, France)] or a combination of these 3 antibiotics were 
dissolved in tap water and were provided in the animal bottles. Supplementary Table 1 
gives an overview of the antibiotics used. The antibiotic solutions were prepared fresh 
every 3 days. After 2 weeks of antibiotic treatment, mice were sacrificed at ZT6.  
In the second set of experiments, twelve six-week-old wild-type (WT) C57BL/ 6J 
male mice were purchased from Charles River and 12 Pxr-/- mice were used in this 
experiment. The Pxr-/- mice were backcrossed on the C57Bl/ 6J background and were 
engineered in Pr. Meyer’s laboratory [20] and were bred for 10 years in our animal facility. 
Mice were acclimatized for two weeks, then randomly allocated to the different 
experimental groups: wild-type control (WT CONT n=6), wild-type PCN-treated (WT PCN, 
n=6), Pxr-/- control (Pxr-/- CONT, n=6), Pxr-/- PCN-treated (Pxr-/- PCN, n=6). Mice were 
treated for 2 weeks with antibiotics (ANV cocktail) in their drinking water or with water only 
as previously described. The last 4 days, PCN-treated mice received a daily intraperitoneal 
injection of PCN (100 mg/ kg) in corn oil while control mice received corn oil only. Mice 
were sacrificed at ZT6, 6 hours after the last PCN injection. 
In the last set of experiments, thirty-four six-week old Pxr+/+ (18 males, 16 females) 
and 36 Pxr-/- (16 males, 20 females) littermate mice were derived from Pxr+/- dams and 
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bred at Toxalim-INRA’s rodent facility. At 6 weeks, mice were randomly allocated to the 
different experimental groups in males: Pxr+/+ control (Pxr+/+ CONT, n=10), Pxr+/+ ATB-
treated (Pxr+/+ ATB, n=8), Pxr-/- control (Pxr-/- CONT, n=8), Pxr-/- ATB-treated (Pxr-/- ATB, n=8); 
and in females: Pxr+/+ control (Pxr+/+ CONT, n=8), Pxr+/+ ATB-treated (Pxr+/+ ATB, n=8), Pxr-/- 
control (Pxr-/- CONT, n=10), Pxr-/- ATB-treated males (Pxr-/- ATB, n=10). Mice were kept in 
cages of 5-6 animals. After 2 weeks of antibiotic treatment, mice were sacrificed at ZT6. 
 
Bacterial Cultivation of Feces 
Feces were collected at the beginning and after 14 days of experiment under sterile 
conditions. Fecal samples from antibiotic-treated mice were diluted at 10-3, 10-4, and 10-5 
then cultured on Schaedler C blood medium anaerobically. Untreated mice samples were 
diluted at 10-5, 10-6, and 10-7 before being spread on the same culture media. Colonies 
forming unit were counted after 24 h of incubation in an anaerobic jar at 37°C. 
 
Blood and tissue sampling 
Body weight was monitored at the beginning and at the end of each experimental 
period. Blood was collected at the submandibular vein into lithium heparin-coated tubes 
(BD Microtainer, Franklin Lake, NJ, USA). Plasma was prepared by centrifugation (1500 g, 
15 min, 4°C) and stored at -80°C. Following euthanasia by cervical dislocation, liver, ileum, 
and colon were removed, weighed, dissected, and snap-frozen in liquid nitrogen and 
stored at -80°C until used for RNA extraction.  
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Plasma Analysis 
   Alanine transaminase (ALT), high- or low-density lipoprotein (HDL-LDL), total 
cholesterol, triglycerides and free fatty acids (FFA) were determined using a Pentra 400 
biochemical analyzer (Anexplo facility, Toulouse, France).  
 
Liver neutral lipids 
Hepatic samples were homogenized in 2:1 (v/v) methanol/ethylene glycol-bis(B-
aminoethyl ether)-N,N,N’, N’-tetraacetic acid (EGTA; 5mM), lipids corresponding to an 
equivalent of 2 mg of tissue were extracted (Bligh and Dryer,1959) in chloroform : 
methanol : water (2.5:2.5:2.1,v/v/v) in the presence of internal standards glyceryl 
trinonadecanoate, stigmasterol, and cholesteryl heptadecanoate (Sigma). TGs, free 
cholesterol, and cholesterol esters were analyzed by gas chromatography on a Focus 
Thermo Electron system using a Zebron-1 Phenomenex (Phenomenex Zebron-1, England) 
fused-silica capillary column [5 m; 0:32 mm internal diameter (i.d.); 0:50 lm film thickness]. 
The oven temperature was programmed from 200 to 350°C at a rate of 5
 
C=min, and the 
carrier gas was hydrogen (0.5 bar). The injector and detector were at 315°C and 345°C, 
respectively.  
 
Liver Fatty Acid Analysis  
To measure all hepatic fatty acid methyl ester (FAME) molecular species, lipids that 
corresponded to an equivalent of 1 mg of liver were extracted in the presence of the 
internal standard glyceryl tri- heptadecanoate (2 µg). The lipid extract was transmethylated 
with 1 mL boron trifluoride (BF3) in methanol (14% solution; Sigma) and 1 mL heptane for 
60 min at 80°C and evaporated to dryness. The FAMEs were extracted with heptane/water 
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(2:1). The organic phase was evaporated to dryness and dissolved in 50 lL ethyl acetate. A 
sample (1 µL) of total FAME was analyzed with gas–liquid chromatography [Clarus 600 
system (PerkinElmer), with FAMEWAX fused silica capillary columns (Restek), 30 m × 0:32 
mm i.d., 0:25 lm film thickness]. Oven temperature was programmed to increase from 
110°C to 220°C at a rate of 2 C=min, and the carrier gas was hydrogen [7.25 pounds per 
square inch (psi)]. Injector and detector temperatures were 225°C and 245°C, respectively. 
 
Gene expression  
Total RNA was extracted with with TRI Reagent® (Molecular Research Center, 
Cincinnati, Ohio, USA). RNAs were quantified using nanodrop (NanoDropTM 1000; 
Thermo Scientific). Two micrograms of total RNA were reverse transcribed using the High-
Capacity cDNA Reverse Transcription Kit (Applied BiosystemsTM). The SYBR Green 
(Applied Biosystems, California) assay primers are presented in supplementary table 1. 
Amplification was performed using an ABI Prism 7300 Real-Time PCR System (Applied 
BiosystemsTM). Quantitative real-time polymerase chain reaction (qPCR) data were 
normalized to TATA-box-binding protein mRNA levels and analyzed with LinRegPCR 
(version 2015.3; Jan Ruijter) to get mean efficiency (NO), which is calculated as follows: 
NO = threshold=ðEff meanCq Þ with Eff mean: mean PCR efficiency and CQ: 
quantification cycle. Primers used are described in Supplementary Table 2.   
 
Microarrays  
Total RNA was extracted with TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Gene 
expression profiles were obtained at the GeT-TRiX facility (GénoToul, Génopole Toulouse 
Midi-Pyrénées, France) using Sureprint G3 Mouse GE v2 microarrays (8 x 60 K; design; 
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074,809; Agilent Technologies, Santa Clara, CA, USA) following the manufacturer’s 
instructions. Microarray data and experimental details are available in NCBI’s Gene 
Expression Omnibus (Edgar, Domrachev, & Lash, 2002) and will be made accessible 
through GEO Series. Microarray data were processed using R (http://www.r-project.org) 
and Bioconductor packages (www.bioconductor.org, v3.0). Raw data (median signal 
intensity) were filtered, log2 transformed, corrected for batch effects (microarray washing 
bath), and normalized using CrossNorm method [21]. The linear model was fitted using 
the limma lmFit function [22]. Pair-wise comparisons between biological conditions were 
applied using specific contrasts. A correction for multiple testing was applied using the 
Benjamini–Hochberg procedure for false discovery rate (FDR). Probes with FDR ≤ 0.05 and 
|fold-change| > 1.5 were considered to be differentially expressed between conditions. 
Gene-annotation enrichment analysis and functional annotation clustering were evaluated 
using DAVID [23].  
 
Testosterone hydroxylation assay 
Chemicals 
Acetic acid, ethanol, sodium chloride, potassium dihydrogen phosphate, dibasic 
potassium phosphate, monobasic sodium phosphate, dibasic heptahydrate sodium 
phosphate, potassium sodium tartrate tetrahydrate, glycerol, Folin & Ciocalteu’s phenol 
reagent, albumin from bovine serum, anhydrous sodium carbonate, NADP, D-glucose 6-
phosphate sodium salt, glucose-6-phosphate dehydrogenase, magnesium chloride, 1-
chloro-2,4-dinitrobenzene, reduced L-glutathione and testosterone were purchased from 
Sigma-Aldrich Merck (Saint Quentin Fallavier, France). Acetonitrile and methanol (HPLC 
grade) were purchased from Thermo Fisher Scientific (Waltham, MA, USA). Ammonium 
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acetate, sodium hydroxide and copper sulfate were purchased from VWR (Fontenay-sous-
Bois, France). Flo-Scint™ II and Ultima Gold™ liquid scintillation cocktails were purchased 
from PerkinElmer (Courtabœuf, France). Ultrapure water produced by a Milli-Q system 
(Millipore, Saint-Quentin-en-Yvelines, France) was used for the preparation of HPLC 
mobile phases.  
 
[14C]-testosterone (specific activity: 2.18 GBq/mmol) was purchased from 
PerkinElmer and its radiopurity was 98.8 %, as determined by radio-HPLC. Standards of 
testosterone metabolites were purchased from Steraloids (Newport, RI, USA): 15β-
hydroxytestosterone, 6α-hydroxytestosterone, 6β-hydroxytestosterone, 19-
hydroxytestostérone, 15α-hydroxytestosterone, 11α-hydroxytestosterone, 6β-
hydroxyandrostenedione, 11α-hydroxyandrostenedione, 16β-hydroxytestosterone, 4-
androsten-16α-ol-3,17-dione, 2α-hydroxytestosterone, 2α-hydroxyandrostenedione, 4,6-
androstadien-17β-ol-3-one, 7α-hydroxytestosterone and from Sigma-Aldrich: 
dihydroandrosterone, androstanolone, 16α-hydroxytestosterone, 11β-
hydroxytestosterone, 2β-hydroxytestosterone, 11β-hydroxyandrost-4-ene-3,17-dione, 1-
dehydrotestosterone, androstenedione, epitestosterone, androsterone, estradiol and 
estrone. 
 
Sub-cellular fraction preparation and protein content 
Following mice euthanasia, livers were collected, immediately perfused using NaCl 
0.9 %. They were weighed and frozen in liquid nitrogen until sub-cellular fraction 
preparation, which was carried out within a month. Livers were thawed and homogenized 
at 4°C using a Potter-Elvehjem Teflon glass homogenizer in 4 volumes/g of ice-cold 
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sodium/phosphate buffer 0.1 M pH 7.4. Microsomal and cytosolic hepatic fractions were 
obtained after two centrifugation steps at 4°C (20 min at 9 000 g and 70 min at 105 000 g) 
using a Beckman Optima XPN-80 ultracentrifuge (Villepinte, France). Microsomes were 
resuspended with gentle homogenization in 1 mL/g of ice-cold sodium/phosphate buffer 
0.1 M pH 7.4 with 20 % glycerol (v/v). Sub-cellular fractions were stored at 80°C in 
cryotubes until use. The protein content of sub-cellular fractions was determined using the 
Lowry et al. (1951) method {Lowry:vb}, which was adapted for microplate reading, using a 
Tecan Infinite 200 (Männedorf, Switzerland). 
 
[14C]-testosterone incubations 
Mice hepatic microsomes (0.5 mg proteins/mL) were incubated at 37°C under 
shaking with 10 µM [14C]-testosterone (3.58 kBq per incubation in 5 µL ethanol) fortified 
with unlabelled testosterone. Incubations were performed in a final volume of 0.5 mL in 
0.1 M sodium/phosphate buffer pH 7.4 with 5 mM MgCl2. Incubations were initiated using 
a NADPH generating system: 1.3 mM NADP, 5 mM glucose-6-phosphate, 1 IU glucose-6-
phosphate dehydrogenase. The kinetic of testosterone metabolites formation was 
established between 10 min and 60 min. An incubation time of 20 min was selected in 
order to ensure a linear formation of testosterone metabolites. Incubations were stopped 
with 1.5 mL methanol, kept 30 min on ice and centrifuged 10 min at 6 500 g, 4°C (3MK 
Sigma centrifuges, Newtown Wem Shropshire, UK). Radioactivity measurements (10 µL) 
were performed before storage at -20°C, pending further radio-HPLC analysis. 
Radioactivity measurements were carried out using a Tri-Carb 2910TR (PerkinElmer) liquid 
scintillation analyzer, using Ultima Gold™ as the scintillation cocktail (PerkinElmer). 
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Sample quenching was compensated by the use of quench curves and external 
standardization. 
For the LC-MS confirmation of major testosterone's metabolites structure, 
additional incubations were carried out using unlabeled testosterone (50 µM) and pooled 
microsomes (1 mg proteins/mL, pool of 10 PXR control mice) during 30 min, in the same 
conditions. 
 
Radio-HPLC profiling and quantification 
Incubation media were individually analyzed by radio-HPLC for testosterone 
metabolites profiling and quantification. Reversed-phase high-performance liquid 
chromatography (R-HPLC) analysis were performed on an Ultimate-3000 system (Thermo 
Fisher Scientific) coupled with a flow scintillation analyzer Flo-One Radiomatic™ 610TR 
(PerkinElmer). The HPLC system consisted of Nucleoshell RP18 column (250 x 4.6 mm, 5 
µm, Macherey-Nagel, Hoerdt, France) coupled to a C18 guard precolumn (Nucleoshell 
RP18 5 µm EC 4/3, Macherey-Nagel), maintained at 35°C. Mobile phases were A: 
ammonium acetate buffer (20 mM, adjusted to pH 3.5 with acetic acid) and B: acetonitrile. 
The flow rate was 1 mL/min and the injection volume was 500 μL. The gradient was as 
follow: 0-35 min A:B from 80:20 to 60:40 (v/v); 35-45 min from 60:40 to 40:60; 45-48 min 
from 40:60 to 100 % B. The system returned to the initial condition at 51 min and held for 
another 4 min. Flo-Scint™ II (PerkinElmer) was used as scintillation cocktail, at a flow rate 
of 2 mL/min, and with a 500-µL detection cell. Each incubation media (800 µL, 
corresponding to ca. 1.5 kBq) was evaporated to dryness and reconstituted in mobile 
phase A:B 80:20 (v/v) prior to HPLC injection.  
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In this system, the retention time (RT) of testosterone was 29.8 min. R-HPLC profiles 
were processed with the A500 software (PerkinElmer) using a background suppression of 
20 cpm (counts per minute) and an efficiency correction (80 % for [14C]). Metabolites were 
quantified by integrating the area under the peaks monitored by radioactivity detection. 
All peaks above 4 % of the detected radioactivity were quantified for each animal.  
 
Mass spectrometry analysis 
Unlabeled testosterone incubation media were analyzed by LC-MS using the same 
chromatographic conditions. Testosterone metabolites structure was established based 
on their mass and on the similarity of their retention time with authentic standards. Media 
were analyzed by LC-MS using a RSLC3000 HPLC system (Thermo Fisher Scientific) 
coupled to a HRMS system LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific) 
with a post-column split (0.2 mL/min in the source) using positive electrospray ionization 
(ESI). The injection volume was 50 µL, the source voltage was 1.80 kV, the capillary voltage 
was 30V, the capillary temperature was 350°C, the sheath gas (N2) flow (arbitrary unit) was 
50, the auxiliary gas (N2) flow (arbitrary unit) was 40, the sweep gas (N2) flow (arbitrary unit) 
was 0 and the tube lens offset was 115 V. 
 
GSTs activity assay 
Glutathione S-transferases (GSTs) specific activities were assessed in cytosolic 
fractions in 96-well plates. The assay is based on the GST-catalyzed reaction between GSH 
and the probe substrate CDNB (1-chloro-2,4-dinitrobenzene) which is metabolized by a 
broad range of GST isozymes. Protein content was between 0.6-1.6 µg proteins per 
incubation (controls: 0), to allow a linear measurement of the formation of CDNB-GSH. 
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Incubations were performed in potassium phosphate buffer 0.1 M pH 6.5, using 2.5 mM 
reduced L-glutathione. The reaction was initiated by the addition of ice-cold CDNB (2.5 
µM final). CDNB-GSH formation was measured by the change in absorbance at 340 nm, 
recorded every min over 10 min, using a Tecan Infinite 200. Mean GSTs specific activities 
(n=5 mice per group) were expressed in nmol of product formed per min per mg of 
proteins (nmol/min/mg).  
 
Proton Nuclear Magnetic Resonance (1H-NMR) Based Metabolomics  
Liver polar and lipid extracts and caecal content water were prepared for NMR 
analysis as described previously [24,25]. All 1H-NMR spectra were obtained on a Bruker 
DRX-600-Avance NMR spectrometer (Bruker) using the AXIOM metabolomics platform 
(MetaToul) operating at 600:13MHz for 1H resonance frequency using an inverse detection 
5-mm 1H-13C-15N cryoprobe attached to a cryoplatform (the preamplifier cooling unit). The 
1H-NMR spectra were acquired at 300 K using a standard one-dimensional noesypr1D 
pulse sequence with water presaturation and a total spin-echo delay (2 ns) of 100 ms. Data 
were analyzed by applying an exponential window function with a 0.3-Hz line broadening 
prior to Fourier transformation. The resulting spectra were phased, baseline-corrected, 
and calibrated to trimethylsilylpropanoic acid (TSP) (0:00 ppm) manually using Mnova 
NMR (version 9.0; Mestrelab Research S.L.). The spectra were subsequently imported into 
MatLab (R2014a; MathsWorks, Inc.). All data were analyzed using full-resolution spectra. 
The region containing the water resonance (4:6– 5:2 ppm) was removed, and the spectra 
were normalized to the probabilistic quotient [26] and aligned using a previously 
published function [27]. 
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Data were mean-centered and scaled using the unit variance scaling prior to 
analysis with orthogonal projection on latent structure-discriminant analysis (O-PLS-DA). 
The O-PLS derived model was evaluated for goodness of prediction (Q2Y value) using n-
fold cross-validation, where n depends on the sample size. The parameters of the final 
models are indicated in the figure legends. Metabolite identification and discrimination 
between the groups were done by calculating the O-PLS-DA correlation coefficients (r2) 
for each variable and back-scaled into a spectral domain so that the shapes of the NMR 
spectra and the signs of the coefficients were preserved [28]. The weights of the variables 
were color-coded according to the square of the O-PLS-DA correlation coefficients. 
Correlation coefficients extracted from significant models were filtered so that only 
significant correlations above the threshold defined by Pearson’s critical correlation 
coefficient (p < 0:05; r > 0.55; for n = 6 per group) were considered significant. For 
illustration purposes, the area under the curve of several signals of interest was integrated 
and significance tested with a univariate test.  
 
High-throughput Sequencing of Bacterial content 
DNA extraction and sequencing of 16S rRNA gene regions.  
The microbial population present in the samples has been determined using next 
generation high throughput sequencing of variable regions of the 16S rRNA bacterial 
gene. The workflow was established by Vaiomer (Labège, France) [29]. Library 
construction and sequencing: The PCR amplification was performed using 16S universal 
primers targeting the V3-V4 regions of the bacterial 16S ribosomal gene (Vaiomer 
universal 16S primers). For each sample, a sequencing library was generated by addition 
of sequencing adapters. The detection of the sequencing fragments was performed with 
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the MiSeq Illumina technology using the 2 x 300 paired-end MiSeq kit. Bioinformatics 
pipeline: The targeted metagenomic sequences from microbiota were analyzed using the 
bioinformatics pipeline established by Vaiomer from the FROGS guidelines [30]. Briefly, 
after demultiplexing of the barcoded Illumina paired reads, single read sequences were 
cleaned and paired for each sample independently into longer fragments. Operational 
taxonomic units (OTUs) were produced via single-linkage clustering and taxonomic 
assignment is performed in order to determine community profiles. 
 
Data Analysis   
Reads obtained from the MiSeq sequencing system have been processed using 
the Vaiomer bioinformatics pipeline. The steps included quality-filtering, clustering into 
OTUs with the Swarm algorithm and taxonomic affiliation. Alpha diversity was analyzed 
with different methods (median + interquartile), 1) Observed, 2) Chao1, 3) Shannon, 4) 
Simpson, and 5) Inverse Simpson. Beta diversity (β-diversity) was measured with numeric 
values for the “all against all” with Jaccard, Bray-Curtis, Unifrac and Weighted Unifrac. 
Graphical representations of the relative proportion of taxa were made at each taxonomic 
level (Phylum, Class, Order, Family, and Genus) for all study samples. “Linear discriminant 
analysis Effect Size” (LEfSe) [31] was the algorithm used to identify taxonomic groups 
characterizing the differences between two or more biological conditions. LEfSe was run 
using default values (alpha value of 0.5 for both the factorial Kruskal-Wallis test among 
classes and the pairwise Wilcoxon-Mann-Whitney test between subclasses, threshold of 
2.0 for the logarithmic LDA score for discriminative features) and the strategy for multi-
class analysis set to ‘all-against-all’. The LEfSe analysis was performed on the complete 
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sequence data (no OTU abundance threshold) for identifying genotype effect on either 
males or females and sex effect on either Pxr+/+ or Pxr-/- mice.  
 
Statistical Analysis  
Statistical analyses were performed using GraphPad Prism for Mac OS X (version 
7.00; GraphPad Software). One-way or two-way analysis of variance (ANOVA) was 
performed, followed by appropriate posthoc tests (Bonferroni) when differences were 
found statistically significant. When only two groups were compared, the Wilcoxon-Mann 
Whitney test was used; p < 0:05 was considered significant.  
 
 
RESULTS  
PXR is a broad sensor of the gut microbiota in the liver and small intestine 
We first treated C57Bl6/J male mice with several individual antibiotics (ampicilin, 
neomycin and vancomycin) or a combination of these (ANV cocktail) for 2 weeks and 
monitored Pxr and its prototypical target genes mRNA expression in the liver, small and 
large intestine (Figure 1). To avoid a direct effect of the drugs on PXR activity in the liver, 
we tested antibiotics that are described as poorly absorbed (Supplementary Table 1). We 
confirm that none of the antibiotic treatments affected Pxr expression, whereas its activity, 
as assessed by the expression of its target genes, was significantly decreased. In the liver, 
ampicilin, vancomycin and the ANV cocktail significantly decreased Cyp3a11 and 
Cyp2c55 expression. Neomycin alone failed to decrease hepatic PXR activity, but this 
treatment did not significantly increased caecum weight either, suggesting a limited 
impact on the gut microbiota (Supplementary figure 1). In the ileum, all treatments almost 
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completely abolished Cyp3a11, Cyp2c55, Cyp3a41a and Cyp3a44 expression. 
Interestingly, in the colon, CYP expression was not significantly affected by any antibiotic 
treatment, demonstrating that PXR is not responsive to gut microbiota-derived signals in 
this intestinal section.   
 
Gut microbiota suppression does not interfere with the pharmacological activation 
of PXR 
 
Next, we wondered if gut microbiota suppression could interfere with PXR’s 
capacity to bind and respond to its ligands. To test this hypothesis, we used WT and Pxr-/- 
male mice treated with antibiotics (ATB), PCN (the pharmacological agonist of PXR) or a 
combination of both (Figure 2). As expected, PCN treatment significantly affected liver 
weight in a PXR-dependent way and ATB treatment increased caecum weight (Figure 2A). 
Plasma alanine amino-transferase and cholesterol levels were significantly changed upon 
PCN treatment, to a similar extent in the PCN and PCN+ATB groups (Figure 2B). In the 
liver, PCN treatment increased triglyceride and cholesterol ester accumulation in a PXR-
dependent manner both in the PCN and PCN+ATB groups (Figure 2C). O-PLS-DA 
modeling of the 1H-NMR metabolic profiling of the hepatic lipidic extracts of WT mice 
shows a significant discrimination between the control and PCN groups vs. ATB and 
ATB+PCN groups (Figure 2D). PCA modeling of the aqueous extracts shows a significant 
discrimination between the PCN-treated groups and the control groups, independently of 
the ATB treatment (Figure 2E). As expected, in Pxr-/- mice, these PCN-dependant effects 
were not observed (Supplementary Figure 3). Finally, induction of Cyp3a11 and Cyp2c55 
was similar in the PCN and PCN+ATB groups in the liver (Figure 2F) or ileum (Figure 2G). 
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Altogether these results show that gut microbiota depletion does not prevent or decrease 
the extent of PXR activation upon pharmacological activation.    
 
Gut microbiota is altered in Pxr-/- mice   
To determine whether PXR conversely affected the gut microbiota, we used Pxr+/+ 
vs. Pxr-/- littermate mice and compared their caecal microbiota using 16S rRNA sequencing 
(Figure 3). No differences were observed regarding biodiversity in males or in females 
(Figure 3A & B). Hierarchical clustering and Principal Coordinate Analysis (PcoA) at the 
OTU level demonstrated significant clustering of Pxr+/+ vs. Pxr-/- mice (Figure 3C-F). This 
clustering seems stronger in male mice since discrimination was seen on the first PCoA 
axis that represents 20.8% of the variance (Figure 3D) than in females, for which 
discrimination between Pxr+/+ and Pxr-/- mice was seen on the second PCoA axis that 
represents 12.5% of the variance (Figure 3F). Using the linear discriminant analysis (LDA) 
effect size (LEfSe) pipeline, we confirmed significant differences in the baseline caecal 
microbiota composition of Pxr-/- mice, as compared to that in Pxr+/+ mice (Figure 3G&H). 
Pxr-/- male mice had a decreased relative abundance of Acetitafactor, (Eubacterieum) 
ruminantium group, Papillibacter, Variovax and increased relative abundance of Blautia, 
Bradyrhizobium, Intestinomonas, lachnoclostridium, Ruminococcaceae UCG-010 
compared to Pxr+/+ mice (Figure 3G, Supplementary Figure 4A). Pxr-/- females had a 
decreased relative abundance of Desulfovibrio and increased relative abundance of 
Akkermansia and Mucispirillum compared to Pxr+/+ mice (Figure 3H, Supplementary 
Figure 4B).  
We next investigated the metabolic profiles of caecal content in Pxr+/+ vs. Pxr-/- mice 
using 1H-NMR profiling (Figure 4). A typical 1H-NMR metabolic profile of caecal content 
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can be found in Supplementary Figure 2. O-PLS-DA coefficient plots highlighted several 
peaks that were increased in Pxr-/- compared to Pxr+/+ males (Figure 4A): one triplet at 
7.006 ppm and two doublets at 6.9 and 6.87 ppm respectively. O-PLS-DA models 
between caecal content profiles of Pxr+/+ vs. Pxr-/- females did not highlight any significant 
differences between the 2 groups (Figure 4B). Integration of the area under the curve for 
the peaks at 7.006 ppm followed by univariate statistics confirmed a significant increase of 
this metabolite in Pxr-/- male mice (Figure 4C). Searches in the literature and in 
metabolomics databases did not allow us to unravel a relevant candidate for the formal 
identification of this metabolite. However, based on the structural information we had 
(summarized in Supplementary Figure 6A & B), we hypothesized that this metabolite 
originated from the gut microbiota metabolism of one of the aromatic amino acid tyrosine 
or phenylalanine. We fed male and female mice with tyrosine by gavage and confirmed 
that all the peaks corresponding to the unknown metabolite were significantly increased 
upon tyrosine gavage in male mice only (Supplementary Figure 5E-H). Moreover, we 
confirmed that this metabolite completely disappeared from the caecal content of ATB-
treated mice (Supplementary Figure 5C & D). Therefore, we demonstrated that this 
metabolite is a gut-microbial derivative of tyrosine metabolism.  
Altogether, these data demonstrate that PXR has a role in shaping the gut 
microbiota in a sexually-dimorphic manner and that this PXR-dependent microbiota might 
play a role in the metabolism of aromatic amino acids.   
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Gut microbiota suppression decreases PXR activity in the liver and in the ileum of 
male mice 
 
To further investigate this potential sexual dimorphism in the gut microbiota-PXR 
interactions, we depleted the gut microbiota of the Pxr+/+ vs. Pxr-/- male and female 
littermate mice with antibiotics. Supplementary Figure 4 confirms the successful depletion 
of the gut microbiota. In these littermate mice, we confirmed a significant decrease in PXR 
activity upon microbiota depletion in male liver (Figure 5A) and small intestine (Figure 
5C). However, surprisingly, in both the liver (Figure 5B) and the ileum (Figure 5D), gut 
microbiota suppression did not impact PXR activity in females.   
 
PXR is a major hepatic sensor of the gut microbiota  
Our results suggest that the PXR-gut microbiota interaction is strongly sexually 
dimorphic and that it affects the liver physiology of the host. To further characterize the 
impact of gut microbiota sensing by PXR on the host’s hepatic physiology, we obtained 
transcriptomic profiles of the liver of Pxr+/+ vs. Pxr-/- littermates treated or not with ATB. 
Using a fold-change cut-off of 1.2 and a corrected p-value < 0.05, we observed that gut 
microbiota depletion using ATB significantly affected the expression of 679 genes in Pxr+/+ 
vs. 109 in Pxr-/- male mice (Supplementary Figure 7C). Using a more stringent fold-change 
cut-off of 1.5, the same proportion holds with 144 genes affected by ATB in Pxr+/+ vs. 44 in 
Pxr-/- male mice (Supplementary Figure 7A). Fifty-seven genes were up-regulated (FC>1.5) 
upon ATB treatment in Pxr+/+ males only, for which pathway enrichment analyses 
highlighted one significantly enriched gene cluster for genes involved in sterol 
biosynthesis and lipid metabolism (Figure 6A & C). Forty-five genes were down regulated 
(FC>1.5) upon ATB treatment in Pxr+/+ males only, which clustered in 3 significantly 
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enriched biological pathways: peroxisome, acyl-CoA thioesterases, and CYPs (Figure 6B & 
D). PCA plots confirmed these results by illustrating a significant discrimination between 
the ATB and control groups in Pxr+/+ male mice (Figure 6E) but not in Pxr-/- male mice 
(Figure 6G). The volcano plots highlight the genes that were the most significantly 
impacted upon ATB treatment (Figure 4F & H), among which many PXR-target genes 
involved in xenobiotic metabolism such as Cyp3a11, Cyp3a16, Cyp3a41a and Cyp3a59, 
but also several genes involved in lipid metabolism such as Acot5 and Vnn1.  
The much lower number of genes affected by ATB treatment in Pxr-/- compared to 
Pxr+/+ male mice suggests that PXR is one of the major sensors of gut microbiota signals in 
the liver. We took advantage of one of our previously published datasets in which the 
hepatic transcriptome of Pxr-/- male mice was compared to that of WT, non-littermate, male 
mice (Barretto et al., 2019) to quantify the impact on PXR deletion in non-littermate vs. 
littermate mice. In mice in which the gut microbiota is tightly controlled (littermates), PXR 
deletion induced 4 to 5 times less changes in the hepatic transcriptome than in mice in 
which the gut microbiota strongly differs (non-littermates) (Supplementary Figure 8), thus 
confirming a major role for hepatic PXR in gut microbiota sensing.      
In females, ATB treatment significantly impacted the expression of 449 genes 
(FC>1.2) in Pxr+/+ animals vs. 274 in Pxr-/- animals. With a more stringent FC>1.5, 90 genes 
were changed upon ATB in Pxr+/+ vs. 45 in Pxr-/- females (Supplementary Figure 7B & D). 
Pathway enrichment analysis did not unravel any significant PXR-dependent biological 
pathway affected upon microbiota depletion in females (Figure 7A & B).  
 
 
187
Chapter 3.3 : Experimental Results 	
Classical hepatic PXR-dependent pathways are controlled by the gut microbiota in a 
sexually dimorphic way 
 
 Our results suggested a strong sexually dimorphic impact of the gut microbiota on 
the liver physiology, in which PXR might play a role. We wondered if this sexual 
dimorphism was also seen in another model of gut microbiota depletion and analyzed a 
previously published RNA-seq dataset obtained in the liver of GF vs SPF male and female 
mice [32]. In GF mice, the impact of gut microbiota depletion on the liver transcriptome 
was highly sexually dimorphic with only 15 to 25% of genes that were significantly 
regulated in both males and females (Supplementary Figure 9A & B). In females, absence 
of gut microbiota did not impact metabolic pathways but rather biological functions linked 
to the cell cycle and cellular structures (see pathway-enrichment analyses in 
Supplementary Figure 9C & D). In males, absence of the gut microbiota affected few 
metabolic pathways mostly involved in sterol synthesis, lipid metabolism and CYP 
(Supplementary Figure 9C & D). In our ATB-treated mice, as expected, the number of 
hepatic genes affected by the gut microbiota depletion was much lower than in GF mice. 
However, the same sexual dimorphism held with only 9-11% of genes affected in both 
males and females (Supplementary Figure 9E & F). Moreover, the metabolic pathways 
affected in males were similar to those seen in GF males (Supplementary Figure 9G & H). 
Interestingly, the same biological pathways are classically disrupted upon PXR activation 
via different ligands [14]. 
 
PXR sensing of the gut microbiota is moderately involved in hepatic fatty acid 
metabolism in male mice 
 
Our previous data suggest that, at least in male mice, PXR sensing of the gut 
microbiota might be involved in fatty acid metabolism. We measured neutral lipids and 
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characterized individual fatty acids in the liver of the Pxr+/+ vs Pxr-/- littermate mice. ATB 
treatment did not change cholesterol or cholesterol ester levels, but slightly decreased 
triglyceride content in the liver of Pxr+/+ but not Pxr-/- male mice (Figure 8A). This was 
confirmed by a PXR-dependent decrease in the relative content of two of the most 
abundant hepatic fatty acids (FA) (C16:0 and C16:1w7) upon ATB treatment (Figure 8B). 
Finally, qPCR analyses confirmed that ATB decreased the expression of genes involved in 
fatty acid-elongation and β-oxidation in the liver of Pxr+/+ male mice (Figure 8C).  
In females, ATB treatment did not significantly impact cholesterol, cholesterol 
esters and triglycerides in Pxr+/+ mice, but surprisingly decreased triglycerides in Pxr-/- 
mice (Figure 9A). Individual FA measurement showed a PXR-dependant decrease in the 
abundance of C16:1w7 but not C16:0 upon ATB treatment (Figure 9B). RT-qPCR analyses 
did not clearly show a PXR-dependant impact of ATB treatment on FA-related genes 
(Figure 9C).  
 
PXR sensing of the gut microbiota controls the host’s hepatic xenobiotic capacities in 
male mice 
 
Another interesting finding of our microarray data is the strong enrichment of the 
xenobiotic metabolism-related pathways in the PXR-dependent genes that were down 
regulated upon ATB treatment (Figure 6B). Figure 10 illustrates the fold-changes in the 
Phase I (Figure 10A) and Phase II (Figure 10C) XMEs upon ATB treatment in Pxr+/+ and Pxr-
/- male mice. We observed that microbiota depletion moderately affected Phase II XMEs 
but strongly affected the expression of CYP belonging to the CYP3 family in a PXR-
dependent way. This was not the case in females (Supplementary Figure 10). In order to 
test the consequence of the downregulation of these CYPs at a more physiological level, 
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the oxidative metabolism of [4-14C] testosterone in male liver microsomes was measured 
as a reflection of the global ability of these enzymes to metabolize sterol compounds 
(Figure 10C, Supplementary Figure 11). This analysis showed that peaks at a retention 
time of 4.4, 8 and 12.5 min were significantly different between Pxr-/- and Pxr+/+ mice, but 
were not affected by ATB treatment, while peaks with a retention time at 10.5 and 14.7 
min were significantly decreased upon microbiota suppression in a PXR-dependent way. 
Several structural hypotheses could be made based (1) on RT comparison with authentic 
testosterone metabolites standards, for those commercially available (LC-MS 
experiments), and (2) on the confirmation of the m/z ions detected in LC-MS (ESI, positive 
mode) when analyzing incubation media from incubations carried out with non-radio 
labeled testosterone (Supplementary Table 3). The 10.5 min peak was formally identified 
as 6β-testosterone. The peak with a RT of 14.7 min was identified as a HO-Δ-testosterone 
(m/z: 303.1955), but no formal identification of the hydroxylation position could be 
achieved. Of note, this metabolite was clearly found to be distinct from 16α-HO-Δ-
testosterone, for which the authentic standard is available. Finally, glutathione transferase-
specific activity was also tested in the hepatic cytosolic fraction and showed a PXR-
dependent decrease in this enzymatic activity upon ATB treatment in male mice (Figure 
10D). 
 
 
DISCUSSION 
In this study, we report that microbiota depletion by various antibiotic procotols 
decreased PXR activity in the liver and ileum of male mice, but did not seem to impact PXR 
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activity in the colon. This confirmed several previously published results that evaluated the 
expression of PXR targets in the liver of GF [17,18,33] or ATB-treated [34] mice. The lack of 
decrease of PXR activity in the colon upon microbiota depletion seems counterintuitive 
with the facts that PXR’s expression is not significantly different between the liver, the small 
and the large intestine (data not shown) and that gut microbiota load is higher in the colon 
than in the ileum. However, many previous studies have shown that the gut microbiota 
modulates the expression of a much larger set of genes in the small intestine than in the 
colon in mice [35-37]. Therefore, our observation is consistent with a role of PXR as a gut 
microbiota sensor and transcriptional regulator of gut microbiota effects.  
Next, we use a combination of a classical pharmacological approach and antibiotic 
treatment and we report that, in the absence of gut microbiota, PXR is still able to bind 
and respond to its ligand. Therefore, we conclude that the ATB-driven decrease in PXR 
activity is not due to a change in the transcriptional machinery of the intestinal epithelial 
cells or of the hepatocytes, but rather to a decrease of microbial-derived ligands. Indeed, 
recent studies on the mechanisms that link the body microbial communities to immune 
education, protection against pathogens or metabolism point to microbiota-derived 
metabolites as key players during the microbe-host interactions. The 3 currently most 
studied class of metabolites involved in the microbiota-host cross-talk are (i) short-chain 
fatty acids that are produced by the microbiota from the fermentation of dietary fibers, (ii) 
tryptophan metabolites [1] and (iii) bile acids, produced in the liver and transformed by 
the microbiota: (i) Not much is known about the interactions between short-chain fatty 
acids and PXR. However, butyrate has been shown to strongly induce the expression of 
PXR upon differentiation of Caco-2 intestinal epithelial cells [38]. (ii) Tryptophan can be 
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converted directly in the gut by microorganisms into indole derivatives, such as indole-3-
propionic acid (IPA). In vitro, IPA has been shown to activate both the mPXR and the hPXR, 
however IPA was a much more potent agonist of the mPXR [16]. In vivo, oral gavage with 
IPA has been shown to decrease intestinal permeability in the small intestine in a PXR-
dependent way [16]. In distant organs, such as the vascular epithelium, IPA has been 
shown to regulate endothelium-dependent vasodilation in vivo, and in vitro experiments 
point to PXR as a potential effector of IPA effects [39]. However, in vivo evidence using 
physiological concentrations of circulating IPA were lacking. Indoxyl-3-sulfate is another by 
product of the microbiota-host tryptophan co-metabolism [40] and has been 
demonstrated to be a direct AhR ligand, however, it failed to activate CAR or PXR in cell 
lines [41]. Therefore, indoles, and IPA in particular, might represent potential microbial 
ligands for PXR that could explain our results in the intestine and in the liver. However, it is 
not clear whether these indoles could reach the liver at a sufficient concentration to 
activate PXR. (iii) Bile acids interact with PXR directly [20,42] or indirectly via regulation of 
the farnesoid X receptor [43]. The secondary bile acid litocholic acid and its 3-keto 
derivative have been shown to bind directly to PXR [20], whereas chenodeoxycholic acid, 
deoxycholic acid and cholic acid only mildly activate PXR [42]. Several other bile acid 
derivatives have been shown to directly bind to PXR using reporter assays [44,45]. 
Conversely, PXR plays a role in the regulation of bile acid metabolism and detoxication by 
inducing genes involved in bile acid synthesis [43,46], conjugation and transport in order 
to enhance their elimination [20,47]. Therefore, bile acids represent putative metabolites 
that could definitely play a role in the microbiota-PXR crosstalk described in our results. 
Conversely, we also observed that PXR had a moderate, but significant role in shaping the 
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microbiota composition, in which differential bile acid metabolism between Pxr+/+ and   
Pxr-/- mice might be implicated.  
Our hepatic transcriptomic analysis of the effect of ATB treatment in male and 
female Pxr+/+ vs Pxr-/- littermate mice revealed first a strong sexually dimorphic impact of 
ATB treatment, independently of PXR. Indeed, we observed that only 5-10% of the hepatic 
genes were commonly regulated in males and females upon ATB-treatment. Our results 
were further confirmed by re-analyzing a previously published dataset that aimed to 
compare liver genes with altered rhythmicity in male and female GF mice [32]. Recent 
studies have highlighted strong sexually dimorphic relationships between the gut 
microbiota and its host. The gut microbes modulate the entero-hepatic recirculation of 
estrogens and androgens, thereby affecting local and systemic levels of sex steroid 
hormones (reviewed in [48]), while estrogens have been shown to directly influence the 
composition of the gut microbiota and contribute to influence the sexual-dimorphism in 
diet-induced metabolic syndrome [49]. The liver is a highly sexually dimorphic organ [50], 
and the gut microbiota is critical for maintaining hepatic sex-biased gene expression [32]. 
Most gene expression studies that have investigated the gut microbes-liver dialogue have 
used male animals [32,33,35,51] and consistently observed that xenobiotic metabolism, 
steroid biosynthesis and lipid metabolism were the most down-regulated pathways in the 
liver of GF mice [32,33,51]. We replicated these findings in our own analysis of the dataset 
of GF mice of Weger et al. and in our ATB-model of gut microbiota depletion. This 
corroborates that our results are mainly driven by a gut microbiota dependent effect on 
the liver and not by a direct effect of antibiotics. It also raises the more general question 
about how much of the current knowledge about the gut microbial impact on the host’s 
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liver and metabolism holds in females. Several recent human studies have indeed 
observed sex-specific associations between gut microbiome and fat distribution [52]. 
Strikingly, PXR has been known for long to control the expression of genes 
involved in the metabolic pathways described previously as the most affected upon 
microbial depletion [9,14]. By comparing the number of genes affected by ATB treatment 
in Pxr+/+ vs Pxr-/- mice, we were surprised to observe that 60-80% of ATB-induced gene 
changes were dependent of PXR. By comparison, it was found that less than 5% of the 
colonic gene expression changes induced by the absence of gut microbiota required 
MyD88 signaling, a major adaptor from the Toll-like receptors signaling [36]. Our result 
therefore demonstrates that PXR is, at least quantitatively, a major sensor or gut microbial 
signals in the liver of both male and female mice. It would be interesting to see whether 
this proportion of microbially-regulated PXR-controlled genes also holds in GF mice 
deleted or not for PXR, and in models of hepatic-specific deletion of PXR.   
Our pathway enrichment analysis of the microbial-driven PXR-dependent hepatic 
function highlighted lipid metabolism. The gut microbiota has been previously shown to 
promote hepatic lipid accumulation in mice via controlling fatty acid desaturation by the 
stearoyl-CoA desaturase (Scd1) [51,53] and fatty acid elongation by fatty acid elongases 
(Elovl) [51]. Acetate originating from the microbial degradation of dietary fibers serves as a 
precursor for the hepatic synthesis of C16 and C18 fatty acids [51]. In our experiment, 
short-term ATB treatment was sufficient to slightly decrease hepatic triglyceride content in 
males, as well as the relative abundance of C16:0 fatty acid. Interestingly, these findings 
were dependent on PXR. Gene expression analysis did not show any impact of ATB-
treatment on FA synthesis, however, this might be due to the time of sacrifice of our 
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animals that was not optimal to observe FA anabolic pathways. At ZT6, food intake is 
indeed usually low. However, we confirm significant effect of gut microbiota depletion on 
fatty acid elongases such as Elovl2, 3 and 5. Interestingly, PXR might play a role in the gut 
microbiota control of FA elongation since these genes were not affected by ATB in Pxr-/- 
mice. Moreover, we observed a significant PXR-dependent decrease in the expression of 
genes involved in FA oxidation upon ATB-treatment. These findings are counter-intuitive 
with the observed decrease in hepatic triglycerides and are not consistent with the 
findings of others that compared Cyp4 expression in GF vs SPF mice [19,54]. However, our 
findings could be explained by the decrease in microbial folate production upon ATB 
therapy that would decrease hepatic PPARα activation, therefore leading to decrease FA 
oxidation [55] but this deserves further investigation. 
Finally, we observed that both in GF, and in ATB-treated male animals, xenobiotic 
metabolism is strongly affected by the gut microbiota. This corroborates many previous 
transcriptomics [19,51], as well as proteomics [51] studies, in which Cyp3a11 is 
systematically one of the top down regulated genes and proteins in GF male mice. We 
add to these previous studies by demonstrating that PXR is the key mediator of these 
perturbations. At the gene level, PXR-dependent sensing of the gut microbiota controlled 
the expression of several CYP3 genes. Our ex-vivo assays also demonstrated that all of the 
significant ATB-induced perturbations in the ability of liver microsomes to oxidize 
testosterone were controlled by PXR, at least in male mice. Testosterone hydroxylation is a 
widely recognized assay that measures the global ability of microsomal enzymes, mostly 
CYP, to metabolize sterol compounds. In particular, we observed the formation of a lower 
amount of 6β-testosterone, a reaction that is primarily performed by CYP3A11 [17]. Our 
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results therefore bring new strong evidence that the gut microbiota controls the host’s 
xenobiotic metabolism. In recent years, the gut microbiota has emerged as a key player in 
clinics and in toxicology with evidences showing that the efficacy and toxicity of orally 
administered drugs [56,57] and/or food pollutants [58] can be strongly affected by gut 
microbial metabolism. However, our findings, and those from others [19,54] shed light on 
another potential mechanism underlying food-drug or drug-drug interactions. In humans, 
CYP3A4, PXR’s prototypical target gene, metabolizes the vast majority of clinically 
administrated drugs [59] and induction or repression of its activity is considered as the 
main risk factor for drug-drug interaction by pharmaceutical companies and regulatory 
agencies [60,61]. Our results indicate that gut microbe may represent an underestimated 
factor that controls part of the interindividual pharmacokinetics and may be relevant 
especially in cases of medications with narrow therapeutic index or potential life-
threatening toxicity, e.g., the non-steroidal anti-inflammatory drugs, opioid analgesics, 
cardiovascular medications, warfarin, anticancer drugs and immunosuppressants [62]. 
Finally, it should be noted that more and more environmental and/or food contaminants 
such as pesticides [63,64], artificial sweeteners [65] or food additives [66] are found to 
perturbate of the gut microbiota composition and metabolism, with toxicological 
consequences for the host. Whether these chronic exposure to microbiota perturbing 
chemicals also interfere with PXR and the host’s xenobiotic capacities remains to be 
determined but might also represent a risk for unexpected food-drug interactions.  
In conclusion, our study identifies PXR as a sensor for gut microbiota-derived 
signals that control the host’s hepatic lipid and xenobiotic metabolism in a sexually 
dimorphic manner. The effectors of these bidirectional PXR-gut microbiota interactions, 
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namely the specific gut bacterial species and metabolites that can activate PXR in the liver, 
as well as the PXR-derived metabolites controlling the gut microbiota composition, remain 
to be determined. These results open a new metagenomic perspective on the sexually 
dimorphic and interindividual differences in pharmacokinetics and sensitivity to 
environmental toxicity. 
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FIGURE LEGENDS 
Figure 1: Effect of individual antibiotic treatments on PXR expression and activity. 
C57Bl6/J male mice were treated with individual treatments of ampicillin, neomycin, 
vancomycin or a cocktail of the three antibiotics (ANV) for 2 weeks in their drinking water. 
RT-qPCR results are presented as mean±SEM for n=8 per group. *p≤0.05, **p≤0.01, 
***p≤0.005 compared to control group. P-values were derived from 1-way ANOVA and 
Bonferroni’s post-tests.  
Figure 2: Effect of microbiota depletion on PXR activation by a pharmacological agonist. 
WT and Pxr-/- male mice were treated with an antibiotic cocktail of ampicillin, neomycin and 
vancomycin (ATB), the pharmacological agonist of PXR (PCN) or a combination of both 
(ATB+PCN). Impact on (A) liver and cecum weight, (B) plasma biochemistry, (C) liver lipid 
content, (D) 1H-NMR-based metabolic profiling of the hepatic lipid phase, (E) 1H-NMR-
based metabolic profiling of the hepatic aqueous phase, (F) PXR’s target gene expression 
in the liver (G) PXR’s target gene expression in the ileum.  Data are mean±SEM of n=5-6 
per group. $p≤0.05, $$p≤0.01, $$$p≤0.001 for PCN effect, #p≤0.05 ##p≤0.01, 
###p≤0.005 for genotype effect using 2-way ANOVA and Bonferroni’s post-tests.  
Figure 3: Gut microbiota composition in Pxr-/- and Pxr+/+ mice. (A&B): Alpha-diversity 
measures in feces of Pxr-/- vs Pxr+/+ (A) male and (B) female littermate mice. (C-F): Beta-
diversity represented by hierarchical clustering based on the Jaccard distances of Pxr-/- 
(blue) vs. Pxr+/+ (red) (C) male or (F) female mice and by PCA analysis based on the Jaccard 
distances in (D) male and (F) female mice. (G&H): Circular cladograms generated from 
LEFSe analysis showing the most differentially abundant taxa enriched in fecal microbiota 
from Pxr+/+ (red) or Pxr-./- (green) (G) male or (H) female mice. Log(LDA scores)>2 and 
significance of α<0.05 determined using Wilcoxon-Mann Whitney test. 
Figure 4: Caecal content metabolomics in P x r - / -  a n d  P x r + / +  mice. (A&B) 
Coefficient plots related to the orthogonal projection on latent structure-discriminant 
analysis (O-PLS-DA) models derived from the caecal extract 1H-NMR-based spectra of (A) 
male and (B) female Pxr+/+ vs Pxr-/- mice. Metabolites are color-coded according to their 
correlation coefficient (R), red indicating a very strong positive correlation. The 
direction of the metabolite indicates the group with which it is positively associated as 
labeled on the diagram. (C&D) Area under the curve of the 1H-NMR spectra was 
integrated for the unknown metabolite signal (triplet at 7.006 ppm) in (C) males and 
(D) females. Data are presented as the mean±SEM. *p<0.05 ***p<0.001 determined 
using a Kruskall-Wallis test.  
Figure 5: PXR activity upon microbiota depletion in male and female Pxr-/- and Pxr+/+ 
littermate mice. C57Bl6/J Pxr+/+ and Pxr-/- male and female littermate mice were treated 
with an antibiotic cocktail of ampicillin, neomycin and vancomycin (ATB) for 2 weeks. 
RT-qPCR gene expression of Pxr, Cyp3a11, Cyp2c55, Cyp2b9, and Fgf21 in the liver of 
(A) male mice and (B) female mice; and the ileum of (C) male mice (D) female mice. Data 
are mean±SEM of n=8-10 per group. *p≤0.05, **p≤0.01, ***p≤0.005 for ATB effect, 
#p≤0.05 ##p≤0.01, ###p≤0.005 for genotype effect using 2-way ANOVA and Bonferroni’s 
post-tests. 
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Figure 6: Impact of gut microbiota depletion on the hepatic transcriptome in male Pxr-/- 
vs Pxr+/+ mice. (A&B) Venn diagram representing the number of genes affected by 
ATB treatment. (C & D) Gene ontology pathway analysis of the 57 and 45 gene 
significantly up- and down-regulated upon ATB in Pxr+/+ males only, respectively. 
Histograms show the enrichment score for each identified pathway. Gene number is 
indicated to the right of the histograms and the corresponding p-value in shown inside 
the bars. (E&G) Principal component analysis (PCA) score plots of transcriptomic 
dataset of (E) Pxr+/+ control vs Pxr+/+ ATB and (G) Pxr-/- control vs Pxr-/- ATB male mice. 
(F&H) Volcano plots showing the 30 genes with the highest fold-changes upon ATB 
treatment in (F) Pxr+/+ control vs Pxr+/+ ATB (H) Pxr-/- control vs Pxr-/- ATB male mice.
Figure 7: Impact of gut microbiota depletion on the hepatic transcriptome in female Pxr-/- 
vs Pxr+/+ mice. (A & B) Venn diagram representing the number of genes affected by 
ATB treatment. (C&E) Principal component analysis (PCA) score plots of the 
transcriptomic dataset of (C) Pxr+/+ control vs Pxr+/+ ATB and (E) Pxr-/- control vs Pxr-/- 
ATB female mice. (D&F) Volcano plot showing the 30 genes with the highest fold 
changes upon ATB treatment in (D) Pxr+/+ control vs Pxr+/+ ATB (F) Pxr-/- control vs Pxr-/- 
ATB female mice.  
Figure 8: Impact of microbiota depletion on hepatic lipid metabolism inPxr-/- vs Pxr+/+ 
male mice. (A) Hepatic neutral lipid content and (B) relative abundance of fatty acids in the 
liver of male mice. (C) Fold changes (ATB vs control) in the relative expression of selected 
genes involved in fatty acid (FA) synthesis, FA elongation, peroxisomal FA oxidation and 
microsomal FA oxidation in Pxr-/- (blue) and Pxr+/+ (red) male mice. Expression of genes 
involved in FA synthesis and elongation was derived from complementary RT-qPCR 
expression using n=8-10 mice per group, while expression of genes involved in FA 
oxidation was derived from microarray measurements (n=5-6 per group). Data are 
mean±SEM. *p≤0.05, **p≤0.01, ***p≤0.005 for ATB effect using Student t-tests for 
qPCR data and corrected p-values from linear models for microarray data. #p≤0.05 
##p≤0.01, ###p≤0.005 for genotype effect using 2-way ANOVA and Bonferroni’s post-tests.  
Figure 9: Impact of microbiota depletion on hepatic lipid metabolism in Pxr-/- vs Pxr+/+ 
female mice. (A) Hepatic neutral lipid content and (B) relative abundance of fatty acids in 
the liver of female mice. (C) Fold changes (ATB vs control) in the relative expression of 
selected genes involved in fatty acid (FA) synthesis, FA elongation, peroxisomal FA 
oxidation and microsomal FA oxidation in Pxr-/- (blue) and Pxr+/+ (red) male mice. 
Expression of genes involved in FA synthesis and elongation was derived from 
complementary RT-qPCR expression using n=8-10 mice per group, while expression of 
genes involved in FA oxidation was derived from microarray measurements (n=5-6 per 
group). Data are mean±SEM. *p≤0.05, **p≤0.01, ***p≤0.005 for ATB effect using Student t-
tests for qPCR data and corrected p-values from linear models for microarray data. #p≤0.05 
##p≤0.01, ###p≤0.005 for genotype effect using 2-way ANOVA and Bonferroni’s post-tests. 
Figure 10: Impact of gut microbiota depletion on hepatic xenobiotic metabolism 
in Pxr-/- vs Pxr+/+ male mice. (A&C) Fold change (ATB vs control) in the relative expression of 
genes involved in phase I (A) and phase II (C) xenobiotic metabolism in Pxr-/- vs Pxr+/
+ male mice. Data are derived from microarrays and are presented as mean±SEM 
for n=5-6 per group. 
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*p≤0.05, **p≤0.01, ***p≤0.005 for ATB effect using corrected p-values from linear models.
(B) Profiles of oxidized metabolites of testosterone after incubation with liver microsomes of 
male mice. (D) Specific glutathione transferase activity after incubation with liver cytosolic 
fraction of male mice. Data are mean±SEM of n=5 per group. *p≤0.05, **p≤0.01, 
***p≤0.005 for ATB effect, #p≤0.05 ##p≤0.01, ###p≤0.005 for genotype effect using 1 or 2-
way ANOVA and appropriate post-tests.
SUPPLEMENTARY FIGURE LEGENDS: 
Supplementary Figure 1: Impact of antibiotic treatment on physiological parameters. 
C57Bl6/J male mice were treated with individual treatments of ampicillin, neomycin, 
vancomycin or a cocktail of the three antibiotics (ANV) for 2 weeks in their drinking water 
Impact on (A) body, (B) liver, (C) caecum weights, and (D) fecal microbial count of 
anaerobic colonies. Results are presented as mean±SEM for n=8 per group. *p≤0.05, 
**p≤0.01, ***p≤0.005 compared to control group. P-values were derived from 1-way 
ANOVA analyses and Bonferroni’s post-tests.  
Supplementary Figure 2: Typical 1H-NMR spectra of liver and caecal mouse extracts. (A) 
Typical 1H-NMR spectra of caecal content extracts. The 5 to 9 ppm region was vertically 
expended 6 times compared to the 0 to 4.5 ppm region. Keys: 1: bile acids (mixed), 2: 
butyrate, 3: leucine, 4: isoleucine, 5: valine, 6: propionate, 7: α-ketoisovalerate, 8: ethanol, 
9: β-hydroxybutyrate, 10: lipids, 11: lactate, 12: alanine, 13: lysine, 14: acetate, 15: N-
acetyl groups, 16: glutamate, 17: succinate, 18: α-ketoglutarate, 19: aspartate, 20: choline, 
21: taurine, 22: β-xylose, 23: β-galactose, 24: β-glucose, 25: α-arabinose, 26: α-xylose, 27: 
α-glucose, 28: α-galactose, 29: uracil, 30: tyrosine, 31: phenylalanine, 32: adenine, 33: 
hypoxanthine, 34: formate.  (B) Typical 1H-NMR spectra liver aqueous extracts. Keys: 1: 
bile acids (mixed), 2: bile acids (tauroconjugated, mixed), 4: leucine, 5: valine, 6: 
isoleucine, 10: 3-hydroxyburyrate, 12: lactate, 13: threonine, 15: alanine, 16: ornithine, 17: 
putrescine, 19: acetate, 21: glutamate, 22: glutamine, 24: oxidized glutathion, 25: reduced 
glutathion, 27: succinate, 30: asparate, 31: dimethylamine, 34: dimethylglycine, 35: 
creatine, 37: choline, 38: o-phosphocholine, 40: betaine, 41: taurine, 43: methanol, 45: 
glucose, 50: glycine, 52: UDP-glucose, 53: UDP-glucuronate, 55: uridine, 56: NADP+, 57: 
NAD+, 60: fumarate, 64: tyrosine, 66: phenylalanine, 69: nicotinurate.    
Supplementary Figure 3: 1H-NMR analysis of liver extracts in Pxr-/- mice treated with ATB, 
PCN or a combination of both. Pxr-/- male mice were treated with an antibiotic cocktail of 
ampicillin, neomycin and vancomycin (ATB), the pharmacological agonist of PXR (PCN) or 
a combination of both (ATB+PCN). (A) O-PLS-DA score plots derived from NMR-based 
metabolic profiling of the hepatic lipid phase and (B) PCA analysis derived from NMR-
based metabolic profiling of the hepatic aqueous phase. 
Supplementary Figure 4: Effect of Pxr deletion on caecal microbiota community 
distribution. Relative abundance per phylum (%). Data represent 5-95% boxplots. #p≤0.05 
##p≤0.01, ###p≤0.005 for genotype effect using Kruskall-Wallis test.  
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Supplementary Figure 5: Effect of ATB treatment on body parameters and microbiota 
depletion in Pxr+/+ vs. Pxr-/- mice. Pxr+/+ and Pxr-/- male and female mice were treated with 
an antibiotic cocktail of ampicillin, neomycin and vancomycin (ATB) for 2 weeks in their 
drinking water. (A) Body weight, (B) water consumption, (C) % body weights of liver and 
spleen, (D) % body weight of caecum and fecal microbial count in male mice. (E) Body 
weight, (F) water consumption, (G) % body weights of liver and spleen, (H) % body weight 
of caecum and fecal microbial count in female mice. Data are mean±SEM of n=8-10 per 
group. *p≤0.05, **p≤0.01,***p≤0.005 for ATB effect, #p≤0.05 ##p≤0.01, ###p≤0.005 for 
genotype effect using 2-way ANOVA and Bonferroni’s post-tests. 
Supplementary Figure 6: Tentative identification of unknown caecal metabolite 
discriminating Pxr-/- vs Pxr+/+ males. (A) Structural information derived from various 
1D and 2D NMR sequences (NOESY, J-RES, COSY, HSQC, TOCSY). (B) Statistical 
total correlation spectroscopy (STOCSY) analysis with triplet at 7.006 ppm as driving 
peak. (C&D) Area under the curve for the 1H-NMR peaks at 7.006 ppm in males (C) and 
females (D). (E-H): Mice were gavaged for 4 days with corn-oil (control) or tyrosine and 
1H-NMR metabolomic profiling was performed in their caecal content. O-PLS-DA 
analysis derived from caecal content spectra from tyrosine vs control male (E) or (F) 
female mice showing a significant increase in the peaks corresponding to tyrosine and 
in the 7.006 ppm peaks corresponding to the unknown metabolite. Area under the curve 
for the 7.006 ppm triplet in this experiment in males (G) and females (H).  
Supplementary Figure 7: Microarray analysis in liver of Pxr-/- vs Pxr+/+ mice. Venn diagram 
representing the number of genes affected by ATB treatment in (A) male and (B) female 
Pxr+/+ and Pxr-/- littermate mice. 
Supplementary Figure 8: Hepatic impact of Pxr deletion in littermate vs. non-
littermate male mice.  
Venn diagrams representing the number of genes affected by Pxr deletion Pxr+/+ vs 
Pxr-/- littermate (green) or WT vs. Pxr-/- non-littermate male mice (purple). Data originate 
from two independent animal experiments conducted in the same animal facility 
and two independent microarray experiments conducted in the same facility using n=5-6 
mice per groups. Genes were selected as significantly regulated using a non-
corrected p-value<0.01 (A) or non-corrected p-value<0.001 (B).    
Supplementary Figure 9: Sexually-dimorphic impact of gut microbiota depletion on the 
liver transcriptome. (A&B) Venn diagram representing the number of genes significantly 
up- (A) and down-regulated (B) in the liver of GF vs Conv males vs. female mice. Data were 
obtained from {Weger:2018dl}. (C&D) Gene ontology pathway analyses. Histograms show 
the enrichment score for each identified pathway. Gene number is indicated in 
parenthesis and the corresponding q-value in shown on the left for each significant cluster. 
(E&F) Venn diagram representing the number of genes significantly up- (E) and down-
regulated (F) in the liver of ATB-treated vs. Control males and female mice. (G&H) Gene 
ontology pathway analyses. Histograms show the enrichment score for each identified 
pathway. Gene number is indicated in parenthesis and the corresponding q-value in 
shown on the left for each significant cluster.    
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Supplementary Figure 10: Impact of gut microbiota depletion on hepatic xenobiotic 
metabolism in Pxr-/- vs Pxr+/+ female mice. (A&B) Fold change (ATB vs control) in 
the relative expression of genes involved in phase II (A) and phase I (B) xenobiotic 
metabolism in Pxr-/- vs Pxr+/+ female mice. Data are derived from microarrays and are 
presented as mean±SEM for n=5-6 per group. *p≤0.05, **p≤0.01, ***p≤0.005 for 
ATB effect using corrected p-values from linear models.  
Supplementary Figure 11: Representative radio-chromatograms obtained from 
microsomal hepatic incubation (0.5 mg proteins, 20 min) of a (A) Pxr+/++ ATB animal and a 
Pxr-/- Control animal (B) with 10 µM [14C]-testosterone. 
SUPPLEMENTARY  TABLE LEGENDS 
Supplementary Table 1: List of antibiotics (ATB) used and their properties (source: 
www.drugbank.ca). 
Supplementary Table 2: List of qPCR primers 
Supplementary Table 3: [14C]-testosterone metabolites structure hypotheses based on 
their mass and on the similarity of their retention time with authentic standards. 
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Figure 1: Effect of individual antibiotic treatments on PXR expression and activity.  
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Figure 2: Effect of microbiota depletion on PXR activation by a pharmacological agonist.  
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Figure 3: Gut microbiota composition in Pxr-/- and Pxr+/+ mice.  
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Figure 4: Caecal content metabolomics in Pxr-/- and Pxr+/+ mice.  
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Figure 5: PXR activity upon microbiota depletion in male and female Pxr-/- and Pxr+/+ 
mice.  
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Figure 6: Impact of gut microbiota depletion on the hepatic transcriptome in male Pxr-/- 
vs Pxr+/+ mice. 
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Figure 7: Impact of gut microbiota depletion on the hepatic transcriptome in female Pxr-/- 
vs Pxr+/+ mice. 
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Figure 8: Impact of microbiota depletion on hepatic lipid metabolism in Pxr-/- vs Pxr+/+ 
male mice.  
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Figure 9: Impact of microbiota depletion on hepatic lipid metabolism in Pxr-/- vs Pxr+/+ 
female mice.  
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Figure 10: Impact of gut microbiota depletion on hepatic xenobiotic metabolism in Pxr-/- 
vs Pxr+/+ male mice.  
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SUPPLEMENTARY FIGURES 
 
Supplementary Figure 1: Impact of antibiotic treatment on physiological parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
218
Chapter 3.3 : Experimental Results 
 
 
Supplementary Figure 2: Partially assigned typical 1H-NMR spectra.  
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Supplementary Figure 3: 1H-NMR based metabolomics analysis in liver extracts of Pxr-/- 
male mice treated with ATB, PCN or a combination of both.  
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Supplementary Figure 4: Effect of Pxr deletion on caecal microbiota community 
distribution.  
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Supplementary Figure 5: Effect of ATB treatment on physiological parameters in Pxr-/- vs 
Pxr+/+ mice.  
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Supplementary Figure 6: Tentative identification of unknown caecal metabolite.  
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Supplementary Figure 7: Microarray analysis in liver of Pxr-/- vs Pxr+/+ mice. 
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Supplementary Figure 8: Hepatic impact of Pxr deletion in littermate vs. non-littermate 
male mice.  
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Supplementary Figure 9: Sexually dimorphic impact of gut microbiota depletion on the 
liver transcriptome.  
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Supplementary Figure 10: Impact of gut microbiota depletion on hepatic xenobiotic 
metabolism in Pxr-/- vs Pxr+/+ female mice. 
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Supplementary Figure 11: Representative radio-chromatograms. 
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SUPPLEMENTARY TABLES 
 
Supplementary Table 1: List of antibiotics and their properties.  
 
 
 
 
Antibiotics Quantity Category Mechanism Spectrum Intestinal absorption Effect on CYP/NR
Ampicillin 1 gram / L Beta-lactam Inhibition of cell wall synthesis Broad spectrum: excellent for gram-negative Partial Almost not metabolized 
Neomycin 1 gram / L Aminoglycoside
Binds to duplex RNA with high 
affinity; Inhibition of protein synthesis 
in bacteria
Broad spectrum: excellent for 
gram-negative
Poor absorption : 3% 
intact intestinal 
mucosa
 *Low CYP450 inhibitory promiscuity
Vancomycin 0.5 gram / L Glycopeptide Inhibition of cell wall synthesis in bacteria Narrow:spectrum; gram-positive Poor
*Substrate : CYP450 3A4                                                                            
Low CYP450 inhibitory promiscuity
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Supplementary Table 2: Oligonucleotide sequences for real-time PCR 
 
    
Gene NCBI Refseq Forward primer (5'-3') Reverse primer (5'-3') 
Acaca NM_133360 TTACAGGATGGTTTGGCCTTTC CAAATTCTGCTGGAGAAGCCAC 
    
Cyp2b9 NM_010000 CTTTGCTGGAACTGAGACCACA GATCTGAAAATCTCTGAATCTCATGG 
    
Cyp2c55 AY206875 TTGTGGAAGAGCTAAGAAAAGCAAAT GAGCACAGCTCAGGATGAATGT 
    
Cyp3a11 NM_007818 TCACACACACAGTTGTAGGCAGAA GTTTACGAGTCCCATATCGGTAGAG 
    
Cyp3a41a NM_017396.3 CCTACAGAGAGTCACACACACACATC GGTTCATCCCTGCTTGTCTGTC 
    
Cyp3a44 NM_177380.3 CCTACAGAGAGTCACACATACATC CCTGCTTGTCTGTCTGCAATTT 
    
Elovl2 NM_019423 GCAGAAGGAAGGCGGCTAC CGCGAACTCGAGAATCTCGT 
    
Elovl3 NM_007703 GCCTCTCATCCTCTGGTCCT TGCCATAAACTTCCACATCCT 
    
Elovl5 NM_134255 TCGATGCGTCACTCAGTACCTATT ATTTTGGTCCCAGCCATACAAT 
    
Elovl6 NM_130450 TCTGATGAACAAGCGAGCCA TGGTCATCAGAATGTACAGCATGT 
    
Fads1 NM_146094 TCAACATGCACCCCCTCTTC GATGGTTGTATGGCATGTGCTT 
    
Fads2 NM_019699 TCCAGTACCAGATCATCATGACAA GGTGTAGAAGAAACGCATATAGTAGCTG 
 
Fasn 
 
NM_007988 
 
AGTCAGCTATGAAGCAATTGTGGA 
 
CACCCAGACGCCAGTGTTC 
    
Fgf21 
 
NM_020013 
 
AAAGCCTCTAGGTTTCTTTGCCA 
 
CCTCAGGATCAAAGTGAGGCG 
 
Pxr NM_010936 AGAGATCATCCCTCTTCTGCCAC GATCTGGTCCTCAATAGGCAGGT 
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Supplementary Table 3: [14C]-testosterone metabolites structure hypotheses based on 
their mass and on the similarity of their retention time with authentic standards. 
 
LC-MS 
Retention 
time (min) 
Corresponding 
radio-HPLC 
Retention time 
(min) 
Metabolites m/z 
7.22 7.9 hydroxytestosterone OH-Testo 305.2111 
7.71   OH-Δ4-
dione 
303.1955 
8.2 
8.8 
15β-hydroxytestosterone 15β-OH-
Testo 
305.2111 
8.25 6α-hydroxytestosterone 6α-OH-
Testo 
305.2111 
8.27   Δ-Testo 287.2006 
8.44   OH-Δ4-
dione 
303.1955 
8.9  hydroxytestosterone OH-Testo 305.2111 
9.2 9.7 7α-hydroxytestosterone 7α-OH-
Testo 
305.2111 
9.21   Δ-Testo 287.2006 
9.66 10.2 6β-hydroxytestosterone 6β-OH-
Testo 
305.2111 
10.18   OH-Δ4-
dione 
303.1955 
11.59 12.2 16α-hydroxytestosterone 16α-OH-
Testo 
305.2111 
12.65 13.5 11α-hydroxytestosterone 11α-OH-
Testo 
305.2111 
12.67   Δ-Testo 287.2006 
13.0   OH-Δ4-
dione 
303.1955 
13.72 14.4  OH-Δ4-
dione 
303.1955 
15.42 16.0 16β-hydroxytestosterone 16β-OH-
Testo 
305.2111 
16.15  4-Androsten-16α-ol-3,17-
dione 
16α-OH-
Δ4-dione 
303.1955 
25.7 26.3 4,6-androstadien-17β-ol-3-
one 
Δ6-Testo 287.2006 
28.63 29.8 Testosterone Testo 289.2162 
32.34 33 Androstenedione = 4-
androsten-3,17-dione 
Δ4-Testo 287.2006 
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Constitutive androstane receptor is a sexually dimorphic hepatic sensor of gut 
microbiota that controls the host xenobiotic and lipid metabolism 
Context: The Constitutive Androstane Receptor (CAR) is a second transcription factor of 
the nuclear receptor superfamily that acts as a xenosensor and controls the transcription 
of key genes involved in detoxification. While CAR and PXR share common ligands and 
regulate the expression of overlapping sets of gene in the liver, little is known regarding 
the activity of CAR in the gut and its putative role in the sensing of microbial metabolites. 
In this chapter, we report data from a set of experiments paralleled to those developed 
in the first three chapters on PXR. Overall, this body of work initiates a project regarding 
the importance of the bi-directional interaction of CAR and gut microbiota that 
requires further experimentation. Therefore, this chapter is not yet presented as a 
publication.  
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Constitutive androstane receptor is a sexually dimorphic hepatic 
sensor of gut microbiota that controls the host xenobiotic and 
lipid metabolism 
Barretto S, Lasserre F et al. 
INTRODUCTION 
Over the past decade, research on the impact of the gut microbiota on its host has 
tremendously progressed. To date these studies have mainly investigated the local effects 
of the gut microbiota-host interactions in the intestine, targeting the various components 
of the intestinal barrier function as a means to understand and treat a variety of diseases 
including metabolic disorders and inflammatory bowel diseases. Symbiotic bacterial 
metabolites in the form of indoles  (indole 3-propionic acid, IPA) have for example been 
shown to regulate gastrointestinal barrier function via the nuclear receptor pregnane X 
receptor (PXR, NR1I2) and Toll-like Receptor 4 (Venkatesh et al., 2014).  
CAR, is highly similar to PXR and is another well-described xenobiotic receptor 
(Gao & Xie, 2010). Both PXR and CAR are referred to as a xenobiotic sensor with a broad 
range of endogenous and exogenous ligands with varying chemical structures. Upon 
ligand-binding, CAR mainly regulates the expression of genes involved in xenobiotic 
metabolism and energy metabolism (Chai et al., 2016). CAR expression is modulated by 
other nuclear receptors, such as hepatocyte nuclear factor 4 alpha (HNF4α), peroxisome 
proliferator-activated receptor alpha (PPARα), glucocorticoid receptor (GR), farensoid X 
receptor (FXR) (Björkholm et al., 2009), liver X receptor (LXR) (Gao & Xie, 2010). Aside 
from their role in xenobiotic metabolism, CAR and PXR regulate homeostasis of bile acids, 
sterol lipids, heme and other endogenous hydrophobic molecules (Björkholm et al., 
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2009). In germ-free mice, it has been shown that lack of intestinal bacteria leads to the 
decreased availability of CAR ligands and therefore of CAR activity (Claus et al., 2011; 
Montagner et al., 2016) 
Although numerous studies show this strong relationship between CAR, energy 
metabolism and the gut microbiota, the key mechanisms are still lacking. 
We aimed to investigate the bidirectional relationships between CAR and the gut 
microbiota.  Our results show that CAR is a broad sensor of the gut microbiota in the liver 
and small intestine. We have also demonstrated that gut microbiota does not interfere 
with the capacity of CAR to bind to its pharmacological ligand. Microbiota depletion 
decreased CAR activity in the liver and ileum of male mice. In the liver, microbiota 
depletion decreased hypotaurine levels, a precursor for glutathione metabolism, and 
decreased several microsomal testosterone hydroxylation activities in a CAR- and sex-
dependent way. Conversely, CAR deletion impacted the gut microbiota composition and 
metabolism in male mice only, while long-term deletion of CAR influenced divergent 
phenotypes, where Car-/- males accumulated white adipose tissue while Car-/- females 
developed a slightly pro-inflammatory intestinal and systemic phenotype. Altogether, we 
have presented here preliminary results suggesting that CAR might be a microbial sensor 
in the liver that controls the host xenobiotic and lipid metabolism in a sexually dimorphic 
way.  
 
MATERIALS AND METHODS 
In vivo studies 
In vivo studies were performed in accordance with European guidelines for the use 
and care of laboratory animals, and were approved by an independent Ethics Committee. 
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All mice were housed at the Toxalim-INRA rodent facility (Toulouse, France). The room 
where the mice were housed was kept at a temperature of 21-23°C on a 12-hour light (ZT0-
ZT12) 12-hour dark (ZT12-ZT24) cycle and mice were allowed free access to the diet 
(Teklad Global 18% Protein Rodent Diet) and tap water. ZT stands for Zeitgeber time; ZT0 is 
defined as the time when the lights are turned on and ZT12 as the time when lights are 
turned off.  
In the first set of experiments, forty male six-week old C57BL/6J mice were 
purchased from Charles River, kept for two weeks of acclimatization and then randomly 
allocated to the different experimental groups: control (CONT, n=8), ampicillin-treated (A, 
n=8), neomycin-treated (N, n=8), vancomycin-treated (WT A, n=8), wild-type ANV cocktail-
treated (WT ANV, n=8). The individual antibiotics [1g/L ampicillin (Euromedex, 
Souffelweyersheim, France), 1 g/L neomycin (Sigma Aldrich, Steinheim, Germany), 0.5 g/L 
vancomycin (MP Biomedicals, Illkirch, France)] and the ANV cocktail were dissolved to 
their corresponding treatment groups in tap water and was distributed accordingly per 
bottle per cage. The antibiotic treatments were changed every 3 days. Each mouse 
belonging to the antibiotic groups had free access to the antibiotic mixture via their 
drinking water for 14 days. After 2 weeks of antibiotic treatment, mice were then 
sacrificed at ZT6 or ZT18. 
In the second set of experiments, twelve six-week-old wild-type (WT) C57BL/ 6J 
male mice were purchased from Charles River and 12 Car-/- mice were used in this 
experiment. The Car-/- mice were backcrossed on the C57Bl/ 6J background and were 
engineered in Pr. Meyer’s laboratory (Staudinger et al., 2001) and were bred for 10 years 
in our animal facility. Mice were acclimatized for two weeks, then randomly allocated to 
235
Chapter 3.4 : Experimental Results 
the different experimental groups: Wild-type control (WT CONT n= 6), wild-type 
TCPOBOP-treated (WT TCPOBOP, n = 6), Car-/- control (Car-/- CONT, n = 6), Car-/- 
TCPOBOP-treated (Car-/- TCPOBOP, n= 6). TCPOBOP-treated mice received a daily 
intraperitoneal injection of PCN (100 mg/ kg) in corn oil for 4 days while control mice 
received corn oil only. Mice were sacrificed at ZT18, 18 hours after the last TCPOBOP 
injection. 
In the third set of experiments, forty-six-week old Car+/+ (20 males, 20 females) and 
39 Car-/- (19 males, 20 females) littermate mice were bred at Toxalim-INRA’s rodent facility. 
They were then kept for two weeks of acclimatization. After which, mice were randomly 
allocated to the different experimental groups in males: Car+/+ control (Car+/+ CONT, n=10), 
Car+/+ ATB-treated (Car+/+ ATB, n=10), Car-/- control (Car-/- CONT, n=10), Car-/- ATB-treated 
(Car-/- ATB, n=9); and in females : Car+/+ control (Car+/+ CONT, n=10), Car+/+ ATB-treated 
(Car+/+ ATB, n=10), Car-/- control (Car-/- CONT, n=10), Car-/- ATB-treated males (Car-/- ATB, 
n=10). After 2 weeks of antibiotic treatment, mice were then sacrificed at ZT18. 
In the last set of experiments, twenty six-week old Car+/+ (9 males, 11 females) and 
22 Car-/- (12 males, 10 females) littermate mice were bred at Toxalim-INRA’s rodent facility. 
They were then kept for two weeks of acclimatization. After which, mice were randomly 
allocated to the different experimental groups in males: Car+/+ control (Car+/+ CONT, n=9), 
Car-/- control (Car-/- CONT, n=12); and in females: Car+/+ control (Car+/+ CONT, n=11), and 
Car-/- control (Car-/- CONT, n=10). After aging the mice for 37 weeks, mice were then 
sacrificed at ZT18. 
 
 
236
Chapter 3.4 : Experimental Results 
Bacterial Cultivation of Feces 
Feces were collected at the beginning, at 7 days, and at 14 days of experimental 
diets under sterile conditions. Fecal samples from antibiotic-treated rats were diluted at 
10-3, 10-4, and 10-5 then cultured on plate count agar medium aerobically and on 
Schaedler C blood medium anaerobically. Untreated mice samples were diluted at 10-5, 
10-6, and 10-7 before being spread on the same culture media. Colonies forming unit were 
counted after 24 h at 37°C. 
 
Blood and tissue sampling 
Body weight was monitored at the beginning and at the end of each experimental 
period. Blood was collected at the submandibular vein into lithium heparin-coated tubes 
(BD Microtainer, Franklin Lake, NJ, USA) as described in Golde et al. (2005). Plasma was 
prepared by centrifugation (1500 g, 15 min, 4°C) and stored at -80°C. Following 
euthanasia by cervical dislocation, liver, ileum, and colon were removed, weighed, 
dissected, and snap-frozen in liquid nitrogen and stored at -80°C until used for RNA 
extraction.  
 
Plasma Analysis 
   Alanine transaminase (ALT), high- or low-density lipoprotein (HDL-LDL), total 
cholesterol, triglycerides and free fatty acids (FFA) were determined using a Pentra 400 
biochemical analyzer (Anexplo facility, Toulouse, France).  
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Gene expression Studies 
Total RNA was extracted with with TRI Reagent® (Molecular Research Center). 
RNAs were quantified using nanodrop (NanoDropTM 1000; Thermo Scientific). Two 
micrograms of total RNA were reverse transcribed using the High-Capacity cDNA Reverse 
Transcription Kit (Applied BiosystemsTM). The SYBR Green (Applied Biosystems, 
California) assay primers are presented in supplementary table 1. Amplification was 
performed using an ABI Prism 7300 Real-Time PCR System (Applied BiosystemsTM). 
Quantitative real-time polymerase chain reaction (qPCR) data were normalized to TATA-
box-binding protein mRNA levels and analyzed with LinRegPCR (version 2015.3; Jan 
Ruijter) to get mean efficiency (NO), which is calculated as follows: NO = threshold=ðEff 
meanCq Þ with Eff mean: mean PCR efficiency and CQ: quantification cycle.  
 
Testosterone hydroxylation assay 
Chemicals 
Acetic acid, ethanol, sodium chloride, potassium dihydrogen phosphate, dibasic 
potassium phosphate, monobasic sodium phosphate, dibasic heptahydrate sodium 
phosphate, potassium sodium tartrate tetrahydrate, glycerol, Folin & Ciocalteu’s phenol 
reagent, albumin from bovine serum, anhydrous sodium carbonate, NADP, D-glucose 6-
phosphate sodium salt, glucose-6-phosphate dehydrogenase, magnesium chloride, 1-
chloro-2,4-dinitrobenzene, reduced L-glutathione and testosterone were purchased from 
Sigma-Aldrich Merck (Saint Quentin Fallavier, France). Acetonitrile and methanol (HPLC 
grade) were purchased from Thermo Fisher Scientific (Waltham, MA, USA). Ammonium 
acetate, sodium hydroxide and copper sulfate were purchased from VWR (Fontenay-sous-
Bois, France). Flo-Scint™ II and Ultima Gold™ liquid scintillation cocktails were purchased 
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from PerkinElmer (Courtabœuf, France). Ultrapure water produced by a Milli-Q system 
(Millipore, Saint-Quentin-en-Yvelines, France) was used for the preparation of HPLC 
mobile phases.  
 
[14C]-testosterone (specific activity: 2.18 GBq/mmol) was purchased from 
PerkinElmer and its radiopurity was 98.8 %, as determined by radio-HPLC. Standards of 
testosterone metabolites were purchased from Steraloids (Newport, RI, USA): 15β-
hydroxytestosterone, 6α-hydroxytestosterone, 6β-hydroxytestosterone, 19-
hydroxytestostérone, 15α-hydroxytestosterone, 11α-hydroxytestosterone, 6β-
hydroxyandrostenedione, 11α-hydroxyandrostenedione, 16β-hydroxytestosterone, 4-
androsten-16α-ol-3,17-dione, 2α-hydroxytestosterone, 2α-hydroxyandrostenedione, 4,6-
androstadien-17β-ol-3-one, 7α-hydroxytestosterone and from Sigma-Aldrich: 
dihydroandrosterone, androstanolone, 16α-hydroxytestosterone, 11β-
hydroxytestosterone, 2β-hydroxytestosterone, 11β-hydroxyandrost-4-ene-3,17-dione, 1-
dehydrotestosterone, androstenedione, epitestosterone, androsterone, estradiol and 
estrone. 
 
Sub-cellular fraction preparation and protein content 
Following mice euthanasia, livers were collected, immediately perfused using NaCl 
0.9 %. They were weighed and frozen in liquid nitrogen until sub-cellular fraction 
preparation, which was carried out within a month. Livers were thawed and homogenized 
at 4°C using a Potter-Elvehjem Teflon glass homogenizer in 4 volumes/g of ice-cold 
sodium/phosphate buffer 0.1 M pH 7.4. Microsomal and cytosolic hepatic fractions were 
obtained after two centrifugation steps at 4°C (20 min at 9 000 g and 70 min at 105 000 g) 
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using a Beckman Optima XPN-80 ultracentrifuge (Villepinte, France). Microsomes were 
resuspended with gentle homogenization in 1 mL/g of ice-cold sodium/phosphate buffer 
0.1 M pH 7.4 with 20 % glycerol (v/v). Sub-cellular fractions were stored at 80°C in 
cryotubes until use. The protein content of sub-cellular fractions was determined using 
the Lowry et al. (1951) method, which was adapted for microplate reading, using a Tecan 
Infinite 200 (Männedorf, Switzerland) (Lowry et al., 1951). 
 
[14C]-testosterone incubations 
Mice hepatic microsomes (0.5 mg proteins/mL) were incubated at 37°C under 
shaking with 10 µM [14C]-testosterone (3.58 kBq per incubation in 5 µL ethanol) fortified 
with unlabelled testosterone. Incubations were performed in a final volume of 0.5 mL in 
0.1 M sodium/phosphate buffer pH 7.4 with 5 mM MgCl2. Incubations were initiated using 
a NADPH generating system: 1.3 mM NADP, 5 mM glucose-6-phosphate, 1 IU glucose-6-
phosphate dehydrogenase. The kinetic of testosterone metabolites formation was 
established between 10 min and 60 min. An incubation time of 20 min was selected in 
order to ensure a linear formation of testosterone metabolites. Incubations were stopped 
with 1.5 mL methanol, kept 30 min on ice and centrifuged 10 min at 6 500 g, 4°C (3MK 
Sigma centrifuges, Newtown Wem Shropshire, UK). Radioactivity measurements (10 µL) 
were performed before storage at -20°C, pending further radio-HPLC analysis. 
Radioactivity measurements were carried out using a Tri-Carb 2910TR (PerkinElmer) liquid 
scintillation analyzer, using Ultima Gold™ as the scintillation cocktail (PerkinElmer). 
Sample quenching was compensated by the use of quench curves and external 
standardization. 
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For the LC-MS confirmation of major testosterone's metabolites structure, 
additional incubations were carried out using unlabeled testosterone (50 µM) and pooled 
microsomes (1 mg proteins/mL, pool of 10 PXR control mice) during 30 min, in the same 
conditions. 
 
Radio-HPLC profiling and quantification 
Incubation media were individually analyzed by radio-HPLC for testosterone 
metabolites profiling and quantification. Reversed-phase high-performance liquid 
chromatography (R-HPLC) analysis were performed on an Ultimate-3000 system (Thermo 
Fisher Scientific) coupled with a flow scintillation analyzer Flo-One Radiomatic™ 610TR 
(PerkinElmer). The HPLC system consisted of Nucleoshell RP18 column (250 x 4.6 mm, 5 
µm, Macherey-Nagel, Hoerdt, France) coupled to a C18 guard precolumn (Nucleoshell 
RP18 5 µm EC 4/3, Macherey-Nagel), maintained at 35°C. Mobile phases were A: 
ammonium acetate buffer (20 mM, adjusted to pH 3.5 with acetic acid) and B: acetonitrile. 
The flow rate was 1 mL/min and the injection volume was 500 μL. The gradient was as 
follow: 0-35 min A:B from 80:20 to 60:40 (v/v); 35-45 min from 60:40 to 40:60; 45-48 min 
from 40:60 to 100 % B. The system returned to the initial condition at 51 min and held for 
another 4 min. Flo-Scint™ II (PerkinElmer) was used as scintillation cocktail, at a flow rate 
of 2 mL/min, and with a 500-µL detection cell. Each incubation media (800 µL, 
corresponding to ca. 1.5 kBq) was evaporated to dryness and reconstituted in mobile 
phase A:B 80:20 (v/v) prior to HPLC injection.  
In this system, the retention time (RT) of testosterone was 29.8 min. R-HPLC profiles 
were processed with the A500 software (PerkinElmer) using a background suppression of 
20 cpm (counts per minute) and an efficiency correction (80 % for [14C]). Metabolites were 
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quantified by integrating the area under the peaks monitored by radioactivity detection. 
All peaks above 4 % of the detected radioactivity were quantified for each animal. Mean 
results were expressed in nmol/min/mg protein ± SEM (n=5 mice per group).  
 
Mass spectrometry analysis 
Unlabeled testosterone incubation media were analyzed by LC-MS using the same 
chromatographic conditions. Testosterone metabolites structure was established based 
on their mass and on the similarity of their retention time with authentic standards. Media 
were analyzed by LC-MS using a RSLC3000 HPLC system (Thermo Fisher Scientific) 
coupled to a HRMS system LTQ Orbitrap XL mass spectrometer (Thermo Fisher Scientific) 
with a post-column split (0.2 mL/min in the source) using positive electrospray ionization 
(ESI). The injection volume was 50 µL, the source voltage was 1.80 kV, the capillary 
voltage was 30V, the capillary temperature was 350°C, the sheath gas (N2) flow (arbitrary 
unit) was 50, the auxiliary gas (N2) flow (arbitrary unit) was 40, the sweep gas (N2) flow 
(arbitrary unit) was 0 and the tube lens offset was 115 V. 
 
Proton Nuclear Magnetic Resonance (1H-NMR) Based Metabolomics  
Liver  and caecal content polar extracts were prepared for NMR analysis as 
described previously (Beckonert et al., 2007; Martin et al., 2019). All 1H-NMR spectra were 
obtained on a Bruker DRX-600-Avance NMR spectrometer (Bruker) using the AXIOM 
metabolomics platform (MetaToul) operating at 600:13MHz for 1H resonance frequency 
using an inverse detection 5-mm 1H-13C-15N cryoprobe attached to a cryoplatform (the 
preamplifier cooling unit). The 1H-NMR spectra were acquired at 300 K using a standard 
one-dimensional noesypr1D pulse sequence with water presaturation and a total spin-
242
Chapter 3.4 : Experimental Results 
echo delay (2 ns) of 100 ms. Data were analyzed by applying an exponential window 
function with a 0.3-Hz line broadening prior to Fourier transformation. The resulting 
spectra were phased, baseline-corrected, and calibrated to trimethylsilylpropanoic acid 
(TSP) (0:00 ppm) manually using Mnova NMR (version 9.0; Mestrelab Research S.L.). The 
spectra were subsequently imported into MatLab (R2014a; MathsWorks, Inc.). All data 
were analyzed using full-resolution spectra. The region containing the water resonance 
(4:6– 5:2 ppm) was removed, and the spectra were normalized to the probabilistic 
quotient [26] and aligned using a previously published function (Veselkov et al., 2009). 
Data were mean-centered and scaled using the unit variance scaling prior to 
analysis with orthogonal projection on latent structure-discriminant analysis (O-PLS-DA). 
The O-PLS derived model was evaluated for goodness of prediction (Q2Y value) using n-
fold cross-validation, where n depends on the sample size. The parameters of the final 
models are indicated in the figure legends. Metabolite identification and discrimination 
between the groups were done by calculating the O-PLS-DA correlation coefficients (r2) 
for each variable and back-scaled into a spectral domain so that the shapes of the NMR 
spectra and the signs of the coefficients were preserved [28]. The weights of the variables 
were color-coded according to the square of the O-PLS-DA correlation coefficients. 
Correlation coefficients extracted from significant models were filtered so that only 
significant correlations above the threshold defined by Pearson’s critical correlation 
coefficient (p < 0:05; r > 0.55; for n = 6 per group) were considered significant. For 
illustration purposes, the area under the curve of several signals of interest was integrated 
and significance tested with a univariate test.  
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High-throughput Sequencing of Bacterial content 
DNA extraction and sequencing of 16S rRNA gene regions.  
The microbial population present in the samples has been determined using next 
generation high throughput sequencing of variable regions of the 16S rRNA bacterial 
gene. The workflow was established by Vaiomer (Lluch et al., 2015). (1)Library 
construction and sequencing: The PCR amplification was performed using 16S universal 
primers targeting the V3-V4 regions of the bacterial 16S ribosomal gene (Vaiomer 
universal 16S primers). For each sample, a sequencing library was generated by addition 
of sequencing adapters. The detection of the sequencing fragments was performed with 
the MiSeq Illumina technology using the 2 x 300 paired-end MiSeq kit. (2) Bioinformatics 
pipeline: The targeted metagenomic sequences from microbiota were analyzed using the 
bioinformatics pipeline established by Vaiomer from the FROGS guidelines (Escudié et 
al., 2018). Briefly, after demultiplexing of the barcoded Illumina paired reads, single read 
sequences were cleaned and paired for each sample independently into longer 
fragments. Operational taxonomic units (OTUs) were produced via single-linkage 
clustering and taxonomic assignment is performed in order to determine community 
profiles. 
 
Data Analysis 
Reads obtained from the MiSeq sequencing system have been processed using 
the Vaiomer bioinformatics pipeline. The steps included quality-filtering, clustering into 
OTUs with the Swarm algorithm and taxonomic affiliation. Alpha diversity was analyzed 
with different methods (median + interquartile), 1) Observed, 2) Chao1, 3) Shannon, 4) 
Simpson, and 5) Inverse Simpson. Beta diversity (β-diversity) was measured with numeric 
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values for the “all against all” with Jaccard, Bray-Curtis, Unifrac and Weighted Unifrac. 
Graphical representations of the relative proportion of taxa were made at each taxonomic 
level (Phylum, Class, Order, Family, and Genus) for all study samples. “Linear discriminant 
analysis Effect Size” (LEfSe) (Segata et al., 2011) was the algorithm used to identify 
taxonomic groups characterizing the differences between two or more biological 
conditions. LEfSe was run using default values (alpha value of 0.5 for both the factorial 
Kruskal-Wallis test among classes and the pairwise Wilcoxon-Mann-Whitney test between 
subclasses, threshold of 2.0 for the logarithmic LDA score for discriminative features) and 
the strategy for multi-class analysis set to ‘all-against-all’. The LEfSe analysis was 
performed on the complete sequence data (no OTU abundance threshold) for identifying 
genotype effect on either males or females and sex effect on either Car+/+ or Car-/- mice.  
 
Statistical Analysis  
Statistical analyses were performed using GraphPad Prism for Mac OS X (version 
7.00; GraphPad Software). One-way or two-way analysis of variance (ANOVA) was 
performed, followed by appropriate posthoc tests (Bonferroni) when differences were 
found statistically significant. When only two groups were compared, the student’s t-test 
was used; p < 0:05 was considered significant.  
 
 
RESULTS 
Car is a broad sensor of the gut microbiota in the liver and small intestine 
We treated C57Bl6/J male mice with several individual antibiotics (ampicillin, 
neomycin and vancomycin) or the combination of these (ANV cocktail) for 2 weeks and 
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sacrificed them at ZT6 or ZT18 (Figure 1A-C, Supplementary Figure 1). Female C57Bl6/J 
mice were treated with the ANV cocktail for 2 weeks and sacrificed at ZT18 (Figure 1D-F, 
Supplementary Figure 1). We monitored CAR’s prototypical target genes’ (Cyp2b10 and 
Cyp2c55) mRNA expression in the liver, small and large intestine (Figure 1). To avoid a 
direct effect of the drugs on CAR activity in the liver, we tested only antibiotics that are 
described as poorly absorbed (Supplementary Table 1).  
In the liver at ZT6, vancomycin significantly decreased Cyp2c55 expression, while 
the ANV cocktail decreased both Cyp2b10 and Cyp2c55 expression. At ZT18, Cyp2b10 
expression was 3 times higher than at ZT6, and ANV cocktail significantly decreased 
Cyp2b10 and Cyp2c55 expression in both males and females (Figure 1A & D).   
In the ileum, Cyp2b10 expression at ZT18 was 4 times higher than at ZT6 while the 
antibiotic-treated groups did not significantly differ from their controls. Cyp2c55 
expression was significantly decreased across all treatments at both ZT6 and ZT18 in 
males and females (Figure 1B & E).  
Interestingly, in the colon, CYP expression was not significantly affected by any 
antibiotic treatment in males. In females, we observed a slight decrease in Cyp2c55 
expression.  
Altogether, these results first show that CAR activity is sensitive to circadian rhythm 
and is higher at ZT18, confirming previous studies (Montagner et al., 2016). Moreover, 
CAR seems less responsive to gut microbiota-derived signals in the colon than in the 
small intestine and the liver, at least in males.  
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Gut microbiota suppression does not interfere with the pharmacological activation 
of CAR 
 
To determine if gut microbiota suppression could interfere with CAR’s capacity to 
bind and respond to its ligands, we used WT and Car-/- male mice treated with antibiotics 
(ATB), with 1,4-Bis-[2-(3,5-dichloropyridyloxy)]benzene, 3,3′,5,5′-Tetrachloro-1,4-
bis(pyridyloxy)benzene (TCPOBOP, the pharmacological agonist of CAR) or a 
combination of both (Figure 2). TCPOBOP treatment significantly increased liver weight in 
a CAR-dependent way, but to a similar extent in the TCPOBOP and TCPOBOP+ATB 
groups. ATB treatment increased caecum weight, but to a similar extent in the ATB and 
ATB+TCPOBOP groups (Figure 2A). The CAR-dependent induction of Cyp2b10 and 
Cyp2c55 mRNA expression was similar in the TCPOBOP and TCPOBOP+ATB groups in 
the liver (Figure 2B) and ileum (Figure 2C). These results show that gut microbiota 
depletion does not interfere with CAR’s capacity to bind and respond to its 
pharmacological ligand.    
 
Gut microbiota is altered in Car-/- male mice   
To determine whether CAR conversely affected the gut microbiota, we used Car+/+ 
vs Car-/- littermate mice and compared their cecal microbiota using 16S rRNA sequencing 
(Figure 3). In males, CAR depletion significantly increased alpha-diversity (observed and 
chao1 indexes) (Figure 3A), while no significant difference in biodiversity was observed in 
females (Figure 3B). At the OTU level, significant clustering is seen in the hierarchical 
clustering and Principal Coordinate Analysis (PcoA) of Car+/+ vs Car-/- male mice but not in 
females (Figure 3C-F). This clustering in male mice is evident in the first PCoA axis that 
represents 27.8% of the variance (Figure 3D). Using the linear discriminant analysis (LDA) 
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effect size (LEfSe) pipeline, we confirmed significant differences in the baseline caecal 
microbiota composition of Car-/- male mice, as compared to that in Car+/+ mice (Figure 3G 
& H). Car-/- male mice had a decreased relative abundance of Akkermansia, Anaerostipes, 
Lachnoclostridium, and Parabacteroides and a decreased relative abundance of 
Ruminococcus 1, (Eubacterium) ventrosium group, (Eubacterium) xylanophilum group, 
Ruminococcaceae UCG-014, Coprococcus 2, and Odoribacter (Supplementary Figure 
2A). There were no differences found between Car+/+ vs Car-/- females (Supplementary 
figure 2B, Supplementary Figure 3). 
 We then investigated the metabolic profiles of caecal content in Car+/+ vs Car-/- 
mice using 1H-NMR-based profiling (Figure 4). The discrimination between the caecal 
content metabolic profiles of Car+/+ vs Car-/- males was significant (Figure 4A, parameters 
of the O-PLS-DA model: Q2Y=0.65, p=0.001), but not that of Car+/+ vs Car-/- females 
(Figure 4D, Q2Y<0, p>0.05).,The O-PLS-DA coefficient plots illustrate several peaks 
contributing to the significant separation of Car+/+ vs Car-/- males (highlighted in red in 
Figure 4B): one doublet of doublet at 8.12 ppm, two singulets at 6.13 and 6.15 ppm and 
one triplet at 5.99 ppm that were higher in Car-/- mice, while 2 singulets at 8.38 and 8.03 
ppm and five doublets at 7.91, 7.86, 6.07, 5.95 and 5.91 ppm were higher in Car+/+ male 
mice. Statistical total correlation spectroscopy (STOCSY) analyses and additional 2D-NMR 
experiments (COSY and TOCSY) confirmed that these 2 groups of peaks belonged to 2 
metabolites. Spike in experiments of pure standard confirmed that the metabolite higher 
in Car-/- mice could be assigned to uridine monophosphate (UMP) (data not shown), while 
available structural information did not allow us to formally identify the other 
discriminating metabolite. O-PLS-DA models between caecal content profiles of Car+/+ vs 
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Car-/- females (Figure 4E) did not highlight any significant differences between the 2 
groups. Integration of the area under the curve for the discriminating peaks, followed by 
univariate statistics confirmed a higher caecal UMP content and a lower level of the 
unknown metabolite in Car-/- males compared to Car+/+ males (Figure 4C). Interestingly, 
caecal content metabolomics of ATB-treated mice confirmed that the caecal levels of both 
UMP and of this unidentified metabolite depend on the gut microbiota since they were 
lower in ATB-treated mice compared to the control mice (data not shown). 
 Collectively, these data demonstrate that CAR plays a role in shaping the gut 
microbiota in a sexually-dimorphic manner, and that the male-specific CAR-dependant 
microbiota might display significant differences in nucleotide metabolism.  
 
Gut microbiota suppression decreases CAR activity in the liver and in the ileum of 
male mice 
 
To further investigate the gut microbiota-CAR interactions, we depleted the gut 
microbiota of the Car+/+ vs Car-/- male and female littermate mice with ATB. 
Supplementary Figure 4 confirms the successful depletion of the gut microbiota. We 
observed a significant decrease in CAR activity upon microbiota depletion in the liver of 
male (Figure 5A) and female mice (Figure 5B). The same decrease in CAR activity is 
extended in the ileum of male mice (Figure 5C) but surprisingly no difference is seen in 
females (Figure 5D). 
 
Gut microbiota-CAR interaction influences host’s hepatic metabolism 
To determine if these changes in the microbiota could in turn affect the host 
metabolism, we first investigated the effect of ATB on plasma biochemistry in Car+/+ vs 
Car-/- mice (Supplementary Figure 5). CAR deletion significantly influenced circulating 
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cholesterol, HDL and LDL levels. However, no significant effect of ATB was observed in 
male or female Car+/+ mice. 
  We next focused on the liver and first conducted 1H-NMR profiling of liver tissue 
(Figure 6). O-PLS-DA coefficient plots highlighted several peaks (2 triplets at 2.66 and 
3.37 ppm respectively) that were higher in Car+/+ compared to Car-/- male mice (Figure 
6A). This difference was not observed in ATB-treated males (Figure 6B). No significant 
differences were observed between Car+/+ and Car-/- females (Figure 6D & E). Integration 
of the area under the curve for the hypotaurine signals, followed by univariate statistics 
confirmed that hepatic hypotaurine levels were significantly affected by both ATB and 
CAR deletion in males (Figure 6C). Moreover, ATB-induced decrease in hypotaurine level 
was CAR-dependent, since no significant decrease was observed in ATB-treated Car-/- 
males (Figure 6C). In females, hypotaurine levels were also lower upon ATB treatment, 
but were not influenced by CAR deletion (Figure 6F). Hypotaurine is known for its 
antioxidant activity and is a precursor to glutathione metabolism (Aruoma et al., 1988).  
  We next investigated the oxidative metabolism of [4-14C] testosterone in male liver 
microsomes. This measurement shows the global ability of CYPs to metabolize sterol 
compounds (Figure 7). Peak at retention time (RT) of 13.9 minutes was significantly 
different between Car-/- and Car+/+ mice, but was not affected by ATB treatment. Upon 
microbiota suppression, the peak with RT at 14.7 min was significantly decreased in a 
CAR-dependent way, while the peak with RT of 10.0 minutes was significantly increased in 
a CAR-dependent way. Several structural hypotheses could be made based (1) on RT 
comparison with authentic testosterone metabolites standards, for those commercially 
available (LC-MS experiments), and (2) on the confirmation of the m/z ions detected in LC-
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MS (ESI, positive mode) when analyzing incubation media from incubations carried out 
with non-radio labeled testosterone. The peak with a RT of 14.7 min was identified as a 
HO-Δ-testosterone (m/z: 303.1955), but no formal identification of the hydroxylation 
position could be achieved. Of note, this metabolite was clearly found to be distinct from 
16α-HO-Δ-testosterone, for which the authentic standard is available.      
 
Long-term CAR deletion induces a sexually dimorphic phenotype: preliminary 
evidence  
 
Since we observed a significant gut microbiota dysbiosis upon CAR-deletion in 
male mice, we then investigated the long-term consequences of CAR deletion in male 
and female mice. Car+/+ and Car-/- male and female littermate mice were aged until 37 
weeks with free access to a standard rodent chow and tap water. Body weight was 
monitored on a weekly basis and no difference was observed between Car+/+ and Car-/- 
groups in males (Figure 8A) and females (Figure 8C). At age 32 weeks, an oral glucose 
tolerance test (OGTT) was conducted, and no differences were found (Figure 8B & J). 
Upon sacrifice at 37 weeks, no significant difference was observed in plasmatic ALT, HDL, 
LDL, triglyceride, cholesterol and FFA levels in males (Figures 8C-H) and females (Figures 
8K-P).  
At sacrifice, the liver, caecum and spleen were significantly heavier, while colon 
length was significantly shorter in Car-/- compared to Car+/+ females, while no differences 
were found in brown adipose tissue (BAT), perigonadal and subcutaneous white adipose 
tissue (WAT) weights (Figure 9). In males, the perigonadal and subcutaneous WAT were 
heavier in Car-/- mice compared to Car+/+ mice (Figure 9). Thus, a sexually dimorphic 
phenotype was observed on the physiological impact of CAR deletion in littermate mice: 
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in females, CAR deletion induced a slight pro-inflammatory intestinal and systemic 
phenotype, while in males, CAR deletion promoted WAT accumulation. The potential role 
of the CAR-induced gut microbiota dysbiosis in this dimorphic phenotype remains to be 
investigated.  
 
 
DISCUSSION 
This work is ongoing and still requires several complementary experiments. 
Discussion about perspectives of this work will be found in the next general discussion 
chapter.  
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FIGURE LEGENDS 
 
Figure 1: Effect of individual antibiotic treatments on CAR target genes. C57Bl6/J male 
mice were treated with individual treatments of ampicillin, neomycin, vancomycin or a 
cocktail of the three antibiotics (ANV) for 2 weeks in their drinking water and sacrificed at 
ZT6 or ZT18, while females were treated with the ANV cocktail and sacrificed at ZT18. RT-
qPCR results are presented as mean±SEM for n=8 per group. *p≤0.05, **p≤0.01, 
***p≤0.005 for ATB effect compared to control group; # p≤0.05 for ZT effect; $ p≤0.05, $$ 
p≤0.01, $$$ p≤0.005 for sex effect. P-values were derived from 1-way or 2-way ANOVA 
and Bonferroni’s post-tests. 
 
Figure 2: Effect of microbiota depletion on CAR activation via its pharmacological 
agonist. WT and Car-/- male mice were treated with an antibiotic cocktail of ampicillin, 
neomycin and vancomycin (ATB), the pharmacological agonist of CAR (TCPOBOP) or a 
combination of both (ATB+TCPOBOP). Impact on (A) liver and cecum weight, RT-qPCR 
expression of CAR’s target genes in the (B) liver and (C) ileum.  Data are mean±SEM of 
n=5-6 per group. $p≤0.05, $$p≤0.01, $$$p≤0.001 for PCN effect; *p≤0.05, **p≤0.01, 
***p≤0.005 for genotype effect using 2-way ANOVA and Bonferroni’s post-tests 
 
Figure 3: Gut microbiota composition in Car-/- vs Car+/+ mice. Alpha-diversity measures in 
caecal content of Car-/- vs Car+/+ (A) male and (B) female littermate mice. Beta-diversity 
represented by hierarchical clustering based on the Bray distances of Car+/+ (red)  vs. Car-/- 
(blue) (C) male or (E) female mice and by PCoA analysis based on the Bray distances in (D) 
male and (F) female mice. Circular cladograms generated from LEFSe analysis showing the 
most differentially abundant taxa enriched in fecal microbiota from Car+/+ (green) or Car-./- 
(red) (G) male mice. Log(LDA scores)>2 and significance of α<0.05 determined using 
Wicoxon-Mann Whitney test. 
 
Figure 4: 1H-NMR based metabolomics analysis of caecal content extracts in Car-/- and 
Car+/+ mice. Score plots related to the O-PLS-DA models derived from the 1H-NMR spectra 
of caecal content extract from (A) Car+/+ vs Car-/- males and (D) Car+/+ vs Car-/- females. 
Coefficient plots related to the O-PLS-DA models from (B) Car+/+ vs Car-/- males and (E) 
Car+/+ vs Car-/- females. Metabolites are color-coded according to their correlation 
coefficient (R), red indicating a very strong positive correlation. The direction of the 
metabolite indicates the group with which it is positively associated: metabolites pointing 
upward are higher in Car-/- mice and metabolites pointing downward are higher in Car+/+ 
mice. Area under the curve of the 1H-NMR spectra was integrated for the uridine 
monophosphate (UMP) signal (doublet at 8.12 ppm) and the unknown metabolite signals (2 
singulets at 8.38 and 8.03 ppm and five doublets at 7.91, 7.86, 6.07, 5.95 and 5.91 ppm) in 
(C) male and (F) female mice. Data are mean±SEM of n=8-10 per group. *p≤0.05, 
**p≤0.01, ***p≤0.005 for genotype effect using Wilcoxon tests. 
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Figure 5: CAR activity upon microbiota depletion in male and female Car-/- vs Car+/+ 
littermate mice. C57Bl6/J Car+/+ and Car-/- male and female littermate mice were treated 
with an antibiotic cocktail of ampicillin, neomycin and vancomycin (ATB) for 2 weeks. RT-
qPCR gene expression of Car, Cyp2b10 and Cyp2c55  in the liver of (A) male mice and (B) 
female mice; and the ileum of (C) male mice (D) female mice. Data are mean±SEM of n=8-
10 per group. *p≤0.05, **p≤0.01, ***p≤0.005 for ATB effect, #p≤0.05 ##p≤0.01, 
###p≤0.005 for genotype effect using 2-way ANOVA and Bonferroni’s post-tests. 
 
Figure 6: 1H-NMR based metabolomics analysis of hepatic extracts in Car-/- and Car+/+ 
mice. Coefficient plots related to the O-PLS-DA models derived from the 1H-NMR spectra 
of hepatic extract from (A) Car+/+ vs Car-/- males, (B) Car+/++ ATB vs Car-/- + ATB males, (C) 
Car+/+ vs Car-/- females, (D) Car+/++ ATB vs. Car-/- + ATB females. Metabolites are color-
coded according to their correlation coefficient (R), red indicating a very strong positive 
correlation. The direction of the metabolite indicates the group with which it is positively 
associated: metabolites pointing upward are higher in Car+/+ mice and metabolites 
pointing downward are higher in Car-/- mice. Area under the curve of the 1H-NMR spectra 
was integrated for the hypotaurine signals (triplet at 2.65 ppm) in (C) males and (F) 
females. Data are mean±SEM of n=8-10 per group. *p≤0.05, **p≤0.01, ***p≤0.005 for 
ATB effect; #p≤0.05 ##p≤0.01, ###p≤0.005 for genotype effect; §§§ p≤0.005 for gender 
effect using 2-way ANOVA and Bonferroni’s post-tests. 
 
Figure 7: Impact of gut microbiota depletion on hepatic xenobiotic metabolism in Car-/- vs 
Car+/+  male mice. Profile of 14C metabolites of testosterone after incubation with liver 
microsomes from male mice. Data are mean±SEM of n=5 per group. *p≤0.05, **p≤0.01, 
***p≤0.005 for ATB effect, #p≤0.05 ##p≤0.01, ###p≤0.005 for genotype effect using 2-way 
ANOVA and Bonferroni’s post-tests. 
 
Figure 8: Impact of long-term CAR deletion on metabolic parameters and plasma 
biochemistry in Car-/- vs Car+/+ littermate mice. Car+/+ and Car-/- male and female littermate 
mice were aged until 37 weeks with free access to a standard rodent chow and water. 
Body weight in (A) male and (I) female mice, OGTT values and area under the curve (AUC) 
in 32 week-old (B) males and (J) females. Plasmatic alanine aminotransferase (ALT), high 
density lipoprotein (HDL), low density lipoprotein (LDL), triglyceride, cholesterol, and free 
fatty acid levels in male (C-H) and female mice (K-P). 
 
Figure 9: Effect of long-term CAR deletion on organ weights. Car+/+ and Car-/- male and 
female littermate mice were kept until 37 weeks of age with free access to a standard 
rodent chow and water. (A) Body weight, (B) liver weight (C) spleen weight, (D) Brown 
adipose tissue (BAT) weight, (E) perigonadal and subcutaneous white adipose tissue 
(WAT) weights, (F) caecum weight and colon length in male mice. (A) Body weight, (B) liver 
weight (C) spleen weight, (D) BAT weight, (E) perigonadal and subcutaneous WAT 
weights, (F) caecum weight and colon length in female mice. Data are mean±SEM of n=8-
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10 per group. #p≤0.05, ##p≤0.01,###p≤0.005 for genotype effect using unpaired student 
test. 
 
SUPPLEMENTARY FIGURE LEGENDS 
 
Supplementary Figure 1: Effect of various ATB treatment on physiological parameters. 
(A) Body, (B) liver, and (C) caecum weight of male mice sacrificed at ZT6 and ZT18. (D) 
Body and (E) caecum, weight of male and female mice sacrificed at ZT18. Anaerobic fecal 
microbial count after 2 weeks of ANV cocktail treatment of male mice sacrificed at ZT18. 
 
Supplementary Figure 2: Effect of Car deletion on caecal microbiota community 
distribution. Graphical representations of the relative proportion of taxa at the Genus level 
between Car+/+ vs Car-/- (A) male and (B) female mice from the LEfSe analysis. Data are 
mean±SEM of n=8-10 per group. #p≤0.05, ##p≤0.01, ###p≤0.005 for genotype effect 
using unpaired student test. 
 
Supplementary Figure 3: Circular cladograms generated from LEFSe analysis showing the 
most differentially abundant taxa enriched in fecal microbiota from Car+/+ (green) or Car-./- 
(red) female mice. Log(LDA scores)>2 and significance of α<0.05 determined using 
Wicoxon-Mann Whitney test. 
 
Supplementary Figure 4: Effect of ATB treatment on physiological parameters in Car-/- vs 
Car+/+ mice. Car+/+ and Car-/- male and female mice were treated with an antibiotic cocktail 
of ampicillin, neomycin and vancomycin (ATB) for 2 weeks in their drinking water. (A) Body 
weight, (B) water consumption, (C) % body weights of liver and spleen, (D) % body weight 
of caecum and fecal microbial count in male mice. (E) Body weight, (F) water consumption, 
(G) % body weights of liver and spleen, (H) % body weight of caecum and fecal microbial 
count in female mice. Data are mean±SEM of n=8-10 per group. *p≤0.05, **p≤0.01, 
***p≤0.005 for ATB effect, #p≤0.05 ##p≤0.01, ###p≤0.005 for genotype effect using 2-
way ANOVA and Bonferroni’s post-tests. 
 
Supplementary Figure 5: Impact of microbiota depletion on plasma biochemistry in Car-/- 
vs Car+/+ mice. Effect of ATB treatment in (A) male and (B) female mice. Data are 
mean±SEM of n=8-10 per group. *p≤0.05, **p≤0.01, ***p≤0.005 for ATB effect; #p≤0.05 
##p≤0.01, ###p≤0.005 for genotype effect using 2-way ANOVA and Bonferroni’s post-
tests. 
 
SUPPLEMENTARY TABLES 
 
Supplementary Table 1: List of antibiotics and their properties.  
 
Supplementary Table 2. Oligonucleotide sequences for real-time PCR 
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Figure 1: Effect of individual antibiotic treatments on CAR target genes. 
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Figure 2: Effect of microbiota depletion on CAR activation via its pharmacological 
agonist.  
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Figure 3: Gut microbiota composition in Car-/- vs Car+/+ mice.  
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Figure 4: 1H-NMR based metabolomics analysis of caecal content extracts in Car-/- and 
Car+/+ mice.  
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Figure 5: CAR activity upon microbiota depletion in male and female Car-/- vs Car+/+ 
littermate mice.  
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Figure 6: 1H-NMR based metabolomics analysis of hepatic extracts in Car+/+ and Car-/- 
mice.  
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Figure 7: Impact of gut microbiota depletion on hepatic xenobiotic metabolism in Car+/+ 
vs Car-/- male mice.  
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Figure 8: Impact of long-term CAR deletion on metabolic parameters and plasma 
biochemistry in Car-/- vs Car+/+ littermate mice.  
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Figure 9: Effect of long-term CAR deletion on organ weights.  
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Supplementary Figure 1: Effect of various ATB treatment on physiological parameters. 
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Supplementary Figure 2: Effect of Car deletion on caecal microbiota community 
distribution.  
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Supplementary Figure 3: Circular cladograms generated from LEFSe analysis showing the 
most differentially abundant taxa enriched in fecal microbiota from Car+/+ (green) or Car-./- 
(red) female mice. 
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Supplementary Figure 4: Effect of ATB treatment on physiological parameters in Car-/- vs 
Car+/+  mice.  
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Supplementary Figure 5: Impact of microbiota depletion on plasma biochemistry in Car+/+ 
vs Car-/- mice.  
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SUPPLEMENTARY TABLE 
 
Supplementary Table 1: List of antibiotics (ATB) used and their properties (source: www.drugbank.ca). 
 
  
Antibiotics Quantity Category Mechanism Spectrum Intestinal absorption Effect on CYP/NR
Ampicillin 1 gram / L Beta-lactam Inhibition of cell wall synthesis Broad spectrum: excellent for gram-negative Partial Almost not metabolized 
Neomycin 1 gram / L Aminoglycoside
Binds to duplex RNA with high 
affinity; Inhibition of protein synthesis 
in bacteria
Broad spectrum: excellent for 
gram-negative
Poor absorption : 3% 
intact intestinal 
mucosa
 *Low CYP450 inhibitory promiscuity
Vancomycin 0.5 gram / L Glycopeptide Inhibition of cell wall synthesis in bacteria Narrow:spectrum; gram-positive Poor
*Substrate : CYP450 3A4                                                                            
Low CYP450 inhibitory promiscuity
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Supplementary Table 2. Oligonucleotide sequences for real-time PCR 
 
    
Gene NCBI Refseq Forward primer (5'-3') Reverse primer (5'-3') 
Cyp2b10 NM_009999 TTTCTGCCCTTCTCAACAGGAA ATGGACGTGAAGAAAAGGAACAAC 
    
Cyp2c55 AY206875 TTGTGGAAGAGCTAAGAAAAGCAAAT GAGCACAGCTCAGGATGAATGT 
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General Discussion and Perspectives 
  
In the last two decades, research in the field of gut microbiota has progressed from 
correlation-based studies between microbiota composition and diseases to investigating 
molecular pathways of interactions between specific bacterial strains, their metabolites 
and the host. Current knowledge states that gut microbiota composition is variable 
subject to the host’s genetic background complemented with dietary and environmental 
factors. Of note, gut microbiota metabolites also influence the composition and activity of 
microbial communities in the gut (Cani, 2018). Concomitantly, nuclear receptors (NRs) 
play a primordial role by regulating numerous physiological processes in response to 
endocrine, metabolic and environmental stimuli (Evans & Mangelsdorf, 2014). In the liver, 
the nuclear receptors CAR and PXR primarily regulate xenobiotic metabolism and are 
considered as the master regulators of drug metabolism and transport (Gao & Xie, 2010). 
In the recent years, numerous studies have also demonstrated that CAR and PXR play a 
role in energy homeostasis through the regulation of glucose (Kodama et al. , 2004; Miao 
et al., 2006; Zhou et al., 2006) and lipid metabolism (Dong et al., 2009; Gao et al., 2009).  
 
CAR and PXR are broad sensors of the gut microbiota in the liver and ileum 
In this work, we have first demonstrated in several independent experiments that 
microbial depletion by different antibiotic protocols decreased CAR and PXR activity in the 
liver and ileum but not in the colon. This confirmed several previously published results 
that evaluated the expression of PXR and CAR targets in the liver of germ free (GF) male 
mice (Banerjee, Robbins, & Chen, 2013; Björkholm et al., 2009; Claus et al., 2011; 
Kawamoto et al., 2000; Lundin et al., 2008)  and mice treated with antibiotics (ATB) (Oh et 
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al., 2019). This also confirms the few existing studies that have shown that xenobiotic 
enzyme expression is lower in the small intestine of GF vs. conventional mice (Fu et al., 
2017). The colon results were surprising, since we have confirmed that PXR expression is 
not significantly different between the liver, the small and the large intestine (Chapter 4). 
However, CAR expression has been described to be low in the colon (Lundin et al., 2008). 
It was also surprising since gut microbiota load is higher in the colon than in the ileum 
(Eckburg et al., 2005). However, previous studies have already shown that gut microbiota 
affects the expression of a much larger set of genes in the small intestine than in the colon 
in mice (Larsson et al., 2012; Mardinoglu et al., 2015; Sommer et al.,2015). Therefore, our 
results are consistent with the hypothesis that CAR and PXR are indeed gut microbiota 
(GM) sensors and transcriptional regulators of GM effects in the liver and in the ileum 
(Chapter 3.3, Figure10B; Chap 3.4, Figure1). 
Impact of circadian rhythm and sex 
We have observed that the activity of PXR in the basal state and in response to gut 
microbiota was not significantly affected by the circadian rhythm (Chapter 3.3, Figure1A-C 
& 5; Chap 3.2, Figure1). This confirms previous results from our team that showed that 
PXR activity in GF mice was almost completely depleted at all times (Montagner et 
al., 2016) (Figure 16).  
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Figure 16. Circadian Oscillations of xenosensors in mouse. (A) PXR and target gene Cyp3a11, (B) 
CAR and target gene Cyp2b10 (Montagner et al., 2016). 
On the contrary, mice (Montagner et al., 2016)  and rat (Kanno, et al., 2004) studies 
have previously observed that CAR activity has a circadian oscillation that peaks at ZT18-
ZT20 in the liver. This could explain the weak inhibition of CAR activity to the antibiotic 
treatments that we observed at ZT6 contrasting with the significant decreased expression 
of Cyp2b10 and Cyp2c55 at ZT18 (Chapter 3.4, Figure1A-D & 5). Interestingly, upon ATB 
treatment, both Cyp2b10 and Cyp2c55 mRNA levels decreased in the liver and only 
Cyp2c55 mRNA decreased in the ileum. Though there is the tendency to decrease, it is 
rather striking to observe the difference between these two classical CAR target genes. 
CAR and PXR are known to regulate the expression of a number of overlapping or distinct 
set of genes in xenobiotic metabolism, thus, it is noteworthy to know the difference 
between Cyp2b10 from Cyp2c55. Cyp2b10 is strongly induced by a class of xenobiotics 
known as ‘phenobarbital like inducers’, such as phenobarbital or TCPOBOP, which are 
ligands specific to CAR activation (Wei et al., 2002). Conversely, the transcriptional 
regulation of murine Cyp2c genes is poorly understood and are identified to be 
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differentially regulated by CAR or PXR. Of note, Cyp2c55, initially identified to be 
regulated by PXR, is also regulated by CAR in mouse liver and kidney (Konno et al., 2010).  
Furthermore, CAR activity in the liver was particularly sexually dimorphic: Cyp2b10 
expression was 80 times higher and Cyp2c55 two times higher in females compared to 
males (Chapter 3.4, Figure1D). As explained in Chapter 1.6.4., CAR expression itself is 
higher in females compared to males (Petrick & Klaassen, 2007). Moreover, previous 
studies have also shown that when mice were treated with the CAR ligands TCPOBOP 
(Ledda-Columbano et al., 2003), and Zoxozolamine (Hernandez et al., 2009), CAR activity 
was significantly more increased in females compared to males. Therefore, CAR is thought 
to be more active and more inducible in females than in males (Petrick & Klaassen, 2007; 
Wei et al., 2002). This sexually dimorphic activity could due to three main reasons: (1) the 
inhibition of CAR activity in males by androstane (testosterone metabolite), which acts as 
an inverse agonist of CAR. The androgen levels result from the metabolism of testosterone 
via several steps of hydroxylation. Hydroxylase 6a activity is more significant in females 
than the hydroxylase 15a in males. In consequence, the ratio of 6a/15a hydroxylase is 
decreased in CAR deficient females contributing to the masculinization of these mice 
(Hernandez et al., 2009). This ratio is considered a biomarker of androgen levels and 
perturbations (Wilson, et al., 1999). (2) Estrogen mediated CAR activity (Kawamoto et al., 
2000); (3) the significant contribution of  HNF4a in females (Kamiyama et al., 2007; Wiwi, 
Gupte, & Waxman, 2004; Wortham et al. , 2007).  
Altogether, our results are in line with recent data highlighting that circadian 
rhythm and sex are two important parameters to take into consideration when one 
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investigates the gut microbiota-host interaction, and in our case, the gut microbiota-
nuclear receptor interaction (Kuang et al., 2019; Weger et al., 2019).  
Gut microbiota depletion does not interfere with the capacity of CAR and PXR 
to induce transcription upon pharmacological binding 
CAR /PXR activity can be inhibited by the displacement of an agonist or the binding 
of an antagonist that may block the recruitment of RXR or co-activators thereby 
strengthening the interactions of a co-repressor. In addition, post-translational 
modifications may also interfere with CAR/PXR activity. Generally, there have been large 
number of inhibitors reported but it is believed that only a few of these bind at the ligand 
binding pocket (Chai et al., 2016).  Figure 17 shows several classes of chemicals found to 
inhibit CAR and PXR activity. 
Having previously demonstrated the microbial sensing capacity of CAR and PXR, 
we proceeded to investigate if the gut microbiota could interfere with the ligand-binding 
function of CAR and PXR. We have shown that, when mice are exposed to their 
pharmaceutical ligands (PCN for PXR and TCPOBOP for CAR) and/or the ATB treatment, 
these xenosensors consistently and robustly responded to their ligands (Chapter 3.3, 
Figure2F & G; Chapter 3.3, Figure2B & C). This demonstrates that gut microbiota 
depletion does not prevent or decrease the extent of CAR and PXR activity upon 
pharmacological activation. Therefore, we conclude that the antibiotic-driven decrease in 
PXR and CAR activity is not due to a change in the transcriptional machinery of the 
intestinal epithelial cells or of the hepatocytes, but rather to a decrease of microbial-
derived ligands.  
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Figure 17. Reported PXR (top) and CAR (bottom) inhibitors. Compounds described as inhibiting 
both NRs are enclosed in the center (Chai et al., 2016)  
The gut microbiota-xenosensor interaction’s impact on the host hepatic 
xenobiotic metabolism and beyond 
In Chapters 3 and 4 of this work, we have extensively investigated the primary 
metabolic pathway showing that upon pharmacological activation of PXR, the most 
sensitive genes were related to xenobiotic metabolism and that this regulation was shared 
between the liver and intestine. Consistently, we demonstrated in Chapter 3 that the gut 
microbiota-PXR interaction mainly controls the expression and the activity of xenobiotic 
metabolizing enzymes. This corroborates many previous transcriptome (Fu et al., 2017; 
Kindt et al., 2018), as well as proteome (Kindt et al., 2018) analysis, in which Cyp3a11 is 
systematically one of the top down regulated genes and proteins in GF male mice. We 
add to these previous studies by demonstrating that PXR is the key mediator of these 
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perturbations. No microarray analysis was done on the Car+/+ vs Car-/- littermates treated 
with antibiotics. However, previous data from our lab were obtained from hepatic 
transcriptomes of 16-week old WT vs Car-/- mice (Lukowicz et al., submitted for 
publication). Females had a greater number of differentially expressed genes (487 
upregulated, 106 downregulated) than males (100 upregulated, 62 downregulated). In 
males, significant biological functions involved in oxidation and reduction processes 
(including CYPs), cholesterol transport and endoplasmic reticulum were upregulated, 
while genes linked to steroid hormone biosynthesis were downregulated. In females, 
genes specifically involved in the hepatic immune system were upregulated, while genes 
related to steroid hormone biosynthesis, cell junction, transmembrane region, and 
carboxylic ester hydroxylase were down-regulated. Although the mice used by Lukowicz 
et al. were not littermates, the transcriptomic data corroborates with the PXR profile, 
where dysregulated functions were sexually dimorphic and xenobiotic metabolism 
oriented. It would be interesting to see the transcriptomic signature from CAR littermates 
treated or not with ATB, where the confounding effects of microbiota variation between 
strains are controlled (Robertson et al., 2019). In Car+/+ vs Car-/- littermates, antibiotic 
treatment reduced Cyp2b10 expression in the liver and testosterone hydroxylation assays 
also demonstrated functional CAR-dependent alterations of xenobiotic metabolism. CAR 
is recognized to be a regulator of Cyp2 gene family (Bae, Kemper, & Kemper, 2004). Thus, 
we hypothesize that the gut microbiota-CAR interaction also controls mainly xenobiotic 
metabolism through Cyp2 gene family, but further transcriptomic analysis is needed to 
confirm this.  
281
General discussion and perspectives 
Sexual dimorphism 
It would also be intriguing to further investigate the mechanisms of sexual 
dimorphism in the hepatic profile of these mice. We have observed with PXR littermate 
mice that the microbiota depletion by ATB has impacted the transcriptomic profile, 
independently from PXR. It has been previously described that gut microbes can impact 
the entero-hepatic recirculation of estrogens and androgens, thereby affecting local and 
systemic levels of sex steroid hormones (Cross, Kasahara, & Rey, 2018). In addition, 
estrogen can directly influence gut microbiota composition and consequently influence 
the sexual-dimorphism in diet-induced metabolic syndrome (Kailannan et al., 2018). 
Furthermore, estrogen receptors have also been shown to either have an inhibitory or 
activating effect on CAR depending on the presence of ligands (Min et al., 2002). With 
already differences in CAR basal expression and activity in the liver, it would be important 
to understand more, especially on a mechanistic level, how these sex hormones affect 
CAR’s hepatic activity. 
Lipid metabolism 
In Chapters 1 & 3, our results on pathway enrichment analysis from the PXR 
microarray data has also confirmed that lipid metabolism is another PXR-dependent 
hepatic function. In Chapter 1, we confirmed the pro-steatotic effect of PXR activation from 
both induction of lipogenesis and repression of b-oxidation, and that this repression is 
certainly partly mediated through inhibition of PPARa. These data reinforce existing 
studies describing that PXR promotes lipogenesis (Gao et al., 2009) and is associated with 
the induction of fatty acid translocase (FAT/CD36), peroxisome proliferator-activated 
receptor g2 (PPARg2), and stearoyl-CoA desaturase-1(SCD1) (Zhou et al., 2006). 
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Interestingly, we also highlighted possible new pleiotropic effects of PXR through 
its involvement in the regulation of hepatokines such as GDF15 and FGF21. Both GDF15 
and FGF21 are liver-derived hormones of the hepatokine family. These proteins have 
been described as playing many key endocrine roles. For example, GDF15 (Tsai, et al., 
2018) and FGF21 (Kliewer & Mangelsdorf, 2019) have both been reported to influence 
whole body metabolic homeostasis as well as behavioral responses. Therefore, our data 
raises the interesting hypothesis that drugs and other xenobiotics that act as potent 
regulator of PXR activity may induce side effects and endocrine disruption through the 
modulation of hepatokine expression. Further work is required to analyze whether PXR 
mediated regulation of GDF15 and FGF21 occurs through a direct control of gene 
expression and whether the changes we observed in response to a pharmacological 
agonist may also occur in response to other drugs and other xenobiotics. 
In Chapter 3, we extended our results on the moderate impact that gut microbiota 
contributes in hepatic fatty acid metabolism, at least in male mice. Various studies have 
described that gut microbiota can control the profile of the lipids in the gut-liver axis by 
affecting cholesterol-derived compounds and their hepatic recirculation, thereby affecting 
the consequences of liver metabolism (Bitter et al., 2015; Björkholm et al., 2009; Hakkola, 
Rysä, & Hukkanen, 2016; Kodama & Negishi, 2013 ). Inferring from these results, our data 
provides additional insights into how PXR might play a role in liaison with gut microbiota 
in fatty acid elongation (Kindt et al., 2018) 
CAR also plays a role in hepatic lipid homeostasis. CAR activation results in the 
inhibition of hepatic lipogenic genes and alleviate hepatic steatosis by inhibiting LXRa to 
the Srebp-1c gene promoter (Björkholm et al., 2009). In another study, CAR or PXR 
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reduced the level  of SREBP-1c by inducing Insig-1, a protein with antilipogenic properties 
(Roth et al., 2008). CAR activation also results in the inhibition of fatty acid synthesis and 
gluconeogenesis (Björkholm et al., 2009), as well as the increase of energy expenditure in 
brown adipose tissue (Gao et al., 2009). With the equal importance of CAR’s impact on 
lipid metabolism, it would be of timely opportunity to take further steps in completing the 
transcriptional profile with microarray and more gene expression experiments. In addition 
investigating the relative abundance of fatty acids in the liver from littermate mice would 
complement and provide better understanding of the CAR-gut microbiota impact on lipid 
metabolism. 
Altogether, our data provide evidence that the interaction of the gut microbiota 
with CAR and PXR modulates the host’ hepatic xenobiotic metabolism in a sexually 
dimorphic way, which then perturbs the profile of circulating lipids via the gut-liver axis 
thereby affecting pathways important in hepatic lipid metabolism.  
CAR and PXR alters gut microbiota 
The gut microbiota contributes to a wide array of functions, including dietary 
digestion and absorption of nutrients and immunity. The gut has a protective layer of 
epithelial cells of which its integrity is affected by resident microbial metabolites. When 
this layer is compromised, chronic inflammation occurs. This dysfunction of the protective 
layer has been the epicenter of recent research implicating a variety of diseases linked to 
innate immunity and homeostasis in the intestine (Ranhotra et al., 2016). PXR has been 
recently studied and recognized for its role in regulating intestinal mucosal homeostasis 
by xenobiotic and endobiotic sensing of intestinal microbial metabolites (Ranhotra et al., 
2016; Venkatesh et al., 2014). 
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In Chapter 3, our results initially showed no differences between the biodiversity in 
males or in females, but detected significant differences in the baseline caecal microbiota 
composition of Pxr-/- compared to that in Pxr+/+ male mice. Then, we detected a change in 
the profile of a tyrosine-based metabolite demonstrating that PXR has a role in shaping 
the gut microbiota in a sexually-dimorphic manner and that this PXR-dependent 
microbiota might play a role in the metabolism of aromatic amino acids. In vivo 
cardioprotection studies on rat (Lam et al., 2016) have shown that the catabolism of 
aromatic amino acids is a prevalent response of changes in the abundance of specific 
bacterial groups in the rat intestine. Alterations in the abundance of individual groups of 
bacteria (namely Clostridia, Bacilli and Proteobacteria) were not responsible for the 
cardioprotection in rats but the corresponding changes in aromatic amino acid 
metabolites link the intestinal microbiota responsible for this cardioprotective phenotype. 
Amino acid catabolism was by far the most affected pathway, of which metabolites of the 
aromatic amino acids phenylalanine, tryptophan, and tyrosine constituted the majority (33 
of 50) of the affected metabolites. Tryptophan catabolism via specific bacterial strains 
(e.g.,indole positive Clostridium sporogenes) results in the production of indoles. This has 
been demonstrated in mice treated with clindamycin, in which, enteric bacterial 
metabolites of tryptophan (but not host metabolites) decreased compared to untreated 
mice (Jump et al., 2014). Similar results have been seen in germ-free versus conventional 
mice (Wikoff et al., 2009). Tryptophan can be converted directly in the gut by 
microorganisms into indole derivatives, such as indole-3-propionic acid (IPA). In vitro, IPA 
has been shown to activate both the mPXR and the hPXR, however IPA was a much more 
potent agonist of the mPXR (Venkatesh et al., 2014). In vivo, oral gavage with IPA has been 
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shown to decrease intestinal permeability in the small intestine in a PXR-dependent way 
(Venkatesh et al., 2014). In distant organs, such as the vascular epithelium, IPA has been 
shown to regulate endothelium-dependent vasodilation in vivo, and in vitro experiments 
point to PXR as a potential effector of IPA effects (Venu et al., 2019). However, there is 
lacking in vivo evidence using physiological concentrations of circulating IPA. Indoxyl-3-
sulfate is another by product of the microbiota-host tryptophan co-metabolism (Wikoff et 
al., 2009). and has been demonstrated to be a direct AhR ligand, however, it failed to 
activate CAR or PXR in cell lines (Schroeder et al., 2010). Therefore, indoles, and IPA in 
particular, might represent potential microbial ligands for PXR that could explain our 
results in the intestine and in the liver. However, it is not clear whether these indoles could 
reach the liver at a sufficient concentration to activate PXR. 
Conversely, CAR is reportedly involved in modulating hepatic xenobiotic 
metabolism without direct contact to the liver via CAR-ligands (Björkholm et al., 2009). In 
Chapter 4, our results show that CAR depletion significantly increased alpha-diversity in 
males but not in females. We also observed a significant increase in caecal UMP 
concentrations, and a significant decrease of an unidentified metabolite in Car-/- mice 
compared to Car+/+ mice. Interestingly, this unidentified metabolite is gut microbiota and 
CAR dependent in males and is 4 times higher than in females. In addition, hypotaurine 
level in the liver of males was CAR and gut micorbiota-dependent, but in females, only gut 
microbiota-dependent. These results demonstrate that CAR shapes the gut microbiota in 
a sexually-dimorphic manner, and that the male-specific CAR-dependent microbiota 
might display significant differences in nucleotide metabolism. In a previous study in our 
team, CAR induced sexually dimorphic changes in hepatic metabolites. CAR deletion 
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significantly decreased glutathione precursors glycine and hypotaurine in males, while all 
bile signals were decreased in females (Lukowicz et al., submitted for publication). It is 
known that levels of bile acids, steroid hormones and bilirubin are regulated by gut 
microbiota (Chu, Duan et al., 2019; Vítek et al., 2005). In many cases, these cholesterol-
derived metabolites in their unmodified form, act as ligands or activators of NRs in the liver 
to control the endogenous metabolism of the compounds. These studies validate our 
results on the involvement of the CAR-gut microbiota interaction, as well as affecting 
gluthatione metabolism in the liver of males. Finding studies correlating CAR-dependent 
microbiota to its metabolites is a challenge. However, in one study by Björkholm et al. 
(2009), bile acids and steroids have been proposed. Constitutively higher CAR expression 
in the intestine of GF mice was associated with elevated levels of the CAR activators 
bilirubin, bile acids and steroid hormones, although the relative contributions of these are 
so far unknown. This might be a result of the increased levels of cholesterol, and/or the 
direct biochemical effects of the microbiota on these compounds. It is important to 
highlight, though, that these mice were challenged with phenobarbital. Bile acids interact 
with PXR directly (Krasowski et al., 2005; Staudinger et al., 2001) or indirectly via regulation 
of the farnesoid X receptor (Björkholm et al., 2009; Jung, Mangelsdorf, & Meyer, 2006). 
Bile acids and their metabolites help maintain hepatic glucose, cholesterol and 
triglyceride homeostasis.  
Preclinical studies suggest that bile acids can contribute to the development of 
non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). In patients with 
Crohn’s disease or ulcerative colitis with active mild or moderate inflammation, as well as 
in tissues isolated from colitis mice, CAR gene expression is reduced in intestinal mucosal 
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biopsies. Selective activation of CAR enhances wound healing in intestinal epithelial cells 
in culture, an effect driven by enhanced cell migration. Finally, inhibition of CAR delays 
mucosal healing after the induction of experimental colitis, while its pharmacological 
activation accelerates recovery (Hudson et al, 2017). Thus, CAR alters the natural milieu of 
the microbiota (Duszka & Wahli, 2018). CAR in the intestine and in the liver depends on 
the presence of the microbiota (Lundin et al., 2008; Björkholm et al., 2009). Again, 
because CAR and PXR can be activated by the same ligands, upregulation of overlapping 
sets of genes allows for coordinated clearance and detoxification of harmful compounds 
like bile, for example. 
It would be interesting to further explore this fertile area of research, where there 
has been no solid evidence linking CAR dependent metabolites with phenotypes 
associated with inflammation, NAFLD and NASH. The mice used in our results were first of 
all, unchallenged in their diet regimes, thus having milder phenotypes than what is 
described in literature. Next, the microbial depletion implemented with littermate mice 
was only short term. Long-term depletion of gut microbiota via GF models would be an 
interesting perspective to observe long-term effects of this interaction. With the 37-week 
aging of CAR-depleted mice, there were already differing phenotypes where males 
accumulated adipose tissues while females developed a slightly pro-inflammatory 
phenotype. Changes in the microbiota are associated with the development of non-
alcoholic fatty liver (NAFLD) (Le Roy et al, 2013, Bäckhed et al., 2004). Moreover, 
epididymal fat weight, hepatic steatosis, multifocal necrosis and infiltration of liver by 
inflammatory cells were significantly increased in GF mice colonized with faeces from 
patients with NASH and then fed a high-fat diet (HFD) (Chiu et al., 2017). These results 
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indicate that risk of NAFL and NASH can be transmitted by the faecal microbiota (Chu et 
al., 2018). Thus, it would also be very interesting to feed Car-/- and Car+/+ mice with a 
western diet (WD, high carbohydrate and high-fat diet) or HFD to study the impact of the 
CAR-gut microbiota interaction on NAFL and NASH. 
In conclusion, PXR and CAR interact with microbiota and are required for the 
proper functioning of the liver and intestine in xenobiotic and lipid 
metabolism. Importantly, these xenosensors are interconnected (Figure 18) and show a 
high level of coordination and, thus, future research may show that they embody an 
essential pathway in the gut–liver axis and its role in gender specific sensitivity to gastro-
intestinal responses to microbiota derived metabolites.  
These investigations may help us understand gender specific susceptibility to 
xenobiotic exposure and chronic pathologies such as NAFLD. It will not only be critical to 
design appropriated preventive strategies, as well as personalized medication. 
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Figure 18. Bi-directional interactions of CAR and PXR and the gut microbiota in the liver 
and intestine. CAR /PXR-gut microbiota interaction modulates xenobiotic metabolism pathways 
(e.g. glutathione metabolism via a PXR-gut microbiota dependent-change in the hypotaurine 
profile) in a sexually dimorphic way, which then perturbs the profile of circulating lipids via the 
gut-liver axis thereby affecting important pathways in hepatic lipid metabolism. PXR in the 
intestine changed a tyrosine-based metabolite caused by sexually-dimorphic and PXR-dependent 
alterations in the GM composition. CAR significantly alters gut microbiota composition in 
males but not in females, thereby significantly changing the UMP profile in Car-/- male mice and 
the profile of metabolite A in Car+/+ male mice. Thus, inducing a male-specific impact gut 
microbiota metabolism. Altogether, PXR and CAR interact with microbiota and are required for 
the proper functioning of the liver and intestine in xenobiotic and lipid metabolism. 
290
291
BIBLIOGRAPHIC REFERENCES 
292
Bibliographic references 
 
Abdel-Misih, S. R. Z., & Bloomston, M. (2010). Liver anatomy. The Surgical Clinics of North America, 
90(4), 643–653. https://doi.org/10.1016/j.suc.2010.04.017 
 
Abdul Rahim, M. B. H., Chilloux, J., Martinez-Gili, L., Neves, A. L., Myridakis, A., Gooderham, N., & 
Dumas, M.-E. (2019). Diet-induced metabolic changes of the human gut microbiome: 
Importance of short-chain fatty acids, methylamines and indoles. Acta Diabetologica, 56(5), 
493–500. https://doi.org/10.1007/s00592-019-01312-x 
 
Abe, T., Takahashi, M., Kano, M., Amaike, Y., Ishii, C., Maeda, K., … Yoshinari, K. (2017). Activation of 
nuclear receptor CAR by an environmental pollutant perfluorooctanoic acid. Archives of 
Toxicology, 91(6), 2365–2374. https://doi.org/10.1007/s00204-016-1888-3 
 
Agus, A., Planchais, J., & Sokol, H. (2018). Gut Microbiota Regulation of Tryptophan Metabolism in 
Health and Disease. Cell Host & Microbe, 23(6), 716–724. 
https://doi.org/10.1016/j.chom.2018.05.003 
 
Alaynick, W. A. (2008). Nuclear receptors, mitochondria and lipid metabolism. Mitochondrion, 8(4), 
329–337. https://doi.org/10.1016/j.mito.2008.02.001 
 
Archer, R. H., Chong, R., & Maddox, I. S. (1982). Hydrolysis of bile acid conjugates by Clostridium 
bifermentans. European Journal of Applied Microbiology and Biotechnology, 14(1), 41–45. 
https://doi.org/10.1007/BF00508002 
 
Atarashi, K., Nishimura, J., Shima, T., Umesaki, Y., Yamamoto, M., Onoue, M., … Takeda, K. (2008). 
ATP drives lamina propria T(H)17 cell differentiation. Nature, 455(7214), 808–812. 
https://doi.org/10.1038/nature07240 
 
Atkinson, C., Frankenfeld, C. L., & Lampe, J. W. (2005). Gut Bacterial Metabolism of the Soy Isoflavone 
Daidzein: Exploring the Relevance to Human Health. Experimental Biology and Medicine, 
230(3), 155–170. https://doi.org/10.1177/153537020523000302 
 
Auerbach, S. S., Stoner, M. A., Su, S., & Omiecinski, C. J. (2005). Retinoid X receptor-alpha-dependent 
transactivation by a naturally occurring structural variant of human constitutive androstane 
receptor (NR1I3). Molecular Pharmacology, 68(5), 1239–1253. 
https://doi.org/10.1124/mol.105.013417 
 
Bacher, A., Eberhardt, S., Fischer, M., Kis, K., & Richter, G. (2000). Biosynthesis of vitamin b2 
(riboflavin). Annual Review of Nutrition, 20, 153–167. 
https://doi.org/10.1146/annurev.nutr.20.1.153 
 
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., … Gordon, J. I. (2004). The gut 
microbiota as an environmental factor that regulates fat storage. Proceedings of the National 
Academy of Sciences of the United States of America, 101(44), 15718–15723. 
https://doi.org/10.1073/pnas.0407076101 
 
Bäckhed, F., Manchester, J. K., Semenkovich, C. F., & Gordon, J. I. (2007). Mechanisms underlying 
the resistance to diet-induced obesity in germ-free mice. Proceedings of the National 
Academy of Sciences of the United States of America, 104(3), 979–984. 
https://doi.org/10.1073/pnas.0605374104 
293
Bibliographic references 
 
  
Bae, Y., Kemper, J. K., & Kemper, B. (2004). Repression of CAR-mediated transactivation of CYP2B 
genes by the orphan nuclear receptor, short heterodimer partner (SHP). DNA and Cell 
Biology, 23(2), 81–91. https://doi.org/10.1089/104454904322759894 
 
Baes, M., Gulick, T., Choi, H. S., Martinoli, M. G., Simha, D., & Moore, D. D. (1994). A new orphan 
member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic 
acid response elements. Molecular and Cellular Biology, 14(3), 1544–1552. 
https://doi.org/10.1128/mcb.14.3.1544 
 
Baldwin, W. S., & Roling, J. A. (2009). A concentration addition model for the activation of the 
constitutive androstane receptor by xenobiotic mixtures. Toxicological Sciences: An Official 
Journal of the Society of Toxicology, 107(1), 93–105. https://doi.org/10.1093/toxsci/kfn206 
 
Banerjee, M., Robbins, D., & Chen, T. (2013). Modulation of Xenobiotic Receptors by Steroids. 
Molecules, 18(7), 7389–7406. https://doi.org/10.3390/molecules18077389 
 
Barrett, E., Fitzgerald, P., Dinan, T. G., Cryan, J. F., Ross, R. P., Quigley, E. M., … Stanton, C. (2012). 
Bifidobacterium breve with α-linolenic acid and linoleic acid alters fatty acid metabolism in 
the maternal separation model of irritable bowel syndrome. PloS One, 7(11), e48159. 
https://doi.org/10.1371/journal.pone.0048159 
 
Beck, J. A., Lloyd, S., Hafezparast, M., Lennon-Pierce, M., Eppig, J. T., Festing, M. F. W., & Fisher, E. 
M. C. (2000). Genealogies of mouse inbred strains. Nature Genetics, 24(1), 23. 
https://doi.org/10.1038/71641 
 
Beigneux, A. P., Moser, A. H., Shigenaga, J. K., Grunfeld, C., & Feingold, K. R. (2002). Reduction in 
cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive 
androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase 
response. Biochemical and Biophysical Research Communications, 293(1), 145–149. 
 
Belkaid, Y., & Harrison, O. J. (2017). Homeostatic immunity and the microbiota. Immunity, 46(4), 562–
576. https://doi.org/10.1016/j.immuni.2017.04.008 
 
Benson, A. K., Kelly, S. A., Legge, R., Ma, F., Low, S. J., Kim, J., … Pomp, D. (2010). Individuality in gut 
microbiota composition is a complex polygenic trait shaped by multiple environmental and 
host genetic factors. Proceedings of the National Academy of Sciences of the United States 
of America, 107(44), 18933–18938. https://doi.org/10.1073/pnas.1007028107 
 
Bergmark, J., Carlsson, A., Granerus, A. K., Jagenburg, R., Magnusson, T., & Svanborg, A. (1972). 
Decarboxylation of orally administered L-dopa in the human digestive tract. Naunyn-
Schmiedeberg’s Archives of Pharmacology, 272(4), 437–440. 
https://doi.org/10.1007/bf00501249 
 
Bitter, A., Rümmele, P., Klein, K., Kandel, B. A., Rieger, J. K., Nüssler, A. K., … Burk, O. (2015). 
Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by 
distinct lipogenic mechanisms. Archives of Toxicology, 89(11), 2089–2103. 
https://doi.org/10.1007/s00204-014-1348-x 
 
Björkholm, B., Bok, C. M., Lundin, A., Rafter, J., Hibberd, M. L., & Pettersson, S. (2009). Intestinal 
Microbiota Regulate Xenobiotic Metabolism in the Liver. PLOS ONE, 4(9), e6958. 
https://doi.org/10.1371/journal.pone.0006958 
294
Bibliographic references 
 
  
Blizard, D., Sueyoshi, T., Negishi, M., Dehal, S. S., & Kupfer, D. (2001). Mechanism of induction of 
cytochrome p450 enzymes by the proestrogenic endocrine disruptor pesticide-
methoxychlor: Interactions of methoxychlor metabolites with the constitutive androstane 
receptor system. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 29(6), 
781–785. 
 
Bookout, A. L., Jeong, Y., Downes, M., Yu, R. T., Evans, R. M., & Mangelsdorf, D. J. (2006). Anatomical 
profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell, 
126(4), 789–799. https://doi.org/10.1016/j.cell.2006.06.049 
 
Bourguet, W., Ruff, M., Chambon, P., Gronemeyer, H., & Moras, D. (1995). Crystal structure of the 
ligand-binding domain of the human nuclear receptor RXR-alpha. Nature, 375(6530), 377–
382. https://doi.org/10.1038/375377a0 
 
Breuker, C., Moreau, A., Lakhal, L., Tamasi, V., Parmentier, Y., Meyer, U., … Pascussi, J.-M. (2010). 
Hepatic expression of thyroid hormone-responsive spot 14 protein is regulated by 
constitutive androstane receptor (NR1I3). Endocrinology, 151(4), 1653–1661. 
https://doi.org/10.1210/en.2009-1435 
 
Brugman, S., Liu, K.-Y., Lindenbergh-Kortleve, D., Samsom, J. N., Furuta, G. T., Renshaw, S. A., … 
Nieuwenhuis, E. E. S. (2009). Oxazolone-induced enterocolitis in zebrafish depends on the 
composition of the intestinal microbiota. Gastroenterology, 137(5), 1757-1767.e1. 
https://doi.org/10.1053/j.gastro.2009.07.069 
 
Burk, O., Arnold, K. A., Geick, A., Tegude, H., & Eichelbaum, M. (2005). A role for constitutive 
androstane receptor in the regulation of human intestinal MDR1 expression. Biological 
Chemistry, 386(6), 503–513. https://doi.org/10.1515/BC.2005.060 
 
Burt, A. D., Lackner, C., & Tiniakos, D. G. (2015). Diagnosis and Assessment of NAFLD: Definitions 
and Histopathological Classification. Seminars in Liver Disease, 35(3), 207–220. 
https://doi.org/10.1055/s-0035-1562942 
 
Caminero, A., Nistal, E., Herrán, A. R., Pérez-Andrés, J., Ferrero, M. A., Vaquero Ayala, L., … 
Casqueiro, F. J. (2015). Differences in gluten metabolism among healthy volunteers, coeliac 
disease patients and first-degree relatives. The British Journal of Nutrition, 114(8), 1157–
1167. https://doi.org/10.1017/S0007114515002767 
 
Campieri, M., & Gionchetti, P. (2001). Bacteria as the cause of ulcerative colitis. Gut, 48(1), 132–135. 
https://doi.org/10.1136/gut.48.1.132 
 
Cani, P. D. (2018). Human gut microbiome: Hopes, threats and promises. Gut, 67(9), 1716–1725. 
https://doi.org/10.1136/gutjnl-2018-316723 
 
Cerveny, L., Svecova, L., Anzenbacherova, E., Vrzal, R., Staud, F., Dvorak, Z., … Pavek, P. (2007). 
Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive 
androstane receptor and pregnane X receptor pathways. Drug Metabolism and Disposition: 
The Biological Fate of Chemicals, 35(7), 1032–1041. 
https://doi.org/10.1124/dmd.106.014456 
 
295
Bibliographic references 
 
  
Chai, S. C., Cherian, M. T., Wang, Y.-M., & Chen, T. (2016). Small-molecule modulators of PXR and 
CAR. Biochimica Et Biophysica Acta, 1859(9), 1141–1154. 
https://doi.org/10.1016/j.bbagrm.2016.02.013 
 
Chandran, A., & Vishveshwara, S. (2016). Exploration of the conformational landscape in pregnane X 
receptor reveals a new binding pocket: Conformational Landscape in Pregnane X Receptor. 
Protein Science, 25(11), 1989–2005. https://doi.org/10.1002/pro.3012 
 
Chawla, A. (2001). Nuclear Receptors and Lipid Physiology: Opening the X-Files. Science, 294(5548), 
1866–1870. https://doi.org/10.1126/science.294.5548.1866 
 
Chawla, Ajay, Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001). Nuclear Receptors and Lipid 
Physiology: Opening the X-Files. Science, 294(5548), 1866–1870. 
https://doi.org/10.1126/science.294.5548.1866 
 
Chen, W., Chen, G., Head, D. L., Mangelsdorf, D. J., & Russell, D. W. (2007). Enzymatic reduction of 
oxysterols impairs LXR signaling in cultured cells and the livers of mice. Cell Metabolism, 5(1), 
73–79. https://doi.org/10.1016/j.cmet.2006.11.012 
 
Chen, X., Maiti, S., Zhang, J., & Chen, G. (2006). Nuclear receptor interactions in methotrexate 
induction of human dehydroepiandrosterone sulfotransferase (hSULT2A1). Journal of 
Biochemical and Molecular Toxicology, 20(6), 309–317. https://doi.org/10.1002/jbt.20149 
 
Cheng, J., Shah, Y. M., Ma, X., Pang, X., Tanaka, T., Kodama, T., … Gonzalez, F. J. (2010). Therapeutic 
role of rifaximin in inflammatory bowel disease: Clinical implication of human pregnane X 
receptor activation. The Journal of Pharmacology and Experimental Therapeutics, 335(1), 32–
41. https://doi.org/10.1124/jpet.110.170225 
 
Cheng, S., Zou, M., Liu, Q., Kuang, J., Shen, J., Pu, S., … He, J. (2017). Activation of Constitutive 
Androstane Receptor Prevents Cholesterol Gallstone Formation. The American Journal of 
Pathology, 187(4), 808–818. https://doi.org/10.1016/j.ajpath.2016.12.013 
 
Cheng, X., & Klaassen, C. D. (2008). Critical Role of PPAR-α in Perfluorooctanoic Acid– and 
Perfluorodecanoic Acid–Induced Downregulation of Oatp Uptake Transporters in Mouse 
Livers. Toxicological Sciences, 106(1), 37–45. https://doi.org/10.1093/toxsci/kfn161 
 
Cherrington, N. J., Hartley, D. P., Li, N., Johnson, D. R., & Klaassen, C. D. (2002). Organ distribution 
of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of 
Mrp3 by constitutive androstane receptor activators in rats. The Journal of Pharmacology and 
Experimental Therapeutics, 300(1), 97–104. https://doi.org/10.1124/jpet.300.1.97 
 
Cho, C. E., & Caudill, M. A. (2017). Trimethylamine-N-Oxide: Friend, Foe, or Simply Caught in the 
Cross-Fire? Trends in Endocrinology and Metabolism: TEM, 28(2), 121–130. 
https://doi.org/10.1016/j.tem.2016.10.005 
 
Cho, H. Y., Jung, J.-Y., Park, H., Yang, J.-Y., Jung, S., An, J. H., … Shin, C. S. (2014). In vivo deletion of 
CAR resulted in high bone mass phenotypes in male mice. Journal of Cellular Physiology, 
229(5), 561–571. https://doi.org/10.1002/jcp.24478 
 
 
296
Bibliographic references 
 
  
Choi, H., Chung, M., Tzameli, I., Simha, D., Lee, Y., Seol, W., & Moore, D. (1997). Differential 
transactivation by two isoforms of the orphan nuclear hormone receptor CAR. - PubMed—
NCBI. Retrieved June 20, 2019, from https://www-ncbi-nlm-nih-
gov.gate2.inist.fr/pubmed/9295294 
 
Chu, H., Duan, Y., Yang, L., & Schnabl, B. (2019). Small metabolites, possible big changes: A 
microbiota-centered view of non-alcoholic fatty liver disease. Gut, 68(2), 359–370. 
https://doi.org/10.1136/gutjnl-2018-316307 
 
Claus, S. P., Ellero, S. L., Berger, B., Krause, L., Bruttin, A., Molina, J., … others. (2011). Colonization-
induced host-gut microbial metabolic interaction. MBio, 2(2), e00271–10. 
 
Claus, S. P., Guillou, H., & Ellero-Simatos, S. (2016). The gut microbiota: A major player in the toxicity 
of environmental pollutants? NPJ Biofilms and Microbiomes, 2, 16003. 
https://doi.org/10.1038/npjbiofilms.2016.3 
 
Clavel, T., Henderson, G., Engst, W., Doré, J., & Blaut, M. (2006). Phylogeny of human intestinal 
bacteria that activate the dietary lignan secoisolariciresinol diglucoside. FEMS Microbiology 
Ecology, 55(3), 471–478. https://doi.org/10.1111/j.1574-6941.2005.00057.x 
 
Cross, A. J., Ferrucci, L. M., Risch, A., Graubard, B. I., Ward, M. H., Park, Y., … Sinha, R. (2010). A large 
prospective study of meat consumption and colorectal cancer risk: An investigation of 
potential mechanisms underlying this association. Cancer Research, 70(6), 2406–2414. 
https://doi.org/10.1158/0008-5472.CAN-09-3929 
 
Cross, T.-W. L., Kasahara, K., & Rey, F. E. (2018). Sexual dimorphism of cardiometabolic dysfunction: 
Gut microbiome in the play? Molecular Metabolism, 15, 70–81. 
https://doi.org/10.1016/j.molmet.2018.05.016 
 
Cryan, J. F., & Dinan, T. G. (2012). Mind-altering microorganisms: The impact of the gut microbiota 
on brain and behaviour. Nature Reviews. Neuroscience, 13(10), 701–712. 
https://doi.org/10.1038/nrn3346 
 
Currie, R. A., Peffer, R. C., Goetz, A. K., Omiecinski, C. J., & Goodman, J. I. (2014). Phenobarbital and 
propiconazole toxicogenomic profiles in mice show major similarities consistent with the key 
role that constitutive androstane receptor (CAR) activation plays in their mode of action. 
Toxicology, 321, 80–88. https://doi.org/10.1016/j.tox.2014.03.003 
 
Dalile, B., Van Oudenhove, L., Vervliet, B., & Verbeke, K. (2019). The role of short-chain fatty acids in 
microbiota-gut-brain communication. Nature Reviews. Gastroenterology & Hepatology, 
16(8), 461–478. https://doi.org/10.1038/s41575-019-0157-3 
 
Dapito, D. H., Mencin, A., Gwak, G.-Y., Pradere, J.-P., Jang, M.-K., Mederacke, I., … Schwabe, R. F. 
(2012). Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer 
Cell, 21(4), 504–516. https://doi.org/10.1016/j.ccr.2012.02.007 
 
Darfeuille-Michaud, A., Neut, C., Barnich, N., Lederman, E., Di Martino, P., Desreumaux, P., … 
Colombel, J. F. (1998). Presence of adherent Escherichia coli strains in ileal mucosa of 
patients with Crohn’s disease. Gastroenterology, 115(6), 1405–1413. 
https://doi.org/10.1016/s0016-5085(98)70019-8 
297
Bibliographic references 
 
  
Darfeuille-Michaud, Arlette. (2002). Adherent-invasive Escherichia coli: A putative new E. coli 
pathotype associated with Crohn’s disease. International Journal of Medical Microbiology: 
IJMM, 292(3–4), 185–193. https://doi.org/10.1078/1438-4221-00201 
 
David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., … 
Turnbaugh, P. J. (2014). Diet rapidly and reproducibly alters the human gut microbiome. 
Nature, 505(7484), 559–563. https://doi.org/10.1038/nature12820 
 
Day, C. P. (2010). Genetic and environmental susceptibility to non-alcoholic fatty liver disease. 
Digestive Diseases (Basel, Switzerland), 28(1), 255–260. https://doi.org/10.1159/000282098 
 
De Vadder, F., Kovatcheva-Datchary, P., Goncalves, D., Vinera, J., Zitoun, C., Duchampt, A., … 
Mithieux, G. (2014). Microbiota-generated metabolites promote metabolic benefits via gut-
brain neural circuits. Cell, 156(1–2), 84–96. https://doi.org/10.1016/j.cell.2013.12.016 
 
DeKeyser, J. G., Stagliano, M. C., Auerbach, S. S., Prabhu, K. S., Jones, A. D., & Omiecinski, C. J. 
(2009). Di(2-ethylhexyl) phthalate is a highly potent agonist for the human constitutive 
androstane receptor splice variant CAR2. Molecular Pharmacology, 75(5), 1005–1013. 
https://doi.org/10.1124/mol.108.053702 
 
Deloménie, C., Fouix, S., Longuemaux, S., Brahimi, N., Bizet, C., Picard, B., … Dupret, J.-M. (2001). 
Identification and Functional Characterization of Arylamine N-Acetyltransferases in 
Eubacteria: Evidence for Highly Selective Acetylation of 5-Aminosalicylic Acid. Journal of 
Bacteriology, 183(11), 3417–3427. https://doi.org/10.1128/JB.183.11.3417-3427.2001 
 
den Besten, G., van Eunen, K., Groen, A. K., Venema, K., Reijngoud, D.-J., & Bakker, B. M. (2013). The 
role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy 
metabolism. Journal of Lipid Research, 54(9), 2325–2340. 
https://doi.org/10.1194/jlr.R036012 
 
Deshmukh, H. S., Liu, Y., Menkiti, O. R., Mei, J., Dai, N., O’Leary, C. E., … Worthen, G. S. (2014). The 
microbiota regulates neutrophil homeostasis and host resistance to Escherichia coli K1 sepsis 
in neonatal mice. Nature Medicine, 20(5), 524–530. https://doi.org/10.1038/nm.3542 
 
Devlin, A. S., Marcobal, A., Dodd, D., Nayfach, S., Plummer, N., Meyer, T., … Fischbach, M. A. (2016). 
Modulation of a Circulating Uremic Solute via Rational Genetic Manipulation of the Gut 
Microbiota. Cell Host & Microbe, 20(6), 709–715. 
https://doi.org/10.1016/j.chom.2016.10.021 
 
Dingemanse, C., Belzer, C., van Hijum, S. A. F. T., Günthel, M., Salvatori, D., den Dunnen, J. T., … 
Robanus-Maandag, E. C. (2015). Akkermansia muciniphila and Helicobacter typhlonius 
modulate intestinal tumor development in mice. Carcinogenesis, 36(11), 1388–1396. 
https://doi.org/10.1093/carcin/bgv120 
 
Dionne, M. S., & Schneider, D. S. (2008). Models of infectious diseases in the fruit fly Drosophila 
melanogaster. Disease Models & Mechanisms, 1(1), 43–49. 
https://doi.org/10.1242/dmm.000307 
 
Doerner, K. C., Takamine, F., LaVoie, C. P., Mallonee, D. H., & Hylemon, P. B. (1997). Assessment of 
fecal bacteria with bile acid 7 alpha-dehydroxylating activity for the presence of bai-like 
genes. Applied and Environmental Microbiology, 63(3), 1185–1188. 
298
Bibliographic references 
 
  
Dominianni, C., Sinha, R., Goedert, J. J., Pei, Z., Yang, L., Hayes, R. B., & Ahn, J. (2015). Sex, body 
mass index, and dietary fiber intake influence the human gut microbiome. PloS One, 10(4), 
e0124599. https://doi.org/10.1371/journal.pone.0124599 
 
Dong, B., Saha, P. K., Huang, W., Chen, W., Abu-Elheiga, L. A., Wakil, S. J., … Moore, D. D. (2009). 
Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease. Proceedings 
of the National Academy of Sciences of the United States of America, 106(44), 18831–18836. 
https://doi.org/10.1073/pnas.0909731106 
 
Dou, W., Zhang, J., Zhang, E., Sun, A., Ding, L., Chou, G., … Mani, S. (2013). Chrysin ameliorates 
chemically induced colitis in the mouse through modulation of a PXR/NF-κB signaling 
pathway. The Journal of Pharmacology and Experimental Therapeutics, 345(3), 473–482. 
https://doi.org/10.1124/jpet.112.201863 
 
Duret, C., Daujat-Chavanieu, M., Pascussi, J.-M., Pichard-Garcia, L., Balaguer, P., Fabre, J.-M., … 
Gerbal-Chaloin, S. (2006). Ketoconazole and miconazole are antagonists of the human 
glucocorticoid receptor: Consequences on the expression and function of the constitutive 
androstane receptor and the pregnane X receptor. Molecular Pharmacology, 70(1), 329–339. 
https://doi.org/10.1124/mol.105.022046 
 
Duszka, K., & Wahli, W. (2018). Enteric Microbiota−Gut−Brain Axis from the Perspective of Nuclear 
Receptors. International Journal of Molecular Sciences, 19(8). 
https://doi.org/10.3390/ijms19082210 
 
Eckburg, P. B., Bik, E. M., Bernstein, C. N., Purdom, E., Dethlefsen, L., Sargent, M., … Relman, D. A. 
(2005). Diversity of the human intestinal microbial flora. Science (New York, N.Y.), 308(5728), 
1635–1638. https://doi.org/10.1126/science.1110591 
 
Elcombe, C. R., Elcombe, B. M., Foster, J. R., Chang, S.-C., Ehresman, D. J., & Butenhoff, J. L. (2012). 
Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats from dietary 
exposure to potassium perfluorooctanesulfonate results from increased expression of 
xenosensor nuclear receptors PPARα and CAR/PXR. Toxicology, 293(1–3), 16–29. 
https://doi.org/10.1016/j.tox.2011.12.014 
 
Engevik, M. A., & Versalovic, J. (2017). Biochemical features of beneficial microbes: Foundations for 
therapeutic microbiology. Microbiology Spectrum, 5(5). 
https://doi.org/10.1128/microbiolspec.BAD-0012-2016 
 
Evans, R. M., & Mangelsdorf, D. J. (2014). Nuclear Receptors, RXR, and the Big Bang. Cell, 157(1), 
255–266. https://doi.org/10.1016/j.cell.2014.03.012 
 
Falany, C. N., Fortinberry, H., Leiter, E. H., & Barnes, S. (1997). Cloning, expression, and chromosomal 
localization of mouse liver bile acid CoA:amino acid N-acyltransferase. Journal of Lipid 
Research, 38(6), 1139–1148. 
 
Falany, C. N., Johnson, M. R., Barnes, S., & Diasio, R. B. (1994). Glycine and taurine conjugation of 
bile acids by a single enzyme. Molecular cloning and expression of human liver bile acid 
CoA:amino acid N-acyltransferase. The Journal of Biological Chemistry, 269(30), 19375–
19379. 
 
299
Bibliographic references 
 
  
Fennema, D., Phillips, I. R., & Shephard, E. A. (2016). Trimethylamine and Trimethylamine N-Oxide, a 
Flavin-Containing Monooxygenase 3 (FMO3)-Mediated Host-Microbiome Metabolic Axis 
Implicated in Health and Disease. Drug Metabolism and Disposition: The Biological Fate of 
Chemicals, 44(11), 1839–1850. https://doi.org/10.1124/dmd.116.070615 
 
Fontaine, C. A., Skorupski, A. M., Vowles, C. J., Anderson, N. E., Poe, S. A., & Eaton, K. A. (2015). How 
free of germs is germ-free? Detection of bacterial contamination in a germ free mouse unit. 
Gut Microbes, 6(4), 225–233. https://doi.org/10.1080/19490976.2015.1054596 
 
Forman, B. M., Tzameli, I., Choi, H. S., Chen, J., Simha, D., Seol, W., … Moore, D. D. (1998). 
Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta. Nature, 
395(6702), 612–615. https://doi.org/10.1038/26996 
 
Frank, C., Makkonen, H., Dunlop, T. W., Matilainen, M., Väisänen, S., & Carlberg, C. (2005). 
Identification of pregnane X receptor binding sites in the regulatory regions of genes 
involved in bile acid homeostasis. Journal of Molecular Biology, 346(2), 505–519. 
https://doi.org/10.1016/j.jmb.2004.12.003 
 
Frankenfeld, C. L., Atkinson, C., Wähälä, K., & Lampe, J. W. (2014). Obesity prevalence in relation to 
gut microbial environments capable of producing equol or O-desmethylangolensin from the 
isoflavone daidzein. European Journal of Clinical Nutrition, 68(4), 526–530. 
https://doi.org/10.1038/ejcn.2014.23 
 
Friswell, M. K., Gika, H., Stratford, I. J., Theodoridis, G., Telfer, B., Wilson, I. D., & McBain, A. J. (2010). 
Site and strain-specific variation in gut microbiota profiles and metabolism in experimental 
mice. PloS One, 5(1), e8584. https://doi.org/10.1371/journal.pone.0008584 
 
Fu, Z. D., Selwyn, F. P., Cui, J. Y., & Klaassen, C. D. (2017). RNA-Seq Profiling of Intestinal Expression 
of Xenobiotic Processing Genes in Germ-Free Mice. Drug Metabolism and Disposition, 
45(12), 1225–1238. https://doi.org/10.1124/dmd.117.077313 
 
Fukiya, S., Arata, M., Kawashima, H., Yoshida, D., Kaneko, M., Minamida, K., … Yokota, A. (2009). 
Conversion of cholic acid and chenodeoxycholic acid into their 7-oxo derivatives by 
Bacteroides intestinalis AM-1 isolated from human feces. FEMS Microbiology Letters, 293(2), 
263–270. https://doi.org/10.1111/j.1574-6968.2009.01531.x 
 
Fukumasu, H., Cordeiro, Y. G., Rochetti, A. L., Barra, C. N., Sámora, T. S., Strefezzi, R. F., & Dagli, M. L. 
Z. (2015). Expression of NR1I3 in mouse lung tumors induced by the tobacco-specific 
nitrosamine 4-(methylnitrosamino)-4-(3-pyridyl)-1-butanone. Brazilian Journal of Medical and 
Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas, 48(3), 240–244. 
https://doi.org/10.1590/1414-431X20144210 
 
Gao, Jie, He, J., Zhai, Y., Wada, T., & Xie, W. (2009). The Constitutive Androstane Receptor Is an Anti-
obesity Nuclear Receptor That Improves Insulin Sensitivity. Journal of Biological Chemistry, 
284(38), 25984–25992. https://doi.org/10.1074/jbc.M109.016808 
 
Gao, Jie, & Xie, W. (2010). Pregnane X Receptor and Constitutive Androstane Receptor at the 
Crossroads of Drug Metabolism and Energy Metabolism. Drug Metabolism and Disposition, 
38(12), 2091–2095. https://doi.org/10.1124/dmd.110.035568 
300
Bibliographic references 
 
  
Gao, Jie, Yan, J., Xu, M., Ren, S., & Xie, W. (2015). CAR Suppresses Hepatic Gluconeogenesis by 
Facilitating the Ubiquitination and Degradation of PGC1α. Molecular Endocrinology 
(Baltimore, Md.), 29(11), 1558–1570. https://doi.org/10.1210/me.2015-1145 
 
Gao, Jing, Xu, K., Liu, H., Liu, G., Bai, M., Peng, C., … Yin, Y. (2018). Impact of the Gut Microbiota on 
Intestinal Immunity Mediated by Tryptophan Metabolism. Frontiers in Cellular and Infection 
Microbiology, 8. https://doi.org/10.3389/fcimb.2018.00013 
 
Garcia, M., Thirouard, L., Sedès, L., Monrose, M., Holota, H., Caira, F., … Beaudoin, C. (2018). Nuclear 
Receptor Metabolism of Bile Acids and Xenobiotics: A Coordinated Detoxification System 
with Impact on Health and Diseases. International Journal of Molecular Sciences, 19(11). 
https://doi.org/10.3390/ijms19113630 
 
García-Villalba, R., Beltrán, D., Espín, J. C., Selma, M. V., & Tomás-Barberán, F. A. (2013). Time course 
production of urolithins from ellagic acid by human gut microbiota. Journal of Agricultural 
and Food Chemistry, 61(37), 8797–8806. https://doi.org/10.1021/jf402498b 
 
Garg, A., Zhao, A., Erickson, S. L., Mukherjee, S., Lau, A. J., Alston, L., … Hirota, S. A. (2016). Pregnane 
X Receptor Activation Attenuates Inflammation-Associated Intestinal Epithelial Barrier 
Dysfunction by Inhibiting Cytokine-Induced Myosin Light-Chain Kinase Expression and c-Jun 
N-Terminal Kinase 1/2 Activation. The Journal of Pharmacology and Experimental 
Therapeutics, 359(1), 91–101. https://doi.org/10.1124/jpet.116.234096 
 
Gérard, P., Béguet, F., Lepercq, P., Rigottier-Gois, L., Rochet, V., Andrieux, C., & Juste, C. (2004). 
Gnotobiotic rats harboring human intestinal microbiota as a model for studying cholesterol-
to-coprostanol conversion. FEMS Microbiology Ecology, 47(3), 337–343. 
https://doi.org/10.1016/S0168-6496(03)00285-X 
 
Gerbes, A., Zoulim, F., Tilg, H., Dufour, J.-F., Bruix, J., Paradis, V., … Avila, M. A. (2018). Gut 
roundtable meeting paper: Selected recent advances in hepatocellular carcinoma. Gut, 
67(2), 380–388. https://doi.org/10.1136/gutjnl-2017-315068 
 
Germain, P., Staels, B., Dacquet, C., Spedding, M., & Laudet, V. (2006). Overview of nomenclature of 
nuclear receptors. Pharmacological Reviews, 58(4), 685–704. 
https://doi.org/10.1124/pr.58.4.2 
 
Gill, S. R., Pop, M., DeBoy, R. T., Eckburg, P. B., Turnbaugh, P. J., Samuel, B. S., … Nelson, K. E. (2006). 
Metagenomic Analysis of the Human Distal Gut Microbiome. Science (New York, N.Y.), 
312(5778), 1355–1359. https://doi.org/10.1126/science.1124234 
 
Goetz, A. K., Bao, W., Ren, H., Schmid, J. E., Tully, D. B., Wood, C., … Dix, D. J. (2006). Gene 
expression profiling in the liver of CD-1 mice to characterize the hepatotoxicity of triazole 
fungicides. Toxicology and Applied Pharmacology, 215(3), 274–284. 
https://doi.org/10.1016/j.taap.2006.02.016 
 
Goldin, B. R., Peppercorn, M. A., & Goldman, P. (1973). Contributions of host and intestinal microflora 
in the metabolism of L-dopa by the rat. The Journal of Pharmacology and Experimental 
Therapeutics, 186(1), 160–166. 
 
 
301
Bibliographic references 
 
  
Gong, H., Singh, S. V., Singh, S. P., Mu, Y., Lee, J. H., Saini, S. P. S., … Xie, W. (2006). Orphan nuclear 
receptor pregnane X receptor sensitizes oxidative stress responses in transgenic mice and 
cancerous cells. Molecular Endocrinology (Baltimore, Md.), 20(2), 279–290. 
https://doi.org/10.1210/me.2005-0205 
 
Gonzalez-Perez, G., Hicks, A. L., Tekieli, T. M., Radens, C. M., Williams, B. L., & Lamousé-Smith, E. S. 
N. (2016). Maternal Antibiotic Treatment Impacts Development of the Neonatal Intestinal 
Microbiome and Antiviral Immunity. Journal of Immunology (Baltimore, Md.: 1950), 196(9), 
3768–3779. https://doi.org/10.4049/jimmunol.1502322 
 
Goodwin, B., Hodgson, E., & Liddle, C. (1999). The orphan human pregnane X receptor mediates the 
transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. 
Molecular Pharmacology, 56(6), 1329–1339. https://doi.org/10.1124/mol.56.6.1329 
Guéguen, Y., Mouzat, K., Ferrari, L., Tissandie, E., Lobaccaro, J. M. A., Batt, A.-M., … Souidi, M. (2006). 
[Cytochromes P450: Xenobiotic metabolism, regulation and clinical importance]. Annales De 
Biologie Clinique, 64(6), 535–548. 
 
Guo, D., Sarkar, J., & Xu, Y. (2007). Induction of nuclear translocation of constitutive androstane 
receptor by peroxisome proliferator-activated receptor alpha synthetic ligands in mou... - 
PubMed—NCBI. Retrieved June 20, 2019, from https://www-ncbi-nlm-nih-
gov.gate2.inist.fr/pubmed/17962186 
 
Guo, G. L., Staudinger, J., Ogura, K., & Klaassen, C. D. (2002). Induction of rat organic anion 
transporting polypeptide 2 by pregnenolone-16alpha-carbonitrile is via interaction with 
pregnane X receptor. Molecular Pharmacology, 61(4), 832–839. 
https://doi.org/10.1124/mol.61.4.832 
 
Gwag, T., Meng, Z., Sui, Y., Helsley, R. N., Park, S.-H., Wang, S., … Zhou, C. (2019). Non-nucleoside 
reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and 
hepatic steatosis. Journal of Hepatology, 70(5), 930–940. 
https://doi.org/10.1016/j.jhep.2018.12.038 
 
Hager, G. L., Lim, C. S., Elbi, C., & Baumann, C. T. (2000). Trafficking of nuclear receptors in living 
cells. The Journal of Steroid Biochemistry and Molecular Biology, 74(5), 249–254. 
 
Hakkola, J., Rysä, J., & Hukkanen, J. (2016). Regulation of hepatic energy metabolism by the nuclear 
receptor PXR. Biochimica Et Biophysica Acta, 1859(9), 1072–1082. 
https://doi.org/10.1016/j.bbagrm.2016.03.012 
 
Hardie, D. G., & Ashford, M. L. J. (2014). AMPK: Regulating energy balance at the cellular and whole 
body levels. Physiology (Bethesda, Md.), 29(2), 99–107. 
https://doi.org/10.1152/physiol.00050.2013 
 
Haro, C., Rangel-Zúñiga, O. A., Alcalá-Díaz, J. F., Gómez-Delgado, F., Pérez-Martínez, P., Delgado-
Lista, J., … Camargo, A. (2016). Intestinal Microbiota Is Influenced by Gender and Body Mass 
Index. PloS One, 11(5), e0154090. https://doi.org/10.1371/journal.pone.0154090 
 
Haughton, E. L., Tucker, S. J., Marek, C. J., Durward, E., Leel, V., Bascal, Z., … Wright, M. C. (2006). 
Pregnane X receptor activators inhibit human hepatic stellate cell transdifferentiation in vitro. 
Gastroenterology, 131(1), 194–209. https://doi.org/10.1053/j.gastro.2006.04.01 
 
302
Bibliographic references 
 
  
Heinzel, T., Lavinsky, R. M., Mullen, T. M., Söderstrom, M., Laherty, C. D., Torchia, J., … Rosenfeld, M. 
G. (1997). A complex containing N-CoR, mSin3 and histone deacetylase mediates 
transcriptional repression. Nature, 387(6628), 43–48. https://doi.org/10.1038/387043a0 
 
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., … Flavell, R. A. (2012). 
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature, 
482(7384), 179–185. https://doi.org/10.1038/nature10809 
 
Hernandez, J. P., Mota, L. C., & Baldwin, W. S. (2009). Activation of CAR and PXR by Dietary, 
Environmental and Occupational Chemicals Alters Drug Metabolism, Intermediary 
Metabolism, and Cell Proliferation. Current Pharmacogenomics and Personalized Medicine, 
7(2), 81–105. https://doi.org/10.2174/187569209788654005 
 
Hernandez, Juan P., Huang, W., Chapman, L. M., Chua, S., Moore, D. D., & Baldwin, W. S. (2007). The 
environmental estrogen, nonylphenol, activates the constitutive androstane receptor. 
Toxicological Sciences: An Official Journal of the Society of Toxicology, 98(2), 416–426. 
https://doi.org/10.1093/toxsci/kfm107 
 
Hildebrand, F., Nguyen, T. L. A., Brinkman, B., Yunta, R. G., Cauwe, B., Vandenabeele, P., … Raes, J. 
(2013). Inflammation-associated enterotypes, host genotype, cage and inter-individual 
effects drive gut microbiota variation in common laboratory mice. Genome Biology, 14(1), 
R4. https://doi.org/10.1186/gb-2013-14-1-r4 
 
Holloway, M. G., Miles, G. D., Dombkowski, A. A., & Waxman, D. J. (2008). Liver-specific hepatocyte 
nuclear factor-4alpha deficiency: Greater impact on gene expression in male than in female 
mouse liver. Molecular Endocrinology (Baltimore, Md.), 22(5), 1274–1286. 
https://doi.org/10.1210/me.2007-0564 
 
Honkakoski, P., Sueyoshi, T., & Negishi, M. (2003). Drug-activated nuclear receptors CAR and PXR. 
Annals of Medicine, 35(3), 172–182. 
 
Hooper, L. V., Littman, D. R., & Macpherson, A. J. (2012). Interactions between the microbiota and 
the immune system. Science (New York, N.Y.), 336(6086), 1268–1273. 
https://doi.org/10.1126/science.1223490 
 
Howe, K., Sanat, F., Thumser, A. E., Coleman, T., & Plant, N. (2011). The statin class of HMG-CoA 
reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR 
and FXR, as well as their downstream target genes. Xenobiotica; the Fate of Foreign 
Compounds in Biological Systems, 41(7), 519–529. 
https://doi.org/10.3109/00498254.2011.569773 
 
Huang, W., Zhang, J., Wei, P., Schrader, W. T., & Moore, D. D. (2004). Meclizine is an agonist ligand 
for mouse constitutive androstane receptor (CAR) and an inverse agonist for human CAR. 
Molecular Endocrinology (Baltimore, Md.), 18(10), 2402–2408. 
https://doi.org/10.1210/me.2004-0046 
 
Hudson, G. M., Flannigan, K. L., Erickson, S. L., Vicentini, F. A., Zamponi, A., Hirota, C. L., … Hirota, S. 
A. (2017). Constitutive androstane receptor regulates the intestinal mucosal response to 
injury. British Journal of Pharmacology, 174(12), 1857–1871. 
https://doi.org/10.1111/bph.13787 
303
Bibliographic references 
 
  
Hugenholtz, F., & de Vos, W. M. (2018). Mouse models for human intestinal microbiota research: A 
critical evaluation. Cellular and Molecular Life Sciences: CMLS, 75(1), 149–160. 
https://doi.org/10.1007/s00018-017-2693-8 
 
Ihunnah, C. A., Jiang, M., & Xie, W. (2011). Nuclear receptor PXR, transcriptional circuits and 
metabolic relevance. Biochimica Et Biophysica Acta, 1812(8), 956–963. 
https://doi.org/10.1016/j.bbadis.2011.01.014 
 
Ingelfinger, J. R. (2008). Melamine and the Global Implications of Food Contamination. New England 
Journal of Medicine, 359(26), 2745–2748. https://doi.org/10.1056/NEJMp0808410 
 
Iroz, A., Montagner, A., Benhamed, F., Levavasseur, F., Polizzi, A., Anthony, E., … Postic, C. (2017). A 
Specific ChREBP and PPARα Cross-Talk Is Required for the Glucose-Mediated FGF21 
Response. Cell Reports, 21(2), 403–416. https://doi.org/10.1016/j.celrep.2017.09.065 
 
Jackson, J. P., Ferguson, S. S., Moore, R., Negishi, M., & Goldstein, J. A. (2004). The constitutive 
active/androstane receptor regulates phenytoin induction of Cyp2c29. Molecular 
Pharmacology, 65(6), 1397–1404. https://doi.org/10.1124/mol.65.6.1397 
 
Jarukamjorn, K., Sakuma, T., & Nemoto, N. (2002). Sexual dimorphic expression of mouse hepatic 
CYP2B: Alterations during development or after hypophysectomy. Biochemical 
Pharmacology, 63(11), 2037–2041. 
 
Jones, S. A., Moore, L. B., Shenk, J. L., Wisely, G. B., Hamilton, G. A., McKee, D. D., … Moore, J. T. 
(2000). The pregnane X receptor: A promiscuous xenobiotic receptor that has diverged 
during evolution. Molecular Endocrinology (Baltimore, Md.), 14(1), 27–39. 
https://doi.org/10.1210/mend.14.1.0409 
 
Jump, R. L. P., Polinkovsky, A., Hurless, K., Sitzlar, B., Eckart, K., Tomas, M., … Donskey, C. J. (2014). 
Metabolomics analysis identifies intestinal microbiota-derived biomarkers of colonization 
resistance in clindamycin-treated mice. PloS One, 9(7), e101267. 
https://doi.org/10.1371/journal.pone.0101267 
 
Jung, D., Mangelsdorf, D. J., & Meyer, U. A. (2006). Pregnane X receptor is a target of farnesoid X 
receptor. The Journal of Biological Chemistry, 281(28), 19081–19091. 
https://doi.org/10.1074/jbc.M600116200 
 
Kabat, A. M., Pott, J., & Maloy, K. J. (2016). The Mucosal Immune System and Its Regulation by 
Autophagy. Frontiers in Immunology, 7. https://doi.org/10.3389/fimmu.2016.00240 
 
Kaliannan, K., Robertson, R. C., Murphy, K., Stanton, C., Kang, C., Wang, B., … Kang, J. X. (2018). 
Estrogen-mediated gut microbiome alterations influence sexual dimorphism in metabolic 
syndrome in mice. Microbiome, 6. https://doi.org/10.1186/s40168-018-0587-0 
 
Kamiyama, Y., Matsubara, T., Yoshinari, K., Nagata, K., Kamimura, H., & Yamazoe, Y. (2007). Role of 
human hepatocyte nuclear factor 4alpha in the expression of drug-metabolizing enzymes 
and transporters in human hepatocytes assessed by use of small interfering RNA. Drug 
Metabolism and Pharmacokinetics, 22(4), 287–298. 
 
Kanno, Y., Otsuka, S., Hiromasa, T., Nakahama, T., & Inouye, Y. (2004). Diurnal difference in CAR 
mRNA expression. Nuclear Receptor, 2(1), 6. https://doi.org/10.1186/1478-1336-2-6 
304
Bibliographic references 
 
  
Kasai, C., Sugimoto, K., Moritani, I., Tanaka, J., Oya, Y., Inoue, H., … Takase, K. (2015). Comparison 
of the gut microbiota composition between obese and non-obese individuals in a Japanese 
population, as analyzed by terminal restriction fragment length polymorphism and next-
generation sequencing. BMC Gastroenterology, 15, 100. https://doi.org/10.1186/s12876-
015-0330-2 
 
Kassam, A., Winrow, C. J., Fernandez-Rachubinski, F., Capone, J. P., & Rachubinski, R. A. (2000). The 
peroxisome proliferator response element of the gene encoding the peroxisomal beta-
oxidation enzyme enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase is a target for 
constitutive androstane receptor beta/9-cis-retinoic acid receptor-mediated transactivation. 
The Journal of Biological Chemistry, 275(6), 4345–4350. 
https://doi.org/10.1074/jbc.275.6.4345 
 
Kast, H. R., Goodwin, B., Tarr, P. T., Jones, S. A., Anisfeld, A. M., Stoltz, C. M., … Edwards, P. A. (2002). 
Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors 
pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. 
The Journal of Biological Chemistry, 277(4), 2908–2915. 
https://doi.org/10.1074/jbc.M109326200 
 
Kawamoto, T., Kakizaki, S., Yoshinari, K., & Negishi, M. (2000). Estrogen activation of the nuclear 
orphan receptor CAR (constitutive active receptor) in induction of the mouse Cyp2b10 gene. 
Molecular Endocrinology (Baltimore, Md.), 14(11), 1897–1905. 
https://doi.org/10.1210/mend.14.11.0547 
 
Kellogg, T. F., Knight, P. L., & Wostmann, B. S. (1970). Effect of bile acid deconjugation on the fecal 
excretion of steroids. Journal of Lipid Research, 11(4), 362–366. 
 
Kellogg, T. F., & Wostmann, B. S. (1969). Fecal neutral steroids and bile acids from germfree rats. 
Journal of Lipid Research, 10(5), 495–503. 
 
Kennedy, E. A., King, K. Y., & Baldridge, M. T. (2018). Mouse Microbiota Models: Comparing Germ-
Free Mice and Antibiotics Treatment as Tools for Modifying Gut Bacteria. Frontiers in 
Physiology, 9. https://doi.org/10.3389/fphys.2018.01534 
 
Kindt, A., Liebisch, G., Clavel, T., Haller, D., Hörmannsperger, G., Yoon, H., … Ecker, J. (2018). The 
gut microbiota promotes hepatic fatty acid desaturation and elongation in mice. Nature 
Communications, 9(1), 3760. https://doi.org/10.1038/s41467-018-05767-4 
 
Kisiela, M., Skarka, A., Ebert, B., & Maser, E. (2012). Hydroxysteroid dehydrogenases (HSDs) in 
bacteria: A bioinformatic perspective. The Journal of Steroid Biochemistry and Molecular 
Biology, 129(1–2), 31–46. https://doi.org/10.1016/j.jsbmb.2011.08.002 
 
Kitahara, M., Takamine, F., Imamura, T., & Benno, Y. (2000). Assignment of Eubacterium sp. VPI 12708 
and related strains with high bile acid 7alpha-dehydroxylating activity to Clostridium 
scindens and proposal of Clostridium hylemonae sp. Nov., isolated from human faeces. 
International Journal of Systematic and Evolutionary Microbiology, 50 Pt 3, 971–978. 
https://doi.org/10.1099/00207713-50-3-971 
 
 
 
305
Bibliographic references 
 
  
Kitahara, M., Takamine, F., Imamura, T., & Benno, Y. (2001). Clostridium hiranonis sp. Nov., a human 
intestinal bacterium with bile acid 7alpha-dehydroxylating activity. International Journal of 
Systematic and Evolutionary Microbiology, 51(Pt 1), 39–44. 
https://doi.org/10.1099/00207713-51-1-39 
 
Kliewer, S. A., Umesono, K., Mangelsdorf, D. J., & Evans, R. M. (1992). Retinoid X receptor interacts 
with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. Nature, 
355(6359), 446–449. https://doi.org/10.1038/355446a0 
 
Kliewer, Steven A. (2015). Nuclear receptor PXR: Discovery of a pharmaceutical anti-target. The 
Journal of Clinical Investigation, 125(4), 1388–1389. https://doi.org/10.1172/JCI81244 
Kliewer, Steven A., & Mangelsdorf, D. J. (2019). A Dozen Years of Discovery: Insights into the 
Physiology and Pharmacology of FGF21. Cell Metabolism, 29(2), 246–253. 
https://doi.org/10.1016/j.cmet.2019.01.004 
 
Knight, R., Callewaert, C., Marotz, C., Hyde, E. R., Debelius, J. W., McDonald, D., & Sogin, M. L. (2017). 
The Microbiome and Human Biology. Annual Review of Genomics and Human Genetics, 18, 
65–86. https://doi.org/10.1146/annurev-genom-083115-022438 
 
Kobayashi, K., Sueyoshi, T., Inoue, K., Moore, R., & Negishi, M. (2003). Cytoplasmic accumulation of 
the nuclear receptor CAR by a tetratricopeptide repeat protein in HepG2 cells. Molecular 
Pharmacology, 64(5), 1069–1075. https://doi.org/10.1124/mol.64.5.1069 
 
Kodama, S., Koike, C., Negishi, M., & Yamamoto, Y. (2004). Nuclear Receptors CAR and PXR Cross 
Talk with FOXO1 To Regulate Genes That Encode Drug-Metabolizing and Gluconeogenic 
Enzymes. Molecular and Cellular Biology, 24(18), 7931–7940. 
https://doi.org/10.1128/MCB.24.18.7931-7940.2004 
 
Kodama, S., & Negishi, M. (2013). PXR cross-talks with internal and external signals in physiological 
and pathophysiological responses. Drug Metabolism Reviews, 45(3), 300–310. 
https://doi.org/10.3109/03602532.2013.795585 
 
Konno, Y., Kamino, H., Moore, R., Lih, F., Tomer, K. B., Zeldin, D. C., … Negishi, M. (2010). The Nuclear 
Receptors Constitutive Active/Androstane Receptor and Pregnane X Receptor Activate the 
Cyp2c55 Gene in Mouse Liver. Drug Metabolism and Disposition, 38(7), 1177–1182. 
https://doi.org/10.1124/dmd.110.032334 
 
Koppel, N., Maini Rekdal, V., & Balskus, E. P. (2017). Chemical transformation of xenobiotics by the 
human gut microbiota. Science (New York, N.Y.), 356(6344). 
https://doi.org/10.1126/science.aag2770 
 
Kostic, A. D., Howitt, M. R., & Garrett, W. S. (2013). Exploring host-microbiota interactions in animal 
models and humans. Genes & Development, 27(7), 701–718. 
https://doi.org/10.1101/gad.212522.112 
 
Kovacs, A., Ben-Jacob, N., Tayem, H., Halperin, E., Iraqi, F. A., & Gophna, U. (2011). Genotype is a 
stronger determinant than sex of the mouse gut microbiota. Microbial Ecology, 61(2), 423–
428. https://doi.org/10.1007/s00248-010-9787-2 
 
306
Bibliographic references 
 
  
Krasowski, M. D., Yasuda, K., Hagey, L. R., & Schuetz, E. G. (2005). Evolution of the pregnane x 
receptor: Adaptation to cross-species differences in biliary bile salts. Molecular 
Endocrinology (Baltimore, Md.), 19(7), 1720–1739. https://doi.org/10.1210/me.2004-0427 
 
Krüger, M., Shehata, A. A., Schrödl, W., & Rodloff, A. (2013). Glyphosate suppresses the antagonistic 
effect of Enterococcus spp. On Clostridium botulinum. Anaerobe, 20, 74–78. 
https://doi.org/10.1016/j.anaerobe.2013.01.005 
 
Krych, L., Hansen, C. H. F., Hansen, A. K., van den Berg, F. W. J., & Nielsen, D. S. (2013). Quantitatively 
different, yet qualitatively alike: A meta-analysis of the mouse core gut microbiome with a 
view towards the human gut microbiome. PloS One, 8(5), e62578. 
https://doi.org/10.1371/journal.pone.0062578 
 
Kuang, Z., Wang, Y., Li, Y., Ye, C., Ruhn, K. A., Behrendt, C. L., … Hooper, L. V. (2019). The intestinal 
microbiota programs diurnal rhythms in host metabolism through histone deacetylase 3. 
Science, 365(6460), 1428–1434. https://doi.org/10.1126/science.aaw3134 
 
Lahtela, J. T., Arranto, A. J., & Sotaniemi, E. A. (1985). Enzyme inducers improve insulin sensitivity in 
non-insulin-dependent diabetic subjects. Diabetes, 34(9), 911–916. 
https://doi.org/10.2337/diab.34.9.911 
 
Lam, V., Su, J., Hsu, A., Gross, G. J., Salzman, N. H., & Baker, J. E. (2016). Intestinal Microbial 
Metabolites Are Linked to Severity of Myocardial Infarction in Rats. PLoS ONE, 11(8). 
https://doi.org/10.1371/journal.pone.0160840 
 
Lamba, V., Yasuda, K., Lamba, J. K., Assem, M., Davila, J., Strom, S., & Schuetz, E. G. (2004). PXR 
(NR1I2): Splice variants in human tissues, including brain, and identification of neurosteroids 
and nicotine as PXR activators. Toxicology and Applied Pharmacology, 199(3), 251–265. 
https://doi.org/10.1016/j.taap.2003.12.027 
 
Lamousé-Smith, E. S., Tzeng, A., & Starnbach, M. N. (2011). The intestinal flora is required to support 
antibody responses to systemic immunization in infant and germ free mice. PloS One, 6(11), 
e27662. https://doi.org/10.1371/journal.pone.0027662 
 
Larsson, E., Tremaroli, V., Lee, Y. S., Koren, O., Nookaew, I., Fricker, A., … Bäckhed, F. (2012). Analysis 
of gut microbial regulation of host gene expression along the length of the gut and 
regulation of gut microbial ecology through MyD88. Gut, 61(8), 1124–1131. 
https://doi.org/10.1136/gutjnl-2011-301104 
 
Laurenzana, E., Coslo, D., Vigilar, M., Roman, A., & Omieciski, C. (2012). The orphan nuclear receptor 
DAX-1 functions as a potent corepressor of the constitutive androstane receptor (NR1I3). - 
PubMed—NCBI. Retrieved June 20, 2019, from https://www-ncbi-nlm-nih-
gov.gate2.inist.fr/pubmed/?term=laurenzana+2012+car 
 
Laurenzana, E. M., Coslo, D. M., Vigilar, M. V., Roman, A. M., & Omiecinski, C. J. (2016). Activation of 
the Constitutive Androstane Receptor by Monophthalates. Chemical Research in Toxicology, 
29(10), 1651–1661. https://doi.org/10.1021/acs.chemrestox.6b00186 
 
 
 
307
Bibliographic references 
 
  
Lavrijsen, K., van Dyck, D., van Houdt, J., Hendrickx, J., Monbaliu, J., Woestenborghs, R., … Heykants, 
J. (1995). Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut 
of rats, dogs, and humans. Drug Metabolism and Disposition: The Biological Fate of 
Chemicals, 23(3), 354–362. 
 
Le Roy, T., Llopis, M., Lepage, P., Bruneau, A., Rabot, S., Bevilacqua, C., … Gérard, P. (2013). Intestinal 
microbiota determines development of non-alcoholic fatty liver disease in mice. Gut, 62(12), 
1787–1794. https://doi.org/10.1136/gutjnl-2012-303816 
 
Ledda-Columbano, G. M., Pibiri, M., Concas, D., Molotzu, F., Simbula, G., Cossu, C., & Columbano, 
A. (2003). Sex difference in the proliferative response of mouse hepatocytes to treatment 
with the CAR ligand, TCPOBOP. Carcinogenesis, 24(6), 1059–1065. 
https://doi.org/10.1093/carcin/bgg063 
 
Lederberg, J., & McCray, A. (2001). ’Ome Sweet ’Omics—A Genealogical Treasury of Words. 
Retrieved July 5, 2019, from The Scientist Magazine® website: https://www.the-
scientist.com/commentary/ome-sweet-omics---a-genealogical-treasury-of-words-54889 
 
Lehouritis, P., Cummins, J., Stanton, M., Murphy, C. T., McCarthy, F. O., Reid, G., … Tangney, M. 
(2015). Local bacteria affect the efficacy of chemotherapeutic drugs. Scientific Reports, 5, 
14554. https://doi.org/10.1038/srep14554 
 
Lempiäinen, H., Molnár, F., Macias Gonzalez, M., Peräkylä, M., & Carlberg, C. (2005). Antagonist- and 
inverse agonist-driven interactions of the vitamin D receptor and the constitutive androstane 
receptor with corepressor protein. Molecular Endocrinology (Baltimore, Md.), 19(9), 2258–
2272. https://doi.org/10.1210/me.2004-0534 
 
Ley, R. E., Bäckhed, F., Turnbaugh, P., Lozupone, C. A., Knight, R. D., & Gordon, J. I. (2005). Obesity 
alters gut microbial ecology. Proceedings of the National Academy of Sciences of the United 
States of America, 102(31), 11070–11075. https://doi.org/10.1073/pnas.0504978102 
 
Ley, R. E., Hamady, M., Lozupone, C., Turnbaugh, P. J., Ramey, R. R., Bircher, J. S., … Gordon, J. I. 
(2008). Evolution of mammals and their gut microbes. Science (New York, N.Y.), 320(5883), 
1647–1651. https://doi.org/10.1126/science.1155725 
 
Li, F., Hao, X., Chen, Y., Bai, L., Gao, X., Lian, Z., … Tian, Z. (2017). The microbiota maintain 
homeostasis of liver-resident γδT-17 cells in a lipid antigen/CD1d-dependent manner. 
Nature Communications, 7, 13839. https://doi.org/10.1038/ncomms13839 
 
Li, J., Jia, H., Cai, X., Zhong, H., Feng, Q., Sunagawa, S., … Wang, J. (2014). An integrated catalog of 
reference genes in the human gut microbiome. Nature Biotechnology, 32(8), 834–841. 
https://doi.org/10.1038/nbt.2942 
 
Li, Lei, Bao, X., Zhang, Q.-Y., Negishi, M., & Ding, X. (2017). Role of CYP2B in Phenobarbital-Induced 
Hepatocyte Proliferation in Mice. Drug Metabolism and Disposition: The Biological Fate of 
Chemicals, 45(8), 977–981. https://doi.org/10.1124/dmd.117.076406 
 
 
 
Li, Linhao, Chen, T., Stanton, J. D., Sueyoshi, T., Negishi, M., & Wang, H. (2008). The peripheral 
benzodiazepine receptor ligand 1-(2-chlorophenyl-methylpropyl)-3-isoquinoline-
308
Bibliographic references 
 
  
carboxamide is a novel antagonist of human constitutive androstane receptor. Molecular 
Pharmacology, 74(2), 443–453. https://doi.org/10.1124/mol.108.046656 
 
Li, M., Wang, B., Zhang, M., Rantalainen, M., Wang, S., Zhou, H., … Zhao, L. (2008). Symbiotic gut 
microbes modulate human metabolic phenotypes. Proceedings of the National Academy of 
Sciences of the United States of America, 105(6), 2117–2122. 
https://doi.org/10.1073/pnas.0712038105 
 
Littman, D. R., & Pamer, E. G. (2011). Role of the commensal microbiota in normal and pathogenic 
host immune responses. Cell Host & Microbe, 10(4), 311–323. 
https://doi.org/10.1016/j.chom.2011.10.004 
 
López-Velázquez, J. A., Carrillo-Córdova, L. D., Chávez-Tapia, N. C., Uribe, M., & Méndez-Sánchez, 
N. (2012). Nuclear receptors in nonalcoholic Fatty liver disease. Journal of Lipids, 2012, 
139875. https://doi.org/10.1155/2012/139875 
 
Lu, Y.-F., Jin, T., Xu, Y., Zhang, D., Wu, Q., Zhang, Y.-K. J., & Liu, J. (2013). Sex differences in the 
circadian variation of cytochrome p450 genes and corresponding nuclear receptors in 
mouse liver. Chronobiology International, 30(9), 1135–1143. 
https://doi.org/10.3109/07420528.2013.805762 
 
Lundin, A., Bok, C. M., Aronsson, L., Björkholm, B., Gustafsson, J.-A., Pott, S., … Pettersson, S. (2008). 
Gut flora, Toll-like receptors and nuclear receptors: A tripartite communication that tunes 
innate immunity in large intestine. Cellular Microbiology, 10(5), 1093–1103. 
https://doi.org/10.1111/j.1462-5822.2007.01108.x 
 
Lynch, C., Pan, Y., Li, L., Heyward, S., Moeller, T., Swaan, P. W., & Wang, H. (2014). Activation of the 
constitutive androstane receptor inhibits gluconeogenesis without affecting lipogenesis or 
fatty acid synthesis in human hepatocytes. Toxicology and Applied Pharmacology, 279(1), 33–
42. https://doi.org/10.1016/j.taap.2014.05.009 
 
Lyte, M. (2011). Probiotics function mechanistically as delivery vehicles for neuroactive compounds: 
Microbial endocrinology in the design and use of probiotics. BioEssays: News and Reviews 
in Molecular, Cellular and Developmental Biology, 33(8), 574–581. 
https://doi.org/10.1002/bies.201100024 
 
Ma, X., Idle, J. R., & Gonzalez, F. J. (2008a). The pregnane X receptor: From bench to bedside. Expert 
Opinion on Drug Metabolism & Toxicology, 4(7), 895–908. 
https://doi.org/10.1517/17425255.4.7.895 
 
Ma, X., Idle, J. R., & Gonzalez, F. J. (2008b). The pregnane X receptor: From bench to bedside. Expert 
Opinion on Drug Metabolism & Toxicology, 4(7), 895–908. 
https://doi.org/10.1517/17425255.4.7.895 
 
Ma, X., Shah, Y. M., Guo, G. L., Wang, T., Krausz, K. W., Idle, J. R., & Gonzalez, F. J. (2007). Rifaximin 
is a gut-specific human pregnane X receptor activator. The Journal of Pharmacology and 
Experimental Therapeutics, 322(1), 391–398. https://doi.org/10.1124/jpet.107.121913 
 
Macdonald, I. A., Bokkenheuser, V. D., Winter, J., McLernon, A. M., & Mosbach, E. H. (1983). 
Degradation of steroids in the human gut. Journal of Lipid Research, 24(6), 675–700. 
309
Bibliographic references 
 
  
Macfarlane, G. T., & Macfarlane, S. (2012). Bacteria, colonic fermentation, and gastrointestinal health. 
Journal of AOAC International, 95(1), 50–60. 
 
Madak-Erdogan, Z., Gong, P., Zhao, Y. C., Xu, L., Wrobel, K. U., Hartman, J. A., … Helferich, W. G. 
(2016). Dietary licorice root supplementation reduces diet-induced weight gain, lipid 
deposition, and hepatic steatosis in ovariectomized mice without stimulating reproductive 
tissues and mammary gland. Molecular Nutrition & Food Research, 60(2), 369–380. 
https://doi.org/10.1002/mnfr.201500445 
 
Maglich, J. M., Watson, J., McMillen, P. J., Goodwin, B., Willson, T. M., & Moore, J. T. (2004). The 
Nuclear Receptor CAR Is a Regulator of Thyroid Hormone Metabolism during Caloric 
Restriction. Journal of Biological Chemistry, 279(19), 19832–19838. 
https://doi.org/10.1074/jbc.M313601200 
 
Mäkinen, J., Frank, C., Jyrkkärinne, J., Gynther, J., Carlberg, C., & Honkakoski, P. (2002). Modulation 
of mouse and human phenobarbital-responsive enhancer module by nuclear receptors. 
Molecular Pharmacology, 62(2), 366–378. https://doi.org/10.1124/mol.62.2.366 
 
Malaplate-Armand, C., Ferrari, L., Masson, C., Visvikis-Siest, S., Lambert, H., & Batt, A. M. (2005). 
Down-regulation of astroglial CYP2C, glucocorticoid receptor and constitutive androstane 
receptor genes in response to cocaine in human U373 MG astrocytoma cells. Toxicology 
Letters, 159(3), 203–211. https://doi.org/10.1016/j.toxlet.2005.04.005 
 
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., … Evans, R. M. 
(1995). The nuclear receptor superfamily: The second decade. Cell, 83(6), 835–839. 
 
Manichanh, C., Borruel, N., Casellas, F., & Guarner, F. (2012). The gut microbiota in IBD. Nature 
Reviews. Gastroenterology & Hepatology, 9(10), 599–608. 
https://doi.org/10.1038/nrgastro.2012.152 
 
Mardinoglu, A., Shoaie, S., Bergentall, M., Ghaffari, P., Zhang, C., Larsson, E., … Nielsen, J. (2015). 
The gut microbiota modulates host amino acid and glutathione metabolism in mice. 
Molecular Systems Biology, 11(10), 834. https://doi.org/10.15252/msb.20156487 
 
Martin, A. M., Sun, E. W., Rogers, G. B., & Keating, D. J. (2019). The Influence of the Gut Microbiome 
on Host Metabolism Through the Regulation of Gut Hormone Release. Frontiers in 
Physiology, 10. https://doi.org/10.3389/fphys.2019.00428 
 
Martin, P., Riley, R., Back, D. J., & Owen, A. (2008). Comparison of the induction profile for drug 
disposition proteins by typical nuclear receptor activators in human hepatic and intestinal 
cells. British Journal of Pharmacology, 153(4), 805–819. 
https://doi.org/10.1038/sj.bjp.0707601 
 
Martin, R., Nauta, A. J., Ben Amor, K., Knippels, L. M. J., Knol, J., & Garssen, J. (2010). Early life: Gut 
microbiota and immune development in infancy. Beneficial Microbes, 1(4), 367–382. 
https://doi.org/10.3920/BM2010.0027 
 
 
Masson, D., Qatanani, M., Sberna, A. L., Xiao, R., Pais de Barros, J. P., Grober, J., … Assem, M. (2008). 
Activation of the constitutive androstane receptor decreases HDL in wild-type and human 
310
Bibliographic references 
 
  
apoA-I transgenic mice. Journal of Lipid Research, 49(8), 1682–1691. 
https://doi.org/10.1194/jlr.M700374-JLR200 
 
Mastropasqua, F., Girolimetti, G., & Shoshan, M. (2018). PGC1α: Friend or Foe in Cancer? Genes, 
9(1). https://doi.org/10.3390/genes9010048 
 
Matur, E., & Eraslan, E. (2012). The Impact of Probiotics on the Gastrointestinal Physiology. New 
Advances in the Basic and Clinical Gastroenterology. https://doi.org/10.5772/34067 
 
McFall-Ngai, M. J., & Ruby, E. G. (1991). Symbiont recognition and subsequent morphogenesis as 
early events in an animal-bacterial mutualism. Science (New York, N.Y.), 254(5037), 1491–
1494. https://doi.org/10.1126/science.1962208 
 
McKenna, N. J., Cooney, A. J., DeMayo, F. J., Downes, M., Glass, C. K., Lanz, R. B., … O’Malley, B. W. 
(2009). Minireview: Evolution of NURSA, the Nuclear Receptor Signaling Atlas. Molecular 
Endocrinology (Baltimore, Md.), 23(6), 740–746. https://doi.org/10.1210/me.2009-0135 
 
Meng, Z., Gwag, T., Sui, Y., Park, S.-H., Zhou, X., & Zhou, C. (2019). The atypical antipsychotic 
quetiapine induces hyperlipidemia by activating intestinal PXR signaling. JCI Insight, 4(3). 
https://doi.org/10.1172/jci.insight.125657 
 
Miao, J., Fang, S., Bae, Y., & Kemper, J. K. (2006). Functional inhibitory cross-talk between constitutive 
androstane receptor and hepatic nuclear factor-4 in hepatic lipid/glucose metabolism is 
mediated by competition for binding to the DR1 motif and to the common coactivators, GRIP-
1 and PGC-1alpha. The Journal of Biological Chemistry, 281(21), 14537–14546. 
https://doi.org/10.1074/jbc.M510713200 
 
Min, G., Kim, H., Bae, Y., Petz, L., & Kemper, J. K. (2002). Inhibitory cross-talk between estrogen 
receptor (ER) and constitutively activated androstane receptor (CAR). CAR inhibits ER-
mediated signaling pathway by squelching p160 coactivators. The Journal of Biological 
Chemistry, 277(37), 34626–34633. https://doi.org/10.1074/jbc.M205239200 
 
Min, Y., Ma, X., Sankaran, K., Ru, Y., Chen, L., Baiocchi, M., & Zhu, S. (2019). Sex-specific association 
between gut microbiome and fat distribution. Nature Communications, 10(1), 2408. 
https://doi.org/10.1038/s41467-019-10440-5 
 
Molly, K., Vande Woestyne, M., & Verstraete, W. (1993). Development of a 5-step multi-chamber 
reactor as a simulation of the human intestinal microbial ecosystem. Applied Microbiology 
and Biotechnology, 39(2), 254–258. https://doi.org/10.1007/bf00228615 
 
Montagner, A., Korecka, A., Polizzi, A., Lippi, Y., Blum, Y., Canlet, C., … Wahli, W. (2016). Hepatic 
circadian clock oscillators and nuclear receptors integrate microbiome-derived signals. 
Scientific Reports, 6, 20127. https://doi.org/10.1038/srep20127 
 
Montagner, A., Polizzi, A., Fouché, E., Ducheix, S., Lippi, Y., Lasserre, F., … Guillou, H. (2016). Liver 
PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD. Gut, 
65(7), 1202–1214. https://doi.org/10.1136/gutjnl-2015-310798 
 
Moore, L. B., Parks, D. J., Jones, S. A., Bledsoe, R. K., Consler, T. G., Stimmel, J. B., … others. (2000). 
Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share 
xenobiotic and steroid ligands. Journal of Biological Chemistry, 275(20), 15122–15127. 
311
Bibliographic references 
 
  
 
Mueller, S., Saunier, K., Hanisch, C., Norin, E., Alm, L., Midtvedt, T., … Blaut, M. (2006). Differences in 
fecal microbiota in different European study populations in relation to age, gender, and 
country: A cross-sectional study. Applied and Environmental Microbiology, 72(2), 1027–1033. 
https://doi.org/10.1128/AEM.72.2.1027-1033.2006 
 
Murray, M., Fiala-Beer, E., & Sutton, D. (2003). Upregulation of cytochromes P450 2B in rat liver by 
orphenadrine. British Journal of Pharmacology, 139(4), 787–796. 
https://doi.org/10.1038/sj.bjp.0705305 
 
Mutoh, S., Osabe, M., Inoue, K., Moore, R., Pedersen, L., Perera, L., … Negishi, M. (2009). 
Dephosphorylation of threonine 38 is required for nuclear translocation and activation of 
human xenobiotic receptor CAR (NR1I3). The Journal of Biological Chemistry, 284(50), 
34785–34792. https://doi.org/10.1074/jbc.M109.048108 
 
Nakatsu, C. H., Armstrong, A., Clavijo, A. P., Martin, B. R., Barnes, S., & Weaver, C. M. (2014). Fecal 
Bacterial Community Changes Associated with Isoflavone Metabolites in Postmenopausal 
Women after Soy Bar Consumption. PLoS ONE, 9(10). 
https://doi.org/10.1371/journal.pone.0108924 
 
Nebert, D. W., Roe, A. L., Dieter, M. Z., Solis, W. A., Yang, Y., & Dalton, T. P. (2000). Role of the aromatic 
hydrocarbon receptor and [Ah] gene battery in the oxidative stress response, cell cycle 
control, and apoptosis. Biochemical Pharmacology, 59(1), 65–85. 
https://doi.org/10.1016/s0006-2952(99)00310-x 
 
Nguyen, T. L. A., Vieira-Silva, S., Liston, A., & Raes, J. (2015). How informative is the mouse for human 
gut microbiota research? Disease Models & Mechanisms, 8(1), 1–16. 
https://doi.org/10.1242/dmm.017400 
 
Ni, J., Wu, G. D., Albenberg, L., & Tomov, V. T. (2017). Gut microbiota and IBD: Causation or 
correlation? Nature Reviews. Gastroenterology & Hepatology, 14(10), 573–584. 
https://doi.org/10.1038/nrgastro.2017.88 
 
Nicholson, J. K., Holmes, E., Kinross, J., Burcelin, R., Gibson, G. R., Jia, W., & Pettersson, S. (2012). 
Host-gut microbiota metabolic interactions. Science, 336(6086), 1262–1267. 
https://doi.org/10.1126/science.1223813 
 
Nicklas, W., Keubler, L., & Bleich, A. (2015). Maintaining and Monitoring the Defined Microbiota 
Status of Gnotobiotic Rodents. ILAR Journal, 56(2), 241–249. 
https://doi.org/10.1093/ilar/ilv029 
 
Nutt, J. G., & Holford, N. H. (1996). The response to levodopa in Parkinson’s disease: Imposing 
pharmacological law and order. Annals of Neurology, 39(5), 561–573. 
https://doi.org/10.1002/ana.410390504 
 
O’Callaghan, D., & Vergunst, A. (2010). Non-mammalian animal models to study infectious disease: 
Worms or fly fishing? Current Opinion in Microbiology, 13(1), 79–85. 
https://doi.org/10.1016/j.mib.2009.12.005 
Oh, H. Y. P., Ellero-Simatos, S., Manickam, R., Tan, N. S., Guillou, H., & Wahli, W. (2019). Depletion of 
Gram-Positive Bacteria Impacts Hepatic Biological Functions During the Light Phase. 
International Journal of Molecular Sciences, 20(4). https://doi.org/10.3390/ijms20040812 
312
Bibliographic references 
 
  
 
O’Hara, A. M., & Shanahan, F. (2006). The gut flora as a forgotten organ. EMBO Reports, 7(7), 688–
693. https://doi.org/10.1038/sj.embor.7400731 
 
O’Mahony, S. M., Clarke, G., Borre, Y. E., Dinan, T. G., & Cryan, J. F. (2015). Serotonin, tryptophan 
metabolism and the brain-gut-microbiome axis. Behavioural Brain Research, 277, 32–48. 
https://doi.org/10.1016/j.bbr.2014.07.027 
 
Oshida, K., Vasani, N., Thomas, R. S., Applegate, D., Rosen, M., Abbott, B., … Corton, J. C. (2015). 
Identification of Modulators of the Nuclear Receptor Peroxisome Proliferator-Activated 
Receptor α (PPARα) in a Mouse Liver Gene Expression Compendium. PLoS ONE, 10(2). 
https://doi.org/10.1371/journal.pone.0112655 
 
O’Toole, P. W., & Claesson, M. J. (2010). Gut microbiota: Changes throughout the lifespan from 
infancy to elderly. International Dairy Journal, 20(4), 281–291. 
https://doi.org/10.1016/j.idairyj.2009.11.010 
 
Pakharukova, M. Y., Smetanina, M. A., Kaledin, V. I., Kobzev, V. F., Romanova, I. V., & Merkulova, T. I. 
(2007). Activation of constitutive androstane receptor under the effect of hepatocarcinogenic 
aminoazo dyes in mouse and rat liver. Bulletin of Experimental Biology and Medicine, 144(3), 
338–341. https://doi.org/10.1007/s10517-007-0327-0 
 
Pascussi, J. M., Gerbal-Chaloin, S., Fabre, J. M., Maurel, P., & Vilarem, M. J. (2000). Dexamethasone 
enhances constitutive androstane receptor expression in human hepatocytes: 
Consequences on cytochrome P450 gene regulation. Molecular Pharmacology, 58(6), 1441–
1450. https://doi.org/10.1124/mol.58.6.1441 
 
Patel, R. D., Hollingshead, B. D., Omiecinski, C. J., & Perdew, G. H. (2007). Aryl-hydrocarbon receptor 
activation regulates constitutive androstane receptor levels in murine and human liver. 
Hepatology (Baltimore, Md.), 46(1), 209–218. https://doi.org/10.1002/hep.21671 
 
Pathak, P., Xie, C., Nichols, R. G., Ferrell, J. M., Boehme, S., Krausz, K. W., … Chiang, J. Y. L. (2018). 
Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid 
receptor-1 signaling to improve metabolism. Hepatology (Baltimore, Md.), 68(4), 1574–1588. 
https://doi.org/10.1002/hep.29857 
 
Peet, D. J., Janowski, B. A., & Mangelsdorf, D. J. (1998). The LXRs: A new class of oxysterol receptors. 
Current Opinion in Genetics & Development, 8(5), 571–575. 
 
Peffer, R. C., Moggs, J. G., Pastoor, T., Currie, R. A., Wright, J., Milburn, G., … Rusyn, I. (2007). Mouse 
liver effects of cyproconazole, a triazole fungicide: Role of the constitutive androstane 
receptor. Toxicological Sciences: An Official Journal of the Society of Toxicology, 99(1), 315–
325. https://doi.org/10.1093/toxsci/kfm154 
 
Peppercorn, M. A., & Goldman, P. (1972). The role of intestinal bacteria in the metabolism of 
salicylazosulfapyridine. The Journal of Pharmacology and Experimental Therapeutics, 181(3), 
555–562. 
Petrick, J. S., & Klaassen, C. D. (2007). Importance of hepatic induction of constitutive androstane 
receptor and other transcription factors that regulate xenobiotic metabolism and transport. 
Drug Metabolism and Disposition: The Biological Fate of Chemicals, 35(10), 1806–1815. 
https://doi.org/10.1124/dmd.107.015974 
313
Bibliographic references 
 
  
 
Pompei, A., Cordisco, L., Amaretti, A., Zanoni, S., Matteuzzi, D., & Rossi, M. (2007). Folate Production 
by Bifidobacteria as a Potential Probiotic Property. Applied and Environmental Microbiology, 
73(1), 179–185. https://doi.org/10.1128/AEM.01763-06 
 
Presley, L. L., Wei, B., Braun, J., & Borneman, J. (2010). Bacteria Associated with Immunoregulatory 
Cells in Mice. Applied and Environmental Microbiology, 76(3), 936–941. 
https://doi.org/10.1128/AEM.01561-09 
 
Prokopec, S. D., Watson, J. D., Lee, J., Pohjanvirta, R., & Boutros, P. C. (2015). Sex-related differences 
in murine hepatic transcriptional and proteomic responses to TCDD. Toxicology and Applied 
Pharmacology, 284(2), 188–196. https://doi.org/10.1016/j.taap.2015.02.012 
 
Puchalska, P., & Crawford, P. A. (2017). Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, 
Signaling, and Therapeutics. Cell Metabolism, 25(2), 262–284. 
https://doi.org/10.1016/j.cmet.2016.12.022 
 
Pulakazhi Venu, V. K., Saifeddine, M., Mihara, K., Tsai, Y.-C., Nieves, K., Alston, L., … Hirota, S. A. 
(2019). The pregnane X receptor and its microbiota-derived ligand indole 3-propionic acid 
regulate endothelium-dependent vasodilation. American Journal of Physiology. 
Endocrinology and Metabolism, 317(2), E350–E361. 
https://doi.org/10.1152/ajpendo.00572.2018 
 
Qatanani, M., Wei, P., & Moore, D. D. (2004). Alterations in the distribution and orexigenic effects of 
dexamethasone in CAR-null mice. Pharmacology, Biochemistry, and Behavior, 78(2), 285–
291. https://doi.org/10.1016/j.pbb.2004.04.001 
 
Quinet, E. M., Savio, D. A., Halpern, A. R., Chen, L., Miller, C. P., & Nambi, P. (2004). Gene-selective 
modulation by a synthetic oxysterol ligand of the liver X receptor. Journal of Lipid Research, 
45(10), 1929–1942. https://doi.org/10.1194/jlr.M400257-JLR200 
 
Rafii, F., Franklin, W., & Cerniglia, C. E. (1990). Azoreductase activity of anaerobic bacteria isolated 
from human intestinal microflora. Applied and Environmental Microbiology, 56(7), 2146–
2151. 
 
Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S., & Medzhitov, R. (2004). Recognition 
of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell, 
118(2), 229–241. https://doi.org/10.1016/j.cell.2004.07.002 
 
Ranhotra, H. S., Flannigan, K. L., Brave, M., Mukherjee, S., Lukin, D. J., Hirota, S. A., & Mani, S. (2016). 
Xenobiotic Receptor-Mediated Regulation of Intestinal Barrier Function and Innate Immunity. 
Nuclear Receptor Research, 3. https://doi.org/10.11131/2016/101199 
 
Rastelli, M., Knauf, C., & Cani, P. D. (2018). Gut Microbes and Health: A Focus on the Mechanisms 
Linking Microbes, Obesity, and Related Disorders. Obesity (Silver Spring, Md.), 26(5), 792–
800. https://doi.org/10.1002/oby.22175 
Régnier, M., Polizzi, A., Lippi, Y., Fouché, E., Michel, G., Lukowicz, C., … Montagner, A. (2018). Insights 
into the role of hepatocyte PPARα activity in response to fasting. Molecular and Cellular 
Endocrinology, 471, 75–88. https://doi.org/10.1016/j.mce.2017.07.035 
 
314
Bibliographic references 
 
  
Repa, J. J., Liang, G., Ou, J., Bashmakov, Y., Lobaccaro, J. M., Shimomura, I., … Mangelsdorf, D. J. 
(2000). Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) 
by oxysterol receptors, LXRalpha and LXRbeta. Genes & Development, 14(22), 2819–2830. 
https://doi.org/10.1101/gad.844900 
 
Rezen, T., Tamasi, V., Lövgren-Sandblom, A., Björkhem, I., Meyer, U. A., & Rozman, D. (2009). Effect 
of CAR activation on selected metabolic pathways in normal and hyperlipidemic mouse 
livers. BMC Genomics, 10, 384. https://doi.org/10.1186/1471-2164-10-384 
 
Ridlon, J. M., & Bajaj, J. S. (2015). The human gut sterolbiome: Bile acid-microbiome endocrine 
aspects and therapeutics. Acta Pharmaceutica Sinica. B, 5(2), 99–105. 
https://doi.org/10.1016/j.apsb.2015.01.006 
 
Ridlon, J. M., Kang, D. J., Hylemon, P. B., & Bajaj, J. S. (2014). Bile acids and the gut microbiome. 
Current Opinion in Gastroenterology, 30(3), 332–338. 
https://doi.org/10.1097/MOG.0000000000000057 
 
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006). Bile salt biotransformations by human intestinal 
bacteria. Journal of Lipid Research, 47(2), 241–259. https://doi.org/10.1194/jlr.R500013-
JLR200 
 
Roager, H. M., & Licht, T. R. (2018). Microbial tryptophan catabolites in health and disease. Nature 
Communications, 9. https://doi.org/10.1038/s41467-018-05470-4 
 
Robertson, S. J., Lemire, P., Maughan, H., Goethel, A., Turpin, W., Bedrani, L., … Philpott, D. J. (2019). 
Comparison of Co-housing and Littermate Methods for Microbiota Standardization in Mouse 
Models. Cell Reports, 27(6), 1910-1919.e2. https://doi.org/10.1016/j.celrep.2019.04.023 
 
Rosenfeld, M. G., & Glass, C. K. (2001). Coregulator codes of transcriptional regulation by nuclear 
receptors. The Journal of Biological Chemistry, 276(40), 36865–36868. 
https://doi.org/10.1074/jbc.R100041200 
 
Roth, A., Looser, R., Kaufmann, M., Blättler, S. M., Rencurel, F., Huang, W., … Meyer, U. A. (2008). 
Regulatory cross-talk between drug metabolism and lipid homeostasis: Constitutive 
androstane receptor and pregnane X receptor increase Insig-1 expression. Molecular 
Pharmacology, 73(4), 1282–1289. https://doi.org/10.1124/mol.107.041012 
 
Rothhammer, V., Mascanfroni, I. D., Bunse, L., Takenaka, M. C., Kenison, J. E., Mayo, L., … Quintana, 
F. J. (2016). Type I interferons and microbial metabolites of tryptophan modulate astrocyte 
activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nature 
Medicine, 22(6), 586–597. https://doi.org/10.1038/nm.4106 
 
Rowland, I., Gibson, G., Heinken, A., Scott, K., Swann, J., Thiele, I., & Tuohy, K. (2018). Gut microbiota 
functions: Metabolism of nutrients and other food components. European Journal of 
Nutrition, 57(1), 1–24. https://doi.org/10.1007/s00394-017-1445-8 
Ruckpaul, K., Rein, H., & Blanck, J. (1985). [Regulation mechanisms of the endoplasmic cytochrome 
P-450 systems of the liver]. Biomedica Biochimica Acta, 44(3), 351–379. 
 
Ruddick, J. P., Evans, A. K., Nutt, D. J., Lightman, S. L., Rook, G. A. W., & Lowry, C. A. (2006). 
Tryptophan metabolism in the central nervous system: Medical implications. Expert Reviews 
in Molecular Medicine, 8(20), 1–27. https://doi.org/10.1017/S1462399406000068 
315
Bibliographic references 
 
  
 
Russell, D. W. (2003). The Enzymes, Regulation, and Genetics of Bile Acid Synthesis. Annual Review 
of Biochemistry, 72(1), 137–174. 
https://doi.org/10.1146/annurev.biochem.72.121801.161712 
 
Saito, K., Moore, R., & Negishi, M. (2013). P38 Mitogen-activated protein kinase regulates nuclear 
receptor CAR that activates the CYP2B6 gene. Drug Metabolism and Disposition: The 
Biological Fate of Chemicals, 41(6), 1170–1173. https://doi.org/10.1124/dmd.113.051623 
 
Sampson, T. R., & Mazmanian, S. K. (2015). Control of brain development, function, and behavior by 
the microbiome. Cell Host & Microbe, 17(5), 565–576. 
https://doi.org/10.1016/j.chom.2015.04.011 
 
Santos-Marcos, J. A., Haro, C., Vega-Rojas, A., Alcala-Diaz, J. F., Molina-Abril, H., Leon-Acuña, A., … 
Camargo, A. (2019). Sex Differences in the Gut Microbiota as Potential Determinants of 
Gender Predisposition to Disease. Molecular Nutrition & Food Research, 63(7), e1800870. 
https://doi.org/10.1002/mnfr.201800870 
 
Saussele, T., Burk, O., Blievernicht, J. K., Klein, K., Nussler, A., Nussler, N., … Zanger, U. M. (2007). 
Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole. 
Clinical Pharmacology and Therapeutics, 82(3), 265–274. 
https://doi.org/10.1038/sj.clpt.6100138 
 
Savary, C. C., Jossé, R., Bruyère, A., Guillet, F., Robin, M.-A., & Guillouzo, A. (2014). Interactions of 
endosulfan and methoxychlor involving CYP3A4 and CYP2B6 in human HepaRG cells. Drug 
Metabolism and Disposition: The Biological Fate of Chemicals, 42(8), 1235–1240. 
https://doi.org/10.1124/dmd.114.057786 
 
Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., … Bäckhed, F. (2013). Gut 
Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic 
Acid, a Naturally Occurring FXR Antagonist. Cell Metabolism, 17(2), 225–235. 
https://doi.org/10.1016/j.cmet.2013.01.003 
 
Sberna, A. L., Assem, M., Gautier, T., Grober, J., Guiu, B., Jeannin, A., … Masson, D. (2011). 
Constitutive androstane receptor activation stimulates faecal bile acid excretion and reverse 
cholesterol transport in mice. Journal of Hepatology, 55(1), 154–161. 
https://doi.org/10.1016/j.jhep.2010.10.029 
 
Schmidt, D., Amrani, A., Verdaguer, J., Bou, S., & Santamaria, P. (1999). Autoantigen-Independent 
Deletion of Diabetogenic CD4+ Thymocytes by Protective MHC Class II Molecules. The 
Journal of Immunology, 162(8), 4627–4636. 
 
Schnabl, B., & Brenner, D. A. (2014). Interactions between the intestinal microbiome and liver 
diseases. Gastroenterology, 146(6), 1513–1524. 
https://doi.org/10.1053/j.gastro.2014.01.020 
Schnorr, S. L., Candela, M., Rampelli, S., Centanni, M., Consolandi, C., Basaglia, G., … Crittenden, A. 
N. (2014). Gut microbiome of the Hadza hunter-gatherers. Nature Communications, 5, 3654. 
https://doi.org/10.1038/ncomms4654 
 
316
Bibliographic references 
 
  
Scholtens, P. A. M. J., Oozeer, R., Martin, R., Amor, K. B., & Knol, J. (2012). The early settlers: Intestinal 
microbiology in early life. Annual Review of Food Science and Technology, 3, 425–447. 
https://doi.org/10.1146/annurev-food-022811-101120 
 
Schroeder, J. C., Dinatale, B. C., Murray, I. A., Flaveny, C. A., Liu, Q., Laurenzana, E. M., … Perdew, G. 
H. (2010). The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human 
aryl hydrocarbon receptor. Biochemistry, 49(2), 393–400. https://doi.org/10.1021/bi901786x 
 
Schubert, A. M., Sinani, H., & Schloss, P. D. (2015). Antibiotic-Induced Alterations of the Murine Gut 
Microbiota and Subsequent Effects on Colonization Resistance against Clostridium difficile. 
MBio, 6(4), e00974-15. https://doi.org/10.1128/mBio.00974-15 
 
Selwyn, F. P., Cheng, S. L., Klaassen, C. D., & Cui, J. Y. (2016). Regulation of Hepatic Drug-
Metabolizing Enzymes in Germ-Free Mice by Conventionalization and Probiotics. Drug 
Metabolism and Disposition: The Biological Fate of Chemicals, 44(2), 262–274. 
https://doi.org/10.1124/dmd.115.067504 
 
Sender, R., Fuchs, S., & Milo, R. (2016). Are We Really Vastly Outnumbered? Revisiting the Ratio of 
Bacterial to Host Cells in Humans. Cell, 164(3), 337–340. 
https://doi.org/10.1016/j.cell.2016.01.013 
 
Shah, Y. M., Ma, X., Morimura, K., Kim, I., & Gonzalez, F. J. (2007). Pregnane X receptor activation 
ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-kappaB target 
gene expression. American Journal of Physiology. Gastrointestinal and Liver Physiology, 
292(4), G1114-1122. https://doi.org/10.1152/ajpgi.00528.2006 
 
Shehata, A. A., Schrödl, W., Aldin, A. A., Hafez, H. M., & Krüger, M. (2013). The effect of glyphosate 
on potential pathogens and beneficial members of poultry microbiota in vitro. Current 
Microbiology, 66(4), 350–358. https://doi.org/10.1007/s00284-012-0277-2 
 
Shi, X., Cheng, Q., Xu, L., Yan, J., Jiang, M., He, J., … Xie, W. (2014). Cholesterol sulfate and 
cholesterol sulfotransferase inhibit gluconeogenesis by targeting hepatocyte nuclear factor 
4α. Molecular and Cellular Biology, 34(3), 485–497. https://doi.org/10.1128/MCB.01094-13 
 
Shibayama, Y., Ushinohama, K., Ikeda, R., Yoshikawa, Y., Motoya, T., Takeda, Y., & Yamada, K. (2006). 
Effect of methotrexate treatment on expression levels of multidrug resistance protein 2, 
breast cancer resistance protein and organic anion transporters Oat1, Oat2 and Oat3 in rats. 
Cancer Science, 97(11), 1260–1266. https://doi.org/10.1111/j.1349-7006.2006.00304.x 
 
Shindo, S., Numazawa, S., & Yoshida, T. (2007). A physiological role of AMP-activated protein kinase 
in phenobarbital-mediated constitutive androstane receptor activation and CYP2B induction. 
The Biochemical Journal, 401(3), 735–741. https://doi.org/10.1042/BJ20061238 
 
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000). Targeted 
disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell, 
102(6), 731–744. 
 
Smith, M. I., Yatsunenko, T., Manary, M. J., Trehan, I., Mkakosya, R., Cheng, J., … Gordon, J. I. (2013). 
Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science (New York, N.Y.), 
339(6119), 548–554. https://doi.org/10.1126/science.1229000 
 
317
Bibliographic references 
 
  
Sommer, F., Nookaew, I., Sommer, N., Fogelstrand, P., & Bäckhed, F. (2015). Site-specific 
programming of the host epithelial transcriptome by the gut microbiota. Genome Biology, 
16, 62. https://doi.org/10.1186/s13059-015-0614-4 
 
Sotaniemi, E. A., Arranto, A. J., Sutinen, S., Stengård, J. H., & Sutinen, S. (1983). Treatment of 
noninsulin-dependent diabetes mellitus with enzyme inducers. Clinical Pharmacology and 
Therapeutics, 33(6), 826–835. https://doi.org/10.1038/clpt.1983.113 
 
Spiljar, M., Merkler, D., & Trajkovski, M. (2017). The Immune System Bridges the Gut Microbiota with 
Systemic Energy Homeostasis: Focus on TLRs, Mucosal Barrier, and SCFAs. Frontiers in 
Immunology, 8. https://doi.org/10.3389/fimmu.2017.01353 
 
Spor, A., Koren, O., & Ley, R. (2011). Unravelling the effects of the environment and host genotype 
on the gut microbiome. Nature Reviews. Microbiology, 9(4), 279–290. 
https://doi.org/10.1038/nrmicro2540 
 
Staudinger, J. L., Goodwin, B., Jones, S. A., Hawkins-Brown, D., MacKenzie, K. I., LaTour, A., … 
Kliewer, S. A. (2001). The nuclear receptor PXR is a lithocholic acid sensor that protects 
against liver toxicity. Proceedings of the National Academy of Sciences of the United States of 
America, 98(6), 3369–3374. https://doi.org/10.1073/pnas.051551698 
 
Staudinger, Jeff L., Madan, A., Carol, K. M., & Parkinson, A. (2003). Regulation of drug transporter 
gene expression by nuclear receptors. Drug Metabolism and Disposition: The Biological Fate 
of Chemicals, 31(5), 523–527. https://doi.org/10.1124/dmd.31.5.523 
 
Stedman, C. A. M., Liddle, C., Coulter, S. A., Sonoda, J., Alvarez, J. G. A., Moore, D. D., … Downes, 
M. (2005). Nuclear receptors constitutive androstane receptor and pregnane X receptor 
ameliorate cholestatic liver injury. Proceedings of the National Academy of Sciences of the 
United States of America, 102(6), 2063–2068. https://doi.org/10.1073/pnas.0409794102 
 
Stickel, F., & Hellerbrand, C. (2010). Non-alcoholic fatty liver disease as a risk factor for hepatocellular 
carcinoma: Mechanisms and implications. Gut, 59(10), 1303–1307. 
https://doi.org/10.1136/gut.2009.199661 
 
Sueyoshi, T., Kawamoto, T., Zelko, I., Honkakoski, P., & Negishi, M. (1999). The repressed nuclear 
receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. The Journal 
of Biological Chemistry, 274(10), 6043–6046. https://doi.org/10.1074/jbc.274.10.6043 
 
Sueyoshi, Tatsuya, Moore, R., Sugatani, J., Matsumura, Y., & Negishi, M. (2008). PPP1R16A, the 
membrane subunit of protein phosphatase 1beta, signals nuclear translocation of the nuclear 
receptor constitutive active/androstane receptor. Molecular Pharmacology, 73(4), 1113–
1121. https://doi.org/10.1124/mol.107.042960 
Sugatani, J., Kojima, H., Ueda, A., Kakizaki, S., Yoshinari, K., Gong, Q. H., … Sueyoshi, T. (2001). The 
phenobarbital response enhancer module in the human bilirubin UDP-
glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR. 
Hepatology (Baltimore, Md.), 33(5), 1232–1238. https://doi.org/10.1053/jhep.2001.24172 
 
Suino, K., Peng, L., Reynolds, R., Li, Y., Cha, J.-Y., Repa, J. J., … Xu, H. E. (2004). The nuclear xenobiotic 
receptor CAR: Structural determinants of constitutive activation and heterodimerization. 
Molecular Cell, 16(6), 893–905. https://doi.org/10.1016/j.molcel.2004.11.036 
 
318
Bibliographic references 
 
  
Sun, L., Zhang, X., Zhang, Y., Zheng, K., Xiang, Q., Chen, N., … He, Q. (2019). Antibiotic-Induced 
Disruption of Gut Microbiota Alters Local Metabolomes and Immune Responses. Frontiers in 
Cellular and Infection Microbiology, 9, 99. https://doi.org/10.3389/fcimb.2019.00099 
 
Sutherland, J. D., & Macdonald, I. A. (1982). The metabolism of primary, 7-oxo, and 7 beta-hydroxy 
bile acids by Clostridium absonum. Journal of Lipid Research, 23(5), 726–732. 
 
Swales, K., & Negishi, M. (2004). CAR, driving into the future. Molecular Endocrinology (Baltimore, 
Md.), 18(7), 1589–1598. https://doi.org/10.1210/me.2003-0397 
 
Swanson, P. A., Kumar, A., Samarin, S., Vijay-Kumar, M., Kundu, K., Murthy, N., … Neish, A. S. (2011). 
Enteric commensal bacteria potentiate epithelial restitution via reactive oxygen species-
mediated inactivation of focal adhesion kinase phosphatases. Proceedings of the National 
Academy of Sciences of the United States of America, 108(21), 8803–8808. 
https://doi.org/10.1073/pnas.1010042108 
 
Teng, S., & Piquette-Miller, M. (2005). The involvement of the pregnane X receptor in hepatic gene 
regulation during inflammation in mice. The Journal of Pharmacology and Experimental 
Therapeutics, 312(2), 841–848. https://doi.org/10.1124/jpet.104.076141 
 
Terc, J., Hansen, A., Alston, L., & Hirota, S. A. (2014). Pregnane X receptor agonists enhance intestinal 
epithelial wound healing and repair of the intestinal barrier following the induction of 
experimental colitis. European Journal of Pharmaceutical Sciences: Official Journal of the 
European Federation for Pharmaceutical Sciences, 55, 12–19. 
https://doi.org/10.1016/j.ejps.2014.01.007 
 
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K. (2008). Targeting bile-acid 
signalling for metabolic diseases. Nature Reviews Drug Discovery, 7(8), 678–693. 
https://doi.org/10.1038/nrd2619 
 
Thomas, S., Izard, J., Walsh, E., Batich, K., Chongsathidkiet, P., Clarke, G., … Prendergast, G. C. (2017). 
The Host Microbiome Regulates and Maintains Human Health: A Primer and Perspective for 
Non-Microbiologists. Cancer Research, 77(8), 1783–1812. https://doi.org/10.1158/0008-
5472.CAN-16-2929 
 
Thompson, P. D., Jurutka, P. W., Haussler, C. A., Whitfield, G. K., & Haussler, M. R. (1998). 
Heterodimeric DNA binding by the vitamin D receptor and retinoid X receptors is enhanced 
by 1,25-dihydroxyvitamin D3 and inhibited by 9-cis-retinoic acid. Evidence for allosteric 
receptor interactions. The Journal of Biological Chemistry, 273(14), 8483–8491. 
https://doi.org/10.1074/jbc.273.14.8483 
Timsit, Y. E., & Negishi, M. (2007). CAR and PXR: The Xenobiotic-Sensing Receptors. Steroids, 72(3), 
231–246. https://doi.org/10.1016/j.steroids.2006.12.006 
 
Tolson, A. H., & Wang, H. (2010). Regulation of drug-metabolizing enzymes by xenobiotic receptors: 
PXR and CAR. Advanced Drug Delivery Reviews, 62(13), 1238–1249. 
 
Torow, N., & Hornef, M. W. (2017). The Neonatal Window of Opportunity: Setting the Stage for Life-
Long Host-Microbial Interaction and Immune Homeostasis. Journal of Immunology 
(Baltimore, Md.: 1950), 198(2), 557–563. https://doi.org/10.4049/jimmunol.1601253 
 
319
Bibliographic references 
 
  
Treuting, P. M., Dintzis, S. M., Liggitt, D., & Frevert, C. W. (2011). Comparative Anatomy and Histology: 
A Mouse and Human Atlas (Expert Consult). Academic Press. 
 
Tsai, V. W. W., Husaini, Y., Sainsbury, A., Brown, D. A., & Breit, S. N. (2018). The MIC-1/GDF15-GFRAL 
Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated 
Diseases. Cell Metabolism, 28(3), 353–368. https://doi.org/10.1016/j.cmet.2018.07.018 
 
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006). An 
obesity-associated gut microbiome with increased capacity for energy harvest. Nature, 
444(7122), 1027–1031. https://doi.org/10.1038/nature05414 
 
Turnbaugh, P. J., Ridaura, V. K., Faith, J. J., Rey, F. E., Knight, R., & Gordon, J. I. (2009). The effect of 
diet on the human gut microbiome: A metagenomic analysis in humanized gnotobiotic mice. 
Science Translational Medicine, 1(6), 6ra14. https://doi.org/10.1126/scitranslmed.3000322 
 
Turroni, S., Brigidi, P., Cavalli, A., & Candela, M. (2018). Microbiota-Host Transgenomic Metabolism, 
Bioactive Molecules from the Inside. Journal of Medicinal Chemistry, 61(1), 47–61. 
https://doi.org/10.1021/acs.jmedchem.7b00244 
 
Tzameli, I., Pissios, P., Schuetz, E. G., & Moore, D. D. (2000). The xenobiotic compound 1,4-bis[2-(3,5-
dichloropyridyloxy)]benzene is an agonist ligand for the nuclear receptor CAR. Molecular 
and Cellular Biology, 20(9), 2951–2958. https://doi.org/10.1128/mcb.20.9.2951-2958.2000 
 
Ueda, A., Hamadeh, H. K., Webb, H. K., Yamamoto, Y., Sueyoshi, T., Afshari, C. A., … Negishi, M. 
(2002). Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in 
response to phenobarbital. Molecular Pharmacology, 61(1), 1–6. 
https://doi.org/10.1124/mol.61.1.1 
 
Usui, T., Tochiya, M., Sasaki, Y., Muranaka, K., Yamakage, H., Himeno, A., … Satoh-Asahara, N. (2013). 
Effects of natural S-equol supplements on overweight or obesity and metabolic syndrome in 
the Japanese, based on sex and equol status. Clinical Endocrinology, 78(3), 365–372. 
https://doi.org/10.1111/j.1365-2265.2012.04400.x 
 
Uzbay, T. (2019). Germ-free animal experiments in the gut microbiota studies. Current Opinion in 
Pharmacology, 49, 6–10. https://doi.org/10.1016/j.coph.2019.03.016 
 
 
Van de Wiele, T., Van den Abbeele, P., Ossieur, W., Possemiers, S., & Marzorati, M. (2015). The 
Simulator of the Human Intestinal Microbial Ecosystem (SHIME®). In K. Verhoeckx, P. Cotter, 
I. López-Expósito, C. Kleiveland, T. Lea, A. Mackie, … H. Wichers (Eds.), The Impact of Food 
Bioactives on Health: In vitro and ex vivo models (pp. 305–317). https://doi.org/10.1007/978-
3-319-16104-4_27 
 
Venkatesh, M., Mukherjee, S., Wang, H., Li, H., Sun, K., Benechet, A. P., … Mani, S. (2014). Symbiotic 
Bacterial Metabolites Regulate Gastrointestinal Barrier Function via the Xenobiotic Sensor 
PXR and Toll-like Receptor 4. Immunity, 41(2), 296–310. 
https://doi.org/10.1016/j.immuni.2014.06.014 
 
Verbeke, K. A., Boobis, A. R., Chiodini, A., Edwards, C. A., Franck, A., Kleerebezem, M., … Tuohy, K. 
M. (2015). Towards microbial fermentation metabolites as markers for health benefits of 
320
Bibliographic references 
 
  
prebiotics. Nutrition Research Reviews, 28(1), 42–66. 
https://doi.org/10.1017/S0954422415000037 
 
Verdaguer, J., Schmidt, D., Amrani, A., Anderson, B., Averill, N., & Santamaria, P. (1997). Spontaneous 
autoimmune diabetes in monoclonal T cell nonobese diabetic mice. The Journal of 
Experimental Medicine, 186(10), 1663–1676. https://doi.org/10.1084/jem.186.10.1663 
 
Vernocchi, P., Del Chierico, F., & Putignani, L. (2016). Gut Microbiota Profiling: Metabolomics Based 
Approach to Unravel Compounds Affecting Human Health. Frontiers in Microbiology, 7. 
https://doi.org/10.3389/fmicb.2016.01144 
 
Visconti, A., Roy, C. I. L., Rosa, F., Rossi, N., Martin, T. C., Mohney, R. P., … Falchi, M. (2019). Interplay 
between the human gut microbiome and host metabolism. Nature Communications, 10(1), 
1–10. https://doi.org/10.1038/s41467-019-12476-z 
 
Visser, T. J., Kaptein, E., Glatt, H., Bartsch, I., Hagen, M., & Coughtrie, M. W. (1998). Characterization 
of thyroid hormone sulfotransferases. Chemico-Biological Interactions, 109(1–3), 279–291. 
 
Vítek, L., Zelenka, J., Zadinová, M., & Malina, J. (2005). The impact of intestinal microflora on serum 
bilirubin levels. Journal of Hepatology, 42(2), 238–243. 
https://doi.org/10.1016/j.jhep.2004.10.012 
 
Volta, U., Bonazzi, C., Bianchi, F. B., Baldoni, A. M., Zoli, M., & Pisi, E. (1987). IgA antibodies to dietary 
antigens in liver cirrhosis. La Ricerca in Clinica E in Laboratorio, 17(3), 235–242. 
 
Wahlström, A., Sayin, S. I., Marschall, H.-U., & Bäckhed, F. (2016). Intestinal Crosstalk between Bile 
Acids and Microbiota and Its Impact on Host Metabolism. Cell Metabolism, 24(1), 41–50. 
https://doi.org/10.1016/j.cmet.2016.05.005 
 
Wang, Han, Geng, C., Li, J., Hu, A., & Yu, C.-P. (2014). Characterization of a novel melamine-
degrading bacterium isolated from a melamine-manufacturing factory in China. Applied 
Microbiology and Biotechnology, 98(7), 3287–3293. https://doi.org/10.1007/s00253-013-
5363-2 
 
 
 
Wang, Hongbing, Faucette, S., Moore, R., Sueyoshi, T., Negishi, M., & LeCluyse, E. (2004). Human 
constitutive androstane receptor mediates induction of CYP2B6 gene expression by 
phenytoin. The Journal of Biological Chemistry, 279(28), 29295–29301. 
https://doi.org/10.1074/jbc.M400580200 
 
Ward, T. G., & Trexler, P. C. (1958). Gnotobiotics: A New Discipline in Biological and Medical 
Research. Perspectives in Biology and Medicine, 1(4), 447–456. 
https://doi.org/10.1353/pbm.1958.0031 
 
Waterston, R. H., Birney, E., Rogers, J., Abril, J. F., Agarwal, P., Agarwala, R., … Lander, E. S. (2002). 
Initial sequencing and comparative analysis of the mouse genome. Nature, 420(6915), 520–
562. https://doi.org/10.1038/nature01262 
 
Weger, B. D., Gobet, C., Yeung, J., Martin, E., Jimenez, S., Betrisey, B., … Gachon, F. (2019). The 
Mouse Microbiome Is Required for Sex-Specific Diurnal Rhythms of Gene Expression and 
321
Bibliographic references 
 
  
Metabolism. Cell Metabolism, 29(2), 362-382.e8. 
https://doi.org/10.1016/j.cmet.2018.09.023 
 
Weghorst, C. M., & Klaunig, J. E. (1989). Phenobarbital promotion in diethylnitrosamine-initiated 
infant B6C3F1 mice: Influence of gender. Carcinogenesis, 10(3), 609–612. 
https://doi.org/10.1093/carcin/10.3.609 
 
Wei, P., Zhang, J., Dowhan, D. H., Han, Y., & Moore, D. D. (2002). Specific and overlapping functions 
of the nuclear hormone receptors CAR and PXR in xenobiotic response. The 
Pharmacogenomics Journal, 2(2), 117–126. 
 
Wei, P., Zhang, J., Egan-Hafley, M., Liang, S., & Moore, D. D. (2000). The nuclear receptor CAR 
mediates specific xenobiotic induction of drug metabolism. Nature, 407(6806), 920–923. 
https://doi.org/10.1038/35038112 
 
Whiteside, S. A., Razvi, H., Dave, S., Reid, G., & Burton, J. P. (2015). The microbiome of the urinary 
tract—A role beyond infection. Nature Reviews. Urology, 12(2), 81–90. 
https://doi.org/10.1038/nrurol.2014.361 
 
Wikoff, W. R., Anfora, A. T., Liu, J., Schultz, P. G., Lesley, S. A., Peters, E. C., & Siuzdak, G. (2009). 
Metabolomics analysis reveals large effects of gut microflora on mammalian blood 
metabolites. Proceedings of the National Academy of Sciences of the United States of 
America, 106(10), 3698–3703. https://doi.org/10.1073/pnas.0812874106 
 
Williams, B. B., Van Benschoten, A. H., Cimermancic, P., Donia, M. S., Zimmermann, M., Taketani, M., 
… Fischbach, M. A. (2014). Discovery and characterization of gut microbiota decarboxylases 
that can produce the neurotransmitter tryptamine. Cell Host & Microbe, 16(4), 495–503. 
https://doi.org/10.1016/j.chom.2014.09.001 
 
Willson, T. M., & Kliewer, S. A. (2002). PXR, CAR and drug metabolism. Nature Reviews. Drug 
Discovery, 1(4), 259–266. https://doi.org/10.1038/nrd753 
 
Wilson, J. D. (1992). Presentation of the Southern Society for Clinical Investigation Founder’s Medal 
to Dr. Daniel W. Foster. The American Journal of the Medical Sciences, 304(1), 1–2. 
 
Wilson, V. S., McLachlan, J. B., Falls, J. G., & LeBlanc, G. A. (1999). Alteration in sexually dimorphic 
testosterone biotransformation profiles as a biomarker of chemically induced androgen 
disruption in mice. Environmental Health Perspectives, 107(5), 377–384. 
https://doi.org/10.1289/ehp.99107377 
 
Wiwi, C. A., Gupte, M., & Waxman, D. J. (2004). Sexually dimorphic P450 gene expression in liver-
specific hepatocyte nuclear factor 4alpha-deficient mice. Molecular Endocrinology 
(Baltimore, Md.), 18(8), 1975–1987. https://doi.org/10.1210/me.2004-0129 
 
Wortham, M., Czerwinski, M., He, L., Parkinson, A., & Wan, Y.-J. Y. (2007). Expression of constitutive 
androstane receptor, hepatic nuclear factor 4 alpha, and P450 oxidoreductase genes 
determines interindividual variability in basal expression and activity of a broad scope of 
xenobiotic metabolism genes in the human liver. Drug Metabolism and Disposition: The 
Biological Fate of Chemicals, 35(9), 1700–1710. https://doi.org/10.1124/dmd.107.016436 
 
322
Bibliographic references 
 
  
Wright, E., Vincent, J., & Fernandez, E. J. (2007). Thermodynamic characterization of the interaction 
between CAR-RXR and SRC-1 peptide by isothermal titration calorimetry. Biochemistry, 
46(3), 862–870. https://doi.org/10.1021/bi061627i 
Wright, M. C. (2006). The impact of pregnane X receptor activation on liver fibrosis. Biochemical 
Society Transactions, 34(Pt 6), 1119–1123. https://doi.org/10.1042/BST0341119 
 
Wu, H.-J., Ivanov, I. I., Darce, J., Hattori, K., Shima, T., Umesaki, Y., … Mathis, D. (2010). Gut-residing 
segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity, 
32(6), 815–827. https://doi.org/10.1016/j.immuni.2010.06.001 
 
Wyde, M. E., Bartolucci, E., Ueda, A., Zhang, H., Yan, B., Negishi, M., & You, L. (2003). The 
environmental pollutant 1,1-dichloro-2,2-bis (p-chlorophenyl)ethylene induces rat hepatic 
cytochrome P450 2B and 3A expression through the constitutive androstane receptor and 
pregnane X receptor. Molecular Pharmacology, 64(2), 474–481. 
https://doi.org/10.1124/mol.64.2.474 
 
Wyde, M. E., Kirwan, S. E., Zhang, F., Laughter, A., Hoffman, H. B., Bartolucci-Page, E., … You, L. 
(2005). Di-n-butyl phthalate activates constitutive androstane receptor and pregnane X 
receptor and enhances the expression of steroid-metabolizing enzymes in the liver of rat 
fetuses. Toxicological Sciences: An Official Journal of the Society of Toxicology, 86(2), 281–
290. https://doi.org/10.1093/toxsci/kfi204 
 
Xiao, L., Feng, Q., Liang, S., Sonne, S. B., Xia, Z., Qiu, X., … Kristiansen, K. (2015). A catalog of the 
mouse gut metagenome. Nature Biotechnology, 33(10), 1103–1108. 
https://doi.org/10.1038/nbt.3353 
 
Xie, W., Barwick, J. L., Downes, M., Blumberg, B., Simon, C. M., Nelson, M. C., … Evans, R. M. (2000). 
Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature, 
406(6794), 435–439. https://doi.org/10.1038/35019116 
 
Xie, Wen, Yeuh, M.-F., Radominska-Pandya, A., Saini, S. P. S., Negishi, Y., Bottroff, B. S., … Evans, R. 
M. (2003). Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X 
receptor and constitutive androstane receptor. Proceedings of the National Academy of 
Sciences of the United States of America, 100(7), 4150–4155. 
https://doi.org/10.1073/pnas.0438010100 
Xie, Y.-B., Nedumaran, B., & Choi, H.-S. (2009). Molecular characterization of SMILE as a novel 
corepressor of nuclear receptors. Nucleic Acids Research, 37(12), 4100–4115. 
https://doi.org/10.1093/nar/gkp333 
 
Xu, C., Li, C. Y.-T., & Kong, A.-N. T. (2005). Induction of phase I, II and III drug metabolism/transport 
by xenobiotics. Archives of Pharmacal Research, 28(3), 249–268. 
 
Yamamoto, Y., Moore, R., Hess, H. A., Guo, G. L., Gonzalez, F. J., Korach, K. S., … Negishi, M. (2006). 
Estrogen receptor alpha mediates 17alpha-ethynylestradiol causing hepatotoxicity. The 
Journal of Biological Chemistry, 281(24), 16625–16631. 
https://doi.org/10.1074/jbc.M602723200 
 
Yan, Jing, Herzog, J. W., Tsang, K., Brennan, C. A., Bower, M. A., Garrett, W. S., … Charles, J. F. (2016). 
Gut microbiota induce IGF-1 and promote bone formation and growth. Proceedings of the 
National Academy of Sciences of the United States of America, 113(47), E7554–E7563. 
https://doi.org/10.1073/pnas.1607235113 
323
Bibliographic references 
 
  
 
Yan, Jiong, Chen, B., Lu, J., & Xie, W. (2015). Deciphering the roles of the constitutive androstane 
receptor in energy metabolism. Acta Pharmacologica Sinica, 36(1), 62–70. 
https://doi.org/10.1038/aps.2014.102 
 
Yang, H., Garzel, B., Heyward, S., Moeller, T., Shapiro, P., & Wang, H. (2014). Metformin represses 
drug-induced expression of CYP2B6 by modulating the constitutive androstane receptor 
signaling. Molecular Pharmacology, 85(2), 249–260. 
https://doi.org/10.1124/mol.113.089763 
 
Yang, X., Downes, M., Yu, R. T., Bookout, A. L., He, W., Straume, M., … Evans, R. M. (2006). Nuclear 
receptor expression links the circadian clock to metabolism. Cell, 126(4), 801–810. 
https://doi.org/10.1016/j.cell.2006.06.050 
 
Yi, P., & Li, L. (2012). The germfree murine animal: An important animal model for research on the 
relationship between gut microbiota and the host. Veterinary Microbiology, 157(1), 1–7. 
https://doi.org/10.1016/j.vetmic.2011.10.024 
 
Yoshinari, K., Kobayashi, K., Moore, R., Kawamoto, T., & Negishi, M. (2003). Identification of the 
nuclear receptor CAR:HSP90 complex in mouse liver and recruitment of protein phosphatase 
2A in response to phenobarbital. FEBS Letters, 548(1–3), 17–20. 
 
Zackular, J. P., Baxter, N. T., Chen, G. Y., & Schloss, P. D. (2016). Manipulation of the Gut Microbiota 
Reveals Role in Colon Tumorigenesis. MSphere, 1(1). 
https://doi.org/10.1128/mSphere.00001-15 
 
Zeller, G., Tap, J., Voigt, A. Y., Sunagawa, S., Kultima, J. R., Costea, P. I., … Bork, P. (2014). Potential 
of fecal microbiota for early-stage detection of colorectal cancer. Molecular Systems Biology, 
10, 766. https://doi.org/10.15252/msb.20145645 
 
Zhang, B., Xie, W., & Krasowski, M. D. (2008). PXR: A xenobiotic receptor of diverse function 
implicated in pharmacogenetics. Pharmacogenomics, 9(11), 1695–1709. 
https://doi.org/10.2217/14622416.9.11.1695 
Zhang, J., Huang, W., Chua, S. S., Wei, P., & Moore, D. D. (2002). Modulation of acetaminophen-
induced hepatotoxicity by the xenobiotic receptor CAR. Science (New York, N.Y.), 298(5592), 
422–424. https://doi.org/10.1126/science.1073502 
 
Zhang, J., Huang, W., Qatanani, M., Evans, R. M., & Moore, D. D. (2004). The constitutive androstane 
receptor and pregnane X receptor function coordinately to prevent bile acid-induced 
hepatotoxicity. The Journal of Biological Chemistry, 279(47), 49517–49522. 
https://doi.org/10.1074/jbc.M409041200 
 
Zhang, X.-J., Shi, Z., Lyv, J.-X., He, X., Englert, N. A., & Zhang, S.-Y. (2015). Pyrene is a Novel 
Constitutive Androstane Receptor (CAR) Activator and Causes Hepatotoxicity by CAR. 
Toxicological Sciences: An Official Journal of the Society of Toxicology, 147(2), 436–445. 
https://doi.org/10.1093/toxsci/kfv142 
 
Zheng, X., Zhao, A., Xie, G., Chi, Y., Zhao, L., Li, H., … Jia, W. (2013). Melamine-induced renal toxicity 
is mediated by the gut microbiota. Science Translational Medicine, 5(172), 172ra22. 
https://doi.org/10.1126/scitranslmed.3005114 
 
324
Bibliographic references 
 
  
Zhou, J., Febbraio, M., Wada, T., Zhai, Y., Kuruba, R., He, J., … Xie, W. (2008). Hepatic fatty acid 
transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. 
Gastroenterology, 134(2), 556–567. https://doi.org/10.1053/j.gastro.2007.11.037 
 
Zhou, J., Zhai, Y., Mu, Y., Gong, H., Uppal, H., Toma, D., … Xie, W. (2006). A novel pregnane X 
receptor-mediated and sterol regulatory element-binding protein-independent lipogenic 
pathway. The Journal of Biological Chemistry, 281(21), 15013–15020. 
https://doi.org/10.1074/jbc.M511116200 
 
Zimmer, J., Lange, B., Frick, J.-S., Sauer, H., Zimmermann, K., Schwiertz, A., … Enck, P. (2012). A vegan 
or vegetarian diet substantially alters the human colonic faecal microbiota. European Journal 
of Clinical Nutrition, 66(1), 53–60. https://doi.org/10.1038/ejcn.2011.141 
 
 
 
 
325
ANNEXES 
326
Annexes 
Associated publications 
Ilchmann-Diounou, H., Olier, M., Lencina, C., Riba, A., Barretto, S., Nankap, M., … Ménard, 
S. (2019). Early life stress induces type 2 diabetes-like features in ageing mice.
Brain, Behavior, and Immunity, 80, 452–463.
https://doi.org/10.1016/j.bbi.2019.04.025
Zhang, X., Grosfeld, A., Williams, E., Vasiliauskas, D., Barretto, S., Smith, L., … Douard, V. 
(2019). Fructose malabsorption induces cholecystokinin expression in the ileum 
and cecum by changing microbiota composition and metabolism. The FASEB 
Journal, 33(6), 7126–7142. https://doi.org/10.1096/fj.201801526RR 
(In review for Scientific Reports) 
Céline Lukowicz1, Sandrine Ellero-Simatos1, Marion Régnier1, Fabiana Oliviero1, Frédéric 
Lasserre1, Arnaud Polizzi1, Alexandra Montagner1, Sarra Smati1, Frédéric Boudou2, 
Françoise Lenfant2, Laurence Guzylack1, Sandrine Menard1, Sharon Baretto1, Anne 
Fougerat1, Yannick Lippi1, Claire Naylies1, Justine Bertrand-Michel3, Afifa Ait 
Belgnaoui1, Vassilia Theodorou1, Pierre Gourdy2, Laurence Gamet-Payrastre1,
Nicolas Loiseau1, Hervé Guillou1, Laila Mselli-Lakhal1(2019). Constitutive 
androstane receptor deficiency leads to sexually dimorphic obesity, diabetes, 
steatosis and endocrine disruptions in mice. 
327
Contents lists available at ScienceDirect
Brain, Behavior, and Immunity
journal homepage: www.elsevier.com/locate/ybrbi
Early life stress induces type 2 diabetes-like features in ageing mice
Hanna Ilchmann-Diounoua, Maïwenn Oliera, Corinne Lencinaa, Ambre Ribaa, Sharon Barrettob,
Michèle Nankapa, Caroline Sommerc, Hervé Guilloub, Sandrine Ellero-Simatosb,
Laurence Guzylack-Pirioua, Vassilia Théodoroua, Sandrine Ménarda,⁎
aNeuro-Gastroenterology and Nutrition Team, Toxalim (Research Centre in Food Toxicology), Université de Toulouse, INRA, ENVT, INP-Purpan, UPS, Toulouse, France
b Integrative Toxicology and Metabolism Team, Toxalim (Research Centre in Food Toxicology), Université de Toulouse, INRA, ENVT, INP-Purpan, UPS, Toulouse, France
c Experimental and Zootechnic Platform, Toxalim (Research Centre in Food Toxicology), Université de Toulouse, INRA, ENVT, INP-Purpan, UPS, Toulouse, France
A R T I C L E I N F O
Keywords:
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A B S T R A C T
Early life stress is known to impair intestinal barrier through induction of intestinal hyperpermeability, low-
grade inflammation and microbiota dysbiosis in young adult rodents. Interestingly, those features are also ob-
served in metabolic disorders (obesity and type 2 diabetes) that appear with ageing. Based on the concept of
Developmental Origins of Health and Diseases, our study aimed to investigate whether early life stress can
trigger metabolic disorders in ageing mice.
Maternal separation (MS) is a well-established model of early life stress in rodent. In this study, MS increased
fasted blood glycemia, induced glucose intolerance and decreased insulin sensitivity in post-natal day 350 wild
type C3H/HeN male mice fed a standard diet without affecting body weight. MS also triggered fecal dysbiosis
favoring pathobionts and significantly decreased IL-17 and IL-22 secretion in response to anti-CD3/CD28 sti-
mulation in small intestine lamina propria. Finally, IL-17 secretion in response to anti-CD3/CD28 stimulation was
also diminished at systemic level (spleen).
For the first time, we demonstrate that early life stress is a risk factor for metabolic disorders development in
ageing wild type mice under normal diet.
1. Introduction
During the last century, the incidence of non-communicable dis-
eases, including metabolic disorders, is expanding in western countries
(Bach, 2002). The causes for this drastic increase are debated. The
concept of Developmental Origins of Health and Disease (DOHaD)
highlights the importance of early life period and raises the hypothesis
that chronic diseases could find their origins in perinatal environment
(Barker et al., 1989; Gluckman et al., 2016). In mice and humans, early
life is important for the development of the immune system, metabolic
switch, microbiota colonization (Tamburini et al., 2016) and the de-
velopment of life-long beneficial host-microbe homeostasis (Hornef and
Fulde, 2014). Adverse events can disturb these mechanisms of adap-
tation. Several observational epidemiological studies have shown an
association between adverse childhood experiences and metabolic dis-
eases in later life (Huang et al., 2015). This study aims to provide ex-
perimental data to support a link between early life stress and
development of metabolic disorders with ageing.
Metabolic disorders, such as obesity and type 2 diabetes are asso-
ciated with modification of intestinal barrier, microbiota dysbiosis and
low grade inflammation (Brun et al., 2007; Cani et al., 2008; Osborn
and Olefsky, 2012; Turnbaugh et al., 2006). In mice, several models
such as diet induced obesity (high-fat or western diets) or genetic
models (ob/ob and db/db, respectively deficient for leptin and leptin
receptor) are used to investigate obesity associated with hyperglycemia.
In those models, a defect of intestinal barrier as well as low-grade in-
flammation were observed, even before the onset of obesity and hy-
perglycemia (Araújo et al., 2017; Brun et al., 2007). Neonatal maternal
separation (MS) is a stress model widely used in rodents as a paradigm
of early life adverse events. We previously observed that, in male mice,
MS triggers long lasting alterations of intestinal homeostasis in young
adult offspring (post-natal-day (PND) 50) including a defect of in-
testinal barrier, microbiota dysbiosis and low-grade inflammation (Riba
et al., 2018). With ageing, intestinal permeability and low-grade
https://doi.org/10.1016/j.bbi.2019.04.025
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Fructose malabsorption induces cholecystokinin
expression in the ileum and cecum by changing
microbiota composition and metabolism
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ABSTRACT: Current fructose consumption levels often overwhelm the intestinal capacity to absorb fructose. We
investigated the impact of fructose malabsorption on intestinal endocrine function and addressed the role of the
microbiota in this process. To answer this question, a mouse model of moderate fructose malabsorption [ketohexo-
kinasemutant (KHK)2/2] andwild-type (WT) littermatemicewereusedand received a 20%-fructose (KHK-F and
WT-F) or 20%-glucosediet.Cholecystokinin (Cck)mRNAandprotein expression in the ileumandcecum,aswell as
preproglucagon (Gcg) and neurotensin (Nts) mRNA expression in the cecum, increased inKHK-Fmice. InKHK-F
mice, triple-label immunohistochemistry showedmajor up-regulation ofCCK inenteroendocrine cells (EECs) that
were glucagon-like peptide-1 (GLP-1)+/Peptide YY (PYY2) in the ileum and colon andGLP-12/PYY2 in the cecum.
The cecalmicrobiota compositionwasdrasticallymodified in theKHK-F inassociationwithan increase inglucose,
propionate, succinate, and lactate concentrations.Antibiotic treatment abolishedfructosemalabsorption-dependent
inductionof cecalCckmRNAexpressionand, inmouseGLUTagandhumanNCI-H716 cells,CckmRNAexpression
levels increased in response to propionate, both suggesting a microbiota-dependent process. Fructose reaching the
lower intestine canmodify the composition andmetabolism of themicrobiota, thereby stimulating the production
of CCK from the EECs possibly in response to propionate.—Zhang, X., Grosfeld, A.,Williams, E., Vasiliauskas, D.,
Barretto,S., Smith,L.,Mariadassou,M.,Philippe,C.,Devime,F.,Melchior,C.,Gourcerol,G.,Dourmap,N., Lapaque,
N.,Larraufie,P.,Blottie`re,H.,Herberden,C.,Gerard,P.,Rehfeld, J., Ferraris,R., Fritton,C.,Ellero-Simatos,S.,Douard,
V. Fructose malabsorption induces cholecystokinin expression in the ileum and cecum by changing microbiota
composition and metabolism. FASEB J. 33, 000–000 (2019). www.fasebj.org
KEY WORDS: CCK • KHK • propionate
ABBREVIATIONS:AB, antibiotic; CCK, cholecystokinin; EEC, enteroendocrine cell; FC, fold change; FFAR, free fatty acid receptor; FROGS, Find, Rapidly,
OTUs with Galaxy Solution; GCG, preproglucagon; GIP, gastric inhibitory polypeptide; GI, gastrointestinal; GLP-1, glucagon-like peptide-1; GLUT,
facilitated glucose/fructose transporter; KHK, ketohexokinase; Math1, atonal bHLH transcription factor 1; NeuroD, neuronal differentiation; Neurog,
neurogenin; NTS, neurotensin; O-PLS-DA, orthogonal projection on latent structure-discriminant analysis; OTU, operational taxonomic unit; Pax,
paired box; PCA, principal component analysis; PYY, peptide YY; qRT-PCR, quantitative PCR; SCFA, short-chain fatty acid; SCT, secretin; SST,
somatostatin; TPH1, tryptophan hydroxylase 1; WT, wild type
1 Correspondence: Micalis Institute, INRA, Domaine du Vilvert, 78352 Jouy-en-Josas, France. E-mail: veronique.douard@inra.fr
doi: 10.1096/fj.201801526RR
This article includes supplemental data. Please visit http://www.fasebj.org to obtain this information.
0892-6638/19/0033-0001 © FASEB 1
Annexes 
326
Constitutive androstane receptor deficiency leads to sexually 
dimorphic obesity, diabetes, steatosis and endocrine disruptions 
in mice 
Céline Lukowicz1, Sandrine Ellero-Simatos1, Marion Régnier1, Fabiana Oliviero1, Frédéric 
Lasserre1, Arnaud Polizzi1, Alexandra Montagner1, Sarra Smati1, Frédéric Boudou2, 
Françoise Lenfant2, Laurence Guzylack1, Sandrine Menard1, Sharon Baretto1, Anne 
Fougerat1, Yannick Lippi1, Claire Naylies1, Justine Bertrand-Michel3, Afifa Ait Belgnaoui1, 
Vassilia Theodorou1, Pierre Gourdy2, Laurence Gamet-Payrastre1, Nicolas Loiseau1, Hervé 
Guillou1, Laila Mselli-Lakhal1,# 
1 Toxalim (Research Centre in Food Toxicology), Université de Toulouse, INRA, ENVT, INP-
Purpan, UPS, Toulouse, France. 
2 I2MC, Institut National de la Santé et de la Recherche Médicale (INSERM)-U 1048, 
Université de Toulouse 3 and CHU de Toulouse, Toulouse, France.  
3 Metatoul-Lipidomic Facility, MetaboHUB, Institut National de la Santé et de la Recherche 
Médicale (INSERM), UMR1048, Institute of Metabolic and Cardiovascular Diseases, 
Toulouse, France 
Keywords: Nuclear receptor - metabolic disease - transcriptomic - metabolomic - 
lipidomic 
Emails of authors: 
Céline Lukowicz: celine.lukowicz@inra.fr, Sandrine Ellero-Simatos: sandrine.ellero--
simatos@inra.fr, Marion Régnier: marion.regnier@inra.fr, Fabiana Oliviero: 
fabiana.oliviero@inra.fr, Frédéric Lasserre: Frederic.lasserre@inra.fr, Arnaud Polizzi: 
arnaud.polizzi@inra.fr, Alexandra Montagner: Alexandra.montagner@inserm.fr, Sarra 
Smati : sarra.smati@inra.fr, Frédéric Boudou: fréderic.boudou@inserm.fr, Françoise 
Lenfant: Françoise.lenfant@inserm.fr, Laurence Guzylack: Laurence.guzylack@inra.fr, 
Sandrine Menard: sandrine.memard@inra.fr, Sharon Baretto: sharon.baretto@inra.fr, Anne 
Fougerat: anne.fougerat@inra.fr, Yannick Lippi: Yannick.lippi@inra.fr, Claire Naylies: 
Claire.naylies@inra.fr, Justine Bertrand-Michel: justine.bertrand-michel@inserm.fr, Afifa Ait 
Belgnaoui: afifa.ait.belgnaoui@gmail.com, Vassilia Theodorou: Vassilia.theodorou@inra.fr, 
Pierre Gourdy: pierre.gourdy@inserm.fr, Laurence Gamet-Payrastre: 
Annexes 
327
laurence.payrastre@inra.fr,  Nicolas Loiseau: Nicolas.loiseau@inra.fr, Hervé Guillou: 
herve.guillou@inra.fr, Laila Mselli-Lakhal: laila.lakhal@inra.fr. 
# Corresponding author 
Contact Information 
Laila Mselli-Lakhal, ToxAlim UMR1331 INRA/INPT/UPS, Integrative Toxicology & 
Metabolism group, 180 chemin de Tournefeuille, BP 93173, 31027 Toulouse Cedex 3, 
FRANCE. Tel: +33 561285524. Fax: +33 561285310. laila.lakhal@inra.fr. 
List of abbreviations 
ALT, alanine transaminase; AST, aspartate transaminase; CAR, constitutive androstane 
receptor; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Sult1a1, 
sulfotransferase family 1A member 1, Sult2a1, sulfotransferase family 2A member 1; 
Srd5a1, steroid 5 alpha-reductase 1.  
Financial support 
This work was supported by grants from the Agence National de la Recherche and from 
the Midi-Pyrénées region (NEWPOM). Céline Lukowicz is funded by grants from the 
French National Institute for Agricultural Research, Animal Health, the Région Midi-
Pyrénées, and the EI Purpan engineering school.  
Annexes 
328
 Abstract 
The constitutive androstane receptor (CAR) is a transcription factor involved in 
detoxification through regulating expression of xenobiotic-metabolizing enzymes. Highly 
expressed in the liver, it is important in protecting the organism against exogenous and 
endogenous toxic molecules such as bile acids and bilirubin and in the catabolism of 
thyroid and steroid hormones. A role has also been assigned to CAR in the regulation of 
energy metabolism, although related mechanisms have been studied primarily in males 
and in physiopathological conditions. Here, we compared the impact of CAR deficiency on 
energy homeostasis regulation between male and female mice in a normal physiological 
context. Large-scale gene expression analysis in 16-week-old animals revealed significant 
sexual dimorphism in the hepatic transcriptome of CAR-/- mice. We monitored these mice 
for different physiological parameters to age 68 weeks. CAR-/- males developed obesity, 
fasted hyperglycemia, and hyperinsulinemia associated with glucose and insulin 
intolerance. They also developed dyslipidemia and important steatosis accompanied by 
increased alanine transaminase and aspartate transaminase, signs of hepatolysis. In 
contrast, CAR-/- females had a different metabolic profile with overweight, improved 
glucose tolerance, no dyslipidemia, and no steatosis. Both sexes of CAR-/- mice displayed 
sex-dependent deregulation of gene expression involved in steroid hormone metabolism, 
leading to alteration of their corticosterone and sexual hormones levels. Ovariectomized 
CAR-/- females developed the same metabolic disorders as CAR-/- males, demonstrating 
that sex-steroid hormones protect female mice against the metabolic disorders observed 
in CAR-/- males. Conclusion: This study reveals a sexually dimorphic role for CAR in the 
regulation of endocrine and metabolic homeostasis.  
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Abstract 
The pregnane X receptor (PXR, NR1I2) and the constitutive androstane receptor (CAR, 
NR1I3) are two liver and intestine-enriched nuclear receptors that act as 
transcriptional regulators of enzymes critical for the detoxification of xenobiotics and 
endogenous metabolites. Previous works have shown that the expression of CAR and PXR 
target genes is significantly reduced in the liver of germ-free mice. In this PhD project, we 
aimed to gain insights into the bidirectional interactions between the gut microbiota and 
these xenosensors.  
We first used a pharmacological approach in WT vs Pxr-/- male mice and performed a 
transcriptomic comparison of the PXR-regulated genes in the liver upon activation via the 
rodent activator PCN. We confirmed that PXR activation increased liver triglyceride 
accumulation and significantly regulated the expression of genes, mostly involved in 
xenobiotic metabolism. We also highlighted a significant overlap between the genes 
downregulated upon PXR activation and a list of fasting-induced PPARδ  target genes. Among 
these, we identified the well-described PPARδ target fibroblast growth factor 21 (Fgf21) as a 
new PXR-regulated gene. PXR activation abolished plasmatic levels of FGF21. This first set of 
results provided a comprehensive signature of PXR activation in the liver and identified new 
PXR target genes that might be involved in the steatogenic and pleiotropic effects of PXR.   
Next, we compared the hepatic vs. intestinal signature of the pharmacological activation of 
PXR. This allowed us to unravel the strongest PXR target genes in both organs. 
Finally, we used Pxr+/+ and Pxr-/- littermate mice and suppressed the gut microbiota using 
antibiotics (ATB). Using the previously identified PXR targets, we confirmed that ATB 
significantly decreased Pxr activity in the liver and ileum. Liver transcriptomic analyses 
showed that ATB decreased a much higher number of PXR-dependent genes in the liver of 
male mice than in females. In males, this gut microbiota-PXR axis controlled xenobiotic 
metabolism and lipid remodelling. Conversely, 16S sequencing and 1H-NMR-based 
metabolic profiling of caecal content revealed subtle but significant differences in the gut 
microbiota composition of male Pxr-/- vs. Pxr+/+ mice, while no difference was observed in 
females. Our results therefore demonstrate that hepatic PXR is a major sensor of the gut 
microbiota that controls the host detoxifying capacities and lipid metabolism in a sexually 
dimorphic way. 
In the final chapter, we investigated the microbiota-CAR interactions. In Car+/+ and 
Car-/- littermate mice. Microbiota suppression by antibiotics decreased CAR activity in the 
liver and ileum of males but only in the liver of females. In caecal content, male-specific 
and CAR-dependant metabolites were also detected through 1H-NMR-based 
metabolomics. Furthermore, 16S sequencing confirmed a significant difference in 
gut microbiota composition of Car-/- vs Car+/+ male mice but not in females. We investigated 
the potential consequences of this sexually dimorphic CAR-dependent dysbiosis and 
observed that long-term Car deletion increased adipose tissue accumulation in male 
mice (at 37 weeks old). Whether the Car-dependent dysbiosis is responsible for this 
phenotype remains to be determined. In 37-week-old females, Car deletion induced a 
significant increase in spleen weight and a decrease in colon length, therefore suggesting a 
role for Car in systemic and intestinal inflammation. Thus, our result show for the first 
time that the CAR-gut microbiota interaction is sexually dimorphic and might control adipose 
deposition in male mice. 
Overall, our results shed new light into the crosstalk between the gut microbiota and 
the host’s xenobiotic receptors CAR and PXR, demonstrating that this cross-talk might be 
involved in the control the host’s hepatic lipid and xenobiotic metabolism. 
Résumé 
Le pregnane X receptor (PXR, NR1I2) et le récepteur constitutif aux androstanes (CAR, 
NR1I3) sont deux récepteurs nucléaires hépatiques et intestinaux qui régulent la transcription 
d'enzymes de détoxification des xénobiotiques. Des travaux antérieurs ont montré que 
l'expression des gènes cibles de CAR et PXR est significativement réduite dans le foie des 
souris axéniques. Dans ce projet de thèse, nous avions pour objectif de mieux 
comprendre les interactions bidirectionnelles entre le microbiote intestinal et ces 
xénosenseurs. 
  Nous avons d'abord utilisé une approche pharmacologique chez les souris mâles WT vs Pxr-/- 
et comparé la signature transcriptomique des gènes régulés par PXR dans le foie lors de 
l'activation via le PCN. L’activation de PXR a augmenté l'accumulation de triglycérides 
hépatiques. Nous avons observé un chevauchement significatif entre les gènes régulés 
négativement lors de l'activation de PXR et une liste de gènes cibles de PPARδ  induits par le 
jeûne. Parmi ceux-ci, nous avons identifié le facteur de croissance de fibroblastes 21 (Fgf21) 
comme un nouveau gène régulé par PXR. L'activation de PXR a aboli les taux plasmatiques de 
FGF21. Ces premiers résultats ont fourni une signature complète de l'activation de PXR dans le 
foie et ont identifié de nouveaux gènes cibles potentiellement impliqués dans les effets 
stéatogènes et pléiotropes de PXR. 
 
Ensuite, nous avons comparé la signature hépatique à la signature intestinale 
de l'activation pharmacologique de PXR, ce qui nous a permis d’identifier les gènes 
cibles communs de PXR dans ces 2 organes.  
Enfin, nous avons utilisé des souris Pxr+/+ et Pxr-/- littermate et supprimé le microbiote 
intestinal au moyen d’antibiotiques (ATB). En utilisant les gènes cibles de PXR 
identifiés précédemment, nous avons confirmé que les ATB réduisaient de manière 
significative l’activité de PXR dans le foie et l’iléon. Des analyses transcriptomiques 
hépatiques ont montré que les ATB diminuaient un nombre beaucoup plus élevé de gènes 
PXR-dépendants dans le foie des souris mâles que chez les femelles. Chez les mâles, l’axe 
microbiote intestinal-PXR contrôlait le métabolisme des xénobiotiques et le remodelage 
des lipides hépatiques. À l'inverse, le séquençage 16S et la métabolomique par RMN du 
contenu caecal ont révélé des différences subtiles mais significatives dans la 
composition du microbiote intestinal des souris Pxr-/- par rapport aux souris Pxr+/+, 
uniquement chez les mâles. Nos résultats démontrent donc que, dans le foie, PXR est un 
senseur majeur du microbiote intestinal qui contrôle les capacités de détoxication de 
l'hôte et le métabolisme des lipides de manière sexuellement dimorphique. Dans le 
dernier chapitre, nous avons étudié les interactions microbiote-CAR. Chez les souris 
Car+/+ et Car-/- littermates, la suppression du microbiote par les antibiotiques a 
diminué l'activité de CAR dans le foie et l'iléon des mâles, mais uniquement dans le foie 
des femelles. Dans le contenu caecal, le séquençage 16S et la metabolomique ont 
montré une différence significative dans la composition et l’activité métabolique du 
microbiote intestinal chez les souris Car+/+ vs Car-/- mâles, mais pas chez les femelles. 
Nous avons cherché les conséquences potentielles de cette dysbiose CAR dépendante 
et avons observé que la délétion de CAR augmentait l'accumulation de tissu adipeux 
chez les souris mâles à 37 semaines. Cependant, l’implication du microbiote CAR-
dépendant dans ce phénotype reste à vérifier. Ainsi, nos résultats montrent pour 
la première fois que l'interaction CAR-microbiote est sexuellement dimorphique et 
pourrait contrôler le dépôt adipeux chez les souris mâles.   
Dans l’ensemble, nos résultats montrent que le dialogue entre le microbiote intestinal 
et les récepteurs aux xénobiotiques CAR et PXR est impliqué de façon 
sexuellement dimorphique dans le contrôle des capacités de détoxification de l’hôte, et 
joue un rôle dans l’homéostasie lipidique. 
